20
1 7
ANNUAL
REPORT
People first. Performance follows.
900 Cottage Grove Road Bloomfield, CT 06002
Cigna.com
TABLE OF CONTENTS
Letter to our shareholders
People
Purpose
Performance
Cigna in perspective
Corporate and Board of Directors
2
8
10
18
22
24
OUR MISSION
To help the people we serve improve their
health, well-being and sense of security.
All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut
General Life Insurance Company, Life Insurance Company of North America, Cigna Life Insurance Company of New York (New York, NY), Cigna Behavioral Health, Inc., Cigna Health
Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation and Cigna Dental Health, Inc. The Cigna name, logo, and other Cigna marks are owned by
Cigna Intellectual Property, Inc.
912978 03/2018 © 2018 Cigna. Some content provided under license.
WHAT
DEFINES
US IS NOT
WHAT.
IT’S WHO.
E
L
P
O
E
P
45K+
EMPLOYEES
1M+
RELATIONSHIPS WITH HEALTH CARE
PROVIDERS, CLINICS AND FACILITIES
95M+
CUSTOMER RELATIONSHIPS1
1. This information provided as of December 31, 2017 (Source: Quarterly Financial Supplement).
OUR FOCUS
IS TO HELP
PEOPLE LIVE
HEALTHIER,
FULLER LIVES.
E
S
O
P
R
U
P
65K+
DOCTORS SIGNED THE CIGNA OPIOID QUALITY
IMPROVEMENT PLEDGE TO HELP REDUCE OPIOID USE
WITHIN THEIR PATIENT COMMUNITIES
24/7/365
FREE NATIONAL VETERAN SUPPORT LINE
LAUNCHED IN 2017
10K+
FREE BIOMETRIC SCREENINGS PROVIDED
NATIONWIDE IN 2017 THROUGH THE CIGNA HEALTH
IMPROVEMENT TOUR
E
C
N
A
M
R
O
F
R
E
P
BECAUSE WHEN
CUSTOMERS DO
WELL, WE ALL
DO WELL.
CIGNA NAMED
TO THE DOW JONES SUSTAINABILITY INDICES IN 2017:
WORLD INDEX AND NORTH AMERICA INDEX
OUR PERFORMANCE IS
INSPIRED BY – AND, IN MANY
WAYS, DEFINED BY – THE
IMPACT WE HAVE ON OUR
CUSTOMERS’ LIVES.
A message from our president and CEO,
David Cordani
CIGNA DELIVERED A STRONG 2017
Cigna delivered exceptionally strong performance on behalf of
our customers, employer clients, partners and shareholders in
2017 – extending our long track record of differentiated results.
Once again, these results were driven by the effective
execution of our “Go” strategy, best-in-class medical cost trend
performance on behalf of our employer clients, and strong
contributions from each of our four priority growth platforms –
Commercial Employer, United States Seniors, Global
Supplemental Benefits, and Group Disability and Life.
I’m proud of our contributions to all of our stakeholders,
energized by the opportunities ahead, and thankful for the
ongoing commitment of more than 45,000 Cigna colleagues
around the world who remain passionate about our mission of
helping to improve the health, well-being and sense of security
of those we serve. We grew to more than 95 million customer
relationships in 2017, and I’m privileged to witness examples
every day of how our Cigna team helps our customers lead
healthier, more productive lives.
ADDRESSING OUR
yet access to affordable,
UNSUSTAINABLE HEALTH
high-quality health care
CARE SYSTEM
At the same time, there’s a
clear consensus around the
need for a more sustainable
health care system, and the
tremendous pressure this puts
on far too many individuals
and families.
remains elusive for many
of our families, friends and
neighbors. People are living
longer on average, but too
frequently are doing so
without the vitality they
desire. Health care costs
are growing, as individual
health status erodes due
Unfortunately, debates around
to behaviors and lifestyles,
health care reform have been
as well as an unsustainable
largely unproductive, and
rise in chronic disease. In
challenges we have long faced
the majority of individual
still remain.
situations, these challenges
For example, United States
are preventable!
health expenditures absorb
This environment is
an increasing proportion of
exacerbated by aging
the gross domestic product,
populations, historical
David M. Cordani
President and
Chief Executive Officer
Cigna Corporation
2
L E T T E R T O O U R S H A R E H O L D E R S
Collectively, our best opportunities to improve
affordability and build a more sustainable health
care system will come from helping to improve
individual health, in a highly personalized way.
“
payment models that fail to incentivize health care
dialogue focused on improving health care outcomes
system participants to maintain or improve health, a
in numerous ways, ranging from community
health care reform debate which too often focuses
engagement – such as our efforts to help reduce
on symptoms – such as the financing of “sick care”
the use of opioids among our customers – and
interventions – rather than on underlying causes. In
our value-based collaborations with health care
short, in most countries, the social narrative equates
professionals, to market-changing consumer support
“health care” solely with “sick care,” rather than with
programs and ongoing, principle-based engagement
the broader aspiration and need of keeping people
with elected officials.
healthy in the first place.
No segment of society can successfully address these
challenges alone, or in a vacuum. Collectively, we need
to commit to building more powerful connections and
solutions among individuals, physicians, health care
companies, governments and communities.
A FOCUS ON THE INDIVIDUAL
In the 1950s, the United States Air Force determined
that planes with cockpits designed to accommodate
the stature of an average-sized pilot were
contributing to an increase in crashes. In fact, a study
of 4,000 Air Force pilots showed none of them to be
Cigna actively works to enable these connections,
“average” based on the measurements used to create
and to catalyze and contribute to a constructive
a cockpit for the “average man.”2
2. Rose, T. (2016, January 16). When U.S. air force discovered the flaw of averages. Retrieved March 02, 2018, from https://www.thestar.com/news/insight/2016/01/16/when-us-air-force-discovered-the-flaw-of-averages.html
3
Equipped with this information, the Air Force shifted to adjustable
– personalized – cockpits.
Averages can help us better understand theoretical groups of
people, but not unique human beings. It didn’t work for the Air
Force. And it doesn’t work in health care.
We fervently believe the most powerful solutions transcend
a monolithic, one-size-fits-all approach; rather, they’re
oriented around the well-being and unique needs of the
individual. Collectively, our best opportunities to improve
affordability and build a more sustainable health care system
will come from helping to improve individual health, in a
highly personalized way.
Too often, our dialogue around well-being is overly
generalized; we forget the vulnerable, uncertain and often
frightened person at the end of the health care equation. In
reality, the definition of well-being is unique to every individual,
and further influenced by factors ranging from the person’s life
goals, to health disparities influenced by their demographics,
lifestyles and behaviors, and where they live. Put differently, at
certain levels, “well-being” is likely to mean something quite
different to someone in Beijing compared with someone in
Boston; however, it may very well also be different for two
people in Boston living on the same block.
This is why we find, time and again, that the best paths for health
improvement are created one community, one neighborhood,
and one person at a time.
Even the nature of what constitutes health improvement itself
is relative and also uniquely individual – any person can achieve
greater vitality regardless of where they are on their health
journey, and rightfully feel good about it. The already-healthy can
be supported in staying healthy. The healthy, “at risk” populations
can lower their risk; this is critical to avoid becoming chronically
or acutely ill in the near future. Those with chronic disease can
be supported to reverse or control their conditions, live life to
the fullest, and avoid becoming acutely ill. Those with acute care
needs can benefit from quality, high-value health care services.
Grassroots engagement is critical, because in addition to all health
being personal, it is local. In fact, health awareness programs
can be instrumental in mobilizing individuals to take a more
active role in managing their health. In the United States in the
1980s, public awareness campaigns reoriented habits around
seat belt use and similarly, campaigns in the 1990s focused on
smoking reduction – each with tremendously positive results.
4
L E T T E R T O O U R S H A R E H O L D E R S
Cigna provided holiday gift cards to hurricane
victims in Houston, where Cigna Market
Leader Michael Koehler greeted families.
5
These give hope to the potential for community
reasons, the community needs to play an essential
engagement and activation to positively affect lifestyle
role, which takes different shapes around the globe.
choices negatively influencing individual health today.
BRIGHT SPOTS: WHERE IT’S WORKING
In this equation, Cigna embraces our role as a
“connective fiber” or enabler, helping to connect and
mobilize employers, health care professionals and
communities to create affordable, high-quality health
outcomes for individuals. Working together, each of
these stakeholders plays a crucial role in contributing to
better and more affordable health care.
Today in the United States, employers provide health
care insurance coverage to more than 175 million
Americans,3 and remain the best positioned to put
into place the benefit designs, physician networks and
onsite health coaching programs that work best for
their employees. Increasingly, employers in countries
around the world are introducing or adopting health
and chronic disease programs to supplement the
In the United States, for example, Cigna was the first
in our industry to step up to the opioid epidemic,
collaborating with physicians and dentists to
dramatically reduce prescribing volumes to protect
health, and expanding access to Medication Assisted
Treatments for those already addicted. Additionally,
we established a multi-city Health Improvement Tour
to bring free health screenings to communities, and
created a Community Ambassador Fellowship Program,
with Cigna colleagues around the world supporting
key initiatives such as clean water, prosthetics, mental
health, children’s health and addiction. These kinds
of community-driven efforts take on even greater
importance given findings that people who feel
connected to their community demonstrate lower rates
of anxiety, isolation and loneliness.7
At Cigna, we support customers on their life and health
journey every day, often at their most vulnerable
services supplied by their government programs. Along
moments. To share just three very different examples:
with another “bright spot” in the American health care
system – Medicare Advantage – these two access
points of coverage collectively provide coverage to
almost two-thirds of the U.S. population,4 and are
highly functioning despite the burden of directly and
indirectly subsidizing the health care system at large.
> One of our case managers worked closely with
Katherine Rodriguez to address her chronic hypertension
following multiple preterm deliveries, one of which
resulted in a miscarriage. Katherine remained susceptible
to preterm delivery, but she and her husband desperately
wanted more children. Our case manager helped ensure
Health care providers are increasingly embracing
she took her medicine to delay preterm labor, which
incentive-based programs which prioritize the value
contributed to her subsequent deliveries of two healthy
of outcomes achieved, over the volume of services
baby boys. Soon after her most recent delivery, Cigna
provided. Through our collaboration with health care
also helped to coordinate Katherine’s family’s evacuation
providers, we have nearly 500 advanced collaborative
plan during Hurricane Harvey.
arrangements across physician practices and hospitals
spanning 33 states.5 Today, 88% of Cigna’s customers
in the United States are within 15 miles of a health care
provider in a collaborative care arrangement.6
> Shawn King was a Marine who prided himself on
physical fitness. Then, he began gaining weight, and
one morning woke up more than 20 pounds heavier
than the day before. He was diagnosed with congestive
Finally, the community piece is especially important
heart failure, and then diabetes – a disease which
here, and too often not considered. The health care
contributed to the deaths of both Shawn’s father
system alone, regardless of its structure, cannot meet
and brother. Through the Cigna Collaborative CareSM
the needs of every individual. The vast majority of
program, a Cigna pharmacist and an embedded care
factors that influence a person’s health exist outside
coordinator from an accountable care provider worked
the doctor’s office, pharmacy or hospital. For these
together to ensure Shawn had the right medicine,
3. Rovner, J. (2016, September 13). A Record Percentage of Americans Now Have Health Insurance. Retrieved March 02, 2018, from http://time.com/money/4490196/health-insurance-coverage-census-2015/
4. Barnett, J., & Berchick, E. (2017, September). Health Insurance Coverage in the United States: 2016. Retrieved March 2, 2018, from https://www.census.gov/content/dam/Census/library/publications/2017/demo/p60-260.pdf
5. Cigna Collaborative Care. (n.d.). Retrieved March 02, 2018, from https://www.cigna.com/newsroom/knowledge-center/aco/
6. Large Healthcare Provider Network for Group Plans | Cigna. (n.d.). Retrieved March 02, 2018, from https://www.cigna.com/business-segments/large-employers/healthcare-provider-network
7. Brody, J. E. (2017, June 12). Social Interaction Is Critical for Mental and Physical Health. Retrieved March 02, 2018, from https://www.nytimes.com/2017/06/12/well/live/having-friends-is-good-for-you.html
6
L E T T E R T O O U R S H A R E H O L D E R S
helped him to find a primary care physician and
Cigna’s ability to develop new digital platforms that
outpatient cardiologist, and to build a fitness regimen.
meet localized needs.
> After being diagnosed with colon cancer, and then
suffering from a heart attack which put him in the
intensive care unit soon after, Robert Harrison took
time off from work to heal. During his recovery, a Cigna
vocational coach worked closely with Robert to create
a personalized “recovery plan” to rebuild his strength
and stamina. His Cigna coach also connected him with
a trainer from Achilles International – an organization,
sponsored by Cigna – which helps people with disabilities
and other ailments to participate in mainstream
athletics. Robert has since completed Achilles running
events and is leading an active and healthy life.
Katherine, Shawn and Robert are three people with
different challenges and definitions of well-being. We
ultimately helped them to meet their needs, and to
achieve greater health outcomes through personalized,
individualized solutions which mobilized employer,
health care provider and community relationships.
BUILDING ON SUCCESS AND CHARTING OUR FUTURE
We updated our successful “Go” strategy in 2017 to
better address evolving market conditions and the
needs of our customers and other stakeholders.
Go Deeper drives Cigna to expand and deepen our
customer, client and partner relationships, while also
intensifying our depth in targeted sub-segments and
geographies.
These efforts range from our collaborative physician
relationships, to our continued growth for our One
Guide® service, which helps our customers make more
informed and more personalized health care choices.
We anticipate doubling our number of One Guide
customers to four million in 2018.
Go Local intensifies our efforts to ensure our solution
suite and services meet customer, client and partner
needs at a local market level – as recently exemplified
by our 2017 acquisitions of Zurich Middle East
and Brighter, one of health care’s most innovative
technology companies, which further accelerated
And Go Beyond means we’ll further innovate and
differentiate our business, the experiences we deliver
and – consistent with Cigna’s emphasis on community –
the overall social impact we have. We’ll do this through
efforts such as our Community Ambassador Fellowship
Program; Cigna was proud to grant nine community
ambassador fellowships in 2017.
LOOKING FORWARD TO 2018 AND BEYOND
As we look ahead to 2018 and beyond, we will continue
creating strong value for our customers, clients,
partners, and, as a result, our shareholders, through
our consistent focus on delivering affordable and
personalized products, services and solutions, as well
as through collaborating with health care professionalss
to help ensure our customers receive access to quality
affordable health care.
Additionally, each of our four growth platforms remain
well-positioned for sustained growth, and we continue
to have a tremendous capital position – giving us
the confidence to recently enhance our long-term
Earnings Per Share8 target to $18 per share by 2021,
resulting in a compounded growth rate at the high
end of our strategic target of 10%–13%, and building
on the prior five years where we also achieved the
high end of this range.
Thank you for your continued confidence and investment
in Cigna. We’re excited about the future, and remain
driven by our unwavering mission of helping to improve
the health, well-being and sense of security of those we
serve around the world – coupled with an unrelenting
commitment to help unleash the unique potential of
every human being we have the opportunity to serve.
David M. Cordani
President and Chief Executive Officer
Cigna Corporation
8. We use the term adjusted income from operations and earnings per share on this same basis as our principal measures of financial performance. Adjusted income (loss) from operations, defined on page 35 of our Form
10-K, is a measure of profitability used by Cigna’s management because it presents the underlying results of operations of Cigna’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net
income. This consolidated measure is not determined in accordance with accounting principles generally accepted in the United States (GAAP) and should not be viewed as a substitute for the most directly comparable GAAP
measure, shareholders’ net income. Management is not able to provide a reconciliation to shareholders’ net income (loss) on a forward-looking basis because we are unable to predict, without unreasonable effort, certain
components thereof including (i) future net realized investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control.
7
R E CO G N I Z I N G A N D R E WA R D I N G
CO L L E AG U E S WO R L DW I D E
As Cigna looks forward to the next
chapter in its 225-year history, the
company made a special one-time
global stock award of five shares to
employees worldwide. The stock award
recognized the passion and commitment
of Cigna employees during a dynamic
and disruptive environment over the past
several years. The stock award represents
an investment in employees’ futures and
promotes an ownership mentality that
fuels our ability to support and change
our customers’ lives for the better.
Additionally, to support employees in
balancing work and life demands, Cigna
launched a Caregiver Leave Program,
a new benefit for U.S. employees that
offers up to four weeks of paid leave for
employees caring for others, including
child bonding, care for a seriously ill
family member or qualifying military
E
L
P
O
E
P
8
support. Cigna also ensured that in all
countries where it operates outside the
United States, employees have a minimum of
12 weeks of full paid maternity leave, and four
weeks of paid paternity and adoption leave.
Invested in our
employees’
futures.“
Cigna also introduced the Community
Ambassador Fellowship program, which
offers eligible employees an opportunity
to take a sabbatical-style paid leave
from work to improve life in communities
where they work and live by supporting
projects that exemplify Cigna’s mission.
Program participants are selected
through a competitive application
process for a one- to three-month
fellowship, and receive full salary and
benefits plus a stipend to support their
community work.
Together, the global stock award and new
benefits signal Cigna’s pride in its employees’
continued high level of performance in a
challenging environment. We’re investing
in a bright future for Cigna, our employees
and the people we serve around the world.
CIGNA RATED A TOP EMPLOYER FOR
DIVERSITY AND INCLUSION
Cigna was recognized as a top employer
for its diversity and inclusion practices and
policies, including its hiring and support of
military veterans. Cigna was designated as a
Military Friendly® Employer by Victory Media,
which provides its list of Military Friendly
Employers to service members and their
families, helping them discover post-military
career opportunities. Companies that have
earned this designation are deemed to have
exceptionally strong hiring programs and
meaningful jobs for transitioning service
members, veterans and spouses.
Companies and organizations earning the
Military Friendly Employer designation are
evaluated using publicly available data from
federal agencies, personal opinion data from
veteran employees and proprietary Military
Friendly survey data from participating
organizations. Cigna also has received multiple
recognitions from Military Times magazine for
being a “Best for Vets” employer.
Additionally, for the sixth year in a row,
Cigna scored a perfect 100 on the Human
Rights Campaign’s Corporate Equality
Index (CEI) and has been recognized by
the HRC Foundation as one of the “Best
Places to Work for LGBTQ Equality.” The
CEI evaluates LGBTQ-related policies and
practices including nondiscrimination
workplace protections, domestic partner
benefits, transgender-inclusive health care
benefits, competency programs, and public
engagement with the LGBTQ community.
Cigna’s commitment to a diverse workforce
runs deep, and includes Colleague Resource
Groups within the company to focus on
the needs of employees as well as those of
diverse customers.
RECOGNIZED BY HRC FOUNDATION
FOR THE SIXTH YEAR IN A ROW,
AS ONE OF THE
CIGNA SCORED A
BEST PLACES
TO WORK
FOR LGBTQ EQUALITY
PERFECT 100
ON THE HUMAN RIGHTS CAMPAIGN’S
CORPORATE EQUALITY INDEX
9
TV DOCTORS HELP CIGNA SAVE
LIVES THROUGH PREVENTIVE CARE
Cigna’s TV Doctors of America campaign
used an ensemble of familiar TV doctors
to promote annual check-ups as a way
to improve an individual’s health and
encourage a dialogue with his or her health
care provider. Actors Patrick Dempsey,
Neil Patrick Harris, Kate Walsh and Donald
Faison donned scrubs and white coats to
take on this role with Cigna. The TV doctors
appeared in a multimedia platform including
television, digital and social channels, using
their star power to help influence consumers
to go get their annual check-ups, know their
key health numbers for blood pressure,
cholesterol, blood sugar and body mass
index (BMI), and take control of their health.
Cigna’s goal is to help save 100,000 lives
a year, the number of lives the Centers
for Disease Control and Prevention (CDC)
estimates would be saved if everyone
received his or her recommended
preventive care.9 The campaign
encourages all consumers to get their
annual check-up – which most U.S. health
plans cover at 100% as part of a suite of
preventive services.10
TV doctors.
Real-life goal:
To help save
100,000 lives.“
9. Source: CDC Prevention Checklist, Centers for Disease Control and Prevention, 2015; http://www.cdc.gov/prevention/
10. Plans may vary. Includes eligible in-network preventive care services. Some preventive care services may not be covered, including most immunizations for travel. Reference plan documents for
a list of covered and non-covered preventive care services.
E
S
O
P
R
U
P
10
HEALTH IMPROVEMENT TOUR DELIVERS
10,000+ SCREENINGS NATIONWIDE IN 2017
Cigna’s Go. Know. Take Control.® Health
Improvement Tour (HIT) delivers free health
screenings and health coaching, reaching
individuals who may not have access to care
through traditional means, and regardless
of whether they are Cigna customers. The
Cigna Foundation arm of the HIT brings free
screenings to our nonprofit partners. This
aspect of the HIT is supported by a generous
grant from the Cordani Family Foundation.
The HIT represents an opportunity to make
a difference – connecting with communities
on the importance of preventive health care.
The program is helping to uncover health
issues for people who may be unaware of
their risks, meeting people where they are
and engaging them in managing their health.
This initiative delivers biometric screenings
for blood pressure, cholesterol, blood sugar
and body mass index in cities across the
11. Cigna Internal Health Equity Data.
country. Cigna has helped participants
become aware of their numbers and
counseled people on how to follow up and
seek medical support.
LEADING THE WAY IN HEALTH EQUITY
Cigna was awarded the Innovation in
Advancing Health Equity Award by the
National Business Group on Health for the
second consecutive year.
New initiatives addressing health disparities
included several personalized programs
that made it easier for customers to better
engage with their providers and the health
care system, resulting in improvements
in health assessments and screenings –
including an 84.7% increase in colorectal
screening rates for Hispanic customers
enrolled in Cigna’s Individual and Family
Plans in Texas and Colorado.11
Additionally, health disparity training
and resources were expanded. More
11
than 5,000 Cigna staff completed the
new internal cultural competency learning
series, and 1,000 providers completed the
external cultural competency training.12
CIGNA CONNECTS RECOGNIZED
FOR COMMITMENT TO CORPORATE
RESPONSIBILITY
To achieve Cigna’s mission of helping to
improve the health, well-being and sense of
security of the people we serve, we work to
create connections that earn trust through
responsible business practices, targeted
corporate citizenship programs and our
commitment to providing superior services
that meet the unique needs of the individuals
we serve.
In 2017, Cigna was named to the Dow Jones
Sustainability Indices, with recognition from
the Dow Jones Sustainability World Index and
the Dow Jones Sustainability North America
Index. Cigna’s score of 78 placed the company
in the leading position within the Health Care
Providers & Services industry sector, where the
industry average score was 35. Cigna scored
in the 95th percentile in its industry for the
Environmental Dimension and in the 100th
percentile in its industry for the Economic and
Social Dimensions.13
12. Cigna Internal Health Equity Data.
13. Dow Jones Sustainability Indices. www.robecosam.com/images/170907-djsi-review-2017-en-vdef.pdf
95TH
PERCENTILE
FOR THE ENVIRONMENTAL DIMENSION
12
Cigna Connects, our approach to corporate
responsibility, supports our mission by
making powerful connections that positively
impact the health of people, communities and
the environment, and by working more closely
with our stakeholders on these topics. We
publish our annual Cigna Connects Corporate
Responsibility Report to communicate our
progress toward our environmental, social
and governance objectives. Our most recent
report was prepared in accordance with the
new Global Reporting Initiative Standards
and includes a GRI Index to assist our
stakeholders in locating corporate
responsibility topics of interest.
Also, as a signatory of the United Nations
Global Compact (UNGC), we communicate
our progress and activities with respect to
the Compact’s 10 principles on human rights,
labor, environment and anti-corruption within
our report. We also provide a UNGC Index
for ease of locating our reporting on these
topics as well as a section discussing our
work to align efforts with the UN Sustainable
Development Goals.
In our latest report, we highlight the key
issues our Cigna Connects platform centered
on; health and well-being, the environment
and inclusive business. For each issue area,
we identified the specific initiatives that
demonstrate how we work to address these
complex social challenges.
100TH
PERCENTILE
FOR THE ECONOMIC AND
SOCIAL DIMENSIONS
13
CIGNA IN THE COMMUNITY
Some of our 2017 World of Difference
nonprofit partners include the Iraq and
Afghanistan Veterans of America, Bright
Star in Chicago, helping to support trauma
counseling for victims of violence; St.
Vincent’s Hospital in Montana, improving the
health of Native American women who are
pregnant and their infants; the University of
Miami, helping to prevent cervical cancer
among the women of Little Haiti; Miles for
Smiles dental clinic in Tennessee; Healthy
Kids Express asthma clinic in St. Louis; and
the Ghetto Film School in New York City,
supporting young filmmakers in highlighting
community health challenges and how
the Cigna Foundation is helping nonprofit
partners improve health in those communities.
In addition to major grants, the Cigna
Foundation also supported the Global
Workplace Wellness Summit in Singapore,
focused on duty of care for non-governmental
organizations; disaster relief through packing
meals with Feeding Children Everywhere.
INVESTED IN COMMUNITIES THROUGH CIGNA U.S. FOUNDATION GIVING, CIGNA U.S CORPORATE GIVING,
CIGNA EMPLOYEE GIVING AND LINA KOREA/THE KOREA FOUNDATION14
$21M+
14. Cigna Civic Affairs Data.
14
Among its many nonprofit partners, the Cigna Foundation
supports a University of Maryland program to train barbers in
talking to customers about health prevention; the Miles for Smiles
Dental Clinic in Tennessee; and Feeding Children Everywhere.
57,751
CIGNA EMPLOYEE VOLUNTEER HOURS
LOGGED BY OUR EMPLOYEES.14
336,000
MEALS FOR HURRICANE VICTIMS IN PUERTO
RICO; AND HOLIDAY GIFT CARDS PROVIDED TO
HURRICANE VICTIMS IN TEXAS.
14. Cigna Civic Affairs Data.
15
TAC K L I N G T H E N AT I O N A L
O P I O I D E P I D E M I C
Cigna has been aggressively fighting the
opioid epidemic by reducing the use of
opioids among customers and collaborating
with physicians and other parties to find
workable solutions.
Cigna has committed to reducing the use
of prescribed opioids among customers by
15. Number of signed pledges received by Cigna for Performance Measurement and Improvement.
25% by 2019, while still providing the right
care at the right time. More than 65,270
doctors,15 through their medical groups,
signed Cigna’s pledge to reduce opioid
prescriptions and treat opioid use disorders
as chronic conditions. And Cigna reached
out to 2,600 prescribers of high-dosage
opioid medications to ensure the dosage of
the opioid medications were appropriate,
medically necessary and safe for the patient.
16
H E L P I N G V E T E R A N S F I G H T
H E A LT H C H A L L E N G E S
Cigna is helping veterans overcome challenges
– including opioid addiction. Many veterans
struggle as they transition back to civilian
life and face chronic pain, post-traumatic
stress disorder, depression and other health
conditions that contribute to the use, and
misuse, of painkillers. The opioid epidemic
has hit veterans harder than other population
groups, with veterans 10 times more likely to
misuse opioids than average Americans.16
While many resources exist to help vets, in
some cases waiting lists and social barriers,
such as feeling embarrassed to seek
assistance, prevent vets from getting the help
they need. Cigna is taking a leadership role in
addressing the unique needs of veterans and
introduced a free national Veteran Support
Line, available 24/7/365 days a year to all
veterans, their families and caregivers, whether
or not the veteran is a Cigna customer. The
support line, available at 855.244.6211, gives
veterans access to services and resources for
pain management, substance use counseling
and treatment, PTSD, and many other needs
related to housing, employment, financial
assistance, family issues and more.
In addition, Cigna also is now offering a weekly
Mindfulness for Vets session, exclusively for
veterans, to help them manage pain and stress
more effectively.
“
They answered
our country’s call.
Now we’re here to
answer theirs.
Cigna views veterans as an important part of
its global team, and commits approximately
10% of its annual recruitment budget in the
United States to recruit veterans and their
spouses. We will continue to look for ways to
give back to those individuals who served and
protected our country.
16. https://www.psychologytoday.com/blog/invisible-wounds/201701/va-says-68000-
vets-addicted-opioid-painkillers
17
Accountable Care Program
Specialist Program
Hospital Program
Delivery system joint venture
MAPPING THE FUTURE OF HEALTH CARE
Cigna is creating the future of health care
through offering greater affordability
and better quality in health care. To
achieve this goal, we reward providers
for the quality of care they deliver, and
the health outcomes they achieve for
patients, as we shift from traditional
fee-for-service reimbursement models to
value-based partnerships.
For the last decade in Cigna’s
Commercial business, and 20 years in the
17. Cigna Internal Company document, National Cigna Collaborative Care Execution report for December 2017.
Greater
affordability.
Better quality
of care.“Cigna-HealthSpring business, we have
focused on collaborative care or aligned
value-based relationships. Today, Cigna
is proud to have approximately 500
of those relationships up and running,
spanning over 30 states.17
500
VALUE-BASED RELATIONSHIPS
UP AND RUNNING
SPANNING OVER
30 STATES
E
C
N
A
M
R
O
F
R
E
P
18
A B R I G H T E R F U T U R E F O R
D I G I TA L C A PA B I L I T I E S
Cigna acquired Brighter Inc.®, a digital
health plan platform leader to enable Cigna
to accelerate and expand its consumer
initiatives and provider partnerships.
Brighter is a technology company that is
working with leading health service and
dental organizations to engage patients and
providers in personalized and seamlessly
integrated experiences to more efficiently
deliver higher-value health care.
The acquisition accelerates Cigna’s
development of mobile and desktop
platforms and the creation of new end-
to-end experiences that connect health
consumers and providers with the guidance,
support and incentives they need to increase
quality of care and maximize cost savings.
Brighter provides Cigna with the
technology, consumer expertise and
speed-to-market capabilities necessary
for the ongoing and critical digital
transformation of health plans. These
capabilities enable consumers to more
regularly and confidently engage with the
plans, providers and wellness programs
that are best able to improve health while
reducing costs.
In addition, providers gain more
cost-efficient ways to provide quality
services by leveraging reduced marketing,
administrative and patient-engagement
expenses, while employer plan sponsors
benefit from population health management
and data-driven recommendations for
ongoing improvements.
19
O N E G U I D E : T H E P OW E R O F D I G I TA L
CO M B I N E D W I T H A H U M A N TO U C H
Cigna One Guide® combines the power
and convenience of an interactive digital
solution with the human touch of a live
person to deliver Cigna’s personalized
service experience. It is designed to support
customers in the optimal use of their benefits
and is uniquely able to proactively connect
customers with health services, tools and
resources they need to achieve better health
outcomes and cost savings.
Cigna One Guide provides customers the
personalized service they need to navigate
a confusing health care system, while
getting the most value from their health care
investment. One Guide is increasing health
engagement by making it easier for customers
to connect with, and use, their health plan
benefits and resources, such as a family health
care provider team, and health and wellness
rewards programs.
One Guide can help improve health and lower
health spending by helping customers find
and choose the right care, at the right place,
for the right price; and get the most value
from their Cigna health plans.
For illustrative purposes only.
20
R E AC H I N G I N T E R N AT I O N A L M I L E S T O N E S
Cigna International brings decades of local experience and expertise in delivering health, well-being
and sense-of-security solutions around the world. Cigna’s mission and strategy are well suited to the
needs of customers and clients around the globe.
(1) Increased its
footprint in the
Middle East after the
successful acquisition
of Zurich Insurance
Middle East.
(2,3) Launched
Cigna Global Health
Indonesia and
Dubai Healthguard.
(4) Introduced
our new DiaMedic
product in Hong
Kong, addressing
the growing
number of patients
with diabetes.
(5) Introduced a
suite of important
products in
South Korea
that specifically
address seniors.
1
3
5
4
2
In addition, the launch of the 2017 Cigna
360° Well-being Survey won a Public Affairs
Asia Gold Standard Award for Best Financial
Communications Campaign of the Year.
We also had cause for celebration when the
U.K.’s Virtual Health app won Best Technology
Provider 2017 at the annual Workplace
Savings & Benefits (WS&B) awards.
In South Korea, the company achieved
the highest ROE in the industry and grew
sales by double digits where the industry
experienced negative growth.18 South Korea
also introduced LINA Bot, a digital customer
and agent service, while the Next Generation
System was rolled out successfully.
18. Cigna competitive analysis in South Korea.
And we contributed to the communities in
which we operate, through local Corporate
Social Responsibility efforts that included full
participation by all our markets as we came
together on September 29 to support World
Heart Day for Cigna.
21
3/7/18 6:59 AM
912978_2017AR_Narrative_v17_3_6_sl_Final.indd 27
CIGNA IN PERSPECTIVE
Global Health Care includes
a commercial line of business
encompassing the United
States and certain international
operations. Commercial offers
a broad line of insured and
self-insured medical, dental,
behavioral health, vision,
prescription drug benefit plans,
health advocacy programs and
other products and services
that may be integrated to
provide comprehensive global
health care benefit programs to
employers and their employees,
and individuals, including globally
mobile individuals.
Global Health Care also includes
a government line of business
that offers Medicare Advantage,
Medicare Part D and Medicaid
plans for Medicare- or Medicaid-
eligible individuals, primarily
seniors. A significant portion
of our Medicare Advantage
customers are served by health
care providers in innovative plan
models, designed to improve
health outcomes and lower
medical costs. Cigna offers
Medicare Advantage plans in
17 states and the District of
Columbia, Medicare Part D plans
in all 50 states and the District of
Columbia, and Medicaid plans in
select markets in Texas.
Global Supplemental Benefits
offers supplemental health, life
and accident insurance products
in select international markets
and the United States. With
licenses and partnerships across
Asia-Pacific, Europe and North
America, Cigna offers products
and services to local citizens and
globally mobile individuals. Global
Supplemental Benefits also offers
Medicare Supplement coverage.
Group Disability and Life
provides insurance products
and related services for group
long- and short-term disability
insurance, group life insurance,
and accident and specialty
insurance. Cigna markets
products in all 50 states, the
District of Columbia, Puerto Rico,
the United States Virgin Islands
and Canada. Group Disability
programs are designed to help
improve employee productivity
and lower employers’ overall
absence costs. Products are
coupled with comprehensive
tools and services for easy
benefit management.
22
GLOBAL HEALTH CARE
BY LINE OF BUSINESS
75% COMMERCIAL
25% GOVERNMENT
25%
Government
PREMIUMS AND FEES
IN MILLIONS
$29,041
75%
Commercial
4%
U.K.
7%
Taiwan
GLOBAL SUPPLEMENTAL
BENEFITS BY COUNTRY
51% SOUTH KOREA
23% UNITED STATES
15% OTHER
7% TAIWAN
4% U.K.
15%
Other
PREMIUMS AND FEES
IN MILLIONS
$3,707
51%
South Korea
23%
United States
6%
Other
GROUP DISABILITY
AND LIFE BY PRODUCT
51% DISABILITY
43% LIFE
6% OTHER
PREMIUMS AND FEES
IN MILLIONS
43%
Life
$4,088
51%
Disability
23
CORPORATE AND BOARD OF DIRECTORS
BOARD OF DIRECTORS
Isaiah Harris, Jr.
Independent Chairman
of the Board, Former President
and Chief Executive Officer
AT&T Advertising and Publishing –
East, a communications
services company
David M. Cordani
President and
Chief Executive Officer
Cigna Corporation
Eric J. Foss
Chairman, President and
Chief Executive Officer
ARAMARK Corporation,
a provider of food services,
facilities management and
uniform services
Jane E. Henney, MD
Former Senior Vice President,
Provost and Professor of Medicine
University of Cincinnati College of
Medicine, an educational institution
Roman Martinez IV
Private Investor
John M. Partridge
Former President
Visa Inc., a consumer
credit company
James E. Rogers
Former Chairman, President
and Chief Executive Officer
Duke Energy Corporation,
an electric power company
Eric C. Wiseman
Former Executive Chairman,
President and Chief Executive Officer
VF Corporation, an apparel
and footwear company
Donna F. Zarcone
President and Chief Executive Officer
The Economic Club of Chicago, a civic
and business leadership organization
William D. Zollars
Former Chairman, President
and Chief Executive Officer
YRC Worldwide Inc., a transportation
and related services holding company
BOARD OF DIRECTORS EXECUTIVE COMMITTEE
PEOPLE RESOURCES
Isaiah Harris, Jr.
Chair
David M. Cordani
Jane E. Henney, MD
Roman Martinez IV
John M. Partridge
William D. Zollars
AUDIT COMMITTEE
Roman Martinez IV
Chair
Jane E. Henney, MD
James E. Rogers
Donna F. Zarcone
COMMITTEE
William D. Zollars
Chair
Eric J. Foss
John M. Partridge
Eric C. Wiseman
EXECUTIVE OFFICERS
David M. Cordani
President and
Chief Executive Officer
Lisa R. Bacus
Executive Vice President
and Chief Marketing and
Customer Officer
CORPORATE GOVERNANCE
Mark L. Boxer
COMMITTEE
Jane E. Henney, MD
Chair
Eric J. Foss
Donna F. Zarcone
William D. Zollars
FINANCE COMMITTEE
John M. Partridge
Chair
Roman Martinez IV
James E. Rogers
Eric C. Wiseman
Executive Vice President and
Chief Information Officer
Brian Evanko
President, Government
Business
Christopher Hocevar
President, Strategy,
Segments and Solutions
Nicole S. Jones
Executive Vice President
and General Counsel
Alan M. Muney, MD, MHA
Executive Vice President
Total Health & Network and
Chief Medical Officer
John M. Murabito
Executive Vice President
Human Resources and Services
Eric Palmer
Executive Vice President
and Chief Financial Officer
Jason D. Sadler
President, International Markets
Michael Triplett
President, U.S. Markets
OTHER OFFICERS
Neil Boyden Tanner
Vice President, Chief Counsel
and Corporate Secretary
Timothy D. Buckley
Vice President and Treasurer
Mary T. Agoglia Hoeltzel
Vice President and
Chief Accounting Officer
2018 ANNUAL MEETING
CIGNA HEALTH AND LIFE
DIRECT DEPOSIT OF DIVIDENDS
Wednesday, April 25 at 8:00 am
Delamar Hotel
1 Memorial Road
West Hartford, CT 06107
INSURANCE COMPANY
900 Cottage Grove Road
Bloomfield, CT 06002
860.226.6000
Proxies and proxy statements
have been made available
to shareholders of record
as of February 26, 2018. On
December 31, 2017, there were
5,618 common shareholders
of record.
FINANCIAL INFORMATION
Cigna’s Form 10-K is available online
at Cigna.com. For a copy of Cigna’s
quarterly earnings’ news releases,
visit our website at Cigna.com and
click on “News.”
OFFICES AND PRINCIPAL
SUBSIDIARIES
Cigna Corporation
900 Cottage Grove Road
Bloomfield, CT 06002
860.226.6000
and
Two Liberty Place
1601 Chestnut Street
Philadelphia, PA 19192-1550
215.761.1000
CONNECTICUT GENERAL
LIFE INSURANCE COMPANY
900 Cottage Grove Road
Bloomfield, CT 06002
860.226.6000
LIFE INSURANCE COMPANY
OF NORTH AMERICA
Two Liberty Place
1601 Chestnut Street
Philadelphia, PA 19192-1550
215.761.1000
DIRECT STOCK PURCHASE PLAN
Shareholders can automatically
reinvest their annual dividends and
make optional cash purchases of
common shares. For information
on these services, please contact:
Computershare
PO Box 505000
Louisville, KY 40233-5000
Toll-free: 800.760.8864
Outside U.S., U.S. territories
and Canada: 201.680.6578
Website:
Computershare.com/investor
SHAREHOLDER ACCOUNT ACCESS
You can access your Cigna
shareholder account online through
the Computershare website:
Computershare.com/investor
Or, call 800.760.8864
Direct deposit of dividends provides
a prompt, efficient way to have your
dividends electronically deposited
into your checking or savings
account. It avoids the possibility of
lost or delayed dividend checks.
The deposit is made electronically
on the payment date. For more
information and an enrollment
authorization form, contact
Computershare at 800.760.8864,
or outside the U.S., U.S. territories
and Canada at 201.680.6578. You
can access your account online
through the Computershare website:
Computershare.com/investor.
STOCK LISTING
Cigna’s common shares are listed
on the New York Stock Exchange.
The ticker symbol is CI.
TRANSFER AGENCY
By regular mail:
Computershare
PO Box 505000
Louisville, KY 40233-5000
By overnight delivery:
Computershare
462 South 4th Street
Suite 1600
Louisville, KY 40202
Toll-free: 800.760.8864
Outside U.S., U.S. territories
and Canada: 201.680.6578
TDD: 800.231.5469
Website:
Computershare.com/investor
CIGNA ONLINE
To access online information about
Cigna, our products and services,
visit Cigna.com
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One) (cid:2) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(cid:2) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017
OR
For the transition period from
to
Commission file number 1-8323
29OCT201118203261
CIGNA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
900 Cottage Grove Road, Bloomfield, Connecticut
(Address of principal executive offices)
06-1059331
(I.R.S. Employer Identification No.)
06002
(Zip Code)
(860) 226-6000
Registrant’s telephone number, including area code
(860) 226-6741 or (215) 761-5511
Registrant’s facsimile number, including area code
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
Title of each class
Name of each exchange on which registered
Common Stock, Par Value $0.25
New York Stock Exchange, Inc.
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
NONE
Indicate by check mark
•
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
•
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K
No
(cid:2)
(cid:2)
(cid:2)
(cid:2)
Yes
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
•
•
•
•
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company’’ and ‘‘emerging growth
company’’ in Rule 12b-2 of the Exchange Act.
Large accelerated filer (cid:2)
Non-accelerated filer (cid:2)
Accelerated filer (cid:2)
Smaller reporting company (cid:2)
Emerging growth company (cid:2)
•
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
•
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
(cid:2)
(cid:2)
(cid:2)
The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2017 was approximately $42.2 billion. As of
January 31, 2018, 242,875,357 shares of the registrant’s Common Stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this Form 10-K incorporates by reference information from the registrant’s definitive proxy statement related to the 2018 annual
meeting of shareholders.
Table of Contents
FREQUENTLY REQUESTED 10-K INFORMATION
Risk Factors .................................................................................................................................................
Executive Overview...................................................................................................................................
Health Care Industry Developments....................................................................................................
Liquidity and Capital Resources ...........................................................................................................
Critical Accounting Estimates................................................................................................................
Segment Information................................................................................................................................
Revenues by Product Type.....................................................................................................................
Page
21
35
40
41
44
105
107
Page
CAUTIONARY STATEMENT
PART I
Item 1.
Business
.
.
.
.
.
.
.
.
Overview
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Investments and Investment Income
Regulation
Miscellaneous
............................................................................................................................
1
................................................................................................................
3
..................................................................................................
10
........................................................................................................
12
.................................................................................................................
14
..........................................................................................
14
.........................................................................................................................
15
....................................................................................................................
20
Item 1A. Risk Factors..................................................................................................................................................................21
Item 1B. Unresolved Staff Comments ................................................................................................................................. 30
Properties.................................................................................................................................................................... 30
Item 2.
Legal Proceedings.................................................................................................................................................... 30
Item 3.
Item 4. Mine Safety Disclosures.......................................................................................................................................... 30
EXECUTIVE OFFICERS OF THE REGISTRANT....................................................................................................................31
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases
of Equity Securities...................................................................................................................................................32
Selected Financial Data.......................................................................................................................................... 34
Item 6.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations ............35
Item 7A. Quantitative and Qualitative Disclosures about Market Risk..................................................................... 56
Financial Statements and Supplementary Data..............................................................................................57
Item 8.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ........109
Item 9A. Controls and Procedures ......................................................................................................................................109
Item 9B. Other Information....................................................................................................................................................109
PART III
Page
Item 10. Directors, Executive Officers and Corporate Governance..........................................................110
110
110
110
110
Item 11. Executive Compensation..........................................................................................................110
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related
....................................................................................................
.........................................................................................
...........................................................
..............................................................
Directors of the Registrant
Executive Officers of the Registrant
Code of Ethics and Other Corporate Governance Disclosures
Section 16(a) Beneficial Ownership Reporting Compliance
A.
B.
C.
D.
Stockholder Matters ................................................................................................................................................. 111
Item 13. Certain Relationships and Related Transactions, and Director Independence ..................................... 111
Item 14. Principal Accountant Fees and Services............................................................................................................ 111
PART IV
Item 15. Exhibits and Financial Statement Schedules ............................................................................ 112
10-K Summary ......................................................................................................................... 115
Item 16.
SIGNATURES ................................................................................................................................................................................. 116
INDEX TO FINANCIAL STATEMENT SCHEDULES......................................................................................................... FS-1
EXHIBITS.........................................................................................................................................................................................E-1
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are based on Cigna’s current expectations and projections about future trends, events and uncertainties.
These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or
operating performance, including our ability to deliver personalized and innovative solutions for our customers and clients; future growth,
business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace
and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for
growth in the coming years; and other statements regarding Cigna’s future beliefs, expectations, plans, intentions, financial condition or
performance. You may identify forward-looking statements by the use of words such as ‘‘believe,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘intend,’’ ‘‘anticipate,’’
‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘may,’’ ‘‘should,’’ ‘‘will’’ or other words or expressions of similar meaning, although not all forward-looking
statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ
materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our
ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price
effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications
to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such
transactions; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in
existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and/or guaranty fund assessments;
uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our
information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency
movements; acts of war, terrorism, natural disasters or pandemics; as well as more specific risks and uncertainties discussed in Part I,
Item 1A – Risk Factors and Part II, Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of this
Form 10-K and as described from time to time in our future reports filed with the Securities and Exchange Commission (the ‘‘SEC’’).
You should not place undue reliance on forward-looking statements that speak only as of the date they are made, are not guarantees of future
performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no
obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may
be required by law.
PART I
ITEM 1. Business
PART I
ITEM 1.
Business
Overview
Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as ‘‘Cigna,’’ the ‘‘Company,’’ ‘‘we,’’ ‘‘our’’ or ‘‘us’’)
is a global health services organization dedicated to a mission of helping individuals improve their health, well-being and sense of security.
Since 2009, our strategy in support of our mission has been to ‘‘Go Deep, Go Global and Go Individual’’. To further accelerate the differentiated
value we deliver for our customers, clients, partners and communities, we have evolved this strategy in order to expand avenues for growth and
performance. Cigna’s evolved strategy is to ‘‘Go Deeper’’, ‘‘Go Local’’ and ‘‘Go Beyond’’.
To improve the health, well-being and sense of security of the people we serve
Our Mission
Our Strategy
Go Deeper: To expand and deepen our customer, client and partner relationships; depth in targeted
sub-segments, geographies
Go Local: To ensure our solution suite and services meet customer, client and partner needs at a
local market level
Go Beyond: To innovate and further differentiate our businesses, the experiences we deliver, and
overall social impact
How We Will Win
Affordability
Personalization
Be the
Undisputed
Partner of
Choice
Accelerating
Next
Generation
Integration
Make the
Complex
Simpler
Customer
Value
21FEB201816080645
We execute on this strategy with a differentiated set of medical, pharmacy, behavioral, dental, disability, life and accident insurance and related
products and services offered by our subsidiaries.
In an increasingly retail-oriented marketplace, we focus on delivering affordable and personalized products and services to customers
through employer-based, government-sponsored and individual coverage arrangements. We increasingly collaborate with health care
providers to continue the transition from volume-based fee for service arrangements toward a more value-based system designed to increase
quality of care, lower costs and improve health outcomes. We operate a customer-centric organization enabled by keen insights regarding
customer needs, localized decision-making and talented professionals committed to bringing our ‘‘Together All the Way’’ brand promise to
life.
CIGNA CORPORATION - 2017 Form 10-K 1
PART I
ITEM 1. Business
In particular, over the past several years, to achieve the goals of better health, affordability, localization and an improved experience for the
customer, we have continued expanding our participation in collaborative care and other delivery arrangements with health care professionals
across the care delivery spectrum, including large and small physician groups, specialist groups and hospitals. More recently, we have
developed innovative tools and flexible provider arrangements that provide a truly personalized customer experience. These arrangements
and tools are discussed in more detail in the ‘‘Global Health Care’’ section of this Annual Report on Form 10-K (‘‘Form 10-K’’) beginning on
page 3.
We present the financial results of our businesses in the following three reportable segments:
Global Health Care aggregates the Commercial and Government operating segments.
•
The Commercial operating segment encompasses both the U.S. commercial and certain international health care businesses serving
employers and their employees, other groups, and individuals. In this segment, we refer to employer or other groups as the ‘‘client’’ and the
individual as the ‘‘customer.’’ Products and services include medical, dental, behavioral health, vision, and prescription drug benefit plans,
health advocacy programs and other products and services to insured and self-insured customers.
•
The Government operating segment offers Medicare Advantage and Medicare Part D plans to seniors as well as Medicaid plans.
Global Supplemental Benefits offers supplemental health, life and accident insurance products in selected international markets and in the
United States.
Group Disability and Life provides group long-term and short-term disability, group life, accident and specialty insurance products and related
services.
Financial Results for the year ended and as of December 31, 2017 (in billions)
Consolidated basis:
Total revenues
Operating revenues (1)
Total assets
Reportable segments’ results: (2)
Operating revenues (1)
$ 41.6
$ 41.4
$ 61.8
Consolidated basis:
Shareholders’ net income
Adjusted income from operations (1)
Total shareholders’ equity
Reportable segments’ results: (2)
$40.9
Adjusted income from operations (1)
$ 2.2
$ 2.7
$ 13.7
$ 2.8
(1) See page 35 for the definition of these metrics.
(2) Global Health Care, Global Supplemental Benefits and Group Disability and Life segments
Operating Revenue by Segment %
Adjusted Income from Operations by Segment %
11%
9%
10%
13%
80%
77%
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Global Health Care
Global Supplemental Benefits
Group Disability and Life
21FEB201813420426
We present the remainder of our segment results in Other Operations, consisting of the corporate-owned life insurance business (‘‘COLI’’),
run-off reinsurance and settlement annuity businesses and deferred gains associated with the sales of the individual life insurance and annuity
and retirement benefits businesses.
Our revenues are derived principally from premiums on insured products, fees from self-insured products and services, mail-order pharmacy
sales and investment income.
The ACA and Health Care Reform
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively referred to throughout this
Form 10-K as the ‘‘ACA’’ or ‘‘PPACA’’) continues to have a significant impact on our business operations. The future of the ACA is uncertain due
to congressional efforts to repeal and replace the ACA, various executive actions of the Trump administration, and repeal of the individual
mandate as part of H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal
Year 2018 (referred to throughout this Form 10-K as the ‘‘Tax Cuts and Jobs Act’’ or ‘‘U.S. tax reform legislation’’). The effects of the ACA, and
efforts to repeal and replace it, are discussed throughout this Form 10-K where appropriate, including in the Global Health Care business
description, Regulation, Risk Factors, Management’s Discussion and Analysis of Financial Condition and Results of Operations (‘‘MD&A’’), and
the Notes to the Consolidated Financial Statements.
2 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
Other Information
The financial information included in this Annual Report on Form 10-K for the fiscal year ended December 31, 2017 is in conformity with
accounting principles generally accepted in the United States of America (‘‘GAAP’’) unless otherwise indicated. Industry rankings and
percentages set forth herein are for the year ended December 31, 2017 unless otherwise indicated. In addition, statements set forth in this
document concerning our rank or position in an industry or particular line of business have been developed internally based on publicly
available information unless otherwise noted.
Cigna Corporation was incorporated in Delaware in 1981. Our annual, quarterly and current reports, proxy statements and other filings, and any
amendments to these filings, are made available free of charge on our website (http://www.cigna.com, under the ‘‘Investors – Quarterly
Reports and SEC Filings’’ captions) as soon as reasonably practicable after we electronically file these materials with, or furnish them to, the
Securities and Exchange Commission (the ‘‘SEC’’). We use our website as a channel of distribution for material company information.
Important information, including news releases, analyst presentations and financial information regarding Cigna is routinely posted on and
accessible at www.cigna.com. See ‘‘Code of Ethics and Other Corporate Governance Disclosures’’ in Part III, Item 10 beginning on page 110 of
this Form 10-K for additional available information.
Global Health Care
How We Win
•
Broad and deep portfolio of solutions across Commercial and Government operating segments
•
Committed to highest quality health outcomes and customer experiences
•
Collaborative physician engagement models emphasizing value over volume of services
•
Integrated solutions that deliver value for our customers, clients and partners
•
Technology powering actionable insights and affordable, personalized solutions
•
Talented and caring people embracing change and putting customers at the center of all we do
Products and Services
Funding Solutions
•
•
•
•
Medical
Stop Loss
Dental
Vision
•
•
•
Pharmacy
Behavioral
Health Advocacy and
Coaching
•
•
•
Medicare Advantage
Medicare Part D
Medicaid
•
•
•
Administrative Services
Only (ASO or
self-funded)
Insured – Guaranteed
Cost
Insured – Experience
Rated
Physician Engagement
Market Segments
Distribution Channels
•
•
•
•
Collaborative Accountable
Care Organizations
Independent Practice
Associations
CareAllies(cid:3)
Delivery System Alliances
•
•
•
•
•
•
National
Middle Market
Select
Individual
Government
International
•
•
•
•
•
Insurance brokers and
consultants
Cigna Sales representatives
Cigna private exchange
3rd party private exchanges
Public exchanges
We seek to differentiate ourselves in this business by providing innovative personalized and affordable health care benefit solutions to our
clients and customers. We sub-segment and target distinct buyer groups in a personalized and localized way. We focus on anticipating,
understanding, and meeting their needs and we will continue to drive growth by deepening our approach to consultative partnership,
accelerating the value of our integrated solutions, and enhancing the customer experience. As a leader in the drive to transition the health care
delivery system from volume-based reimbursements to a value orientation, our strategy is to accelerate our engagement with employers and
individuals in order to: 1) increase our customers’ involvement in their health care and 2) develop deep insights into customer needs. Our
differentiated approach to partnering with health care providers allows us to leverage information, incentives and care resources to help them
evolve towards value-based care delivery and improve the quality and affordability of care for our customers and clients.
Innovation is core to the way we do business and will be a critical factor to our success in the highly dynamic health care industry. We have
delivered innovative solutions that improve affordability and are more personalized, such as the Cigna One Guide(cid:3) program that combines a
state-of-the-art digital experience with a human concierge service; and the Cigna SureFit(cid:3) network that allows individual family members to
choose their personal care networks, consistent with their health needs and provider preferences.
CIGNA CORPORATION - 2017 Form 10-K 3
PART I
ITEM 1. Business
Principal Products and Services
Commercial Medical Health Plans – U.S. and International
The Commercial operating segment, either directly or through its partners, offers some or all of its products in all 50 states, the District of
Columbia, the U.S. Virgin Islands, Canada, Europe, the Middle East, Asia, Africa and Australia. We offer a variety of medical plans including:
•
•
•
•
Managed Care Plans including HMO, Network, Network Open Access and Open Access Plus. Through our insurance companies, Health
Maintenance Organizations (‘‘HMOs’’) and third party administrator (‘‘TPA’’) companies, we offer insured and self-insured indemnity and
managed care benefit plans that use meaningful cost-sharing incentives to encourage the use of ‘‘in-network’’ versus ‘‘out-of-network’’ health
care providers and provide the option to select a primary care physician. The national provider network for Managed Care Plans is somewhat
smaller than the national network used with the preferred provider (‘‘PPO’’) plan product line. If a particular plan covers non-emergency
services received from a non-participating health care provider, the customer’s cost-sharing obligation is usually greater for the
out-of-network care.
PPO Plans. Our PPO product line features a network with broader provider access than the Managed Care Plans. The preferred provider
product line may be at a higher cost than our Managed Care Plans.
Consumer-Driven Products. Cigna’s suite of consumer-driven products – health savings accounts (‘‘HSAs’’), health reimbursement accounts
(‘‘HRAs’’) and flexible spending accounts (‘‘FSAs’’) – are typically paired with a high-deductible medical plan and offer customers a
tax-advantaged way to pay for eligible health care expenses. The nature of these products encourages customers to play an active role in
managing their health and their health care costs. When integrated with a Cigna medical plan, we can deliver a seamless experience for our
customers and clients. More than three million customers have chosen one of these integrated product solutions.
Cigna Connect is an individual plan offered in markets within eight states. The product is comprised of a network of health care providers in a
geographic area who have been selected with cost and quality in mind. Customers who participate in the Connect network will receive care at
Cigna’s lower negotiated rates to help keep out-of-pocket costs down. Out-of-network coverage is not available except for urgent and
emergent care.
Approximately 90% of our commercial medical customers are enrolled in medical plans with either ASO or experience rated funding
arrangements that allow the corporate client to directly benefit from lower medical costs.
The funding arrangements available for our commercial medical and dental health plans are as follows:
Chart presents percentage of customers by
funding solution as of December 31, 2017.
ASO
Guaranteed Cost
Shared Returns
Funding Solutions: Commercial
ASO
•
Plan sponsors self-fund all claims, but may purchase
integrated stop loss insurance to limit exposure.
•
We collect fees from plan sponsors for providing access to
our participating provider network and for other services
and programs including: claims administration; behavioral
health; disease management; utilization management; cost
containment; dental; and pharmacy benefit management.
6%
13%
81%
21FEB201815523798
Insured – Experience Rated (‘‘Shared Returns’’ funding suite)
•
Premium rates are established at the beginning of a policy period and are typically based on prior claim experience of the policyholder.
The policyholder receives detailed claim and utilization reporting to understand actual plan costs and help make informed decisions
about future benefit plan design.
•
The policyholder participates, or shares in, favorable claim experience. When claims and expenses are less than the premium charged
(an ‘‘experience surplus’’ or ‘‘margin’’), the policyholder may be credited for a portion of this experience surplus/margin. If claims and
expenses exceed the premium charged (an ‘‘experience deficit’’), we bear these costs. In certain cases, experience deficits incurred
while the policy is in effect are accumulated and may be recovered through future policy year experience surpluses/margins.
Insured – Guaranteed Cost (‘‘Fully Insured’’)
Premium rates are established at the beginning of a policy period and, depending on group size, may be based in whole or in part on
•
prior experience of the policyholder or on a pool of similar policyholders. We generally cannot subsequently adjust premiums to reflect
actual claim experience until the next annual renewal.
•
The policyholder does not participate, or share in, actual claim experience. We keep any experience surplus/margin if costs are less than
the premium charged (subject to minimum medical loss ratio rebate requirements discussed below) and bear the risk for actual costs in
excess of the premium charged.
4 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
In most states, individual and group insurance premium rates must be approved by the applicable state regulatory agency (typically
department of insurance) and state or federal laws may restrict or limit the use of rating methods. Premium rates for groups and individuals are
subject to state review for reasonableness. In addition, the ACA subjects individual and small group policy rate increases above an identified
threshold to review by the United States Department of Health and Human Services (‘‘HHS’’) and requires payment of premium refunds on
individual and group medical insurance products if minimum medical loss ratio (‘‘MLR’’) requirements are not met. The MLR represents the
percentage of premiums used to pay medical claims and expenses for activities that improve the quality of care. In our individual business,
premiums may also be adjusted as a result of the government risk adjustment program that takes into account the relative health status of our
customers. See the ‘‘Regulation’’ section of this Form 10-K for additional information on the commercial MLR requirements and the risk
mitigation programs of the ACA.
Government Health Plans
Medicare Advantage
We offer Medicare Advantage plans in 17 states and the District of Columbia through our Cigna-HealthSpring brand. Under such a plan,
Medicare-eligible beneficiaries may receive health care benefits, including prescription drugs, through a managed care health plan such as our
coordinated care plans. A significant portion of our Medicare Advantage customers receive medical care from our value based models that
focus on developing highly engaged physician networks, aligning payment incentives to improved health outcomes, and using timely and
transparent data sharing. We are focused on continuing to expand these models in the future.
We receive revenue from the Centers for Medicare and Medicaid Services (‘‘CMS’’) for each plan customer based on customer demographic
data and actual customer health risk factors compared to the broader Medicare population. We also may earn additional revenue from CMS
related to quality performance measures (known as ‘‘Star Ratings’’). See the ‘‘Executive Overview’’ section of our MD&A beginning on page 35
of this Form 10-K for additional discussion of our Star Ratings. Premiums may be received from customers when our plan premium exceeds the
revenue received from CMS. The ACA requires Medicare Advantage and Medicare Part D plans to meet a minimum MLR of 85%. If the MLR for a
CMS contract is less than 85%, we are required to pay a rebate to CMS and could be required to make additional payments if the MLR continues
to be less than 85% for successive years.
Medicare Part D
Our Medicare Part D prescription drug program provides a number of plan options, as well as service and information support, to Medicare and
Medicaid eligible customers. Our plans are available in all 50 states and the District of Columbia and offer the savings of Medicare combined
with the flexibility to provide enhanced benefits and a drug list tailored to individuals’ specific needs. Eligible beneficiaries benefit from broad
network access and value-added services intended to help keep them well and save them money.
Medicaid
We offer Medicaid coverage to low income individuals in select markets in Texas. We also offered Medicaid coverage to low income individuals
in select markets in Illinois throughout 2017; however, as of December 31, 2017, all of our Medicaid contracts with the state of Illinois have been
terminated. Our Medicaid customers benefit from many of the coordinated care aspects of our Medicare Advantage programs.
We receive revenue from the states of Texas and Illinois for our Medicaid only customers. For customers eligible for both Medicare and
Medicaid (‘‘dual eligible’’) we receive revenue from both the state and CMS. All revenue is based on customer demographic data and actual
customer health risk factors. Similar to Medicare Advantage, there are minimum MLR requirements in Illinois (85% for the dual product and 88%
for the Medicaid only product). However, Texas utilizes an experience rebate in an effort to provide better value to consumers and increase
transparency. The Texas experience rebate takes into account operating expenses and requires a rebate of dollars to the state as different
profitability thresholds are met.
Specialty Products and Services
Our specialty products and services described below are designed to improve the quality of care, lower cost and help customers achieve better
health outcomes. Many of these products can be sold on a standalone basis, but we believe they are most effective when integrated with a
Cigna-administered health plan. Our specialty products are focused in the areas of medical, behavioral, pharmacy management, dental and
vision.
Medical Specialty
•
Stop Loss. We offer stop loss insurance coverage for ASO clients that provides reimbursement for claims in excess of a predetermined
amount for individuals (‘‘specific’’), the entire group (‘‘aggregate’’), or both.
•
•
Cost-Containment Service. We administer cost-containment programs on behalf of our clients and customers for health care services and
supplies that are covered under health benefit plans. These programs may involve vendors who perform activities designed to control health
costs by reducing out-of-network utilization and costs, educating customers regarding the availability of lower cost in-network services,
negotiating discounts, reviewing provider bills, and recovering overpayments from other payers or health care providers. We charge fees for
providing or arranging for these services.
Consumer Health Engagement. We offer an array of medical management, disease management, and wellness services to customers
covered under plans administered by Cigna, or by third-party administrators. Our Medical Management programs include case, specialty and
utilization management including a 24-hour nurse information line. Our Health Advocacy programs and services include early intervention in
the treatment of chronic conditions and an array of health and wellness coaching. Additionally, we administer incentives to motivate
customers to engage in and improve their health.
CIGNA CORPORATION - 2017 Form 10-K 5
PART I
ITEM 1. Business
Pharmacy Management
We offer prescription drug plans to our commercial and government customers both in conjunction with our medical products and on a
standalone basis. With a network of over 69,000 pharmacies, Cigna Pharmacy Management is a comprehensive pharmacy benefits manager
(‘‘PBM’’) offering clinical programs and specialty pharmacy solutions. We also offer high quality, efficient, and cost-effective mail order,
telephone and on-line pharmaceutical fulfillment services through our home delivery operation.
Our medical and pharmacy coverage meets the needs of customers with complex medical conditions requiring specialty pharmaceuticals.
These types of medications are covered under the pharmacy or medical benefit depending on whether they are dispensed by a pharmacy to
the customer or administered to the customer by a health care professional or facility. Uses of these typically expensive medications often
require associated lab work and coordination between the pharmacy and the patient’s medical professionals may be critical in improving
clinical outcomes and affordability. Customers with Cigna-administered medical and pharmacy coverage may experience greater continuity of
care and affordability, and clients may benefit from integrated reporting and meaningful unit cost discounts on specialty drugs.
Behavioral Health
We arrange for behavioral health care services for customers through our network of approximately 122,000 participating behavioral health
care professionals and 14,000 facilities and clinics. We offer behavioral health care case management services, employee assistance programs
(‘‘EAP’’), and work/life programs to employers, government entities and other groups sponsoring health benefit plans. We focus on integrating
our programs and services with medical, pharmacy and disability programs to facilitate customized, holistic care.
Dental
We offer a variety of insured and self-insured dental benefit solutions including dental health maintenance organization plans (‘‘Dental HMO’’)
in 37 states, dental preferred provider organization (‘‘Dental PPO’’) plans in 49 states and the District of Columbia, exclusive dental provider
organization plans, traditional dental indemnity plans and a dental discount program. Employers and other groups can purchase our products
as standalone products or in conjunction with medical products. Additionally, individual customers can purchase Dental PPO plans as
standalone products or in conjunction with individual medical policies.
Beginning in 2016 Cigna launched a suite of digital enhancements to our web portal and mobile application, for our dental customers to
schedule appointments online, compare out-of-pocket costs across multiple dentists, and access information that evaluates the dentist’s
professional history, affordability and patient experience. Cigna’s recent acquisition of Brighter, a leader in digital engagement with health care
consumers, will accelerate developing and delivering deep end-to-end experiences that further connect our dental consumers with high
quality providers.
As of December 31, 2017, our dental customers totaled 15.8 million worldwide and approximately 67% are enrolled in plans with funding
arrangements that allow clients to directly benefit from lower dental costs. Our U.S. customers access care from one of the largest Dental PPO
networks and Dental HMO networks, with approximately 140,600 Dental PPO and 19,900 Dental HMO health care professionals.
Vision
Cigna Vision offers flexible, cost-effective PPO coverage that includes a range of both in and out-of-network benefits for routine vision services
offered in conjunction with our medical and dental product offerings. Our national vision care network, consisting of approximately 89,800
health care providers in over 26,300 locations, includes private practice ophthalmologist and optometrist offices, as well as retail eye care
centers.
Service and Quality
Customer Service
For U.S.-based customers, we operate 22 service centers that together in 2017 processed approximately 168 million claims and handled
33 million calls providing our customers service 24 hours a day, 365 days a year.
In our international health care business, we have a service model dedicated to the unique needs of our 1.5 million customers around the world.
We service them from 12 globally deployed service centers that allow us to provide service 24 hours a day, 365 days a year.
Technology
Cigna Information Technology supports the Go Deeper, Go Local, Go Beyond strategy by focusing first and foremost on strong foundational
technology services and delivering against an aligned business and technology portfolio that creates market differentiation. We target specific
innovation in the customer experience, digital capabilities, advanced analytics and artificial intelligence that provide key areas of competitive
advantage. Our goal is to continue to focus on targeted technology investments to enable our strategic business objectives. This goal is
accomplished by delivering innovative technology that enables more efficient operations, improves process integrity and cyber-protections,
builds stronger relationships with our key stakeholders; optimizes our economies of scale; and maximizes flexible payment arrangements,
innovative products and services and intelligent analytics to support evidence-based medicine. Through continued execution of these
capabilities, we are able to better and more rapidly deliver market-differentiating and innovative solutions.
Technology plays an essential role, both as a critical enabler and as a core asset, in Cigna’s drive to be the partner of choice and to deliver a
superior experience to numerous stakeholders. To support these goals, our global IT strategy continues to focus on technology, infrastructure
and platforms, as well as adopting Agile development methods. Execution across each of these dimensions results in improved delivery, quality
and speed, stronger integration, improved transparency and greater optionality. As part of the execution of our global IT strategy, we have
launched a growing portfolio of innovative solutions that leverage technologies such as virtual reality, mobile, advanced analytics and machine
learning. Utilizing virtual reality technology coupled with biometrics and brain wave analysis, we developed a solution that monitors and
6 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
manages the stress level of call center agents. We also have introduced a global mobile application that enables access to a virtual health team
as well as personalized health content, internet of things integration and consolidated medical record information. We are leveraging machine
learning and analytics to proactively engage customers with our new, integrated customer decision support and service program, One Guide(cid:3).
We are also using analytics to address the opioid epidemic. In addition to collaborating with our network of doctors, we leverage our Opioid
Likely Overdose Risk Model, which uses machine learning with integrated claims data and analytics to detect opioid use patterns that suggest
possible misuse.
Innovation is core to the way we do business; we continuously seek opportunities to drive efficiencies and create a superior customer
experience through technology. Our business strategy is predicated on providing customers with differentiated, easy to use, seamless and
secure products and solutions that leverage analytics and information to meet their increasing expectations. That means we need to anticipate
those needs and meet customers where they are. From predicting and preventing chronic diseases, to mining data to reduce payment and
claims fraud, to using the data from wearable’s to optimize health, we foresee even more opportunities going forward to use sophisticated
artificial intelligence and machine learning techniques. This will allow us to build even better models to answer the complex questions, and will
lead to better health care outcomes.
Data Analytics
Cigna has transformed substantial investments in analytics talent, data infrastructure, and machine learning capabilities over the past several
years into a closed loop, self-learning insights system that guides our decision making and executing on our strategy. Our Insights That Matter
analytics process helps our business leaders identify the questions that matter most to our customers and partners. We focus our data science
experts on answering those questions with innovative methodologies and transform our insights into targeted business actions.
Cigna is using advanced analytic capabilities throughout all facets of the business to:
•
•
•
Identify and quantify the financial and clinical cost of discrete health opportunities and insights into how to best engage individual customers
(e.g., digital, phone, or physician-based interactions). We convert these insights into a Health Matters Score that is used to connect each
customer to the right clinical services and drive better clinical, financial, and quality outcomes.
Enable customized service experiences. In our pharmacy business we are proactively offering our customers value added pharmacy and
medical services during inbound customer calls, realizing the value of an integrated medical and pharmacy offering. To maximize impact, we
apply our proprietary Customer Segmentation models to tailor customer communications to make interactions more meaningful.
Build a deep understanding of risk adjusted total cost and quality performance metrics at the individual physician level and aggregate market
level to develop relative benchmarks. This data is being used to fuel our drive to fee for value physician reimbursements and flexible provider
networks.
•
Leverage advanced analytic models and tools to better identify prospects that best align with Cigna’s mission and value proposition for our
client engagement team.
Going forward, we view insights as a strategic imperative and will continue to heavily invest in expanding and strengthening our capabilities to
meet and exceed our customer and partner expectations.
Quality Health Care
Our commitment to promoting quality health care to the people we serve is reflected in a variety of activities.
Health Improvement through Engaging Providers and Customers
Cigna improves health outcomes, reduces health care costs, and delivers a better customer and provider experience by enabling optimized
relationships that connect care between customers and providers. We refer to this as our Connected Care strategy. Key aspects of this strategy
include engaging customers in their health, collaborating with providers to help them improve their performance, and connecting customers
and providers through aligned health goals and incentives and actionable information to enable better decisions and outcomes. Cigna is
committed to developing innovative solutions that span the health care delivery system and can be applied to different types of providers.
Currently we have numerous collaborative arrangements with our participating health care providers and are actively developing new
arrangements to support our Connected Care strategy. The key principles that guide our innovative solutions include:
•
improving access to care at the local market level;
•
collaborating with and supporting providers to be successful with value-based care;
•
leveraging actionable, personalized patient information, enhancing the patient experience; and,
•
shifting reimbursement incentives to reward quality medical and cost outcomes.
We continue to increase our engagement with physicians and hospitals by rapidly developing the types of arrangements discussed below.
Over two million medical customers are currently serviced by more than 136,000 health care providers in these types of arrangements.
•
Cigna Collaborative Care.
•
Accountable Care Program – we have over 200 collaborative care arrangements with primary care groups built on the patient-
centered medical home and accountable care organization (‘‘ACO’’) models. Our arrangements span over 30 states and reach over
2.4 million customers. We are committed to increasing the number of groups over the next several years. Our goal is to reach 280
programs by the end of 2020.
CIGNA CORPORATION - 2017 Form 10-K 7
PART I
ITEM 1. Business
•
•
Hospital Quality Program – we have contracts with over 450 hospitals where reimbursements are tied to quality metrics. We expect
to grow this number to over 600 hospitals by the end of 2020.
Specialist Programs – we have approximately 150 arrangements with specialist groups in value-based reimbursement arrangements.
Our goal is to reach approximately 260 arrangements by the end of 2020. Programs include arrangements with several types of
specialist groups around the country, including orthopedics, obstetrics and gynecology, cardiology, gastroenterology, oncology,
nephrology, and neurology. Arrangements include care coordination, and episodes of care reimbursements, for meeting cost and
quality goals.
•
•
•
•
Independent Practice Associations are value based physician engagement models in our Cigna-HealthSpring business that allow the
physician groups to share financial outcomes with us. The Cigna-HealthSpring clinical model also includes outreach to new and at-risk
patients to ensure they are accessing their primary care physician.
CareAllies(cid:3). In 2016, we announced the formation of CareAllies(cid:3); this U.S.-based population health company is focused on helping
physicians manage the health of their patients and improve their health outcomes. CareAllies(cid:3) partners with physicians, provider groups and
health systems to develop customized solutions that help them meet their goals across all patients and all payers.
Delivery System Alliances. Cigna is collaborating with select health care delivery systems to develop compelling and unique strategic
relationships focused on addressing the local market’s unique health care needs. This includes jointly developed products designed to
improve the experience of Cigna customers by offering integrated health care and providing access to quality, value-based care in local
communities.
Customer Engagement Products – Cigna One Guide(cid:3). Cigna is also delivering a personalized experience to help our customers navigate the
complex health care system and make important health care choices. Cigna One Guide(cid:3) provides customers with access to guided
consultations via phone, mobile application and ‘‘Click-to-Chat’’ to help with choosing their benefits, building a personal health team of
doctors, clinicians and coaches, navigating their health benefits and reducing their health expenses through reward programs.
In the international health care business we use the Net Promoter Score (‘‘NPS’’) approach to continually gather insights from customers and
health care professionals around the world and to guide how we proactively enhance product and service offerings.
Participating Provider Network
We provide our customers with an extensive network of participating health care professionals, hospitals, and other facilities, pharmacies and
providers of health care services and supplies. In most instances, we contract with them directly; however, in some instances, we contract with
third parties for access to their provider networks and care management services. In addition, we have entered into strategic alliances with
several regional managed care organizations (e.g., Tufts Health Plan, HealthPartners, Inc., Health Alliance Plan, and MVP Health Plan) to gain
access to their provider networks and discounts.
We credential physicians, hospitals and other health care professionals in our participating provider networks using quality criteria that meet
or exceed the standards of external accreditation or state regulatory agencies, or both. Typically, most health care professionals are
re-credentialed every three years.
The Cigna Care Network(cid:3) is a benefit-plan design option offered in 74 service areas. The network distinguishes physicians in 21 specialties (3
primary care and 18 other specialties) who participate in our network, based on specific quality and/or cost-efficiency criteria. The benefit
design is intended to encourage Cigna customers to consider using a Cigna Care Network(cid:3) physician, affords a lower co-payment or
coinsurance for services provided by a physician in this network than if the individual were to select a participating, non-Cigna Care Network(cid:3)
physician.
LocalPlus(cid:3) is a locally-tailored network of select health care providers and facilities designed to provide cost-effective and quality care. It links
multiple local networks across geographic markets to provide consistency for both employers and the customers. LocalPlus(cid:3) was available in
23 markets as of the end of 2017, and will be available in 24 markets by the end of 2018.
The Cigna SureFit(cid:3) network is built around a focused, local network of doctors and hospitals, who are rewarded for collaborating and providing
quality care. Customers choose a primary care provider (‘‘PCP’’) at enrollment, which helps ensure care is coordinated within the network –
creating a better, more affordable customer experience. This creates network efficiencies that result in significant client savings over our Open
Access Plus (‘‘OAP’’) product. Traditional and alternative funding options are paired with integrated medical, pharmacy and behavioral health
products to further maximize savings.
Medical Care and Onsite Services
•
Cigna Medical Group is a multi-specialty medical group practice that delivers primary care and certain specialty care services through 20
medical facilities and 120 clinicians in Phoenix, Arizona. These health care centers have received the highest accreditation (level 3) from the
National Committee for Quality Assurance (‘‘NCQA’’).
•
•
LivingWell Health Centers – HealthSpring(cid:3). Medicare Advantage customers may receive care from one of our four free-standing clinics and
13 ‘‘embedded’’ clinics that incorporate the principles and resources of stand-alone clinics while allowing the customer access to their primary
care physician.
Cigna Onsite Health provides employer-based onsite or nearby health centers and health and wellness coaches with nearly 60 health centers
and 160 health coaches. Care delivery services include acute, episodic care through full primary care services. Additional services include a
range of health and wellness and preventive services, pre-packaged generic prescription dispensing, biometrics screenings and health and
wellness coaching for diet and nutrition as well as chronic condition management. Cigna Onsite Health also offers virtual health services to
extend access to care for both coaching and treatment services.
8 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
External Validation
We continue to demonstrate our commitment to quality and have a broad scope of quality programs validated through nationally recognized
external accreditation organizations. We achieved Health Plan accreditation from the NCQA in 38 of our markets. Additional NCQA
recognitions include Full Accreditation for Managed Behavioral Healthcare Organization for Cigna Behavioral Health, Accreditation with
Performance Reporting for Wellness & Health Promotion, Accreditation for our Disease Management programs and Physician & Hospital
Quality Certification for our provider transparency program. We have Full Accreditation for Health Utilization Management, Case Management,
Pharmacy Benefit Management and Specialty Pharmacy from URAC, an independent, nonprofit health care accrediting organization
dedicated to promoting health care quality through accreditation, certification and commendation. We participate in the NCQA’s Health Plan
Employer Data and Information Set (‘‘HEDIS(cid:3)’’) Quality Compass Report, whose Effectiveness of Care measures are a standard set of metrics
to evaluate the effectiveness of managed care clinical programs.
Markets and Distribution
We offer health care and related products and services in the following market segments:
National
Middle Market
Select
Individual
Government
International
Multi-state employers with 5,000 or more U.S.-based, full-time employees. We offer primarily ASO funding solutions in
this market segment.
Employers generally with 250 to 4,999 U.S.-based, full-time employees. This segment also includes single-site employers
with more than 5,000 employees and Taft-Hartley plans and other groups. We offer ASO, experience rated and
guaranteed cost insured funding solutions in this market segment.
Employers generally with 51-249 eligible employees. We usually offer ASO with stop loss insurance coverage and
guaranteed cost insured funding solutions in this market segment.
In 2017, we offered plans in fifteen states. We had plans on public health insurance exchanges in seven states (Colorado,
Illinois, Maryland, Missouri, North Carolina, Tennessee and Virginia) and off-exchange in eight states (Arizona, California,
Connecticut, Florida, Georgia, New Jersey, South Carolina, and Texas). In 2018, we offer plans in nine states. We have
plans on public health insurance exchanges in six states (Colorado, Illinois, Missouri, North Carolina, Tennessee, and
Virginia) and off-exchange in three states (Arizona, Florida, and New Jersey). Consistent with the regulations for
Individual ACA compliant plans, we offer plans only on a guaranteed cost basis in this market segment.
Individuals who are post-65 retirees, as well as employer group sponsored pre- and post-65 retirees. We offer Medicare
Advantage, Prescription Drug programs, and Medicaid products in this market segment including dual-eligible members
who receive both Medicare and Medicaid benefits.
Local and multinational companies, international organizations and governments and their local and globally-mobile
employees and dependents working or travelling in more than 190 countries and jurisdictions. We offer guaranteed cost,
experience rated insured and ASO funding solutions in this market segment.
% of Medical
Customers
23%
53%
9%
2%
3%
10%
Cigna Guided Solutions(cid:3) is Cigna’s benefit administration and private exchange solution that targets clients who value fully integrated
solutions and focus on engaging employees in their benefit offering. It leverages Cigna’s ability to provide a fully integrated solution with our
broad spectrum of products, benefit plans, services, and full suite of funding options focused on improving total cost, health, and productivity.
Through Cigna Guided Solutions(cid:3), employers enjoy simplified administration and the convenience of single source purchasing while
employees receive more choice via an easy-to-use shopping experience and year round engagement. Together with integrated robust
decision-support tools, employees are able to make personalized decisions to select the right benefit offering and get the most value from
their plans.
In addition, Cigna participates on many third party private exchanges. We actively evaluate private exchange participation opportunities as
they emerge in the market, and target our participation to those models that best align with our mission and value proposition.
We employ sales representatives to distribute our products and services through insurance brokers and insurance consultants or directly to
employers, unions and other groups or individuals. We also employ sales representatives to sell access to our national participating provider
network, utilization review services, behavioral health care and pharmacy management services, and employee assistance services directly to
insurance companies, HMOs and third party administrators. As of December 31, 2017, our field sales force consisted of over 1,200 sales
representatives in 124 field locations. In our Government business, Medicare Advantage enrollment is generally a decision made individually by
the customer, and accordingly, sales agents and representatives focus their efforts on in-person contacts with potential enrollees, as well as
telephonic and group selling venues.
Competition
Our business is subject to intense competition and continuing industry consolidation creates an even more competitive business environment.
In certain geographic locations, some health care companies may have significant market share positions, but no one competitor dominates
the health care market nationally. Given the current economic and political environment, we expect a continuing trend of consolidation across
the health care industry supply chain (including insurers, hospitals, pharmaceutical companies, and providers).
Competition in the health care market exists both for employers and other groups sponsoring plans and for employees in those instances
where the employer offers a choice of products from more than one health care company. Most group insurance policies are subject to annual
review by the plan sponsor, who may seek competitive quotations prior to renewal. Since the inception of the Individual Exchange
marketplaces many carriers have incurred significant financial losses leading to many exiting the market. With the continued debate regarding
the ACA and the health care industry more broadly, it is likely that legislative and regulatory changes to the ACA will occur in the future.
CIGNA CORPORATION - 2017 Form 10-K 9
PART I
ITEM 1. Business
The primary competitive factors affecting our business are quality and cost-effectiveness of service and provider networks; effectiveness of
medical care management; products that meet the needs of employers and their employees; total cost management; technology; and
effectiveness of marketing and sales. Financial strength of the insurer, as indicated by ratings issued by nationally recognized rating agencies, is
also a competitive factor. We believe that our health advocacy capabilities, holistic approach to consumer engagement, breadth of product
offerings, clinical care and medical management capabilities and array of product funding options are competitive advantages in meeting the
diverse needs of our customer base. We also believe that our focus on helping to improve the health, well-being and sense of security of the
customers we serve will allow us to differentiate ourselves from our competitors.
Our primary competitors in our U.S.-based health care businesses include:
•
other national insurance and health services companies that provide group health insurance products, including Aetna, Anthem, Humana,
Kaiser Permanente and UnitedHealth Group;
•
not-for-profit managed care organizations, including Blue Cross/Blue Shield plans;
•
other regional stand-alone managed care and specialty companies, including newer health plans seeking to disrupt in part through
technology (e.g. Bright Health and Oscar)
•
managed care organizations affiliated with major insurance companies and hospitals; and
•
national managed pharmacy, behavioral health and utilization review services companies.
Our primary competitors in the international health care business include U.S.-based insurers such as Aetna, UnitedHealth Group GeoBlue and
MetLife; global competitors such as BUPA and Allianz; and local and regional insurers in a range of countries.
In addition to our traditional competitors, new sources of competition continue to emerge. These newer competitors are focused on delivering
lower cost benefits and services through internet-enabled technology that allows consumers to take a more active role in the management of
their health. This can be accomplished through financial incentives, access to enhanced quality medical data and other information sharing.
The effective use of our health advocacy, customer insight and physician engagement capabilities, along with decision support tools (some of
which are web-based) and enabling technology are critical to success in the health care industry, and we believe our capabilities in these areas
will be competitive differentiators.
Industry Developments
The health insurance marketplace will continue to be shaped by the ACA over the near term. However, Congressional efforts to repeal and
replace the ACA, various executive actions of the Trump administration, and the repeal of the individual mandate as part of the recently signed
U.S. tax reform legislation make the future of the ACA uncertain. See the ‘‘Regulation’’ and ‘‘Risk Factors’’ sections of the Form 10-K for
additional discussion about these developments.
Global Supplemental Benefits
How We Win
•
Leveraging deep consumer insights to drive product innovation
•
Targeting the growing middle class and seniors populations globally
•
Easy to understand, affordable products designed to fill gaps in either private or public coverage
•
Leading innovative, direct to consumer distribution capabilities
•
Locally licensed and managed by strong, locally developed talent
Products
and Services
Key Geographies and
Growth Markets
Distribution
Channels
•
•
•
•
•
•
•
•
Hospitalization
Dental
Medicare Supplement
Critical Illness
Personal Accident
Term Life
Variable Universal Life
Individual Private Medical
Insurance
•
•
•
Asia: South Korea, China,
Taiwan, Hong Kong, Indonesia
and India
Turkey
United States
•
•
•
•
•
Telemarketing
Home Shopping & Direct
Response Television
Independent agents
Bancassurance
Internet
We continue to distinguish ourselves in the global supplemental health, life and accident businesses through our differentiated
direct-to-consumer distribution, customer insights and marketing capabilities. We enter new markets when the opportunity to bring our product
and health solutions is attractive. Over the past several years, we have continued to extend our product offerings and geographic reach.
10 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
Principal Products and Services
Supplemental Health, Life and Accident Insurance
Supplemental health, life and accident insurance products generally provide simple, affordable coverage of risks for the health and financial
security of individuals. Supplemental health products provide specified payments for a variety of health risks and include personal accident,
accidental death, critical illness, hospitalization, travel, dental, cancer and other dread disease coverages. We also offer customers individual
private medical insurance, term and variable universal life insurance and certain savings products.
Medicare Supplement Plans
We offer individual Medicare Supplement plans that provide retirees with federally standardized Medigap-style plans. Retirees may select among
the various plans with specific plan options to meet their unique needs and may visit, without the need for a referral, any health care professional or
facility that accepts Medicare throughout the United States.
Pricing and Reinsurance
Premium rates for our global supplemental benefits products are based on assumptions about mortality, morbidity, customer acquisition and
retention, customer demographics, expenses and target profit margins, as well as interest rates. For variable universal life insurance products, fees
consist of mortality, administrative, asset management and surrender charges assessed against the contractholder’s fund balance. Mortality
charges on variable universal life may be adjusted prospectively to reflect expected mortality experience. Most contracts permit premium rate
changes at least annually.
A global approach to underwriting risk management allows each local business to underwrite and accept risk within specified limits. Retentions
are centrally managed through cost effective use of external reinsurance to limit our liability on per life, per risk and per event (catastrophe) bases.
Markets and Distribution
Our supplemental health, life and accident insurance products sold in foreign countries are generally marketed through distribution partners with
whom the individual insured has an affinity relationship. These products are sold primarily through direct marketing channels, such as outbound
telemarketing, and in-branch bancassurance (when we partner with a bank and use the bank’s sales channels to sell our insurance products).
Marketing campaigns are conducted through these channels under a variety of arrangements with affinity partners, including banks, credit card
companies and other financial and non-financial institutions. We also market directly to consumers via direct response television and the Internet.
In certain countries, we market our products through captive and third party brokers and agents. Our Medicare supplement product line is
distributed primarily through independent agents and telemarketing directly to the consumer.
South Korea represents our single largest geographic market for Global Supplemental Benefits. For information on this concentration of risk for
the Global Supplemental Benefits segment’s business in South Korea, see ‘‘Other Items Affecting Results of Global Supplemental Benefits’’ in the
Global Supplemental Benefits section of the MD&A beginning on page 49 of this Form 10-K.
For our supplemental health, life and accident insurance products sold in foreign markets we are increasingly exposed to geopolitical, currency
and other risks inherent in foreign operations. Also, given that we bill and collect a significant portion of premiums through credit cards, a
substantial contraction in consumer credit could impact our ability to retain existing policies and sell new policies. A decline in customer retention
would result in both a reduction of revenue and an acceleration of the amortization of acquisition-related costs. Changes in regulation for
permitted distribution channels also may impact our business or results.
Competition
We expect that the competitive environment for global supplemental benefits will continue to intensify as U.S., Europe and other regionally-based
insurance and financial services providers more aggressively pursue expansion opportunities across geographies, especially in Asia. We believe
competitive factors will include branding, product and distribution innovation and differentiation, efficient management of marketing processes
and costs, commission levels paid to distribution partners, the quality of claims, local network coverage, customer services and talent acquisition
and retention. Additionally, in most overseas markets, perception of financial strength also will likely continue to be an important competitive
factor.
Our competitors are primarily locally-based insurance companies, including insurance subsidiaries of banks primarily in Asia and Europe and
multi-national companies. Insurance company competitors in this segment primarily focus on traditional product distribution through captive
agents, with direct marketing being secondary channels. We estimate that we have less than 3% market share of the total insurance premiums in
any given market in which we operate.
In the Medicare supplement business, the principal competitive factors are underwriting and pricing, relative operating efficiency, broker relations
and the quality of claims and customer service. Our primary competitors in this business include U.S.-based health insurance companies.
Industry Developments
Pressure on social health care systems, a rapidly aging population and increased wealth and education in developing insurance markets are
leading to higher demand for products providing health insurance and financial security. In the supplemental health, life and accident business,
direct marketing channels continue to grow and attract new competitors with industry consolidation among financial institutions and other affinity
partners.
Data privacy regulation has tightened in all markets in the wake of data privacy news scandals, impacting affinity partner and customer attitudes
toward direct marketing of insurance and other financial services.
CIGNA CORPORATION - 2017 Form 10-K 11
PART I
ITEM 1. Business
Most of the businesses in this segment operate through foreign subsidiaries. We continue to maintain a capital management strategy to retain
overseas a significant portion of the earnings from these foreign operations. These undistributed earnings are deployed outside of the United
States in support of the liquidity and capital requirements of our foreign operations. As a result of U.S. tax reform legislation enacted in
December 2017, we recorded additional U.S. taxes of $88 million related to the Company’s accumulated unremitted foreign earnings. Most of
these taxes were incurred in the Global Supplemental Benefits segment. See the Management’s Discussion and Analysis section of this
Form 10-K for additional discussion of our capital management strategy and the impact of tax reform.
Group Disability and Life
How We Win
•
Disability absence management model that reduces overall costs to employers
•
Integration of disability products with medical and specialty offerings, promoting health and wellness and optimizing employee
productivity
•
Complementary portfolio of group disability, life and accident offerings
•
Disciplined underwriting, pricing and investment strategies supporting profitable long-term growth
•
•
•
•
•
•
•
Short-term disability
Long-term disability
Leave administration
Paid family leave
Basic-term life
Voluntary term life
Group universal life
Products and Services
Distribution Channels
•
•
•
Personal and voluntary accident
Business travel accident
Critical illness, Accidental injury and Hospital indemnity
•
•
Insurance brokers and consultants
Sales representatives
Customer Segments
•
•
•
National
Middle Market
Select
Our Group Disability and Life business markets its products and services in all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin
Islands and Canada.
Products and Services
Group Disability
Long-term and short-term group disability insurance products generally provide a fixed level of income to replace a portion of wages lost
because of disability. Group disability coverage is typically employer-paid or a combination of employer and employee-paid, but also may
include coverage paid for entirely by employees. As part of our group disability insurance products, we also provide assistance to employees in
returning to work and assistance to employers with resources to manage the cost of employee disability. We are an industry leader in helping
employees return to work quickly, resulting in higher productivity and lower cost for employers and a better quality of life for their employees.
We seek to integrate the administration of our disability insurance products with other disability benefit programs, behavioral programs,
medical programs, social security advocacy and administration of federal Family and Medical Leave Act (‘‘FMLA’’), State Leave Laws and other
leave of absence programs. We believe this integration provides our customers with increased efficiency and effectiveness in disability claims
management, enhances productivity and reduces overall costs to employers. This integration also provides early insight into employees at risk
for future disability claims. Coordinating the administration of these disability programs with medical programs offered by our health care
business provides enhanced opportunities to influence outcomes, reduce the cost of both medical and disability events and improve the return
to work rate. The benefits of this integrated approach also include:
•
•
using information from the health care and disability databases to help identify, treat and manage disabilities before they become longer in
duration or chronic and more costly; and
proactively reaching out to assist employees suffering from a mental health or chronic condition, either as a primary condition or as a result of
another condition.
Our disability products and services are offered on a fully insured, experience-rated and ASO basis, although most are fully insured. As
measured by 2017 premiums and fees, disability constituted 51% of this segment’s business. Approximately 15,400 disability insurance policies
covering approximately 8.8 million lives were in force as of December 31, 2017.
Group Life Insurance
Group life insurance products offered include term life and universal life. Group term life insurance may be employer-paid basic life insurance,
employee-paid supplemental life insurance or a combination thereof. Group universal life insurance is an employee-paid, voluntary life
insurance product in which the owner may accumulate a cash value. The cash value earns interest at rates declared from time to time, subject to
a minimum guaranteed contracted rate, and may be borrowed, withdrawn, or, within certain limits, used to fund future life insurance coverage.
12 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
As measured by 2017 premiums and fees, group life insurance constituted approximately 43% of this segment’s business. Approximately 9,200
group life insurance policies covering approximately 6.5 million lives were in force as of December 31, 2017.
Other Products and Services
We also offer personal accident insurance coverage, consisting primarily of accidental death and dismemberment and travel accident
insurance to employers. Group accident insurance may be employer-paid or employee-paid. In addition, we offer specialty insurance services
that consist primarily of disability and life, accident and hospital indemnity products to professional or trade associations and financial
institutions.
We also provide a number of voluntary products and services that are typically paid by the employee and offered at the employer’s worksite.
Our plans provide employers with administrative solutions designed to provide employers with a complete and simple way to manage their
benefits program. In recent years, we have brought to market three additional voluntary offerings: accidental injury insurance, critical illness
coverage and hospital indemnity. These products provide additional dollar payouts to employees for unexpected accidents, hospitalization or
more serious illnesses.
Pricing and Reinsurance
Premiums charged for disability and term life insurance products are usually established in advance of the policy period and are generally
guaranteed for one to three years and selectively guaranteed for up to five years; policies are generally subject to termination by the
policyholder or by the insurance company annually. Premium rates reflect assumptions about future claims, expenses, credit risk, investment
returns and profit margins. These assumptions may be based in whole or in part on prior experience of the account or on a pool of accounts,
depending on the group size and the statistical credibility of the experience that varies by product.
Premiums for group universal life insurance products consist of mortality and administrative charges assessed against the policyholder’s fund
balance. Interest credited and mortality charges for group universal life may be adjusted prospectively to reflect expected interest and
mortality experience. Mortality charges are subject to maximum guaranteed rates and interest credited on cash values is subject to minimum
guaranteed rates as stated in the policy.
The premiums for these products are typically collected within the coverage year and then invested in assets that match the duration of the
expected benefit payments that occur over many future years (primarily for disability benefits). With significant investments in longer-
duration securities, net investment income is a critical element of profitability for this segment.
The effectiveness of return-to-work programs and morbidity levels will impact the profitability of disability insurance products. Our previous
claim experience and industry data indicate a correlation between disability claim incidence levels and economic conditions, with submitted
claims rising under adverse economic conditions, although this impact is not clear. For life insurance products, the degree to which future
experience deviates from mortality and expense assumptions also affects profitability.
To reduce our exposure to large individual and catastrophic losses under group life, disability and accidental death policies, as well as our more
recent accidental injury and critical illness policies, we purchase reinsurance from a diverse group of unaffiliated reinsurers. Our comprehensive
reinsurance program consists of excess of loss treaties and catastrophe coverage designed to mitigate earnings volatility and provide surplus
protection.
Markets and Distribution
We market our group disability and life insurance products and services to employers, employees, professional and other associations and
groups in the National, Middle Market and Select segments (see definitions of these segments on page 9). In marketing these products, we
primarily sell through insurance brokers and consultants and employ a direct sales force consisting of approximately 250 sales professionals in
27 office locations as of December 31, 2017.
Competition
The principal competitive factors that affect the Group Disability and Life segment are underwriting and pricing, the quality and effectiveness
of claims management, relative operating efficiency, investment and risk management, distribution methodologies and producer relations, the
breadth and variety of products and services offered, the quality of customer service and, more importantly, the state of the tools and
technology available for customers, clients, consultants and producers. For certain products with longer-term liabilities, such as group
long-term disability insurance, the financial strength of the insurer, as indicated by ratings issued by nationally recognized rating agencies, is
also a competitive factor.
The principal competitors of our group disability, life and accident businesses are other large and regional insurance companies that market
and distribute these or similar types of products and include Unum, The Hartford, Prudential, Lincoln and MetLife.
As of December 31, 2017, we are one of the top providers of group disability, life and accident insurance in the United States, based on
premiums.
Industry Developments
Employers are expressing a growing interest in employee wellness, absence management and productivity and likewise are recognizing a
strong link between employee health, productivity and their profitability. As this interest grows, we believe our healthy lifestyle and
return-to-work programs and integrated family medical leave, disability and health care programs position us to deliver integrated solutions for
employers and employees. We also believe that our strong disability management portfolio and fully integrated programs provide tools for
employers and employees to improve health status. This focus on managing the employee’s total absence enables us to increase the number
and effectiveness of interventions and minimize disabling events.
CIGNA CORPORATION - 2017 Form 10-K 13
PART I
ITEM 1. Business
The group insurance market remains highly competitive as the rising cost of providing medical coverage to employees has forced companies to
re-evaluate their overall employee benefit spending, resulting in lower volumes of group disability and life insurance business and more
competitive pricing. Demographic shifts have further driven demand for products and services that are sufficiently flexible to meet the
evolving needs of employers and employees who want innovative, cost-effective solutions to their insurance needs. Employers continue to
shift towards greater employee participatory coverage and voluntary purchases. With our broad suite of voluntary offerings and continued
focus on developing additional voluntary products and service capabilities, we believe we are well positioned to meet the needs of both
employers and employees as the market shifts to become more retail-focused.
Over the past few years, there has been heightened review by state regulators of the claims handling practices within the disability and life
insurance industry. This has resulted in an increase in coordinated, multi-state examinations that target specific market practices in addition to
regularly recurring examinations of an insurer’s overall operations conducted by an individual state’s regulators. We have been subject to such
an examination over the past several years. See Note 21(E) to our Consolidated Financial Statements for additional information.
The depressed level of interest rates in the United States over the last several years has constrained earnings growth in this segment due to
lower yields on our fixed-income investments and higher benefit expenses resulting from the discounting of future claim payments at lower
interest rates.
Other Operations
Other Operations includes the following four businesses:
Corporate-owned Life Insurance
The principal products of the COLI business are permanent insurance contracts sold to corporations to provide coverage on the lives of certain
employees for the purpose of financing employer-paid future benefit obligations. Permanent life insurance provides coverage that, when
adequately funded, does not expire after a term of years. The contracts are primarily non-participating universal life policies. Fees for universal
life insurance products consist primarily of mortality and administrative charges assessed against the policyholder’s fund balance. Interest
credited and mortality charges for universal life and mortality charges on variable universal life may be adjusted prospectively to reflect
expected interest and mortality experience. To reduce our exposure to large individual and catastrophe losses, we purchase reinsurance from
unaffiliated reinsurers.
Run-off Settlement Annuity Business
Our settlement annuity business is a closed, run-off block of single premium annuity contracts. These contracts are primarily liability
settlements with approximately 20% of the liabilities associated with payments that are guaranteed and not contingent on survivorship. For
contracts that involve non-guaranteed payments, such payments are contingent on the survival of one or more parties involved in the
settlement.
Run-off Reinsurance
Our reinsurance operations are an inactive business in run-off mode.
In February 2013, we effectively exited the guaranteed minimum death benefit (‘‘GMDB’’) and guaranteed minimum income benefit (‘‘GMIB’’)
business by reinsuring 100% of our future exposures, net of retrocessional arrangements in place at that time, up to a specified limit. For
additional information regarding this reinsurance transaction and the arrangements that secure our reinsurance recoverables, see Note 9 to our
Consolidated Financial Statements.
Individual Life Insurance and Annuity and Retirement Benefits Businesses
This business includes deferred gains recognized from the 1998 sale of the individual life insurance and annuity business and the 2004 sale of
the retirement benefits business. For more information regarding the arrangements that secure our reinsurance recoverables for the retirement
benefits business, see Note 9 to our Consolidated Financial Statements.
Investments and Investment Income
General Accounts
Our investment operations provide investment management and related services for our corporate invested assets and the insurance-related
invested assets in our General Account (‘‘General Account Invested Assets’’). We acquire or originate, directly or through intermediaries, a
broad range of investments including private placement and public securities, commercial mortgage loans, real estate, mezzanine, private
equity partnerships and short-term investments. Invested assets also include policy loans that are fully collateralized by insurance policy cash
values. Invested assets are managed primarily by our subsidiaries and, to a lesser extent, external managers with whom our subsidiaries
contract. Net investment income is included as a component of adjusted income from operations for each of our reporting segments and
Corporate. Realized investment gains (losses) are reported by segment but excluded from adjusted income from operations. For additional
information about invested assets, see the ‘‘Investment Assets’’ section of the MD&A beginning on page 52 and Notes 10 to 12 of our
Consolidated Financial Statements.
We manage our investment portfolios to reflect the underlying characteristics of related insurance and contractholder liabilities and capital
requirements, as well as regulatory and tax considerations pertaining to those liabilities and state investment laws. Insurance and
contractholder liabilities range from short duration health care products to longer term obligations associated with disability and life insurance
products and the run-off settlement annuity business. Assets supporting these liabilities are managed in segregated investment portfolios to
14 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
facilitate matching of asset durations and cash flows to those of corresponding liabilities. Investment strategy and results are affected by the
amount and timing of cash available for investment, competition for investments, economic conditions, interest rates and asset allocation
decisions. We routinely monitor and evaluate the status of our investments, obtaining and analyzing relevant investment-specific information
and assessing current economic conditions, trends in capital markets and other factors such as industry sector, geographic and property-
specific information.
Separate Accounts
Our subsidiaries or external advisors manage Separate Account invested assets on behalf of contractholders; including the Cigna Pension Plan,
variable universal life products sold through our corporate-owned life insurance business, and other disability and life products. These assets
are legally segregated from our other businesses and are not included in General Account Invested Assets. Income, gains and losses generally
accrue directly to the contractholders.
Regulation
The laws and regulations governing our business continue to increase each year and are subject to frequent change. We are regulated by state,
federal and international regulatory agencies that generally have discretion to issue regulations and interpret and enforce laws and rules. These
regulations can vary significantly from jurisdiction to jurisdiction, and the interpretation of existing laws and rules also may change periodically.
Domestic and international governments continue to enact and consider various legislative and regulatory proposals that could materially
impact the health care system.
Our insurance and HMO subsidiaries must be licensed by the jurisdictions in which they conduct business. These subsidiaries are subject to
numerous state, federal and international regulations related to their business operations, including, but not limited to:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the form and content of customer contracts including benefit mandates (including special requirements for small groups);
premium rates and medical loss ratios;
the content of agreements with participating providers of covered services;
producer appointment and compensation;
claims processing, payment and appeals;
underwriting practices;
reinsurance arrangements;
solvency and financial reporting;
unfair trade and claim practices;
market conduct;
protecting the privacy and confidentiality of the information received from customers;
risk sharing arrangements with providers;
reimbursement or payment levels for Medicare services;
reimbursement or payment levels for out-of-network emergency care services;
claim appeal procedures;
provider directory and network adequacy requirements;
advertising; and
the operation of consumer-directed plans (including health savings accounts, health reimbursement accounts, flexible spending accounts
and debit cards).
The business of administering and insuring employee benefit programs in the United States, particularly health care programs, is heavily
regulated by state and federal laws and administrative agencies, such as state departments of insurance, and federal agencies including HHS,
CMS, the Internal Revenue Service (‘‘IRS’’) and the Departments of Labor (‘‘DOL’’), Treasury and Justice (‘‘DOJ’’), as well as the courts. Health
savings accounts, health reimbursement accounts and flexible spending accounts also are regulated by the Department of the Treasury and
the IRS.
Our operations, accounts and other books and records are subject to examination at regular intervals by regulatory agencies, including state
insurance and health and welfare departments, state boards of pharmacy, CMS, DOL, and comparable international regulators to assess
compliance with applicable laws and regulations. In addition, our current and past business practices are subject to review by, and from time to
time we receive subpoenas and other requests of information from various state insurance and health care regulatory authorities, state
attorneys general, the Office of Inspector General (‘‘OIG’’), the DOJ, the DOL and other state, federal and international authorities, including
inquiries by, and testimony before committees and subcommittees of the U.S. Congress regarding certain of our business practices. These
examinations, reviews, subpoenas and requests may result in changes to or clarifications of our business practices, as well as fines, penalties or
other sanctions.
Our international subsidiaries are subject to regulations in international jurisdictions where foreign insurers may face more rigorous regulations
than their domestic competitors. In addition, the expansion of our operations into foreign countries increases our exposure to certain U.S. laws,
such as the Foreign Corrupt Practices Act of 1977 (‘‘FCPA’’). See page 19 for further discussion of international regulations.
Patient Protection and the Affordable Care Act (ACA)
The ACA mandated broad changes affecting insured and self-insured health benefit plans that impact our current business model, including
our relationship with current and future producers and health care providers, products, services, processes and technology. Several bills were
CIGNA CORPORATION - 2017 Form 10-K 15
PART I
ITEM 1. Business
introduced in Congress in 2017 to repeal and replace the ACA, though none had passed the House and Senate. Discussions on the ACA
continue in Congress.
Throughout 2017, President Trump took several steps to limit the utility of the ACA. In January 2017, he signed an executive order instructing
agencies to waive, defer, grant exemptions from, or delay the implementation of any provision or requirement of the ACA that would impose a
fiscal burden on any state or a cost, fee, tax, penalty, or regulatory burden on individuals, providers, insurers, recipients of health care services,
purchasers of health insurance or makers of medical devices, products or medications. In October 2017, President Trump issued another
executive order that could result in significant changes to the individual and group health insurance markets. Among other things, the
executive order permits the expansion of association health plans where small businesses and individuals join together to form a plan. It may
also expand the use of short term health plans that generally have lower premiums and less coverage than policies sold on the exchanges. At
this time, we are unable to determine the effect, if any, of these actions on our business or results of operations.
Also in October 2017, the Trump administration stopped payment of cost-sharing reduction subsidies to insurers. Cost-sharing reduction
subsidies lower the amount that qualifying customers pay for deductibles, copayments and coinsurance. The federal government had provided
funding for the cost-sharing reduction subsidies to the qualifying customer’s insurer until the President’s executive order. The attorneys
general of 18 states and the District of Columbia have sued the Trump administration, seeking to require the administration to continue paying
these subsidies. While the litigation is at a preliminary stage, in October 2017, the court denied the attorney generals’ request for an injunction,
allowing the government to cease providing the cost-sharing reduction payments to insurers during the pendency of the matter. We will
continue to monitor developments as the case proceeds.
In December 2017, the U.S. tax reform legislation was signed into law that, among other things, repealed the penalty charged to individuals
without health insurance, known as the ‘‘individual mandate,’’ effective January 1, 2019.
As a result of these actions, the future of the ACA is uncertain.
Key Provisions of the ACA
Various fees, including the health insurance industry tax, were assessed beginning in 2014. The health insurance industry assessment, totaling
$14.3 billion in 2018, is not tax deductible. While federal appropriations legislation imposed a one-year moratorium on the industry tax for 2017
and 2019, the industry tax has been reinstated for 2018. For 2020 and beyond, the annual industry tax will equal the amount for the preceding
year increased by a rate of premium growth for the preceding year less the rate of growth in the consumer price index for the preceding
calendar year. Our share of this industry tax is determined based on our proportion of premiums for both our commercial and government risk
businesses to the industry total.
Each state has a state-based, a state and federal partnership, or a federally-facilitated health insurance exchange for individuals and small
employer groups to purchase insurance coverage. Because individuals seeking to purchase health insurance coverage either on or off the
exchanges are guaranteed to be issued a policy, the ACA provided programs designed to reduce the risk for participating health insurance
companies. The ACA includes a permanent program that adjusts premiums based on the relative health status of the customer base (‘‘risk
adjustment’’). Two other programs, a reinsurance program and a risk corridor program, were temporary in nature (2014-2016).
MLR requirements, as prescribed by HHS, require payment of premium rebates to group and individual policyholders if certain annual MLRs are
not met in our commercial business. Expatriate health coverage is excluded from certain provisions of the ACA, including the MLR requirement.
Other provisions of the ACA in effect include reduced Medicare Advantage premium rates, the requirement to cover preventive services with
no enrollee cost-sharing, banning the use of lifetime and annual limits on the dollar amount of essential health benefits, increasing restrictions
on rescinding coverage and extending coverage of dependents to the age of 26. The employer mandate requires employers with 50 or more
full-time employees to offer affordable health insurance that provides minimum value (each as defined under the ACA) to full-time employees
and dependent children up to age 26 or be subject to penalties based on employer size. The ACA also changed certain tax laws that effectively
limit tax deductions for certain employee compensation paid by health insurers.
Management continues to be actively engaged with the Trump administration, Congress, regulators and policymakers with respect to the ACA.
However, President Trump’s and Congress’ attempts to scale back the ACA, such as through the repeal of the individual mandate, regulatory
challenges to the ACA, and pending litigation challenging aspects of the law and related executive orders, will continue to create uncertainty
about the ultimate impact of the ACA.
See also the ‘‘Executive Overview’’ section of our MD&A beginning on page 35 of this Form 10-K. In addition, accounting policies around the
government’s risk mitigation programs are further disclosed in Note 2 to our Consolidated Financial Statements.
Medicare and Medicaid Regulations
Several of our subsidiaries engage in businesses that are subject to federal Medicare regulations, such as:
•
•
those offering individual and group Medicare Advantage coverage; and
those offering Medicare Pharmacy (Part D) products.
In our Medicare Advantage and Medicare Part D business, we contract with CMS to provide services to Medicare beneficiaries. As a result, our
ability to obtain payment (and the determination of the amount of such payments), enroll and retain members and expand into new service
areas is subject to compliance with CMS’ numerous and complex regulations and requirements that are frequently modified and subject to
administrative discretion. Marketing and sales activities (including those of third-party brokers and agents) are also heavily regulated by CMS
and other governmental agencies, including applicable state departments of insurance. We will continue to allocate significant resources to our
compliance, ethics and fraud, waste and abuse programs to comply with the laws and regulations governing Medicare Advantage and
Medicare Part D programs.
Our Medicare Advantage and Medicare Part D prescription drug plan businesses also have been impacted by the ACA (and other programs) in
a variety of ways, including mandated minimum reductions to risk scores, transition of Medicare Advantage ‘‘benchmark’’ rates to Medicare
16 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
fee-for-service parity, reduced enrollment periods and limitations on disenrollment and mandated consumer discounts on brand name and
generic prescription drugs for Medicare Part D plan participants in the coverage gap.
The ACA ties a portion of each Medicare Advantage plan’s and Medicare Part D plan’s reimbursement to the plan’s ‘‘Star Rating’’ by CMS; those
plans receiving a rating of four or more stars are eligible for quality-based bonus payments. The Star Rating system considers various measures
adopted by CMS, including, for example, quality of care, preventative services, chronic illness management, coverage determinations and
appeals and customer satisfaction. The star rating system is subject to change annually by CMS, which may make it more difficult to achieve
four stars or greater.
The ACA requires Medicare Advantage and Medicare Part D plans to meet a minimum MLR of 85%. If the MLR for a CMS contract is less than
85%, we are required to pay a penalty to CMS and could be required to make additional payments or be subject to other penalties if the MLR
continues to be less than 85% for successive years. Through the ACA and other federal legislation, funding for Medicare Advantage plans has
been and may continue to be altered.
Our Medicaid and dual eligible products are also regulated by CMS and state Medicaid agencies that audit our performance to determine
compliance with contracts and regulations. We continue to work in collaboration with applicable state agencies regarding our Medicaid plan in
Texas to ensure ongoing compliance and sustainability.
Section 111 of the Medicare, Medicaid and SCHIP Extension Act of 2007 requires us to report specific information regarding claimants and claim
settlements involving Medicare participants so CMS can recover Medicare funds expended to provide health care treatment to the claimant.
Strict sanctions, including fines and penalties, exclusion from the Medicare and Medicaid programs and criminal penalties may be imposed for
non-compliance with these laws and regulations.
Federal and State Audits of Government-Sponsored Health Care Programs
Participation in government-sponsored health care programs subjects us to a variety of federal and state laws and regulations and risks
associated with audits conducted under these programs. These audits may occur in years subsequent to our providing the relevant services.
These risks may include potential fines and penalties, restrictions on our ability to participate or expand our presence in certain programs and
restrictions on marketing our plans. For example, with respect to our Medicare Advantage business, CMS and the OIG perform audits to
determine a health plan’s compliance with federal regulations and contractual obligations, including program audits, compliance with proper
coding practices (sometimes referred to as ‘‘Risk Adjustment Data Validation Audits’’ or ‘‘RADV audits’’). For our Medicare Part D business,
compliance with fraud and abuse enforcement practices is monitored through Recovery Audit Contractor (‘‘RAC’’) audits in which third-party
contractors conduct post-payment reviews on a contingency fee basis to detect and correct improper payments. In addition, negative
performance points may be accumulated for noncompliance, including failure to perform satisfactorily during an audit. Negative past
performance points could restrict our ability to expand our Medicare Advantage business geographically. The DOJ is currently conducting an
industry review of the risk adjustment data submission practices and business processes, including review of medical charts, of Medicare
Advantage organizations under Medicare Parts C and D.
The federal government has made investigating and prosecuting health care fraud, waste and abuse a priority. Fraud, waste and abuse
prohibitions encompass a wide range of activities, including kickbacks for inducement to refer customers, billing for unnecessary medical
services, coding, network adequacy and improper marketing. The False Claims Act (which includes whistleblower provisions) enables the
federal government to bring a lawsuit against an entity that it believes has knowingly presented a false or fraudulent request for payment from
the federal government, or who has made a false statement or used a false record to get a claim approved. The regulations and contractual
requirements in this area are complex, are frequently modified, and are subject to administrative discretion and judicial interpretation. A
number of states have also adopted false claims acts and whistleblower provisions. We expect to continue to allocate significant resources to
comply with these regulations and requirements and to maintain audit readiness.
Pharmacy-related Laws and Regulations
Certain of our subsidiaries are pharmacies that dispense prescription drugs to participants of benefit plans administered or insured by our
HMO and insurance company subsidiaries. These pharmacy-subsidiaries are subject to state licensing requirements and regulation as well as
U.S. Drug Enforcement Agency registration requirements, U.S. Food and Drug Administration requirements and third party accreditation
requirements. Other laws and regulations affecting our pharmacy-subsidiaries include federal and state laws concerning labeling, packaging,
advertising, handling and adulteration of prescription drugs and dispensing of controlled substances.
Our pharmacy benefit management (PBM) services are subject to numerous laws and regulations, including, for example the False Claims Act
and federal and state anti-kickback laws. These laws and regulations govern, and proposed legislation and regulations may govern, critical PBM
practices, including disclosure, receipt and retention of rebates and other payments received from pharmaceutical manufacturers; receipt and
retention of transmission fees from contracted pharmacies; use of, administration of, and/or changes to drug formularies, maximum allowable
cost list pricing, and/or clinical programs; disclosure of data to third parties; drug utilization management practices; the level of duty a
pharmacy benefit manager owes its customers; configuration of pharmacy networks; the operations of our subsidiary pharmacies; disclosure
of negotiated provider reimbursement rates; calculation of customer cost share for prescription drug claims; disclosure of fees associated with
administrative service agreements and patient care programs that are attributable to customers’ drug utilization; and registration or licensing
of pharmacy benefit managers.
Other Federal and State Regulations
Employee Retirement Income Security Act and the Public Health Service Act
Our domestic subsidiaries sell most of their products and services to sponsors of employee benefit plans that are governed by the Employee
Retirement Income Security Act of 1974, as amended (‘‘ERISA’’). ERISA is a complex set of federal laws and regulations enforced by the IRS and
the Department of Labor, as well as the courts. ERISA regulates certain aspects of the relationship between us, the employers that maintain
employee welfare benefit plans subject to ERISA and participants in such plans. Our domestic subsidiaries are subject to requirements
CIGNA CORPORATION - 2017 Form 10-K 17
PART I
ITEM 1. Business
imposed by ERISA affecting claim payment and appeals procedures for individual health insurance and insured and self-insured group health
plans and for the insured dental, disability, life and accident plans we administer. Our domestic subsidiaries also may contractually agree to
comply with these requirements on behalf of the self-insured dental, disability, life and accident plans they administer.
Many provisions of the ACA impacting insured and self-insured group health plans were incorporated into ERISA. The health insurance reform
provisions under ERISA were also incorporated into the Public Health Service Act and are directly applicable to health insurance issuers
(i.e., health insurers and HMOs).
Plans subject to ERISA also can be subject to state laws and the legal question of whether and to what extent ERISA preempts a state law will
continue to be subject to court interpretation.
Privacy, Security and Data Standards Regulations
The federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (‘‘HIPAA’’) imposes minimum
standards on health insurers, HMOs, health plans, health care providers and clearinghouses for the privacy and security of protected health
information. HIPAA also established rules that standardize the format and content of certain electronic transactions, including, but not limited
to, eligibility and claims.
The Health Information Technology for Economic and Clinical Health Act (‘‘HITECH’’) imposes additional contracting requirements for covered
entities, the extension of privacy and security provisions to business associates, the requirement to provide notification to various parties in the
event of a data breach of protected health information, and enhanced financial penalties for HIPAA violations, including potential criminal
penalties for individuals. In the conduct of our business, depending on the circumstances, we may act as either a covered entity or a business
associate.
The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-affiliated third parties,
and requires financial institutions, including insurers, to provide customers with notice regarding how their non-public personal information is
used, including an opportunity to ‘‘opt out’’ of certain disclosures. State departments of insurance and certain federal agencies adopted
implementing regulations as required by federal law.
A number of states have adopted data security laws and regulations regulating data security and requiring security breach notification that
may apply to us in certain circumstances and are increasingly focused on protecting individuals from identity theft. Neither HIPAA nor the
Gramm-Leach-Bliley privacy regulations preempt more stringent state laws and regulations. In addition, international laws, rules and
regulations governing the use and disclosure of personal information are generally more stringent than in the United States, and they vary from
jurisdiction to jurisdiction.
The Cybersecurity Information Sharing Act of 2015 (‘‘CISA’’) encourages organizations to share cyber threat indicators with the federal
government and, among other things, directs HHS to develop a set of voluntary cybersecurity best practices for organizations in the health
care industry. States have also begun to issue regulations specifically related to cybersecurity. In October 2017, the National Association of
Insurance Commissioners (‘‘NAIC’’) adopted the Insurance Data Security Model Law that creates rules for insurers and other covered entities
addressing data security, investigation and notification of breaches. This includes maintaining an information security program based on
ongoing risk assessment, overseeing third-party service providers, investigating data breaches and notifying regulators of a cybersecurity
event. As the model law is intended to serve as model legislation only, states will need to enact legislation for the model law to become
mandatory and enforceable. We will continue to monitor states’ activity regarding cybersecurity regulation.
Consumer Protection Laws
We engage in direct-to-consumer activities and are increasingly offering mobile and web-based solutions to our customers. We are therefore
subject to federal and state regulations applicable to electronic communications and other consumer protection laws and regulations, such as
the Telephone Consumer Protection Act and the CAN-SPAM Act. In particular, the Federal Trade Commission is increasingly exercising its
enforcement authority in the areas of consumer privacy and data security, with a focus on web-based, mobile data and ‘‘big data.’’ Federal
consumer protection laws may also apply in some instances to privacy and security practices related to personally identifiable information.
Dodd-Frank Act and Investment-Related Regulations
The Dodd-Frank Wall Street Reform and Consumer Protection Act (the ‘‘Dodd-Frank Act’’) provides for a number of reforms and regulations in
the corporate governance, financial reporting and disclosure, investments, tax and enforcement areas. The Dodd-Frank Act established a
Federal Insurance Office (the ‘‘FIO’’) to develop federal policy on insurance matters. While the FIO does not have authority over health
insurance, it may have authority over other parts of our business, such as life insurance. Additional rulemaking by the SEC and other regulatory
authorities continues. In February 2017, President Trump signed an executive order directing the Secretary of the Treasury to conduct a review
of the Dodd-Frank Act. We continue to monitor how these regulations might impact us.
Depending upon their nature, our investment management activities are subject to U.S. federal securities laws, ERISA and other federal and
state laws governing investment related activities. In many cases, the investment management activities and investments of individual
insurance companies are subject to regulation by multiple jurisdictions.
Office of Foreign Assets Control Sanctions and Anti-Money Laundering
We also are subject to regulation by the Office of Foreign Assets Control of the Department of the Treasury that administers and enforces
economic and trade sanctions based on U.S. foreign policy and national security goals against targeted foreign countries and regimes.
Certain of our products are subject to Department of the Treasury anti-money laundering regulations under the Bank Secrecy Act.
In addition, we may be subject to similar regulations in non-U.S. jurisdictions in which we operate.
18 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1. Business
Regulation of Insurance Companies
Financial Reporting, Internal Control and Corporate Governance
Regulators closely monitor the financial condition of licensed insurance companies and HMOs. States regulate the form and content of
statutory financial statements, the type and concentration of permitted investments, and corporate governance over financial reporting. Our
insurance and HMO subsidiaries are required to file periodic financial reports and schedules with regulators in most of the jurisdictions in which
they do business as well as annual financial statements audited by independent registered public accounting firms. Certain insurance and HMO
subsidiaries are required to file an annual report of internal control over financial reporting with most jurisdictions in which they do business.
Insurance and HMO subsidiaries’ operations and accounts are subject to examination by such agencies. Many states have expanded regulations
relating to corporate governance and internal control activities of insurance and HMO subsidiaries as a result of model regulations adopted by
the NAIC with elements similar to corporate governance and risk oversight disclosure requirements under federal securities laws.
Guaranty Associations, Indemnity Funds, Risk Pools and Administrative Funds
Most states and certain non-U.S. jurisdictions require insurance companies to support guaranty associations or indemnity funds that are
established to pay claims on behalf of insolvent insurance companies. Some states have similar laws relating to HMOs and other payers, such as
consumer operated and oriented plans (co-ops) established under the ACA. In the United States, these associations levy assessments on
member insurers licensed in a particular state to pay such claims. Certain states require HMOs to participate in guaranty funds, special risk
pools and administrative funds. For additional information about guaranty fund and other assessments, see Note 21 to our Consolidated
Financial Statements.
Certain states continue to require health insurers and HMOs to participate in assigned risk plans, joint underwriting authorities, pools or other
residual market mechanisms to cover risks not acceptable under normal underwriting standards, although some states have eliminated these
requirements as a result of the ACA.
Solvency and Capital Requirements
Many states have adopted some form of the NAIC model solvency-related laws and risk-based capital rules (‘‘RBC rules’’) for life and health
insurance companies. The RBC rules recommend a minimum level of capital depending on the types and quality of investments held, the types
of business written and the types of liabilities incurred. If the ratio of the insurer’s adjusted surplus to its risk-based capital falls below statutory
required minimums, the insurer could be subject to regulatory actions ranging from increased scrutiny to conservatorship.
In addition, various non-U.S. jurisdictions prescribe minimum surplus requirements that are based upon solvency, liquidity and reserve
coverage measures. Our HMOs and life and health insurance subsidiaries, as well as non-U.S. insurance subsidiaries, are compliant with
applicable RBC and non-U.S. surplus rules.
The Risk Management and Own Risk and Solvency Assessment Model Act (‘‘ORSA’’), adopted by the NAIC, provides requirements and
principles for maintaining a group solvency assessment and a risk management framework and reflects a broader approach to U.S. insurance
regulation. ORSA includes a requirement to file an annual ORSA Summary Report in the lead state of domicile. To date, an overwhelming
majority of the states have adopted the same or similar versions of ORSA. We file our ORSA report annually as required.
Holding Company Laws
Our domestic insurance companies and certain of our HMOs are subject to state laws regulating subsidiaries of insurance holding companies.
Under such laws, certain dividends, distributions and other transactions between an insurance company or an HMO subsidiary and its affiliates
may require notification to, or approval by, one or more state insurance commissioners. In addition, the holding company acts of states in which
our subsidiaries are domiciled restrict the ability of any person to obtain control of an insurance company or HMO subsidiary without prior
regulatory approval.
Marketing, Advertising and Products
In most states, our insurance companies and HMO subsidiaries are required to certify compliance with applicable advertising regulations on an
annual basis. Our insurance companies and HMO subsidiaries are also required by most states to file and secure regulatory approval of
products prior to the marketing, advertising, and sale of such products.
Licensing Requirements
Certain subsidiaries contract to provide claim administration, utilization management and other related services for the administration of
self-insured benefit plans. These subsidiaries may be subject to state third-party administration and other licensing requirements and
regulation, as well as third party accreditation requirements.
Our international subsidiaries are often required to be licensed when entering new markets or starting new operations in certain jurisdictions.
The licensure requirements for these subsidiaries vary by country and are subject to change.
International Regulations
Our operations outside the United States expose us to laws of multiple jurisdictions and the rules and regulations of various governing bodies
and regulators, including those related to financial and other disclosures, corporate governance, privacy, data protection, data mining, data
transfer, intellectual property, labor and employment, consumer protection, direct-to-consumer communications activities, tax,
anti-corruption and anti-money laundering. Foreign laws and rules may include requirements that are different from or more stringent than
similar requirements in the United States.
CIGNA CORPORATION - 2017 Form 10-K 19
PART I
ITEM 1. Business
Our operations in countries outside the United States:
•
•
•
are subject to local regulations of the jurisdictions where we operate;
in some cases, are subject to regulations in the jurisdictions where customers reside; and
in all cases, are subject to the FCPA.
In particular, in South Korea where we are selling insurance products directly to individual customers, regulators are focused on protecting the
rights of individual customers by enforcing ‘‘Treating Customers Fairly’’ concepts. This regulatory focus results in rigorous data localization
requirements, network separation obligations, and system monitoring restrictions, as well as obligations to closely monitor marketing
communications and sales scripts. Anti-money laundering requirements in South Korea also impose obligations on the Company to collect
certain information about each customer at time of sale and to risk rank each customer to determine possible future money laundering risk.
The FCPA prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official or employee
to obtain or retain business or otherwise secure a business advantage. Outside of the United States, we may interact with government officials
in several different capacities: as regulators of our insurance business; as clients or partners who are state-owned or partially state-owned; as
health care professionals who are employed by the government; and as hospitals that are state-owned. Violations of the FCPA and other
anti-corruption laws may result in severe criminal and civil sanctions as well as other penalties, and the SEC and Department of Justice have
increased their enforcement activities with respect to FCPA. The UK Bribery Act of 2010 applies to all companies with a nexus to the United
Kingdom. Under this act, any voluntary disclosures of FCPA violations may be shared with United Kingdom authorities, thus potentially
exposing companies to liability and potential penalties in multiple jurisdictions.
If our employees or agents fail to comply with applicable laws governing our international operations, we may face investigations, prosecutions
and other legal proceedings and actions that could result in civil penalties, administrative remedies and criminal sanctions. See the Risk Factors
section beginning on page 21 for a discussion of risks related to our global operations.
Miscellaneous
Premiums and fees from CMS represented 17% of our total consolidated revenues for the year ended December 31, 2017 under a number of
contracts. We are not dependent on business from one or a few customers. Other than CMS, no one customer accounted for 10% or more of our
consolidated revenues in 2017. We are not dependent on business from one or a few brokers or agents. In addition, our insurance businesses are
generally not committed to accept a fixed portion of the business submitted by independent brokers and agents, and generally all such
business is subject to approval and acceptance.
We had approximately 46,000 employees as of December 31, 2017.
20 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1A. Risk Factors
ITEM 1A.
Risk Factors
As a large company operating in a complex industry, we encounter a variety of risks and uncertainties that could have a material adverse effect
on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of
the risks and uncertainties discussed below, together with other information contained in this Annual Report on Form 10-K, including
Management’s Discussion and Analysis of Results of Operations and Financial Condition. These risks and uncertainties are not the only ones we
face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us. The
following risk factors have been organized by category for ease of use; however many of the risks may have impacts in more than one category.
These categories, therefore, should be viewed as a starting point for understanding the significant risks facing us and not as a limitation on the
potential impact of the matters discussed. Risk factors are not necessarily listed in order of importance.
Strategic and Operational Risks
Future performance of our business will depend on our ability to execute our strategic and operational
initiatives effectively.
The future performance of our business will depend in large part on our ability to effectively implement and execute our strategic and
operational initiatives including: (1) driving value creation in our targeted areas of business growth; (2) pursuing additional opportunities to
expand our capabilities through solutions, segments, distribution channels and geographies; and (3) creating additional value through capital
deployment. Successfully executing on these initiatives depends on a number of factors, including our ability to:
•
differentiate our products and services from those of our competitors;
•
•
develop and introduce new and innovative products or programs, particularly in response to government regulation and the increased focus
on consumer-directed products;
grow our commercial product portfolio, including managing the uncertainties associated with the mix and volume of business on public
health insurance exchanges;
•
identify and introduce the proper mix or integration of products that will be accepted by the marketplace;
•
attract and retain sufficient numbers of qualified employees;
•
attract, develop and maintain collaborative relationships with a sufficient number of qualified partners, including physicians and other health
care providers in an environment of growing shortages of primary care professionals and consolidation within the provider industry;
•
attract new and maintain existing customer relationships;
•
transition health care providers from volume-based fee-for-service arrangements to a value-based system;
•
improve medical cost competitiveness in targeted markets;
•
manage our medical and administrative costs effectively;
•
identify and enter into strategic relationships;
•
manage our balance sheet exposures effectively, including our pension funding obligations; and
•
manage our Global Health Care operating expense ratio effectively.
If these initiatives fail or are not executed on effectively, our consolidated financial position and results of operations could be negatively
affected. For example, efforts to reduce operating expenses while maintaining the necessary resources and talent pool are important and, if
not managed effectively, could have long-term effects on our business by negatively impacting our ability to drive improvements in the quality
of our products and services. For our strategic initiatives to succeed, we must effectively integrate our operations, including our acquired
businesses, actively work to ensure consistency throughout the organization, and promote a global mind-set along with a focus on individual
customers. If we fail to do so, our business may be unable to grow as planned, or the result of expansion may be unsatisfactory. In addition, the
current competitive, economic and regulatory environment requires our organization to adapt rapidly and nimbly to new opportunities and
challenges. We will be unable to do so if we do not make important decisions quickly, define our appetite for risk specifically, implement new
governance, managerial and organizational processes smoothly and communicate roles and responsibilities clearly.
We face price competition and other pressures that could result in premiums that are insufficient to
cover the cost of the health care services delivered to our customers.
While health plans compete on the basis of many service and quality-related factors, we expect that price will continue to be a significant basis
of competition. Our client and customer contracts are subject to negotiation as clients and customers seek to contain their costs, including by
reducing benefits offered or elected. Increasingly, our clients seek to negotiate performance guarantees that require us to pay penalties if the
guaranteed performance standard is not met. As brokers and benefit consultants seek to enhance their revenue streams, they look to take on
services that we typically provide. Alternatively, our clients and customers may purchase different types of products that are less profitable, or
move to a competitor to obtain more favorable pricing. Each of these events would likely negatively impact our financial results.
Further, federal and state regulatory agencies may restrict our ability to implement changes in premium rates. For example, the ACA includes
an annual rate review requirement to prohibit unreasonable rate increases in the individual and small group health insurance markets and
established minimum medical loss ratios for certain plans, which could make it more difficult to obtain price increases. Fiscal concerns
regarding the continued viability of programs such as Medicare may cause decreasing reimbursement rates, delays in premium payments or
CIGNA CORPORATION - 2017 Form 10-K 21
PART I
ITEM 1A. Risk Factors
insufficient increases in reimbursement rates for government-sponsored programs in which we participate. Any limitation on our ability to
maintain or increase our premium or reimbursement levels, or a significant loss of customers resulting from our need to increase or maintain
premium or reimbursement levels, could adversely affect our business, cash flows, financial condition and results of operations.
In addition, factors such as business consolidations and strategic alliances will likely continue to create pressure to contain or otherwise restrict
price increases for products and services, despite increasing medical costs. Continuing consolidation among physicians, hospitals and other
health care providers, the emergence of accountable care organizations, vertical integration of health care providers and other entities,
changes in the organizational structures chosen by physicians, hospitals and health care providers, new market entrants, including those not
traditionally in the health care industry, and the ability of larger employers to contract directly with providers may impact how we compete and
the way we price our products. Technological advancements, such as those that allow customers and providers to access medical information
remotely and telemedicine, may also affect how we compete and price our products. Our product margins and growth depend, in part, on our
ability to compete effectively in our markets, set prices appropriately in highly competitive markets to keep or increase our market share,
increase customers as planned, and avoid losing accounts with favorable medical cost experience while retaining or increasing our customer
base in accounts with unfavorable medical cost experience.
Premiums in the health care business are generally set for one-year periods and are priced well in advance of the date on which the contract
commences. Our revenue on Medicare policies is based on bids submitted mid-year in the year before the contract year. Although we base the
premiums we charge and our Medicare bids on our estimate of future health care costs over the contract period, actual costs may exceed what
we estimate and charge in premiums due to factors such as medical cost inflation, higher than expected utilization of medical services, new or
costly drugs, treatments and technology and customer mix. Our health care costs also are affected by external events that we cannot forecast
or project and over which we have little or no control, such as influenza-related health care costs, epidemics, pandemics, terrorist attacks or
other man-made disasters, natural disasters or other events that materially increase utilization of medical and/or other covered services, as
well as changes in customers’ health care utilization patterns and provider billing practices. Relatively small differences between predicted and
actual medical costs or utilization rates as a percentage of revenue can result in significant changes in our financial results. Our profitability
depends, in part, on our ability to accurately predict, price for and effectively manage future health care costs through disciplined
underwriting, provider contracting, utilization management and product design.
The reserves we hold for expected medical claims are based on estimates that involve an extensive
degree of judgment and are inherently variable. If actual claims exceed our estimates, our operating
results could be materially adversely affected, and our ability to take timely corrective actions to contain
future costs may be limited.
We maintain and record medical claims reserves on our balance sheet for estimated future payments. Our estimates of health care costs
payable are based on a number of factors, including historical claim experience, but this estimation process requires extensive judgment.
Considerable variability is inherent in such estimates, and the accuracy of the estimates is highly sensitive to changes in medical claims
submission and processing patterns and/or procedures, changes in customer base and product mix, changes in the utilization of medical
and/or other covered services, changes in medical cost trends, changes in our medical management practices and the introduction of new
benefits and products. Furthermore, if we are not able to accurately and promptly anticipate and detect medical cost trends, our ability to take
timely corrective actions to limit future costs and reflect our current benefit cost experience in our pricing process may be limited. In addition,
while we continually review estimates of future payments relating to medical claims costs for services incurred in the current and prior periods
and make adjustments to our reserves, the actual health care costs may exceed the reserves we have recorded.
If we fail to develop and maintain satisfactory relationships with physicians, hospitals and other health
care providers, our business and results of operations may be adversely affected.
We directly and indirectly contract with physicians, hospitals and other health care professionals and facilities to provide health care services
to our customers. Our results of operations are substantially dependent on our ability to contract for these services at competitive prices. In
any particular market, physicians, hospitals and health care providers may enter into exclusive arrangements with competitors or simply refuse
to contract with us, demand higher payments or take other actions that could result in higher medical costs or less desirable products for our
customers. In some markets, certain providers, particularly hospitals, physician/hospital organizations and multi-specialty physician groups,
may have significant or controlling market positions that could result in a diminished bargaining position for us. If providers refuse to contract
with us, use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, our ability to market
products or to be profitable in those areas could be materially and adversely affected. Establishing collaborative arrangements with physician
groups, specialist groups, independent practice associations, hospitals and health care delivery systems is key to our strategic focus to
transition from volume-based fee-for-service arrangements to a value-based health care system. If such collaborative arrangements do not
result in the lower medical costs that we project or if we fail to attract health care providers to such arrangements, or are less successful at
implementing such arrangements than our competitors, our attractiveness to customers may be reduced and our ability to profitably grow our
business may be adversely affected.
Our ability to develop and maintain satisfactory relationships with health care providers also may be negatively impacted by other factors not
associated with us, such as changes in Medicare and/or Medicaid reimbursement levels, increasing pressure on revenue and other pressures on
health care providers and increasing consolidation activity among hospitals, physician groups and health care providers. For example, ongoing
reductions by CMS and state governments in amounts payable to providers, particularly hospitals, for services provided to Medicare and
Medicaid enrollees may exacerbate the cost shift to private payors, thereby adversely impacting our ability to maintain or develop new
cost-effective health care provider contracts or result in a loss of revenues or customers.
Continuing consolidation among physicians, hospitals and other health care providers, the emergence of accountable care organizations,
vertical integration of health care providers and other entities, changes in the organizational structures chosen by physicians, hospitals and
health care providers and new market entrants, including those not traditionally in the health care industry, may affect the way providers
interact with us and may change the competitive landscape in which we operate. In some instances, these organizations may compete directly
22 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1A. Risk Factors
with us, potentially affecting the way that we price our products and services or cause us to incur increased costs if we change our operations
to be more competitive.
Out-of-network providers are not limited by any agreement with us in the amounts they bill. While benefit plans place limits on the amount of
charges that will be considered for reimbursement, out-of-network providers have become increasingly sophisticated and aggressive and such
limitations can be difficult to enforce. As a result, the outcome of disputes where we do not have a provider contract may cause us to pay higher
medical or other benefit costs than we projected.
As a global company, we face political, legal, operational, regulatory, economic and other risks that
present challenges and could negatively affect our multinational operations and/or our long-term growth.
As a global company, our business is increasingly exposed to risks inherent in foreign operations. These risks can vary substantially by market,
and include political, legal, operational, regulatory, economic and other risks, including government intervention that we do not face in our U.S.
operations. The global nature of our business and operations may present challenges including, but not limited to, those arising from:
•
varying regional and geopolitical business conditions and demands;
•
regulation that may discriminate against U.S. companies, favor nationalization or expropriate assets;
•
•
price controls or other pricing issues and exchange controls or other restrictions that prevent us from transferring funds from these
operations out of the countries in which we operate or converting local currencies that our foreign operations hold into U.S. dollars or other
currencies;
foreign currency exchange rates and fluctuations that may have an impact on the future costs or on future sales and cash flows from our
international operations, and any countermeasures that we may implement may not be effective in reducing the effect of volatile currencies
and other risks of our international operations;
•
tax positions and applicable regulations that may be subject to interpretation or uncertainty to a greater extent than in the United States;
•
our reliance on local sales forces for some operations in countries that may have labor problems and/or less flexible employee relationships
that can be difficult and expensive to terminate, where laws and regulations regarding employment status may be less clear, or where
changes in local regulation or law may disrupt business operations;
•
effectively managing our partner relationships in countries outside of the United States;
•
managing more geographically diverse operations and projects;
•
operating in new foreign markets that may require considerable management time before operations generate any significant revenues and
earnings;
•
providing data protection on a global basis and sufficient levels of technical support in different locations;
•
the global trend for companies to enact local data residency requirements;
•
political conditions, including the June 2016 referendum in the United Kingdom to leave the European Union and tensions in the Korean
Peninsula;
•
acts of war, terrorism, natural disasters or pandemics in locations where we operate; and
•
general economic and political conditions.
These factors may increase in significance as we continue to expand globally, and any one of these challenges could negatively affect our
operations or long-term growth. For example, due to the concentration of our international business in South Korea, the Global Supplemental
Benefits segment is exposed to potential losses resulting from economic and regulatory changes in that country and the geopolitical climate in
the Korean Peninsula, as well as foreign currency movements affecting the South Korean currency, that could have a significant impact on the
segment’s results and our consolidated financial results.
International operations also require us to devote significant resources to implement controls and systems in new markets to comply with, and
to ensure that our vendors and partners comply with, U.S. and foreign laws prohibiting bribery, corruption and money laundering, in addition to
other regulations regarding, among other things, our products, direct-to-consumer communications, customer privacy, data protection and
data residency. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees,
restrictions or outright prohibitions on the conduct of our business and significant reputational harm. We must regularly reassess the size,
capability and location of our global infrastructure and make appropriate changes, and must have effective change management processes
and internal controls in place to address changes in our business and operations. Our success depends, in part, on our ability to anticipate these
risks and manage these challenges. Our failure to comply with laws and regulations governing our conduct outside the United States or to
establish constructive relations with non-U.S. regulators could have a material adverse effect on our business, results of operations, financial
condition, liquidity and long-term growth.
We are dependent on the success of our relationships with third parties for various services and
functions, including, but not limited to, certain pharmacy benefit management services.
To improve operating costs, productivity and efficiencies, we contract with third parties for the provision of specific services, such as certain
pharmacy benefit management services, information technology, medical management services, call center and claim services. Our operations
may be adversely affected if a third party fails to satisfy its obligations to us or if the arrangement is terminated in whole or in part or if there is a
contractual dispute between us and the third party. Even though contracts are intended to provide certain protections, we have limited control
CIGNA CORPORATION - 2017 Form 10-K 23
PART I
ITEM 1A. Risk Factors
over the actions of third parties. For example, noncompliance with any privacy or security laws and regulations or any security breach involving
one of our third-party vendors or a dispute between us and a third party vendor related to our arrangement could have a material adverse
effect on our business, results of operations, financial condition, liquidity and reputation. In addition, with respect to services or functions
outsourced to third parties in foreign jurisdictions, we also are exposed to risks inherent in conducting business outside of the United States.
Outsourcing also may require us to change our existing operations, adopt new processes for managing these service providers and/or
redistribute responsibilities to realize the potential productivity and operational efficiencies. If there are delays or difficulties in changing
business processes or our third party vendors do not perform as expected, we may not realize, or not realize on a timely basis, the anticipated
economic and other benefits of these relationships. This could result in substantial costs or regulatory compliance issues, divert management’s
attention from other strategic activities, negatively affect employee morale or create other operational or financial problems for us.
Terminating or transitioning in whole or in part arrangements with key vendors could result in additional costs or penalties, risks of operational
delays or potential errors and control issues during the termination or transition phase. We may not be able to find an alternative vendor in a
timely manner or on acceptable terms. If there is an interruption in business or loss of access to data resulting from a termination or transition in
services, we may not be able to meet the demands of our customers and, in turn, our business and results of operations could be adversely
impacted.
Acquisitions, joint ventures and other transactions involve risks and we may not realize the expected
benefits because of integration difficulties, underperformance relative to our expectations and other
challenges.
As part of our growth strategy, we regularly consider and enter into strategic transactions, including mergers, acquisitions, joint ventures,
licensing arrangements and other relationships (collectively referred to as ‘‘transactions’’), with the expectation that these transactions will
result in various benefits. Our ability to achieve the anticipated benefits of these transactions is subject to numerous uncertainties and risks,
including our ability to integrate operations, resources and systems, including data security systems, in an efficient and effective manner. We
could also face challenges in implementing business plans; changes in laws and regulations or conditions imposed by regulations applicable to
the business; retaining key employees; and general competitive factors in the marketplace. These events could result in increased costs,
decreases in expected revenues, earnings or cash flow, and goodwill or other intangible asset impairment charges. Further, we may finance
transactions by issuing common stock for some or all of the purchase price that could dilute the ownership interests of our shareholders, or by
incurring additional debt that could impact our ability to access capital in the future.
In addition, effective internal controls are necessary to provide reliable and accurate financial reports and to mitigate the risk of fraud. The
integration of businesses is likely to cause increasing complexity in our systems and internal controls and make them more difficult to manage.
Any difficulties in assimilating businesses into our control system could cause us to fail to meet our financial reporting obligations. Ineffective
internal controls also could cause investors to lose confidence in our reported financial information that could negatively impact the trading
price of our stock and our access to capital.
Our business depends on our ability to effectively invest in, implement improvements to and properly
maintain the uninterrupted operation and data integrity of our information technology and other business
systems.
Our business is highly dependent on maintaining effective information systems as well as the integrity and timeliness of the data we use to
serve our customers and health care professionals and to operate our business. If our data were found to be inaccurate or unreliable due to
fraud or other error, or if we, or any of the third-party service providers we engage, were to fail to maintain information systems and data
integrity effectively, we could experience operational disruptions that may impact our clients, customers and health care professionals and
hinder our ability to establish appropriate pricing for products and services, retain and attract clients and customers, establish reserves and
report financial results timely and accurately and maintain regulatory compliance, among other things.
Our information technology strategy and execution are critical to our continued success. Increasing regulatory and legislative changes will
place additional demands on our information technology infrastructure that could have a direct impact on resources available for other
projects tied to our strategic initiatives. In addition, recent trends toward greater consumer engagement in health care require new and
enhanced technologies, including more sophisticated applications for mobile devices. We must continue to invest in long-term solutions that
will enable us to anticipate customer needs and expectations, enhance the customer experience, act as a differentiator in the market and
protect against cybersecurity risks and threats. Our success is dependent, in large part, on maintaining the effectiveness of existing technology
systems and continuing to deliver and enhance technology systems that support our business processes in a cost-efficient and resource-
efficient manner. Connectivity among technologies is becoming increasingly important. The failure of our health care technologies to operate
seamlessly with other products could adversely affect our results of operations, financial position and cash flows. We must also develop new
systems to meet current market standards and keep pace with continuing changes in information processing technology, evolving industry and
regulatory standards and customer needs. Failure to do so may present compliance challenges and impede our ability to deliver services in a
competitive manner. Further, because system development projects are long-term in nature, they may be more costly than expected to
complete and may not deliver the expected benefits upon completion.
In addition, our business is highly dependent upon our ability to perform, in an efficient and uninterrupted fashion, necessary business
functions, such as claims processing and payment, internet support and customer call centers, and processing new and renewal business.
Unavailability, cyber-attack or other failure of one or more of our information technology or other systems could cause slower response times,
resulting in claims not being processed as quickly as clients or customers desire, decreased levels of client or customer service and satisfaction,
and harm to our reputation. Because our information technology and other systems interface with and depend on third-party systems, we
could experience service denials if demand for such service exceeds capacity or a third-party system fails or experiences an interruption. If
sustained or repeated, such business interruptions, systems failures or service denials could have material adverse effects on our business,
results of operations, financial condition and liquidity.
24 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1A. Risk Factors
As a large health services company, we are subject to cyber-attacks or other privacy or data security
incidents. If we are unable to prevent or contain the effects of any such attacks, we may suffer exposure
to substantial liability, reputational harm, loss of revenue or other damages.
Our business depends on our clients’ and customers’ willingness to entrust us with their health-related and other sensitive personal
information. Computer systems may be vulnerable to physical break-ins, computer viruses or malware, programming errors, attacks by third
parties or similar disruptive problems. We have been, and will likely continue to be, the target of computer viruses or other malicious codes,
unauthorized access, cyber-attacks or other computer-related penetrations. There have been large scale cyber-attacks within the health care
industry. As we increase the amount of personal information that we store and share digitally, our exposure to data security and related
cybersecurity risks increases, including the risk of undetected attacks, damage, loss or unauthorized access or misappropriation of proprietary
or personal information, and the cost of attempting to protect against these risks also increases. We have implemented security technologies,
processes and procedures to protect consumer identity and provide employee awareness training around phishing, malware and other cyber
risks; however, there are no assurances that such measures will be effective against all types of breaches. The techniques used change
frequently or are often not recognized until after they have been launched, because cyber-attacks can originate from a wide variety of sources
including third parties such as external service providers. Those parties may also attempt to fraudulently induce employees, customers or other
users of our systems to disclose sensitive information in order to gain access to our data or that of our customers. In addition, while we have
certain standards for all vendors that provide us services, our vendors, and in turn, their own service providers, may become subject to the
same type of security breaches. Finally, our offices may be vulnerable to security incidents or security attacks, acts of vandalism or theft,
misplaced or lost data, human error or similar events that could negatively affect our systems and our customers’ and clients’ data.
The costs to eliminate or address security threats and vulnerabilities before or after a cyber-incident could be significant. Our remediation
efforts may not be successful and could result in interruptions, delays, or cessation of service and loss of existing or potential customers.
In addition, breaches of our security measures and the unauthorized dissemination of sensitive personal information or proprietary information
or confidential information about us, our customers or other third-parties could expose our customers’ private information and our customers
to the risk of financial or medical identity theft. Unauthorized dissemination of confidential and proprietary information about our business and
strategy also could negatively affect the achievement of our strategic initiatives. Such events would also negatively affect our ability to
compete, others’ trust in us, our reputation, customer base and revenues and expose us to mandatory disclosure (including to the media),
litigation and other enforcement proceedings, material fines, penalties and/or remediation costs, and compensatory, special, punitive and
statutory damages, consent orders and other adverse actions, any of which could adversely affect our business, results of operations, financial
condition or liquidity.
Our pharmacy benefit management business and related operations are subject to a number of risks and
uncertainties that are in addition to those we face in our health care business.
Notwithstanding our arrangement with a third-party vendor for certain pharmacy benefit management services, we remain responsible to
regulators and our clients and customers for the delivery of those pharmacy benefit management services that we contract to provide. Our
pharmacy benefit management business is subject to federal and state regulation, including without limitation, federal and state anti-kickback
laws, consumer protection laws, ERISA, HIPAA and laws related to the operation of Internet and mail-service pharmacies, as well as the laws
and regulations of the foreign countries in which we conduct business. In addition, certain of our subsidiaries are pharmacies subject to state
licensing and U.S. Drug Enforcement Agency registration requirements and state and federal laws concerning labeling, packaging, advertising,
handling and adulteration of prescription drugs and dispensing of controlled substances. Noncompliance with applicable regulations by us or
our third-party vendors could have material adverse effects on our business, results of operations, financial condition, liquidity and reputation.
Our pharmacy benefit management business also would be adversely affected by an inability to contract on favorable terms with
pharmaceutical manufacturers and we could suffer exposure to liabilities and reputational harm in connection with purported errors by mail
order or retail pharmacy businesses.
In operating onsite clinics and other types of medical facilities, we may be subject to additional liability
that could result in significant time and expense.
In addition to contracting with physicians and other health care providers for services, we employ physicians and other health care
professionals at onsite low acuity and primary care clinics that we operate for our customers, as well as certain clinics for our employees. In
addition, our Government business operates LivingWell health centers and we own and operate multispecialty health care centers, low acuity
clinics and other types of centers in the Phoenix, Arizona metropolitan area that employ physicians and other health care professionals. As a
direct employer of health care professionals and as an owner or operator of medical facilities, we are subject to liability for negligent acts,
omissions, or injuries occurring at one of these clinics or caused by one of our employees. Even if any claims brought against us are
unsuccessful or without merit, we still have to defend against such claims. The defense of any actions may result in significant expenses that
could have a material adverse effect on our business, results of operations, financial condition, liquidity and reputation.
Legal and Compliance Risks
Our business is subject to substantial government regulation, as well as new laws or regulations or
changes in existing laws or regulations that could have a material adverse effect on our business, results
of operations, financial condition and liquidity.
Our business is regulated at the federal, state, local and international levels. The laws and rules governing our business and related
interpretations, including, among others, those associated with the ACA, are increasing in number and complexity, are subject to frequent
change and can be inconsistent or in conflict with each other. As a public company with global operations, we are subject to the laws of multiple
CIGNA CORPORATION - 2017 Form 10-K 25
PART I
ITEM 1A. Risk Factors
jurisdictions and the rules and regulations of various governing bodies, such as those related to financial and other disclosures, corporate
governance, privacy, data protection, labor and employment, consumer protection, tax and anti-corruption.
We must identify, assess and respond to new trends in the legislative and regulatory environment, as well as comply with the various existing
regulations applicable to our business. Existing or future laws, rules, regulatory interpretations or judgments could force us to change how we
conduct our business, affect the products we offer, restrict revenue and enrollment growth, increase our costs, including operating, health care
technology and administrative costs, and require enhancements to our compliance infrastructure and internal controls environment. Existing
or future laws and rules also could require us to take other actions such as changing our business practices, thereby increasing our liability in
federal and state courts for coverage determinations, contract interpretation and other actions.
Several bills were introduced in Congress in 2017 to repeal and replace the ACA, though none have passed the House and Senate. Discussions
on the ACA continue in Congress. Throughout 2017, President Trump took several steps to limit the utility of the ACA and continues to
advocate for its repeal and replacement. The individual mandate was repealed effective January 1, 2019 as part of the U.S. tax reform legislation
that was signed into law in December 2017. We are unable to predict how these events will ultimately be resolved and what the potential impact
may be on the ACA, and in turn, on our business including, but not limited to, our products, services, processes and technology and on our
relationships with current and future customers, producers, vendors and health care providers. Legal challenges regarding aspects of the ACA,
such as litigation regarding the payment of risk corridor receivables and cost sharing reduction subsidies, have contributed to this uncertainty.
In addition, state legislatures have and will continue to focus on health care issues, particularly in light of the various ACA amendments
proposed by Congress and the Trump administration executive orders.
Further, failure to effectively implement or adjust our strategic and operational initiatives, such as by reducing operating costs, adjusting
premium pricing or benefit design or transforming our business model in response to regulatory changes may have a material adverse effect
on our results of operations, financial condition and cash flows, including, but not limited to, our ability to maintain the value of our goodwill
and other intangible assets.
Our insurance and HMO subsidiaries must be licensed by and are subject to the regulations of the jurisdictions in which they conduct business.
For example, HMOs and insurance companies are regulated under specific state laws and regulations and indirectly affected by other health
care-related laws and regulations. State regulations mandate minimum capital or restricted cash reserve requirements. In addition, state
guaranty fund laws and related regulations subject us to assessments for certain obligations to policyholders and claimants of impaired or
insolvent insurance companies. Some states have similar laws relating to HMOs and other payors, such as consumer operated and oriented
plans (co-ops) established under the ACA. Any such assessment could expose us to the risk of paying a portion of an impaired or insolvent
insurance company’s claims through state guaranty association assessments. We also participate in the private exchange marketplace.
Whether and the extent to which states may issue regulations that apply to private exchanges remains uncertain.
In addition to the regulations discussed above, we are required to obtain and maintain insurance and other regulatory approvals to market
many of our products, increase prices for certain regulated products and consummate some of our acquisitions and dispositions. Delays in
obtaining or failure to obtain or maintain these approvals could reduce our revenue or increase our costs.
The health care industry is also regularly subject to negative media attention, including as a result of the political environment and the ongoing
debate concerning the ACA. Such publicity may adversely affect our stock price and reputation in certain markets.
For more information on regulation, see ‘‘Business – Regulation’’ in Part I, Item 1 of this Form 10-K.
There are various risks associated with participating in government-sponsored programs, such as
Medicare, including dependence upon government funding, compliance with government contracts and
increased regulatory oversight.
Through our Government business, we contract with CMS and various state governmental agencies to provide managed health care services
including Medicare Advantage plans and Medicare-approved prescription drug plans. Revenues from Medicare programs are dependent, in
whole or in part, upon annual funding from the federal government through CMS and/or applicable state or local governments. Funding for
these programs is dependent on many factors outside our control including general economic conditions, continuing government efforts to
contain health care costs and budgetary constraints at the federal or applicable state or local level and general political issues and priorities.
These entities generally have the right to not renew or cancel their contracts with us on short notice without cause or if funds are not available.
Unanticipated changes in funding, such as the application of sequestration by the federal or state governments, could substantially reduce our
revenues and profitability.
The Medicare program has been the subject of regulatory reform initiatives, including the ACA. The premium rates paid to Medicare Advantage
plans and Medicare Part D plans are established by contract, although the rates differ depending on a combination of factors, many of which
are outside our control. The ACA ties a portion of each Medicare Advantage plan’s and Medicare Part D plan’s reimbursement to the plan’s ‘‘Star
Rating’’ by CMS, with those plans receiving a rating of four or more stars eligible for quality-based bonus payments. The Star Rating system
considers various measures adopted by CMS, including, for example, quality of care, preventative services, chronic illness management,
coverage determination appeals and customer satisfaction. The Star Rating system is subject to change annually by CMS, which may make it
more difficult to achieve four stars or greater. Our Medicare Advantage plans’ and Medicare Part D plans’ operating results, premium revenue
and benefit offerings are likely to continue to be significantly determined by their Star Ratings. If we fail to meet our expectations regarding
Star Ratings, are unsuccessful in maintaining or improving our Star Ratings, fail to meet or exceed our competitors’ ratings, or if quality-bonus
payments are eliminated, our financial performance may be adversely affected. See Part II, Item 7 – Management’s Discussion and Analysis of
Financial Condition and Results of Information – Health Care Industry Developments and Other Matters Affecting our Global Health Care
Segment for additional information on our Star Ratings.
Contracts with CMS and the various state governmental agencies contain certain provisions regarding data submission, provider network
maintenance, provider directories, quality measures, claims payment, continuity of care, call center performance and other requirements. If we
fail to comply with these requirements, we may be subject to administrative actions, fines or other penalties that could impact our profitability.
26 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1A. Risk Factors
The ACA established health insurance exchanges for individuals and small employers. Insurers participating on the health insurance exchanges
are required to offer a minimum level of benefits and comply with requirements with respect to premium rates and coverage limitations. Our
participation in these exchanges involves uncertainties associated with mix and volume of business and could adversely affect our results of
operations, financial position and cash flows. The executive order signed by President Trump in October 2017 that halted payment of the cost
sharing reduction subsidies has created additional uncertainty regarding the future of public health insurance exchanges.
In addition, any failure to comply with various state and federal health care laws and regulations, including those directed at preventing fraud
and abuse in government funded programs, could result in investigations or litigation, such as actions under the federal False Claims Act and
similar whistleblower statutes under state laws. This could subject us to fines, penalties or other enforcement actions, restrictions on our ability
to market or enroll new customers, limits on expansion, restrictions or exclusions from programs or other agreements with federal or state
governmental agencies that could adversely impact our business, cash flows, financial condition, results of operations and reputation.
In addition, our Medicare Advantage and Medicare Part D businesses face a number of other risks including potential uncollectible receivables
resulting from processing and/or verifying enrollment, inadequate underwriting assumptions, inability to receive and process correct
information or increased medical or pharmaceutical costs. Actual results may be materially different than our assumptions and estimates
regarding these complex and wide-ranging programs that could have a material adverse effect on our business, financial condition and results
of operations.
We face risks related to litigation, regulatory audits and investigations.
We are routinely involved in numerous claims, lawsuits, regulatory audits, investigations and other legal matters arising, for the most part, in the
ordinary course of business, including that of administering and insuring employee benefit programs. These legal matters could include benefit
claims, breach of contract actions, tort claims, claims arising from consumer protection laws, claims disputes under federal or state laws and
disputes regarding reinsurance arrangements, employment and employment discrimination-related suits, antitrust claims, employee benefit
claims, wage and hour claims, tax, privacy, intellectual property and whistle blower claims, shareholder suits and other securities law claims and
real estate disputes. In addition, we have incurred and likely will continue to incur liability for practices and claims related to our health care
business, such as marketing misconduct, failure to timely or appropriately pay for or provide health care, provider network structure, poor
outcomes for care delivered or arranged, provider disputes including disputes over compensation or contractual provisions, and claims related
to our administration of self-funded business. There are currently, and may be in the future, attempts to bring class action lawsuits against the
company and the industry; individual plaintiffs also may bring multiple claims regarding the same subject matter against us and other
companies in our industry.
With respect to our global operations, contractual rights, tax positions, laws and regulations may be subject to interpretation or uncertainty to
a greater degree than in the United States, and therefore subject us to disputes by customers, governmental authorities or others. Foreign laws
and rules and regulatory audit and investigative practices may differ from or be more stringent than, similar requirements in the United States.
Court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial non-economic or
punitive damages may be sought. We seek to procure insurance coverage to cover some of these potential liabilities. However, certain potential
liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may be insufficient to cover the entire
damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance, and insurance coverage
for all or certain forms of liability may become unavailable or prohibitively expensive in the future. It is possible that the resolution of current or
future legal matters and claims could result in changes to our industry and business practices, losses material to our results of operations,
financial condition and liquidity or damage to our reputation.
We are frequently the subject of regulatory market conduct and other reviews, audits and investigations by state insurance and health and
welfare departments, attorneys general, CMS and the OIG and comparable authorities in foreign jurisdictions. With respect to our Medicare
Advantage and Medicare Part D businesses, CMS and OIG perform audits to determine a health plan’s compliance with federal regulations and
contractual obligations, including compliance with proper coding practices and fraud and abuse enforcement practices through audits
designed to detect and correct improper payments. The Department of Justice is conducting an industry review of the risk adjustment data
submission practices and business processes, including review of medical charts, of Medicare Advantage organizations under Medicare Parts C
and D. There also continues to be heightened review by federal and state regulators of business and reporting practices within the health care,
disability and life insurance industry, including with respect to claims payment and related escheat practices, and increased scrutiny by other
state and federal governmental agencies (such as state attorneys general) empowered to bring criminal actions in circumstances that could
have previously given rise only to civil or administrative proceedings. These regulatory audits or reviews or actions by other governmental
agencies could result in changes to our business practices, retroactive adjustments to certain premiums, significant fines, penalties, civil
liabilities, criminal liabilities or other sanctions, including restrictions on our ability to market certain products or engage in business-related
activities, that could have a material adverse effect on our business, results of operation, financial condition and liquidity. In addition, disclosure
of an adverse investigation or audit or the imposition of fines or other sanctions could negatively affect our reputation in certain markets and
make it more difficult for us to sell our products and services.
A description of material pending legal actions and other legal and regulatory matters is included in Note 21 to our Consolidated Financial
Statements included in this Form 10-K. The outcome of litigation and other legal or regulatory matters is always uncertain.
If we fail to comply with applicable privacy, security and data laws, regulations and standards, our
business and reputation could be materially and adversely affected.
The collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information are regulated at the
federal, state, international and industry levels and requirements are imposed on us by contracts with clients. In some cases, such laws, rules,
regulations and contractual requirements also apply to our vendors and require us to obtain written assurances of their compliance with such
requirements or may hold us liable for any violations by our vendors. International laws, rules and regulations governing the use and disclosure
of such information are generally more stringent than in the United States, and they vary across jurisdictions. We also are subject to various
other consumer protection laws that regulate our communications with customers.
CIGNA CORPORATION - 2017 Form 10-K 27
PART I
ITEM 1A. Risk Factors
These laws, rules, and contractual requirements are subject to change. Compliance with new privacy, security and data laws, regulations and
requirements may result in increased operating costs, and may constrain or require us to alter our business model or operations. For example,
the HITECH amendments to HIPAA may further restrict our ability to collect, disclose and use sensitive personal information and may impose
additional compliance requirements on our business.
HIPAA requires covered entities to comply with the HIPAA privacy, security and breach rules. In addition, business associates must comply with
the HIPAA security and breach requirements. While we provide for appropriate protections through our contracts with our third-party service
providers and in certain cases assess their security controls, we have limited oversight or control over their actions and practices. Several of our
businesses act as business associates to their covered entity customers and, as a result, collect, use, disclose and maintain sensitive personal
information in order to provide services to these customers. HHS has continued its audit program to assess HIPAA compliance efforts by
covered entities and has expanded it to include business associates. In addition, HHS has increased its enforcement efforts. These efforts result
in enforcement actions that are the result of investigations brought on by the notification to HHS of a breach. An audit resulting in findings or
allegations of noncompliance or the implementation of an enforcement action could have an adverse effect on our results of operations,
financial position, cash flows and reputation.
Effective prevention, detection and control systems are critical to maintain regulatory compliance and
prevent fraud and failure of these systems could adversely affect us.
Federal and state governments have made investigating and prosecuting health care and other insurance fraud and abuse a priority. Fraud and
abuse prohibitions encompass a wide range of activities including kickbacks for referral of customers, billing for unnecessary medical services,
improper marketing and violations of patient privacy rights. The regulations and contractual requirements applicable to us are complex and
subject to change. In addition, ongoing vigorous law enforcement, a highly technical regulatory scheme and the Dodd-Frank Act legislation
and related regulations enhance regulators’ enforcement powers and whistleblower incentives and protections. Our compliance efforts in this
area will continue to require significant resources. Failure of our prevention, detection or control systems related to regulatory compliance or
the failure of employees to comply with our internal policies including data systems security or unethical conduct by managers and employees,
could adversely affect our reputation and also expose us to litigation and other proceedings, fines and penalties.
In addition, provider or customer fraud that is not prevented or detected could impact our medical costs or those of our self-insured clients.
Further, during an economic downturn, we may experience increased fraudulent claims volume that may lead to additional costs due to an
increase in disputed claims and litigation.
Economic Risks
Significant stock market or interest rate declines could result in additional unfunded pension obligations
resulting in the need for additional plan funding by us and increased pension expenses.
We currently have unfunded obligations in our frozen pension plans. A significant decline in the value of the plans’ equity and fixed income
investments or unfavorable changes in applicable laws or regulations could materially increase our expenses and change the timing and
amount of required plan funding. This could reduce the cash available to us, including our subsidiaries. We also are exposed to interest rate and
equity risk associated with our pension and other post-retirement obligations. Sustained declines in interest rates could have an adverse
impact on the funded status of our pension plans and our reinvestment yield on new investments. See Note 15 to our Consolidated Financial
Statements for more information on our obligations under the pension plan.
Significant changes in market interest rates affect the value of our financial instruments that promise a
fixed return or benefit and the value of particular assets and liabilities.
As an insurer, we have substantial investment assets that support insurance and contractholder deposit liabilities. Generally low levels of
interest rates on investments, such as those experienced in U.S. and foreign financial markets during recent years, have negatively impacted
our level of investment income earned in recent periods.
A substantial portion of our investment assets are in fixed interest-yielding debt securities of varying maturities, fixed redeemable preferred
securities and commercial mortgage loans. The value of these investment assets can fluctuate significantly with changes in market conditions.
A rise in interest rates would likely reduce the value of our investment portfolio and increase interest expense if we were to access our available
lines of credit.
A downgrade in the financial strength ratings of our insurance subsidiaries could adversely affect new
sales and retention of current business, and a downgrade in our debt ratings would increase the cost of
borrowed funds and could negatively affect our ability to access capital.
Financial strength, claims paying ability and debt ratings by recognized rating organizations are each important factors in establishing the
competitive position of insurance and health benefits companies. Ratings information by nationally recognized ratings agencies is broadly
disseminated and generally used throughout the industry. We believe that the claims paying ability and financial strength ratings of our
principal insurance subsidiaries are important factors in marketing our products to certain customers. Our debt ratings impact both the cost
and availability of future borrowings and, accordingly, our cost of capital. Each of the rating agencies reviews ratings periodically and there can
be no assurance that current ratings will be maintained in the future. A downgrade of these ratings in the future could make it more difficult to
either market our products successfully or raise capital to support business growth within our insurance subsidiaries.
28 CIGNA CORPORATION - 2017 Form 10-K
PART I
ITEM 1A. Risk Factors
Global market, economic and geopolitical conditions may cause fluctuations in equity market prices,
interest rates and credit spreads that could impact our ability to raise or deploy capital and affect our
overall liquidity.
If the equity and credit markets experience extreme volatility and disruption, there could be downward pressure on stock prices and access to
capital for certain issuers without regard to those issuers’ underlying financial strength. Extreme disruption in the credit markets could
adversely impact our availability and cost of capital in the future.
As of December 31, 2017, our outstanding long-term debt totaled $5.2 billion. In the event of adverse economic and industry conditions, we
may be required to dedicate a greater percentage of our cash flow from operations to the payment of principal and interest on our debt,
thereby reducing the funds we have available for other purposes, such as investments and other expenditures in ongoing businesses,
acquisitions, dividends and stock repurchases. In these circumstances, our ability to execute our strategy may be limited, our flexibility in
planning for or reacting to changes in business and market conditions may be reduced, or our access to capital markets may be limited such
that additional capital may not be available or may be available only on unfavorable terms.
Unfavorable developments in economic conditions may adversely affect our business, results of
operations and financial condition.
Many factors, including geopolitical issues, future economic downturns, availability and cost of credit and other capital and consumer
spending can negatively impact the U.S. and global economies. Our results of operations could be materially and adversely affected by the
impact of unfavorable economic conditions on our customers (both employers and individuals), health care providers and third-party vendors.
For example:
•
•
•
Employers may take action to reduce their operating costs by modifying, delaying or canceling plans to purchase our products or making
changes in the mix of products purchased that are unfavorable to us.
Higher unemployment rates and workforce reductions could result in lower enrollment in our employer-based plans (including an increase in
the number of employees who opt out of employer-based plans) or our individual plans.
Because of unfavorable economic conditions or the ACA, employers may stop offering health care coverage to employees or elect to offer
this coverage on a voluntary, employee-funded basis as a means to reduce their operating costs.
•
Our historical disability claim experience and industry data indicate that submitted disability claims rise under adverse economic conditions.
•
•
•
If customers are not successful in generating sufficient funds or are precluded from securing financing, they may not be able to pay, or may
delay payment of, accounts receivable that are owed to us.
Our customers or potential customers may force us to compete more vigorously on factors such as price and service to retain or obtain their
business.
A prolonged unfavorable economic environment could adversely impact the financial position of hospitals and other health care providers,
potentially increasing our medical costs as these providers attempt to maintain revenue levels in their efforts to adjust to their own economic
challenges.
•
Our third-party vendors could significantly and quickly increase their prices or reduce their output to reduce their operating costs. Our
business depends on our ability to perform necessary business functions in an efficient and uninterrupted fashion.
These factors could lead to a decrease in our customer base, revenues or margins and/or an increase in our operating costs.
In addition, during a prolonged unfavorable economic environment, state and federal budgets could be materially and adversely affected,
resulting in reduced or delayed reimbursements or payments in state and federal government programs such as Medicare and Social Security.
These state and federal budgetary pressures also could cause the government to impose new or a higher level of taxes or assessments on us,
such as premium taxes on insurance companies and HMOs and surcharges or fees on select fee-for-service and capitated medical claims.
Although we could attempt to mitigate or cover our exposure from such increased costs through, among other things, increases in premiums,
there can be no assurance that we will be able to mitigate or cover all of such costs, which may have a material adverse effect on our business,
results of operations, financial condition and liquidity.
We are subject to the credit risk of our reinsurers.
We enter into reinsurance arrangements with other insurance companies, primarily to limit losses from large exposures or to permit recovery of
a portion of direct losses. We also may enter into reinsurance arrangements in connection with acquisition or divestiture transactions when the
underwriting company is not being acquired or sold.
Under all reinsurance arrangements, reinsurers assume insured losses, subject to certain limitations or exceptions that may include a loss limit.
These arrangements also subject us to various obligations, representations and warranties with the reinsurers. Reinsurance does not relieve us
of liability as the originating insurer. We remain liable to the underlying policyholders if a reinsurer defaults on obligations under the
reinsurance arrangement. Although we regularly evaluate the financial condition of reinsurers to minimize exposure to significant losses from
reinsurer insolvencies, reinsurers may become financially unsound. If a reinsurer fails to meet its obligations under the reinsurance contract or if
the liabilities exceed any applicable loss limit, we will be forced to cover the claims on the reinsured policies.
The collectability of amounts due from reinsurers is subject to uncertainty arising from a number of factors, including whether the insured
losses meet the qualifying conditions of the reinsurance contract, whether reinsurers or their affiliates have the financial capacity and
willingness to make payments under the terms of the reinsurance contract, and the magnitude and type of collateral supporting our
reinsurance recoverable, such as holding sufficient qualifying assets in trusts or letters of credit issued. Although a portion of our reinsurance
exposures are secured, the inability to collect a material recovery from a reinsurer could have a material adverse effect on our results of
operations, financial condition and liquidity.
CIGNA CORPORATION - 2017 Form 10-K 29
PART I
ITEM 1B. Unresolved Staff Comments
ITEM 1B.
Unresolved Staff Comments
None.
ITEM 2.
Properties
Our global real estate portfolio consists of approximately 7.9 million square feet of owned and leased properties. Our domestic portfolio has
approximately 5.7 million square feet in 38 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Our international properties
contain approximately 2.2 million square feet located throughout the following countries: Belgium, Canada, China, Hong Kong, India, Indonesia,
Kenya, New Zealand, Singapore, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, and the United Kingdom.
Our principal domestic office locations include the Wilde Building located at 900 Cottage Grove Road in Bloomfield, Connecticut (our
corporate headquarters) and Two Liberty Place located at 1601 Chestnut Street in Philadelphia, Pennsylvania. The Wilde Building measures
approximately 893,000 square feet and is owned, while Two Liberty Place measures approximately 322,000 square feet and is leased space.
We believe our properties are adequate and suitable for our business as presently conducted. The foregoing does not include information on
investment properties.
ITEM 3.
Legal Proceedings
The information contained under ‘‘Litigation Matters’’, ‘‘Regulatory Matters’’ and ‘‘Other Legal Matters’’ in Note 21 to our Financial Statements
beginning on page 102 of this Form 10-K, is incorporated herein by reference.
ITEM 4.
Mine Safety Disclosures
Not applicable.
30 CIGNA CORPORATION - 2017 Form 10-K
PART I
EXECUTIVE OFFICERS OF THE REGISTRANT
EXECUTIVE OFFICERS OF THE REGISTRANT
All officers are elected to serve for a one-year term or until their successors are elected. Principal occupations and employment during the past
five years are listed below.
LISA R. BACUS, 53, Executive Vice President and Global Chief Marketing Officer of Cigna beginning May 2013 and Chief Customer Officer
beginning February 2017; Executive Vice President and Chief Marketer at American Family Insurance from February 2008 until May 2013.
MARK L. BOXER, 58, Executive Vice President and Global Chief Information Officer of Cigna beginning April 2011; Deputy Chief Information
Officer, Xerox Corporation; and Group President, Government Health Care, for Xerox Corporation/Affiliated Computer Services from March
2009 until April 2011.
DAVID M. CORDANI, 52, Chief Executive Officer of Cigna beginning December 2009; Director since October 2009; President beginning June
2008; and Chief Operating Officer from June 2008 until December 2009.
BRIAN C. EVANKO, 41, President, Government Business beginning November 2017; President, U.S. Individual Business from August 2013 to
November 2017; Business Financial Officer, Cigna Global Individual, Health, Life and Accident from September 2012 to August 2013; Chief
Actuary, Cigna Global Individual, Health, Life and Accident, from December 2008 to September 2012.
CHRISTOPHER J. HOCEVAR, 44, President, Strategy, Segments and Solutions beginning February 2017; President, Pharmacy and Select
Business from June 2013 to February 2017; President, Select Business beginning February 2011.
NICOLE S. JONES, 47, Executive Vice President and General Counsel of Cigna beginning June 2011; Senior Vice President and General Counsel
of Lincoln Financial Group from May 2010 until June 2011; Vice President and Deputy General Counsel of Cigna from April 2008 until May 2010;
and Corporate Secretary of Cigna from September 2006 until April 2010.
ALAN M. MUNEY, MD, MHA, 64, Executive Vice President, Total Health & Network and Chief Medical Officer beginning February 2017; joined
Cigna as Senior Vice President, Total Health & Network in 2010 and named Chief Medical Officer in 2011.
JOHN M. MURABITO, 59, Executive Vice President, Human Resources and Services of Cigna beginning August 2003.
ERIC P. PALMER, 41, Executive Vice President and Chief Financial Officer beginning June 2017; Deputy Chief Financial Officer from February
2017 until June 2017; Senior Vice President, Chief Business Financial Officer from November 2015 to February 2017; Vice President, Business
Financial Officer, Health Care from April 2012 to November 2015; and Vice President, Business Financial Officer, U.S. Commercial Markets from
June 2010 to April 2012.
JASON D. SADLER, 49, President, International Markets beginning June 2014; President, Global Individual Health, Life and Accident from July
2010 until June 2014, and Managing Director Insurance Business Hong Kong, HSBC Insurance Asia Limited from January 2007 until July 2010.
MICHAEL W. TRIPLETT, 56, President, U.S. Markets beginning February 2017; Regional Segment Lead from June 2009 to February 2017.
CIGNA CORPORATION - 2017 Form 10-K 31
PART II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
PART II
ITEM 5.
Market for Registrant’s Common Equity, Related
Stockholder Matters and Issuer Purchases of
Equity Securities
The information under the caption ‘‘Quarterly Financial Data – Stock and Dividend Data’’ appears on page 108 of this Form 10-K. As of
December 31, 2017, the number of shareholders of record was 5,618. Cigna’s common stock is listed with, and trades on, the New York Stock
Exchange under the symbol ‘‘CI’’.
Issuer Purchases of Equity Securities
The following table provides information about Cigna’s share repurchase activity for the quarter ended December 31, 2017:
Period
October 1-31, 2017
November 1-30, 2017
December 1-31, 2017
Total
Total # of
shares
purchased (1)
1,416,046
1,116,284
1,358,593
3,890,923
Average
price paid
per share
$ 190.43
$ 200.39
$ 205.88
$
198.68
Total # of shares
purchased as
part of publicly
announced
program (2)
1,415,061
1,114,334
1,357,938
3,887,333
Approximate dollar value
of shares that may yet
be purchased as part of
publicly announced
program (3)
$
$
$
1,501,096,013
1,277,792,524
998,215,883
N/A
(1) Represents shares tendered by employees as payment of taxes withheld on vesting of restricted stock and strategic performance shares granted under the Company’s equity
compensation plans.
(2) Additionally, the Company maintains a share repurchase program, authorized by the Board of Directors. Under this program, the Company may repurchase shares from time to time,
depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business
and market conditions and alternate uses of capital. The share repurchase program may be effected through open market purchases or privately negotiated transactions in compliance
with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans. The program may be suspended or discontinued at any time. In 2017,
the Company repurchased approximately 16 million shares for $2.8 billion. Remaining authorization under the program was approximately $1 billion as of December 31, 2017. From
January 1, 2018 through January 31, 2018, the Company repurchased 1.2 million shares for approximately $260 million.
(3) Approximate dollar value of shares is as of the last date of the applicable month.
32 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Five Year Cumulative Total Shareholder Return*
December 31, 2012 – December 31, 2017
$400
$350
$300
$250
$200
$150
$100
$50
$0
12/31/12
12/31/13
12/31/14
12/31/15
12/31/16
12/31/17
Cigna
S&P 500
S&P Managed Health Care, Life & Health Ins. Indexes**
24FEB201811322104
Cigna
S&P 500
S&P Managed Health Care, Life & Health Ins. Indexes**
12/31/2012
12/31/2013
12/31/2014
12/31/2015
12/31/2016
12/31/2017
$ 100
$ 100
$ 100
$
$
$
164
132
152
$
$
$
193
151
190
$
$
$
274
153
220
$
$
$
250
171
265
$
$
$
381
208
368
* Assumes that the value of the investment in Cigna common stock and each index was $100 on December 31, 2012 and that all dividends were reinvested.
** Weighted average of S&P Managed Health Care (75%) and Life and Health Insurance (25%) Indexes.
CIGNA CORPORATION - 2017 Form 10-K 33
PART II
ITEM 6. Selected Financial Data
ITEM 6.
Selected Financial Data
The selected financial data should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of
Operations and the Consolidated Financial Statements and accompanying notes included elsewhere herein.
Highlights
(Dollars in millions, except per share amounts)
Total revenues
Shareholders’ net income
Net income
Shareholders’ net income per share
Basic
Diluted
Common dividends declared per share
Cash and investments
Total assets
Long-term debt
Total liabilities
Shareholders’ equity
2017
41,616
2,237
2,232
8.92
8.77
0.04
31,591
61,753
5,199
47,969
13,735
$
$
$
$
$
$
$
$
$
$
$
2016
39,668
1,867
1,843
7.31
7.19
0.04
30,000
59,360
4,756
45,575
13,723
$
$
$
$
$
$
$
$
$
$
$
2015
37,876
2,094
2,077
8.17
8.04
0.04
26,681
57,088
5,020
44,975
12,035
$
$
$
$
$
$
$
$
$
$
$
2014
34,914
2,102
2,094
7.97
7.83
0.04
25,762
55,870
4,979
44,991
10,774
$
$
$
$
$
$
$
$
$
$
$
2013
32,380
1,476
1,478
5.28
5.18
0.04
25,160
54,306
4,984
43,629
10,567
$
$
$
$
$
$
$
$
$
$
$
34 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
ITEM 7.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
Executive Overview
Liquidity and Capital Resources
Critical Accounting Estimates
Segment Reporting
....................................................................................................................................................................................................................
...........................................................................................................................................................................
................................................................................................................................................................................
...................................................................................................................................................................................................
............................................................................................................................................................................................
........................................................................................................................................................................
.................................................................................................................................................................................
...............................................................................................................................................................................................
..............................................................................................................................................................................................................
.....................................................................................................................................................................................................
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Investment Assets
Page
35
41
44
47
47
49
50
51
51
52
Management’s Discussion and Analysis of Financial Condition and Results of Operations (‘‘MD&A’’) is intended to provide information to assist
you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in
conjunction with our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K (‘‘Form 10-K’’) and the
‘‘Risk Factors’’ contained in Part I, Item 1A of this Form 10-K.
Unless otherwise indicated, financial information in the MD&A is presented in accordance with accounting principles generally accepted in the
United States of America (‘‘GAAP’’). See Note 2 to our Consolidated Financial Statements for additional information regarding the Company’s
significant accounting policies. In some of our financial tables in this MD&A, we present either percentage changes or ‘‘N/M’’ when those
changes are so large as to become not meaningful. Changes in percentages are expressed in basis points (‘‘bps’’).
In this MD&A, our consolidated measures ‘‘operating revenues’’ and ‘‘adjusted income from operations’’ are not determined in accordance with
GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures ‘‘total revenues’’ and ‘‘shareholders’ net
income.’’
We define operating revenues as total revenues excluding realized investment results. We exclude realized investment results from this
measure because our portfolio managers may sell investments based on factors largely unrelated to the underlying business purposes of each
segment. As a result, gains or losses created in this process may not be indicative of past or future underlying performance of our businesses.
We use adjusted income from operations as our principal financial measure of operating performance because management believes it best
reflects the underlying results of our business operations and permits analysis of trends in underlying revenue, expenses and profitability. We
define adjusted income from operations as shareholders’ net income excluding after-tax realized investment gains and losses, net amortization
of other acquired intangible assets and special items. Income or expense amounts are excluded from adjusted income from operations for the
following reasons:
•
•
Realized investment results are excluded because, as noted above, our portfolio managers may sell investments based on factors largely
unrelated to the underlying business purposes of each segment.
Net amortization of other intangible assets is excluded because it relates to costs incurred for acquisitions and, as a result, it does not relate to
the core performance of the Company’s business operations. In 2015, the amortization amount was net of a bargain purchase gain on an
acquisition.
•
Special items are excluded because management believes they are not representative of the underlying results of operations. See Note 22 to
our Consolidated Financial Statements for descriptions of special items.
Executive Overview
Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as ‘‘Cigna,’’ the ‘‘Company,’’ ‘‘we,’’ ‘‘our’’ or ‘‘us’’)
is a global health services organization dedicated to a mission of helping individuals improve their health, well-being and sense of security. To
execute on our mission, Cigna’s evolved strategy is to ‘‘Go Deeper’’, ‘‘Go Local’’ and ‘‘Go Beyond’’ with a differentiated set of medical, dental,
disability, life and accident insurance and related products and services offered by our subsidiaries. In addition to these ongoing operations, we
also have certain run-off operations.
For further information on our business and strategy, please see Item 1, ‘‘Business’’ in this Form 10-K. See Note 1 to our Consolidated Financial
Statements for a description of our reporting segments.
CIGNA CORPORATION - 2017 Form 10-K 35
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Summary
Summarized below are certain key measures of our performance for the years ended December 31:
(Dollars in millions, except per share amounts)
Total revenues (1)
Operating revenues (1)
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total operating revenues (1)
Shareholders’ net income (1)
Adjusted Income (Loss) From Operations (1)
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total adjusted income from operations (1)
Earnings per share (diluted)
Shareholders’ net income (1)
Adjusted income from operations (1)
Global medical customers (in thousands)
For the Years Ended
December 31,
$
$
2017
41,616
32,617
3,872
4,441
468
(19)
2016
2015
$ 39,668
$ 37,876
$
31,199
3,385
4,443
472
–
$ 29,929
3,149
4,271
485
(15)
$ 41,379
$ 39,499
$
$
$
$
$
2,237
2,173
369
285
67
(226)
2,668
8.77
10.46
15,907
$
$
$
$
$
1,867
1,852
294
125
70
(237)
2,104
7.19
8.10
15,197
$
$
$
$
$
$
37,819
2,094
1,848
262
324
75
(253)
2,256
8.04
8.66
14,999
Increase
(Decrease)
2017 vs. 2016
Increase
(Decrease)
2016 vs. 2015
5%
5%
14
–
(1)
N/M
5%
20%
17%
26
128
(4)
5
27%
22%
29%
5%
5%
4%
7
4
(3)
100
4%
(11)%
–%
12
(61)
(7)
6
(7)%
(11)%
(6)%
1%
(1) See Consolidated Results of Operations beginning on page 38 for reconciliations of operating revenues to total revenues and adjusted income from operations
to shareholders’ net income on a dollar and per share basis.
The charts on the following pages provide a comparison of our 2017 and 2016 results compared with each prior year.
Total revenues in billions
22FEB201803355535
(GAAP) (1)
$37.9
$39.7
$41.6
2017 versus 2016 and 2016 versus 2015 – Increases in both 2017 and 2016
primarily reflected higher operating revenues driven by business growth as
discussed further below.
2015
2016
22FEB201815314964
2017
Total operating revenues in billions
22FEB201803355415
(non-GAAP) (1)
$37.8
$39.5
$41.4
2017 versus 2016 – Increase driven by business growth in Global Health
Care and Global Supplemental Benefits.
2016 versus 2015 – Increase resulted from business growth across all of our
ongoing reportable segments.
$50.0
$40.0
$30.0
$20.0
$10.0
$0.0
$50.0
$40.0
$30.0
$20.0
$10.0
$0.0
2015
2016
22FEB201815314838
2017
(1) See Consolidated results of operations starting on page 38 for reconciliations of operating revenues to total revenues and adjusted income from operations to
shareholders’ net income on a dollar and per share basis.
36 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Shareholders' net income
22FEB201803355655
per share (GAAP) (1)
$10.0
$8.0
$6.0
$4.0
$2.0
$0.0
$12.0
$10.0
$8.0
$6.0
$4.0
$2.0
$0.0
$8.04
$7.19
$8.77
2017 versus 2016 – Increase due to higher adjusted income from
operations across our reporting segments. Debt extinguishment costs and
charges resulting from U.S. tax reform, both reported as special items in
2017, partially offset these increases.
2016 versus 2015 – Decrease due to lower adjusted income from
operations, primarily in the Group Disability and Life segment. Increased
special item charges in 2016 (primarily higher transaction costs and the
2016 risk corridor allowance) also contributed to the decline.
2015
2016
2017
22FEB201815314585
Total adjusted income from operations
22FEB201803355294
per share (non-GAAP) (1)
$8.66
$8.10
$10.46
2015
2016
2017
22FEB201815314713
2017 versus 2016 – Increase driven by higher earnings in each of our
ongoing reportable segments. These increases were primarily a result of
customer growth in Global Health Care and Global Supplemental Benefits
and increased specialty contributions in Global Health Care. Improved
claim experience in Group Disability and Life also contributed to the
increase.
2016 versus 2015 – Decrease was a result of significantly lower earnings in
Group Disability and Life reflecting unfavorable claim experience. Costs
related to the Government segment’s response to the Centers for Medicare
and Medicaid Services (‘‘CMS’’) audit also contributed to the decline.
Increased earnings contributions in Global Supplemental Benefits and the
Commercial segment partially offset those unfavorable impacts.
(1) See Consolidated results of operations starting on page 38 for reconciliations of operating revenues to total revenues and adjusted income from operations to
shareholders’ net income on a dollar and per share basis.
Global medical customers in thousands
22FEB201803484799
14,999
15,197
15,907
2017 versus 2016 and 2016 versus 2015 – Increases in both 2017 and 2016
reflected growth in targeted markets for our Commercial segment. In 2017,
these favorable effects were partially offset by expected disenrollment in
the Government segment.
20,000
15,000
10,000
5,000
0
2015
2016
22FEB201815314450
2017
Further discussion of detailed components of revenues and expenses can be found in the ‘‘Consolidated Results of Operations’’ section of this
MD&A beginning on page 38. For further analysis and explanation of individual segment results, see the ‘‘Segment Reporting’’ section of this
MD&A beginning on page 47.
Key Developments
U.S. Tax Reform Legislation
Major U.S. tax reform legislation was signed into law on December 22, 2017. The legislation is highlighted by a reduction in the corporate
income tax rate from the current 35% to 21% effective January 1, 2018. As further described on page 39 of this Form 10-K, we expect a
significant decline in our effective tax rate beginning in 2018 as a result of the rate reduction. The remaining provisions of the law, most of which
take effect on January 1, 2018, are not expected to have a material impact on the Company’s results of operations beginning in 2018.
We recorded additional tax expense of $232 million in 2017 resulting from this legislation, comprised of $144 million due to the revaluation of
deferred tax assets and liabilities to reflect the reduction in the corporate tax rate and $88 million due to the assessment of U.S. taxes related to
the Company’s accumulated unremitted foreign earnings. The legislation provides an election to pay these taxes over eight years and we
expect to adopt this election. Both the revaluation of deferred tax assets and liabilities and the taxes on accumulated unremitted foreign
earnings are considered provisional as certain adjustments used to calculate the tax at year-end were based on estimates.
CIGNA CORPORATION - 2017 Form 10-K 37
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Also as a result of tax reform, the Company recorded a reduction in operating expenses of $56 million ($36 million after-tax) reflecting a
decrease in a liability to reimburse a reinsurer for taxes related to a block of business sold through reinsurance. An offsetting tax effect is
included in the $144 million charge discussed above, resulting in no after-tax effect for this item.
See Note 20 to our Consolidated Financial Statements for additional information.
Termination of Proposed Merger with Anthem, Inc.
On May 12, 2017, we announced that the merger agreement between Cigna and Anthem, Inc. had been terminated.
See Note 21(E) to our Consolidated Financial Statements in this Form 10-K for additional details.
Consolidated Results of Operations (GAAP Basis)
Financial Summary
(In millions)
Premiums
Fees and other revenues
Net investment income
Mail order pharmacy revenues
Operating revenues
Net realized investment gains
Total revenues
Global Health Care medical costs
Other benefit expenses
Mail order pharmacy costs
Other operating expenses
Amortization of other acquired intangible assets, net
Benefits and expenses
Income before income taxes
Income taxes
Net income
Less: net (loss) attributable to noncontrolling interests
For the Years Ended
December 31,
2017
$ 32,307
4,867
1,226
2,979
2016
$ 30,626
4,760
1,147
2,966
2015
$ 29,642
4,488
1,153
2,536
41,379
237
41,616
19,967
5,439
2,456
10,033
115
38,010
3,606
1,374
2,232
(5)
39,499
169
39,668
19,009
5,477
2,468
9,584
151
36,689
2,979
1,136
1,843
(24)
37,819
57
37,876
18,354
4,936
2,134
8,982
143
34,549
3,327
1,250
2,077
(17)
Increase
(Decrease)
2017 vs. 2016
Increase
(Decrease)
2016 vs. 2015
$ 1,681
107
79
13
1,880
68
1,948
958
(38)
(12)
449
(36)
1,321
627
238
389
19
5%
2
7
–
$ 984
272
(6)
430
5
40
5
5
(1)
–
5
(24)
4
21
21
21
79
1,680
112
1,792
655
541
334
602
8
2,140
(348)
(114)
(234)
(7)
3%
6
(1)
17
4
196
5
4
11
16
7
6
6
(10)
(9)
(11)
(41)
Shareholders’ net income
$ 2,237
$
1,867
$ 2,094
$ 370
20%
$ (227)
(11)%
Reconciliation of Shareholders’ Net Income (GAAP) to Adjusted Income from Operations
(non-GAAP):
(In millions)
Shareholders’ net income
After-tax adjustments required to reconcile to adjusted income
from operations
– Net realized investment (gains)
– Amortization of other acquired intangible assets, net
Special items
– U.S. tax reform (see Note 20 to our Consolidated Financial
Statements)
– Debt extinguishment costs (see Note 5 to our Consolidated
Financial Statements)
– Long-term care guaranty fund assessment (see Note 21(D) to
our Consolidated Financial Statements)
– Transaction-related costs (see Note 3 to our Consolidated
Financial Statements)
– Risk corridor allowance (see Note 22 to our Consolidated
Financial Statements)
– Charges associated with litigation matters discussed in
Note 21(E) to our Consolidated Financial Statements
2017
$ 2,237
(156)
66
196
209
83
33
–
–
For the Years Ended
December 31,
2016
2015
Increase
(Decrease)
2017 vs. 2016
Increase
(Decrease)
2016 vs. 2015
$ 1,867
$ 2,094
$ 370
20%
$ (227)
(11)%
(109)
94
(40)
80
–
–
–
147
80
25
–
65
–
57
–
–
(47)
(28)
196
209
83
(114)
(80)
(25)
(69)
14
–
(65)
–
90
80
25
Adjusted income from operations
$ 2,668
$ 2,104
$ 2,256
$ 564
27%
$ (152)
(7)%
38 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Other Key Consolidated Financial Data
Earnings per share (diluted)
Shareholders’ net income
Per share impact of after-tax adjustments to shareholders’ net income
– Net realized investment (gains)
– Amortization of other acquired intangible assets, net
– Special items (see Note 22 to our Consolidated Financial
Statements for details)
Adjusted income from operations
Effective tax rate
For the Years Ended
December 31,
2017
2016
2015
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$ 8.77
$
7.19
$ 8.04
$
1.58
22%
$ (0.85)
(11)%
(0.61)
0.26
2.04
(0.42)
0.36
(0.15)
0.30
(0.19)
(0.10)
0.97
0.47
1.07
(0.27)
0.06
0.50
$ 10.46
$ 8.10
$ 8.66
$ 2.36
29%
$ (0.56)
(6)%
38.1%
38.1%
37.6%
-bps
(50)bps
Consolidated Results of Operations: 2017 versus 2016 and 2016 versus 2015
Revenues. The components of revenue changes are discussed further below:
•
•
•
•
•
Premiums. The increase in 2017 compared with 2016 was primarily due to customer growth in the Commercial segment and in Global
Supplemental Benefits. Expected decreases in Government segment premiums due to Medicare disenrollment partially offset these
increases. In 2016, premiums increased compared with 2015, reflecting customer growth in Global Health Care, Global Supplemental
Benefits as well as Group Disability and Life. Rate actions in our commercial health care businesses consistent with medical cost trend
also contributed to these increases.
Fees and other revenues. The increases in both 2017 and 2016 compared with each prior year primarily reflected growth from
specialty products offered through our Global Health Care segment and an increased customer base for our administrative services
only business.
Net investment income increased in 2017 compared with 2016 driven by growth in average invested assets partially offset by lower
yields. In 2016, net investment income decreased slightly compared with 2015, as lower investment yields in the protracted low
interest rate environment were partially offset by higher average invested assets. Unfavorable foreign currency effects also
contributed to the declines in 2016.
Mail order pharmacy revenues were flat in 2017 compared with 2016, reflecting increased Commercial customers, specialty
medication prices and utilization (e.g., certain injectables) offset by lower oral medication volumes and Medicare customers. In 2016,
mail order pharmacy revenues increased compared with 2015, driven by greater volume, primarily for specialty medications due to
our higher customer base and increased utilization. In each period, changes in mail order pharmacy costs were driven by the same
factors as mail order pharmacy revenues.
•
Realized investment results increased in 2017 compared with 2016 primarily due to higher gains on sales of alternative and real
estate investments as well as lower impairment losses. Realized investment results increased in 2016 compared with 2015 due to
significantly lower impairment losses.
•
•
•
•
•
Global Health Care medical costs. The increases in 2017 and 2016 compared with each prior year resulted primarily from customer growth in
our commercial health care businesses and medical cost trend. In 2017, the impact of Medicare disenrollment partially offset these effects.
Other benefit expenses declined slightly in 2017 compared with 2016 as improvements in our disability and life claims experience were
largely offset by customer growth in Global Supplemental Benefits. The increase in 2016 compared with 2015 was driven by unfavorable
disability and life claim experience due primarily to changes in the disability claims management process in 2016 and elevated life claims
during the second quarter of 2016. Business growth in our Group Disability and Life and Global Supplemental Benefits segments also
contributed to the 2016 increase.
Other operating expenses. In 2017, the increase in other operating expenses compared with 2016 reflected debt extinguishment costs, a
long-term care guaranty fund assessment and higher volume-based expenses reflecting business growth. These increases were offset by the
moratorium on the health insurance industry tax in 2017 and a reduction in costs related to our CMS audit response. The increase in 2016
compared with 2015 was due to costs associated with our CMS audit response, business growth, strategic investment across our segments
and special item charges including transaction-related costs and a risk corridor allowance described in Note 22 to our Consolidated Financial
Statements.
Amortization of other acquired intangible assets, net. The decrease in 2017 compared with 2016 was driven by the expected continuing
decline in amortization from our 2012 acquisition of HealthSpring, Inc. The increase in 2016 compared with 2015 was driven by the absence of
the $23 million bargain purchase gain recorded in 2015 for an acquisition. This factor was partially offset by the decline in our
HealthSpring, Inc. amortization.
The consolidated effective tax rate was flat in 2017 compared with 2016. The unfavorable impact of additional tax expense associated with
the recently enacted U.S. tax reform legislation was offset by the favorable effects of a moratorium on the health insurance industry tax in
2017 and an incremental tax benefit associated with previously non-deductible transaction-related costs. See Note 20 to our Consolidated
Financial Statements for additional information. The increase in our effective tax rate in 2016 compared with 2015 was largely driven by an
increase in non-tax deductible transaction-related costs reported in 2016, partially offset by the tax benefits on stock compensation
recognized in net income as a result of our early adoption of Accounting Standard Update (‘‘ASU’’) 2016-09.
We expect our effective tax rate in 2018 to decrease significantly from 2017 as a result of enactment of the U.S. tax reform legislation. This
favorable effect will be partially offset by the resumption of the health insurance industry tax.
CIGNA CORPORATION - 2017 Form 10-K 39
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Health Care Industry Developments and Other Matters Affecting Our Global Health
Care Segment
The ‘‘Regulation’’ section of this Form 10-K provides a detailed description of The Patient Protection and Affordable Care Act (the ‘‘ACA’’)
provisions and other legislative initiatives that impact our health care business, including regulations issued by CMS and the Departments of
the Treasury and Health and Human Services (‘‘HHS’’). In October 2017, President Trump issued an executive order that could result in a variety
of changes to the individual and group health insurance markets when implemented. At this time, we are unable to determine the effect, if any,
of these changes on our business or results of operations. In addition, the President ordered the immediate cessation of cost sharing reduction
subsidy payments to insurers. Discussions on the ACA continue in the U.S. Congress. The table presented below provides an update of the
impact of these items and other matters affecting our Global Health Care segment as of December 31, 2017.
Item
Medicare Advantage (‘‘MA’’)
ACA Taxes and Fees
•
Industry Tax
Description
CMS sanctions: On June 16, 2017, the Company received notification from CMS that the marketing and
enrollment sanctions imposed by CMS on January 21, 2016 had been lifted. Cigna has resumed marketing of its
Medicare Advantage-Prescription Drug and Medicare Part D Plans and began enrolling beneficiaries with
effective dates beginning July 1, 2017.
For the year ended December 31, 2017, Medicare enrollment and consolidated revenues were materially
impacted due to our inability to participate in 2017 annual enrollment. However, 2017 shareholders’ net income
was not materially affected because the margin impact of the revenue loss was offset by lower operating
expenses due to reduced remediation costs and other operational efficiencies that improved 2017 results. The
impact of disenrollment was not material to 2016 consolidated revenues or earnings.
Medicare Star Quality Ratings (‘‘Star Ratings’’): Medicare Advantage plans must have a Star Rating of four
Stars or higher to qualify for bonus payments. We expect that approximately 60% of our Medicare Advantage
customers will be in a four Star or greater plan for bonus payments to be received in 2018. In October 2017,
CMS announced Star Ratings for plans for the 2019 payment year. We expect that approximately 40% of our
Medicare Advantage customers will be in a four Star or greater plan for bonus payments to be received in 2019.
Management continues to evaluate various actions to improve the Company’s Star Ratings.
2018 and 2019 MA Rates: Final MA reimbursement rates for 2018 were published by CMS in April 2017.
Preliminary MA reimbursement rates for 2019 were published by CMS in February 2018. We expect these
changes in rates to have an immaterial impact on our consolidated results of operations in 2018 and 2019.
Health Insurance Industry Tax: Federal legislation imposed a moratorium on the health insurance industry tax
for 2017 and 2019. The industry tax is being assessed in 2018 and, under current law, will return again in 2020
and beyond. For 2017, our premium rates reflected the moratorium and we would expect our target pricing
actions to reflect the moratorium in 2019. The amount of the tax was approximately $310 million in both 2016
and 2015 ($170 million for Commercial and $140 million for Government in each year).
The industry tax for Cigna in 2018 is expected to approximate $390 million ($260 million for Commercial and
$130 million for Government). For our Commercial business, the fee is reflected in our 2018 premium rates, and
is expected to result in an immaterial effect on shareholders’ net income. For our Medicare business, we
anticipate that the earnings impact of the tax will be more significant than in our Commercial business.
However, we expect to offset its earnings impact in 2018 with benefit and pricing changes as well as growth.
Because this tax is not deductible for federal income tax purposes, it will negatively impact our effective tax
rate in 2018.
•
Reinsurance Fee
Reinsurance Fee: This fee was applicable only from 2014 through 2016. For our insured business, the amount of
the fee was approximately $45 million in 2016 and $70 million in 2015.
Public Health Exchanges
Market Participation: For 2017, we offered individual coverage on seven public health insurance exchanges in
the following states: Colorado, Illinois, Maryland, Missouri, North Carolina, Tennessee and Virginia. For 2018, we
are offering individual coverage on the same exchanges with the exception of Maryland.
Cost Sharing Reduction Subsidies: The ACA provides for cost sharing reductions that lower the amount that
qualifying customers pay for deductibles, copayments and coinsurance. The federal government has provided
funding for the cost sharing reduction subsidies to the qualifying customer’s insurer. In October 2017, the Trump
administration stopped payment of these subsidies to insurers. The attorneys general of 18 states and the
District of Columbia have sued the Trump administration, seeking to require the administration to continue
paying these subsidies. While the litigation is at a preliminary stage, on October 25, 2017, the court denied the
request of the attorneys general for an injunction, allowing the government to cease providing the cost sharing
reduction payments to insurers during the pendency of the matter. We will continue to monitor developments
as the case proceeds. The impact of suspending cost sharing reduction subsidies was not material to 2017
consolidated earnings. Our pricing actions for the 2018 plan year have anticipated that the government would
no longer pay for these subsidies, and we expect the impact on our future results of operations to be
immaterial.
Individual Mandate Repeal: The U.S. tax reform legislation also repealed the penalty charged to individuals
without health insurance (known as the ‘‘individual mandate’’) effective January 1, 2019. While the impact on
future premium rates and enrollment in the individual market is uncertain, we expect this repeal to have an
immaterial impact on our future results of operations.
40 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Risk Mitigation Programs
See Note 2(K) to our Consolidated Financial Statements for a description of and our accounting policy for these programs that commenced in
2014. The risk corridor and reinsurance programs ended as of December 31, 2016.
The following table presents the after-tax (charges) and benefits to shareholders’ net income from these programs for the years ended
December 31, 2017, 2016 and 2015 and our net (payable) receivable balances as of December 31, 2017 and 2016.
(In millions)
Net risk adjustment (1)(2)
Net risk corridor (1)
Reinsurance (3)
Total risk mitigation balances
Net Receivable (Payable) Balance
As of December 31,
After-tax Impact on Shareholders’ Net Income
For the Years Ended December 31,
$
2017
(181)
–
8
$ (173)
2016
1
–
63
64
$
$
2017
$ (105)
–
–
$ (105)
$
2016
25
(86)
30
$ (31)
$
2015
92
49
125
$ 266
(1) Risk adjustment and risk corridor receivables, net of allowances, are reported in premiums, accounts and notes receivable in the Consolidated Balance Sheets. Risk adjustment
receivables totaled $69 million as of December 31, 2017 and $52 million as of December 31, 2016.
(2) Risk adjustment payables are reported in accounts payable, accrued expenses and other liabilities in the Consolidated Balance Sheets. Risk adjustment payables totaled $250 million as of
December 31, 2017 and $51 million as of December 31, 2016.
(3) Reinsurance receivables are reported in reinsurance recoverables.
In 2016, we recorded an allowance for the balance of our risk corridor receivable based on court decisions and the large risk corridor program
deficit. As of December 31, 2017, we continued to hold an allowance for the balance of our risk corridor receivable of $109 million based on the
current status of court decisions. However, we continue to believe that the government has a binding obligation to satisfy the risk corridor
receivable.
Liquidity And Capital Resources
Financial Summary
(In millions)
Short-term investments
Cash and cash equivalents
Short-term debt
Long-term debt
Shareholders’ equity
2017
199
2,972
240
5,199
13,735
$
$
$
$
$
2016
691
3,185
276
4,756
13,723
$
$
$
$
$
2015
381
1,968
149
5,020
12,035
$
$
$
$
$
Liquidity
We maintain liquidity at two levels: the subsidiary level and the parent company level.
Liquidity requirements at the subsidiary level generally consist of:
• medical costs and benefit payments to policyholders;
• expense requirements, primarily for employee compensation and benefits, information technology and facilities costs; and
• income taxes.
Our subsidiaries normally meet their operating requirements by:
• maintaining appropriate levels of cash, cash equivalents and short-term investments;
• using cash flows from operating activities;
• matching investment durations to those estimated for the related insurance and contractholder liabilities;
• selling investments; and
• borrowing from affiliates, subject to applicable regulatory limits.
Liquidity requirements at the parent company level generally consist of:
• debt service and dividend payments to shareholders;
• pension plan funding; and
• repurchases of common stock.
The parent company normally meets its liquidity requirements by:
• maintaining appropriate levels of cash and various types of marketable investments;
• collecting dividends from its subsidiaries;
• using proceeds from issuance of debt and equity securities; and
• borrowing from its subsidiaries, subject to applicable regulatory limits.
Cash flows for the years ended December 31, were as follows:
(In millions)
Net cash provided by operating activities (1)(2)
Net cash (used in) investing activities (2)
Net cash (used in) financing activities (1)
2017
2016
2015
4,086
$
$ (1,703)
$ (2,651)
4,026
$
$ (2,574)
(225)
$
2,933
$
$ (1,736)
(609)
$
(1) As required in adopting ASU 2016-09 in 2016, we retrospectively reclassified $79 million of cash payments from operating to financing activities in 2015. These payments were related to
employee tax obligations associated with stock compensation. The comparable amounts reported in financing activities were $61 million in 2017 and $72 million in 2016.
(2) As required in adopting ASU 2016-15 in 2016, the Company retrospectively reclassified cash distributions from partnership earnings of $137 million from investing to operating activities in
2015. The comparable amounts reported in operating activities were $161 million in 2017 and $144 million in 2016.
CIGNA CORPORATION - 2017 Form 10-K 41
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Operating activities
Cash flows from operating activities consist of cash receipts and disbursements for premiums and fees, mail order pharmacy, other revenues,
investment income, taxes, benefits and expenses. Because certain income and expense transactions do not generate cash, and because cash
transactions related to revenues and expenses may occur in periods different from when those revenues and expenses are recognized in
shareholders’ net income, cash flows from operating activities can be significantly different from shareholders’ net income.
Cash flows from operating activities increased slightly in 2017 compared with 2016 primarily driven by higher net income, partially offset by
lower receipts from Medicare Part D and Medicare Advantage programs and a voluntary pension contribution of $150 million in 2017.
Cash flows from operating activities increased in 2016 compared with 2015 due to higher receipts from Medicare Part D and Medicare
Advantage programs.
Investing activities
Cash flows from investing activities generally consist of net investment purchases or sales and net purchases of property and equipment
including capitalized software, as well as cash used to acquire businesses.
Cash used in investing activities decreased in 2017 compared with 2016, primarily due to lower net investment purchases. In 2017, more cash
was deployed to share repurchase than investment purchases in accordance with our capital management strategy discussed in the below
‘‘Capital Resources’’ section of this MD&A.
Cash used in investing activities increased in 2016 compared with 2015, due to higher purchases of fixed maturity investments.
Financing activities
Cash flows from financing activities are generally comprised of issuances and re-payment of debt at the parent company level, proceeds on the
issuance of common stock resulting from stock option exercises, and stock repurchases. In addition, the subsidiaries report deposits to and
withdrawals from investment contract liabilities (including universal life insurance liabilities) because such liabilities are considered financing
activities with policyholders.
Cash used in financing activities increased in 2017 compared with 2016, primarily due to higher share repurchases. The 2017 proceeds from the
Company’s $1.6 billion debt issuance were largely offset by $1.3 billion paid to extinguish $1.0 billion of debt, as well as repaying maturing debt
in the first quarter of 2017.
Cash used in financing activities decreased in 2016 compared with 2015, primarily due to lower share repurchases offset by lower proceeds
from employees’ exercise of stock options.
Share repurchase
We maintain a share repurchase program, authorized by our Board of Directors. Under this program, we may repurchase shares from time to
time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a
variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be
effected through open market purchases or privately negotiated transactions in compliance with Rule 10b-18 under the Securities Exchange
Act of 1934, as amended, including through Rule 10b5-1 trading plans. The program may be suspended or discontinued at any time.
In 2017, we repurchased 15.7 million shares for $2.8 billion. From January 1, 2018 through January 31, 2018 we repurchased 1.2 million shares for
approximately $260 million. We repurchased 0.8 million shares for $110 million in 2016 and 5.5 million shares for $683 million in 2015.
Interest Expense
Interest expense on long-term debt, short-term debt and capital leases was as follows:
(In millions)
Interest expense
2017
2016
2015
$ 243
$
251
$ 252
Interest expense reported above excluded losses on the early extinguishment of debt.
The weighted average interest rate for outstanding short-term debt (primarily commercial paper) was 1.63% as of December 31, 2017. There
was no commercial paper outstanding as of December 31, 2016.
Capital Resources
Our capital resources (primarily retained earnings and proceeds from the issuance of debt and equity securities) provide protection for
policyholders, furnish the financial strength to underwrite insurance risks and facilitate continued business growth.
Management, guided by regulatory requirements and rating agency capital guidelines, determines the amount of capital resources that we
maintain. Management allocates resources to new long-term business commitments when returns, considering the risks, look promising and
when the resources available to support existing business are adequate.
42 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
We prioritize our use of capital resources to:
•
provide the capital necessary to support growth and maintain or improve the financial strength ratings of subsidiaries and to fund pension
obligations;
•
consider acquisitions that are strategically and economically advantageous; and
•
return capital to investors through share repurchase.
The availability of capital resources will be impacted by equity and credit market conditions. Extreme volatility in credit or equity market
conditions may reduce our ability to issue debt or equity securities.
Liquidity and Capital Resources Outlook
At December 31, 2017, there was approximately $1.2 billion in cash and marketable investments available at the parent company level. In 2018,
the parent company’s combined cash obligations are expected to approximate $480 million for repayment of debt, interest and dividends. We
expect to have sufficient liquidity to meet the obligations discussed above, based on the parent company’s current cash position and current
projections for subsidiary dividends. In addition, we actively monitor our debt obligations and engage in issuance or redemption activities as
needed in accordance with our capital management strategy.
Our cash projections may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience
unexpected shortfalls in earnings, or we experience material adverse effects from one or more risks or uncertainties described more fully in the
Risk Factors section of this Form 10-K. In those cases, we expect to have the flexibility to satisfy liquidity needs through a variety of measures,
including intercompany borrowings. The parent company may borrow up to $1.1 billion from its insurance subsidiaries without additional state
approval. We have additional liquidity available through short-term commercial paper borrowings and a committed $1.5 billion revolving credit
facility. The revolving credit and letter of credit agreement is subject to the maximum debt leverage covenant. As of December 31, 2017, we
have $9.3 billion of maximum borrowing capacity in the debt leverage covenant, in addition to the $5.4 billion of debt outstanding. See Note 5
to our Consolidated Financial Statements for additional information regarding the credit facility.
Though we believe we have adequate sources of liquidity, significant disruption or volatility in the capital and credit markets could affect our
ability to access those markets for additional borrowings or increase costs associated with borrowing funds.
The state of Illinois continues to experience financial difficulties; however, some of their immediate cash flow constraints were alleviated by a
bond offering issued during the fourth quarter of 2017. As a result, we have collected most of the receivables due as of December 31, 2017. The
remaining amount due to us from the state of Illinois under our commercial and Medicaid contracts as of December 31, 2017 was immaterial. As
of December 31, 2017, all of our contracts with the state of Illinois had been terminated.
We continue to maintain a capital management strategy to retain overseas a significant portion of the earnings from our foreign operations.
These undistributed earnings are deployed outside of the United States predominantly in support of the liquidity and regulatory capital
requirements of our foreign operations as well as to support growth initiatives overseas. As a result of the U.S. tax reform legislation enacted in
December 2017, we recorded additional U.S. taxes of $88 million related to these undistributed earnings. The legislation provides an election to
pay these taxes over eight years. We expect to adopt that election.
Unfunded Pension Plan Liability. As of December 31, 2017, our unfunded pension liability was $688 million, reflecting a decrease of
$223 million from December 31, 2016. The decrease in the unfunded liability reflected strong investment asset returns and a contribution of
$150 million in 2017, partially offset by the impact of a decrease in discount rates of approximately 45 basis points. No contributions are
required in 2018 under the Pension Protection Act of 2006. See Note 15 to our Consolidated Financial Statements for additional information
regarding our pension plans.
Guarantees and Contractual Obligations
We are contingently liable for various contractual obligations entered into in the ordinary course of business. See the ‘‘Liquidity and Capital
Resources’’ section of this MD&A beginning on page 41 for additional background on how we manage our liquidity requirements related to
these obligations. The maturities of our primary contractual cash obligations, as of December 31, 2017, are estimated to be as follows:
(In millions, on an undiscounted basis)
On-Balance Sheet
Insurance liabilities
Contractholder deposit funds
Future policy benefits
Global Health Care medical costs payable
Unpaid claims and claim expenses
Short-term debt
Long-term debt
Other long-term liabilities
Off-Balance Sheet
Purchase obligations
Operating leases
Total
Total
Less than
1 year
1-3 years
4-5 years
After
5 years
$ 6,797
11,497
2,735
5,570
244
8,185
687
1,806
582
$
706
709
2,635
1,792
244
235
129
661
130
$
907
1,445
41
1,071
1,011
105
780
207
$
739
1,213
13
721
1,493
114
278
131
$
4,445
8,130
46
1,986
5,446
339
87
114
$ 38,103
$
7,241
$ 5,567
$ 4,702
$ 20,593
CIGNA CORPORATION - 2017 Form 10-K 43
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
On balance sheet:
Insurance liabilities. Excluded from the table above are $5 billion of insurance liabilities associated with the sold retirement benefits and
•
individual life insurance and annuity businesses, as well as the reinsured workers’ compensation, personal accident and supplemental benefits
businesses ($3 billion in contractholder deposit funds; $2 billion in future policy benefits) as their related net cash flows are not expected to
impact our cash flows. Excluding these amounts, the sum of the obligations presented above exceeds the corresponding insurance and
contractholder liabilities of $21 billion recorded on the balance sheet because some of the recorded insurance liabilities reflect discounting for
interest and the recorded contractholder liabilities exclude future interest crediting, charges and fees. The timing and amount of actual future
cash flows may differ from those presented above as actual results differ from those assumed.
• Contractholder deposit funds: see Note 2(F) to our Consolidated Financial Statements for our accounting policy for this liability.
Expected future cash flows presented above also include estimated future interest crediting on current fund balances based on
current investment yields less the estimated cost of insurance charges and mortality and administrative fees for universal life policies.
• Future policy benefits, Global Health Care medical costs payable and unpaid claims and claim expenses: see Notes 2(G), 7 and 8 to
our Consolidated Financial Statements for our accounting policies for these liabilities. Expected future cash flows for these liabilities
presented in the table above are undiscounted. The expected future cash flows for guaranteed minimum death benefit (‘‘GMDB,’’
reported in future policy benefits) do not consider any of the related reinsurance arrangements.
•
Short-term debt represents current maturities of long-term debt and related interest payments, and current obligations under capital leases.
•
•
Long-term debt includes scheduled interest payments. Capital leases are included in long-term debt and primarily represent obligations for
information technology network storage, servers and equipment.
Other long-term liabilities include estimated payments for guaranteed minimum income benefit (‘‘GMIB’’) contracts (without considering
any related reinsurance arrangements), pension and other postretirement and postemployment benefit obligations, supplemental and
deferred compensation plans, interest rate and foreign currency swap contracts, and reinsurance liabilities. These items are presented in
accounts payable, accrued expenses and other liabilities in our Consolidated Balance Sheets. Estimated payments of $68 million for deferred
compensation, non-qualified and international pension plans and other postretirement and postemployment benefit plans are expected to
be paid in less than one year and are included in the table above. We do not expect to make any additional contributions to the qualified
domestic pension plans during 2018. We expect to make payments subsequent to 2018 for these obligations; however, subsequent payments
have been excluded from the table as their timing is based on plan assumptions that may materially differ from actual activities. See Note 15 to
our Consolidated Financial Statements for further information on pension and other postretirement benefit obligations.
Off-Balance Sheet:
Purchase obligations. As of December 31, 2017, purchase obligations consisted of estimated payments required under contractual
arrangements for future services and investment commitments as follows:
(In millions)
Fixed maturities
Commercial mortgage loans
Limited liability entities (other long-term investments)
Total investment commitments
Future service commitments
Total purchase obligations
$
118
21
1,178
1,317
489
$
1,806
See Note 11 to our Consolidated Financial Statements for additional information.
Our estimated future service commitments primarily represent contracts for certain outsourced business processes and information
technology maintenance and support. We generally have the ability to terminate these agreements, but do not anticipate doing so at this time.
Purchase obligations exclude contracts that are cancelable without penalty and those that do not contractually require minimum levels of
goods or services to be purchased.
Operating leases. For additional information, see Note 18 to our Consolidated Financial Statements.
Guarantees
We are contingently liable for various financial and other guarantees provided in the ordinary course of business. See Note 21 to our
Consolidated Financial Statements for additional information on guarantees.
Critical Accounting Estimates
The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions
that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate
to be critical if:
•
it requires assumptions to be made that were uncertain at the time the estimate was made; and
•
changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of
operations or financial condition.
Management has discussed the development and selection of its critical accounting estimates with the Audit Committee of our Board of
Directors and the Audit Committee has reviewed the disclosures presented below.
In addition to the estimates presented in the following table, there are other accounting estimates used in the preparation of our Consolidated
Financial Statements, including estimates of liabilities for future policy benefits, as well as estimates with respect to postemployment and
postretirement benefits other than pensions, certain compensation accruals, and income taxes.
44 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate.
However, if actual experience differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the
resulting changes could have a material adverse effect on our consolidated results of operations and, in certain situations, could have a material
adverse effect on our liquidity and financial condition. The table below presents the adverse impacts of certain possible changes in
assumptions. The effect of assumption changes in the opposite direction would be a positive impact to our consolidated results of operations,
liquidity or financial condition, except for the assessments of impairment for goodwill and fixed maturities carried at a fair value below cost. The
tax rate used to calculate the after-tax impact of assumption changes is based on the new corporate income tax rate discussed in the ‘‘Key
Developments’’ section of this MD&A.
See Note 2 to our Consolidated Financial Statements for further information on significant accounting policies.
Balance Sheet Caption / Nature of Critical Accounting Estimate
Effect if Different Assumptions Used
Goodwill
At the acquisition date, goodwill represents the excess of the cost of businesses
acquired over the fair value of their net assets.
We completed our annual evaluations of goodwill for impairment during the
third quarter of 2017. These evaluations were performed at the reporting unit
level, based on discounted cash flow analyses or market data. The evaluations
indicated that no impairment was required.
Fair values of reporting units are estimated using models and assumptions that
we believe a hypothetical market participant would use to determine a current
transaction price. The significant assumptions and estimates used in
determining fair value include the discount rate and future cash flows. A range
of discount rates is used, corresponding with the reporting unit’s weighted
average cost of capital, consistent with that used for investment decisions
considering the specific and detailed operating plans and strategies within the
reporting unit. Projections of future cash flows are consistent with our annual
planning process for revenues, claims, operating expenses, taxes, capital levels
and long-term growth rates. In addition to these assumptions, we consider
market data to evaluate the fair value of each reporting unit.
In our Government operating segment we contract with CMS and various state
governmental agencies to provide managed health care services, including
Medicare Advantage plans and Medicare-approved prescription drug plans.
Estimated future cash flows for this reporting unit’s business incorporate the
potential effects of Medicare Advantage reimbursement rates for 2018 and
beyond as discussed in the ‘‘Executive Overview’’ section of this MD&A.
Revenues from the Medicare programs are dependent, in whole or in part, upon
annual funding from the federal government through CMS. Funding for these
programs is dependent on many factors including general economic
conditions, continuing government efforts to contain health care costs and
budgetary constraints at the federal level and general political issues and
priorities.
Goodwill as of December 31 was as follows (in millions):
•
•
2017 – $6,164
2016 – $5,980
See Note 17 to our Consolidated Financial Statements for additional discussion
of our goodwill.
Accounts payable, accrued expenses and other liabilities – pension liabilities
These liabilities are estimates of the present value of the qualified and
nonqualified pension benefits to be paid (attributed to employee service to
date) net of the fair value of plan assets. The accrued pension benefit liability as
of December 31 was as follows (in millions):
•
2017 – $688
•
2016 – $911
See Note 15 to our Consolidated Financial Statements for assumptions and
methods used to estimate pension liabilities.
If we do not achieve our earnings objectives or the cost of capital rises
significantly, the assumptions and estimates underlying these impairment
evaluations could be adversely affected and result in future impairment
charges that would negatively impact our operating results.
Based on our most recent evaluations, the fair value estimates of our reporting
units exceed their carrying values by adequate margins.
Future changes in the funding for our Medicare programs by the federal
government could materially reduce revenues and profitability in our
Government reporting unit and have a significant impact on its fair value.
The discount rate is typically the most significant assumption in measuring the
pension liability. We develop the discount rate by applying actual annualized
yields at various durations from a discount rate curve constructed from high
quality corporate bonds. Based on our historical experience, we believe that a
50 basis point change in the discount rate and a 10% decline in plan assets are
reasonably possible outcomes.
If discount rates for the qualified and nonqualified pension plans decreased by
50 basis points, the accrued pension benefit liability would increase by
approximately $190 million as of December 31, 2017, resulting in an after-tax
decrease to shareholders’ equity of approximately $150 million.
If the December 31, 2017 fair values of domestic qualified plan assets decreased
by 10%, the accrued pension benefit liability would increase by approximately
$425 million as of December 31, 2017, resulting in an after-tax decrease to
shareholders’ equity of approximately $335 million.
CIGNA CORPORATION - 2017 Form 10-K 45
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Balance Sheet Caption / Nature of Critical Accounting Estimate
Effect if Different Assumptions Used
Global Health Care medical costs payable
Medical costs payable for the Global Health Care segment includes both
reported claims and estimates for losses incurred but not yet reported.
The liabilities for medical costs payable as of December 31 were as follows
(in millions):
•
2017 – gross $2,719; net $2,454
•
2016 – gross $2,532; net $2,257
These liabilities are presented above both gross and net of reinsurance and
other recoverables.
See Note 7 to our Consolidated Financial Statements for additional information
regarding assumptions and methods used to estimate this liability.
Unpaid claims and claim expenses – long-term disability reserves
The liability for long-term disability reserves is the present value of estimated
future benefits payments over the expected disability period and includes
estimates for both reported claims and for claims incurred but not yet reported.
Long-term disability reserves as of December 31 were as follows (in millions):
•
2017 – gross $3,884; net $3,790
•
2016 – gross $3,708; net $3,622
These liabilities are presented above both gross and net of reinsurance
recoverables.
See Note 8 to our Consolidated Financial Statements for additional information
regarding assumptions and methods used to estimate this liability.
As described in Note 7, Global Health Care medical costs payable is primarily
impacted by assumptions related to completion factors and medical cost trend.
Changes in either assumption from actual results could impact the Global
Health Care medical costs payable balance as noted below. A large number of
factors may cause the medical cost trend to vary from the Company’s
estimates, including: changes in medical management practices, changes in the
level and mix of benefits offered and services utilized, and changes in medical
practices. Completion factors may be affected if actual claims submission rates
from providers differ from estimates (that can be influenced by a number of
factors, including provider mix, and electronic versus manual submissions), or if
changes to the Company’s internal claims processing patterns occur. Based on
studies of our claim experience, it is reasonably possible that a 100 basis point
change in the medical cost trend and a 50 basis point change in completion
factors could occur in the near term.
A 100 basis point increase in the medical cost trend rate would increase this
liability by approximately $35 million, resulting in a decrease in net income of
approximately $30 million after-tax, and a 50 basis point decrease in
completion factors would increase this liability by approximately $75 million,
resulting in a decrease in net income of approximately $60 million after-tax.
As described in Note 8, key assumptions in the calculation of long-term
disability reserves include the discount rate and claim resolution rates, both of
which are reviewed annually and updated when experience or future
expectations would indicate a necessary change. Based on recent and
historical resolution rate patterns and changes in investment portfolio yields, it
is reasonably possible that a 5 percent change in claim resolution rates and a
25 basis point change in the discount rate could occur.
The discount rate is the interest rate used to discount the projected future
benefit payments to their present value. The discount rate assumption is based
on the projected investment yield of the assets supporting the reserves. A
25 basis point decrease in the discount rate would increase long-term disability
reserves by approximately $45 million and decrease net income by
approximately $35 million after-tax.
Claim resolution rate assumptions involve many factors including claimant
demographics, the type of contractual benefit provided and the time since
initially becoming disabled. The Company uses its own historical experience to
develop its claim resolution rates. A 5 percent decrease in the claim resolution
rate would increase long-term disability reserves by approximately $90 million
and decrease net income by approximately $70 million after-tax.
Valuation of fixed maturity investments
Typically, the most significant input in the measurement of fair value is the
Most fixed maturities are classified as available for sale and are carried at fair
value with changes in fair value recorded in accumulated other comprehensive market interest rate used to discount the estimated future cash flows of the
instrument. Such market rates are derived by calculating the appropriate
income (loss) within shareholders’ equity.
spreads over comparable U.S. Treasury securities, based on the credit quality,
industry and structure of the asset.
Fair value is defined as the price at which an asset could be exchanged in an
orderly transaction between market participants at the balance sheet date.
If the interest rates used to calculate fair value increased by 100 basis points,
the fair value of the total fixed maturity portfolio of $23 billion would decrease
by approximately $1.5 billion, resulting in an after-tax decrease to shareholders’
equity of approximately $0.9 billion.
Determining fair value for a financial instrument requires management
judgment. The degree of judgment involved generally correlates to the level of
pricing readily observable in the markets. Financial instruments with quoted
prices in active markets or with market observable inputs to determine fair
value, such as public securities, generally require less judgment. Conversely,
private placements including more complex securities that are traded
infrequently are typically measured using pricing models that require more
judgment as to the inputs and assumptions used to estimate fair value. There
may be a number of alternative inputs to select based on an understanding of
the issuer, the structure of the security and overall market conditions. In
addition, these factors are inherently variable in nature as they change
frequently in response to market conditions. Approximately two-thirds of our
fixed maturities are public securities, and one-third are private placement
securities.
See Notes 10 and 11(A) to our Consolidated Financial Statements for a
discussion of our fair value measurements, the procedures performed by
management to determine that the amounts represent appropriate estimates
and our accounting policy regarding unrealized appreciation on fixed
maturities.
46 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Balance Sheet Caption / Nature of Critical Accounting Estimate
Effect if Different Assumptions Used
If we subsequently determine that the excess of amortized cost over fair value
is other-than-temporary for any or all of these fixed maturities, the amount
recorded in accumulated other comprehensive income would be reclassified to
shareholders’ net income as an impairment loss.
Assessment of ‘‘other-than-temporary’’ impairments on fixed maturities
Certain fixed maturities with a fair value below amortized cost are carried at fair
value with changes in fair value recorded in accumulated other comprehensive
income. For these investments, we have determined that the decline in fair
value below its amortized cost is temporary. To make this determination, we
evaluated the expected recovery in value and our intent to sell or the likelihood
of a required sale of the fixed maturity prior to an expected recovery. In making
this evaluation, we considered a number of general and specific factors
including the regulatory, economic and market environments, length of time
and severity of the decline, and the financial health and specific near term
prospects of the issuer.
The after-tax amounts as of December 31
in Accumulated Other
Comprehensive Income for fixed maturities in an unrealized loss position were
as follows (in millions):
•
2017 – ($80)
•
2016 – ($115)
See Note 11 to our Consolidated Financial Statements for additional discussion
of our review of declines in fair value, including information regarding our
accounting policies for fixed maturities.
Segment Reporting
The following section of this MD&A discusses the results of each of our reporting segments. In these segment discussions, we present
‘‘operating revenues,’’ defined as total revenues excluding realized investment results and ‘‘adjusted income from operations,’’ defined as
shareholders’ net income excluding after-tax realized investment results, net amortization of other acquired intangible assets and special
items. Ratios presented in this segment discussion exclude the same items as adjusted income from operations. See Note 22 to our
Consolidated Financial Statements for additional discussion of these metrics.
In these segment discussions, we also present ‘‘adjusted margin,’’ defined as adjusted income from operations divided by operating revenues.
See the MD&A Executive Overview beginning on page 35 for summarized financial results of each of our reporting segments.
Global Health Care Segment
As described in the Segment Reporting introduction above, the performance of the Global Health Care segment is measured using adjusted
income from operations. The key factors affecting adjusted income from operations for this segment are:
•
customer growth;
•
sales of specialty products;
•
medical costs as a percentage of premiums (medical care ratio or ‘‘MCR’’) for our commercial and government businesses; and
•
operating expense as a percentage of operating revenues (operating expense ratio).
Results of Operations
Financial Summary
(In millions)
Operating revenues
Adjusted income from operations
Adjusted margin
Medical Care Ratios
Commercial
Government
Consolidated Global Health Care
Operating expense ratio
For the Years
Ended December 31,
2017
32,617
2,173
$
$
$
$
6.7%
79.9%
84.9%
81.4%
20.9%
2016
31,199
1,852
5.9%
79.3%
85.3%
81.6%
21.5%
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$
$
1,418
321
5%
17%
$
$
1,270
4
4%
–%
2015
29,929
1,848
$
$
6.2%
78.1%
85.2%
80.9%
21.4%
80bps
(60)bps
40bps
20bps
60bps
(30)bps
(120)bps
(10)bps
(70)bps
(10)bps
CIGNA CORPORATION - 2017 Form 10-K 47
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Dollars in millions, customers in thousands)
Global Health Care medical costs payable
Customers
Total commercial risk
Total government
Total risk
Service
Total medical customers
As of December 31,
$
2017
2,719
2,957
487
3,444
12,463
15,907
$
2016
2,532
2,576
566
3,142
12,055
15,197
$
2015
2,355
2,502
567
3,069
11,930
14,999
Increase
(Decrease)
2017 vs. 2016
Increase
(Decrease)
2016 vs. 2015
$
187
7%
$
177
381
(79)
302
408
710
15%
(14)%
10%
3%
5%
74
(1)
73
125
198
8%
3%
–%
2%
1%
1%
2017 versus 2016
Operating revenues. The increase was primarily due to customer growth in our Commercial risk business, partially offset by lower customer
enrollment in our Government segment.
Adjusted income from operations increased, reflecting higher earnings in both our Commercial and Government operating segments. The
increase in the Commercial segment reflects customer growth including increased contributions from our specialty products and favorable
claim experience in our U.S. Individual business. The Government segment’s earnings growth reflects lower operating expenses related to the
moratorium on the health insurance industry tax in 2017 and our 2016 CMS audit response, partially offset by lower customer enrollment.
Adjusted income from operations included favorable after-tax prior year reserve development of $112 million for 2017; prior year reserve
development in 2016 was not material.
Medical care ratios. The Commercial medical care ratio increased, reflecting the 2017 moratorium on the health insurance industry tax, offset
by improved performance in our U.S. Individual business and favorable prior year reserve development.
The Government medical care ratio decreased slightly, reflecting increased premium rates and favorable prior year reserve development,
partially offset by higher medical costs.
Operating expense ratio. The decrease was primarily due to the moratorium on the health insurance industry tax in 2017 and lower costs
related to our 2016 CMS audit response.
2016 versus 2015
Operating revenues. The increase in operating revenues was due to growth in our Commercial segment primarily from increased specialty
revenues and growth in Medicare Advantage customer volumes. Higher premium rates for most products (primarily to recover underlying
medical cost trend) also contributed to the increase. These increases were partially offset by lower customer volumes in our Medicare Part D
and U.S. Individual businesses.
Adjusted income from operations was flat, reflecting earnings growth in our Commercial segment, primarily due to increased contributions
from specialty products partially offset by lower margins in our U.S. Individual business. This increase was offset by lower earnings in our
Government segment primarily driven by costs related to our CMS audit response.
Medical care ratios. The Commercial medical care ratio increased, reflecting a less favorable medical care ratio in our stop loss business,
lower premium due to the anticipated reduction of the ACA mandated fees in 2017 and less favorable prior year reserve development.
The Government medical care ratio increased slightly, reflecting higher medical costs in our Medicaid business and less favorable prior year
development, mostly offset by improvements in the Medicare Part D business.
Operating expense ratio. The operating expense ratio increased slightly, reflecting costs related to our CMS audit response. Excluding those
costs, the operating expense ratio decreased, reflecting higher revenue and operating efficiencies, partially offset by business initiative
investments.
Other Items Affecting Health Care Results
Global Health Care Medical Costs Payable
Medical costs payable was higher as of December 31, 2017 compared with 2016, primarily due to customer growth in our commercial risk
businesses and medical cost trend across all businesses. Medical costs payable was higher as of December 31, 2016 compared with 2015,
primarily due to medical cost trend across all businesses and customer growth in our Commercial group business. See Note 7 to our
Consolidated Financial Statements for additional information.
48 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Medical Customers
A medical customer is defined as a person meeting any one of the following criteria:
•
is covered under a medical insurance policy, managed care arrangement or service agreement issued by us;
•
has access to our provider network for covered services under their medical plan; or
•
has medical claims that are administered by us.
Our medical customer base increased as of December 31, 2017 compared with 2016, reflecting growth across our Commercial market
segments, partially offset by declines in our Medicare Advantage business. Our medical customer base increased as of December 31, 2016
compared with 2015, primarily driven by growth in our middle market, select and international market segments.
Global Supplemental Benefits Segment
As described in the Segment Reporting introduction on page 47, the performance of the Global Supplemental Benefits segment is measured
using adjusted income from operations. The key factors affecting adjusted income from operations for this segment are:
•
premium growth, including new business and customer retention;
•
benefit expenses as a percentage of premiums (loss ratio);
•
operating expense and acquisition expense as a percentage of operating revenues (expense ratio and acquisition cost ratio); and
•
the impact of foreign currency movements.
Throughout this discussion and the table presented below, prior period currency adjusted income from operations and operating revenues are
calculated by applying the current period’s exchange rates to reported results in the prior period. A strengthening U.S. dollar against foreign
currencies decreases these measures, while a weakening U.S. dollar produces the opposite effect.
Results of Operations
Financial Summary
(In millions)
Operating revenues
Adjusted income from operations
Operating revenues, using actual 2017 currency exchange
rates
Adjusted income from operations, using actual 2017
currency exchange rates
Adjusted margin
Loss ratio
Acquisition cost ratio
Expense ratio (excluding acquisition costs)
For the Years
Ended December 31,
$
$
$
$
2017
3,872
369
3,872
369
9.5%
55.2%
17.3%
17.4%
$
$
$
$
2016
3,385
294
3,426
300
8.7%
55.3%
18.6%
17.9%
$
$
$
$
2015
3,149
262
3,106
259
8.3%
55.3%
19.3%
18.3%
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$
$
$
$
487
75
446
69
80bps
10bps
130bps
50bps
14%
26%
13%
23%
$
$
$
$
236
32
320
41
7%
12%
10%
16%
40bps
–bps
70bps
40bps
2017 versus 2016
Operating revenues increased primarily due to business growth, particularly in the United States and South Korea, and the favorable impact of
foreign currency movements, primarily in the South Korean Won.
Adjusted income from operations increased, reflecting business growth, primarily in South Korea and China, and lower acquisition cost ratios.
The segment’s loss ratio decreased, primarily due to favorable claims experience, largely offset by a shift in business mix to products with
higher loss ratios.
The acquisition cost ratio decreased due to lower spending in certain markets and a shift toward higher premium markets with lower
acquisition costs, primarily in South Korea and the United States.
The decrease in the expense ratio (excluding acquisition costs) was primarily driven by strong expense management.
2016 versus 2015
Operating revenues were higher primarily due to new sales, particularly in South Korea and the United States, reflecting both customer growth
and sales of higher premium products. These higher premiums were partially offset by lower persistency in the U.K. and the unfavorable impact
of foreign currency movements, primarily in South Korea and the U.K.
CIGNA CORPORATION - 2017 Form 10-K 49
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Adjusted income from operations increased primarily due to business growth, largely in South Korea, and lower acquisition and operating cost
ratios. These factors were partially offset by higher income taxes and the unfavorable impact of foreign currency movements, primarily in
South Korea.
The segment’s loss ratio was flat, reflecting favorable claims in South Korea, largely offset by a shift in business mix to products with higher loss
ratios.
The acquisition cost ratio decreased due to a shift toward higher premium products with lower acquisition costs primarily in South Korea and
the United States.
The decrease in the expense ratio (excluding acquisition costs) was primarily driven by operating efficiencies.
Other Items Affecting Global Supplemental Benefits Results
South Korea is the single largest geographic market for our Global Supplemental Benefits segment. South Korea generated 51% of the
segment’s operating revenues and 89% of the segment’s adjusted income from operations in 2017. In 2017, our Global Supplemental Benefits
segment operations in South Korea represented 5% of our consolidated operating revenues and 12% of consolidated adjusted income from
operations.
As a global company, our business is exposed to risks inherent in foreign operations. We continue to monitor and evaluate the impacts of
tensions in the Korean Peninsula.
Significant movements in foreign currency exchange rates could materially affect the reported results of the Global Supplemental Benefits
segment.
Group Disability and Life Segment
As described in the Segment Reporting introduction on page 47, the performance of the Group Disability and Life segment is measured using
adjusted income from operations. The key factors affecting adjusted income from operations for this segment are:
•
premium growth, including new business and customer retention;
•
net investment income;
•
benefit expenses as a percentage of premiums (loss ratio); and
•
operating expense as a percentage of operating revenues excluding net investment income (expense ratio).
Results of Operations
Financial Summary
(In millions)
Operating revenues
Adjusted income from operations
Adjusted margin
Loss ratio
Operating expense ratio
$
$
For the Years
Ended December 31,
$
$
2017
4,441
285
6.4%
77.2%
23.1%
$
$
2016
4,443
125
2.8%
83.8%
22.4%
2015
4,271
324
7.6%
76.3%
21.9%
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$
$
(2)
160
–%
128%
$
$
172
(199)
4%
(61)%
360bps
660bps
(70)bps
(480)bps
(750)bps
(50)bps
During the first half of 2016, the Group Disability and Life segment experienced significant unfavorable claims in its disability and life
businesses. While claims experience moderated during the second half of 2016 and normalized in 2017, the first half results dampened full year
2016 earnings.
Disability: We implemented modifications to our disability claims management process in the first quarter of 2016 to drive improved quality
and consistency. These modifications extended the claims processing cycle and lowered the disability claim resolution rate. As our modified
disability claims management process continued to mature during the latter half of 2016, our claim resolution rate significantly improved and
operational margins normalized over the course of 2017.
Life: We experienced a period of elevated life claims in the second quarter of 2016, driven by substantially higher new claim incidence and
sizes, both of which have normalized in subsequent periods.
2017 versus 2016
Operating revenues were relatively flat in 2017 compared with 2016 with higher investment income driven by higher asset levels offset by
cancelations in non-core products.
50 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Adjusted income from operations increased in 2017 compared with 2016 reflecting lower disability new claim incidence and a higher resolution
rate as modifications to the disability claims management process discussed above continued to mature. In addition, life claims have returned
to normal levels after a period of significantly elevated claims and a $17 million after-tax unfavorable reserve review, both in the second quarter
of 2016.
The loss ratio decreased in 2017 compared with 2016 due to improvement in the disability claim resolution rate as noted above, lower disability
new claim incidence and significantly improved life claims experience.
Operating expense ratio. The 2017 operating expense ratio increased compared with 2016 due to higher overhead costs.
2016 versus 2015
Operating revenues. Premiums and fees increased in 2016 compared with 2015 due to new business growth from disability and life sales. Net
investment income also increased primarily due to higher average assets partially offset by lower yields.
Adjusted income from operations. Results decreased in 2016 compared with 2015 due primarily to unfavorable disability and life claims
experience as well as the absence of favorable reserve reviews and a higher operating expense ratio. Results in 2016 included the unfavorable
impact of reserve reviews of $18 million after-tax compared with a favorable impact of $55 million after-tax in 2015.
The loss ratio increased in 2016 compared with 2015 due to lower claim resolutions in disability, higher life claim incidence and sizes in the
second quarter of 2016, and the unfavorable impact of reserve reviews as discussed above.
Operating expense ratio. The operating expense ratio increased in 2016 compared with 2015 primarily reflecting higher disability claim
management costs.
Other Operations
As described in the Segment Reporting introduction on page 47, the performance of the Other Operations segment is measured using
adjusted income from operations. Cigna’s corporate-owned life insurance (‘‘COLI’’) business contributes the majority of earnings in Other
Operations. Cigna’s Other Operations segment also includes the results from the run-off reinsurance and settlement annuity businesses, as well
as the remaining deferred gains recognized from the sale of the individual life insurance and annuity and retirement benefits businesses.
Results of Operations
Financial Summary
(In millions)
Operating revenues
Adjusted income from operations
Adjusted margin
For the Years
Ended December 31,
2016
2017
2015
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$
$
468
67
$
$
14.3%
472
70
14.8%
$
$
485
75
$
$
(4)
(3)
(1)% $
(4)% $
(13)
(5)
(3)%
(7)%
15.5%
(50)bps
(70)bps
Operating revenues decreased in 2017 compared with 2016 primarily due to lower investment income yields across all businesses, partially
offset by lower ceded premiums in the COLI business. The decrease in operating revenues in 2016 compared with 2015 was largely due to lower
net investment income driven by lower investment yields.
Adjusted income from operations in 2017 decreased compared with 2016, reflecting less favorable mortality experience partially offset by
higher interest margins in COLI. Adjusted income from operations decreased in 2016 compared with 2015, reflecting less favorable mortality
experience and lower interest margins in COLI.
Corporate
Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net
investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters,
intersegment eliminations, compensation cost for stock options and related excess tax benefits, expense associated with our frozen pension
plans and certain overhead and project costs.
Financial Summary
(In millions)
Adjusted loss from operations
For the Years
Ended December 31,
2017
2016
2015
Change
Favorable
(Unfavorable)
2017 vs. 2016
Change
Favorable
(Unfavorable)
2016 vs. 2015
$ (226)
$ (237)
$ (253)
$
11
5%
$
16
6%
CIGNA CORPORATION - 2017 Form 10-K 51
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Corporate’s adjusted loss from operations was lower in 2017 compared with 2016, primarily due to higher excess tax benefits on stock
compensation driven by increased option exercise activity in 2017. Higher net investment income also contributed to the lower loss, partially
offset by higher operating expenses. Corporate’s adjusted loss from operations decreased in 2016 compared with 2015, primarily due to
recognizing excess tax benefits on stock compensation in net income beginning in 2016 as a result of our early adoption of ASU 2016-09.
Investment Assets
The following table presents our invested asset portfolio, excluding separate account assets, as of December 31, 2017 and 2016. Additional
information regarding our investment assets and related accounting policies is included in Notes 2, 10, 11, 12, 13, and 14 to our Consolidated
Financial Statements.
(In millions)
Fixed maturities
Equity securities
Commercial mortgage loans
Policy loans
Other long-term investments
Short-term investments
Total
$
2017
23,138
588
1,761
1,415
1,518
199
$
2016
20,961
583
1,666
1,452
1,462
691
$
28,619
$
26,815
Fixed Maturities
Investments in fixed maturities include publicly traded and privately placed debt securities, mortgage and other asset-backed securities and
preferred stocks redeemable by the investor. These investments are classified as available for sale and are carried at fair value on our balance
sheet. Additional information regarding valuation methodologies, key inputs and controls is included in Note 10 to our Consolidated Financial
Statements. More detailed information about fixed maturities by type of issuer and maturity dates is included in Note 11 to our Consolidated
Financial Statements.
The following table reflects our fixed maturity portfolio by type of issuer as of December 31, 2017 and 2016.
(In millions)
Federal government and agency
State and local government
Foreign government
Corporate
Mortgage and other asset-backed
Total
$
2017
779
1,287
2,487
18,088
497
$
2016
877
1,435
2,113
16,050
486
$
23,138
$
20,961
The fixed maturity portfolio increased $2.2 billion during the 12 months ended December 31, 2017, primarily reflecting an increase in investable
funds. As of December 31, 2017, $20.5 billion, or 89%, of the fixed maturities in our investment portfolio were investment grade (Baa and above,
or equivalent), and the remaining $2.6 billion were below investment grade. The majority of the bonds that are below investment grade are
rated at the higher end of the non-investment grade spectrum. These quality characteristics have not materially changed from the prior year
and are consistent with our investment strategy.
State and local government. Our investment in state and local government securities, with an average quality rating of Aa2, was diversified
by issuer and geography with no single exposure greater than $35 million as of December 31, 2017. We assess each issuer’s credit quality based
on a fundamental analysis of underlying financial information and do not rely solely on statistical rating organizations or monoline insurer
guarantees.
Foreign government. We invested in high quality foreign government obligations with an average quality rating of Aa3 as of December 31,
2017. These investments were concentrated in Asia, primarily South Korea, consistent with the geographic locations of our international
business operations. Foreign government obligations also included $243 million of investments in European sovereign debt, none of which are
in countries with significant political or economic concerns such as Portugal, Italy, Ireland, Greece, Spain and Turkey.
Corporate. As of December 31, 2017, corporate fixed maturities included the following:
•
•
•
•
Private placement investments were $6 billion. These investments are generally less marketable than publicly-traded bonds; however yields
on these investments tend to be higher than yields on publicly-traded bonds with comparable credit risk. We perform a credit analysis of each
issuer, diversify investments by industry and issuer and require financial and other covenants that allow us to monitor issuers for deteriorating
financial strength and pursue remedial actions, if warranted.
Investments in companies that are domiciled or have significant business interests in Italy, Ireland, Spain and Turkey were $400 million. These
investments have an average quality rating of Baa2 and are diversified by industry sector, including less than 2% invested in financial
institutions.
Investments in the energy and natural gas sector were $1.8 billion with gross unrealized losses of $9 million. These investments have an
average quality rating of Baa2 and are diversified by issuer with no single exposure greater than $65 million.
Retail sector fixed maturity investments were approximately $460 million with gross unrealized losses of $3 million. These investments had
an average quality rating of Baa2 and were diversified across approximately 40 issuers with no exposure exceeding $50 million.
52 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
In addition to amounts classified in fixed maturities on our Consolidated Balance Sheets, we operate an insurance joint venture in China in
which we have a 50% ownership interest. We account for this joint venture on the equity basis of accounting and report it in other assets,
including other intangibles. This entity had an investment portfolio of approximately $4.9 billion supporting this business that is primarily
invested in local Chinese corporate and government fixed maturities. There were no investments with a material unrealized loss as of
December 31, 2017.
Equity Securities
As of December 31, 2017, approximately $400 million in equity securities were invested in an exchange traded fund (‘‘ETF’’) as part of a
program to invest available cash in high quality and liquid assets. The underlying assets of the ETF are primarily U.S. investment grade
corporate bonds and there was a gross unrealized gain of $10 million as of December 31, 2017 due to a decrease in market yields since purchase.
Commercial Mortgage Loans
Our commercial mortgage loans are fixed rate loans, diversified by property type, location and borrower. Loans are secured by high quality
commercial properties and are generally made at less than 70% of the property’s value at origination of the loan. Property value, debt service
coverage, quality, building tenancy and stability of cash flows are all important financial underwriting considerations. We hold no direct
residential mortgage loans and do not originate or service securitized mortgage loans.
We completed the annual in-depth review of our commercial mortgage loan portfolio during the second quarter of 2017. The results of the 2017
review were in line with the prior year and confirmed the strength of the overall portfolio. For further discussion of the results of this review and
changes in key loan metrics, see Note 11 to our Consolidated Financial Statements.
Commercial real estate capital markets remain very active for well-leased, quality commercial real estate located in strong institutional
investment markets. The vast majority of properties securing the mortgages in our mortgage loan portfolio possess these characteristics. As of
December 31, 2017, we had $135 million of commercial mortgage loans in the retail sector for various shopping centers in the United States. The
loan-to-value ratio for these loans was 49%, and the debt service coverage ratio was 2.15. All of these loans are current.
As of December 31, 2017, the $1.8 billion commercial mortgage loan portfolio consisted of approximately 60 loans that are all in good standing.
Given the quality and diversity of the underlying real estate, positive debt service coverage and significant borrower cash investment generally
ranging between 30 and 40%, we remain confident that borrowers will continue to perform as expected under their contract terms.
Other Long-term Investments
Other long-term investments of $1.5 billion included investments in securities limited partnerships and real estate limited partnerships as well
as direct investments in real estate joint ventures. The funds typically invest in mezzanine debt or equity of privately held companies (securities
partnerships) and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher
level of risk for higher expected returns. To mitigate risk, these investments are diversified across approximately 125 separate partnerships, and
approximately 60 general partners who manage one or more of these partnerships. Also, the funds’ underlying investments are diversified by
industry sector or property type, and geographic region. No single partnership investment exceeded 4% of our securities and real estate
partnership portfolio.
Problem and Potential Problem Investments
‘‘Problem’’ bonds and commercial mortgage loans are either delinquent by 60 days or more or have been restructured as to terms, including
concessions by us for modification of interest rate, principal payment or maturity date. ‘‘Potential problem’’ bonds and commercial mortgage
loans are considered current (no payment is more than 59 days past due), but management believes they have certain characteristics that
increase the likelihood that they may become problems. The characteristics management considers include, but are not limited to, the
following:
•
request from the borrower for restructuring;
•
principal or interest payments past due by more than 30 but fewer than 60 days;
•
downgrade in credit rating;
•
collateral losses on asset-backed securities; and
•
for commercial mortgages, deterioration of debt service coverage below 1.0 or value declines resulting in estimated loan-to-value ratios
increasing to 100% or more.
We recognize interest income on problem bonds and commercial mortgage loans only when payment is actually received because of the risk
profile of the underlying investment. The amount that would have been reflected in net income if interest on non-accrual investments had been
recognized in accordance with their original terms was not significant for 2017 or 2016.
CIGNA CORPORATION - 2017 Form 10-K 53
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following table shows problem and potential problem investments at amortized cost, net of valuation reserves and write-downs:
(In millions)
Problem bonds
Problem commercial mortgage loans
Foreclosed real estate
Total problem investments
Potential problem bonds
Potential problem commercial mortgage loans
Total potential problem investments
December 31, 2017
Reserve
Gross
$
$
$
$
25
–
46
71
31
–
31
$
$
$
$
(7)
–
–
(7)
(1)
–
(1)
$
$
$
$
Net
18
–
46
64
30
–
30
December 31, 2016
Reserve
Gross
Net
$
$
$
$
70
26
49
145
12
–
12
$
$
$
$
(9)
(5)
–
(14)
(7)
–
(7)
$
$
$
$
61
21
49
131
5
–
5
Problem and potential problem investments decreased by $42 million since December 31, 2016 primarily due to payoffs and paydowns of
problem bonds and mortgage loans.
Investment Outlook
Although financial markets in the United States remained stable during 2017, we continue to closely monitor global macroeconomic trends and
their potential impact to our investment portfolio. Certain sectors, such as retail, energy and natural gas have experienced stress and volatility
and we expect that to continue. See the fixed maturities and commercial mortgage loan sections of this MD&A for further information on our
investments in these sectors. Future realized and unrealized investment results will be driven largely by market conditions that exist when a
transaction occurs or at the reporting date. These future conditions are not reasonably predictable; however, we believe that the vast majority
of our investments will continue to perform under their contractual terms. Based on our strategy to match the duration of invested assets to the
duration of insurance and contractholder liabilities, we expect to hold a significant portion of these assets for the long term. Although future
impairment losses resulting from interest rate movements and credit deterioration due to both investment-specific and the global economic
uncertainties discussed above remain possible, we do not expect these losses to have a material adverse effect on our financial condition or
liquidity.
Market Risk
Financial Instruments
Our assets and liabilities include financial instruments subject to the risk of potential losses from adverse changes in market rates and prices.
Consistent with disclosure requirements, the following items have been excluded from this consideration of market risk for financial
instruments:
•
changes in the fair values of insurance-related assets and liabilities because their primary risks are insurance rather than market risk;
•
•
changes in the fair values of investments recorded using the equity method of accounting and liabilities for pension and other postretirement
and postemployment benefit plans (and related assets); and
changes in the fair values of other significant assets and liabilities such as goodwill, deferred policy acquisition costs, taxes, and various
accrued liabilities. Because they are not financial instruments, their primary risks are other than market risk.
Excluding these items, our primary market risk exposures from financial instruments are:
•
•
Interest-rate risk on fixed-rate, medium-term instruments. Changes in market interest rates affect the value of instruments that promise a
fixed return.
Foreign currency exchange rate risk of the U.S. dollar primarily to the South Korean won, Euro, Taiwan dollar, Chinese yuan renminbi, and
British pound. An unfavorable change in exchange rates reduces the carrying value of net assets denominated in foreign currencies.
Our Management of Market Risks
We predominantly rely on three techniques to manage our exposure to market risk:
•
Investment/liability matching. We generally select investment assets with characteristics (such as duration, yield, currency and liquidity)
that correspond to the underlying characteristics of our related insurance and contractholder liabilities so that we can match the investments
to our obligations. Shorter-term investments generally support shorter-term life and health liabilities. Medium-term, fixed-rate investments
support interest-sensitive and health liabilities. Longer-term investments generally support products with longer pay out periods such as
annuities and long-term disability liabilities.
•
Use of local currencies for foreign operations. We generally conduct our international business through foreign operating entities that
maintain assets and liabilities in local currencies. While this technique does not reduce foreign currency exposure on our net assets, it
substantially limits exchange rate risk to those net assets.
•
Use of derivatives. We use derivative financial instruments to minimize certain market risks.
See Note 12 to our Consolidated Financial Statements for additional information about derivative financial instruments.
54 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Effect of Market Fluctuations
The examples that follow illustrate the adverse effect of hypothetical changes in market rates or prices on the fair value of certain financial
instruments including:
•
•
a hypothetical increase in market interest rates, primarily for fixed maturities and commercial mortgage loans, partially offset by liabilities for
long-term, largely fixed-rate debt; and
a hypothetical strengthening of the U.S. dollar to foreign currencies, primarily for financial instruments held by foreign subsidiaries
denominated in a foreign currency.
The effects of hypothetical changes in market rates or prices on the fair values of certain of our financial instruments, subject to the exclusions
noted above (particularly insurance liabilities), would have been as follows as of December 31:
Market scenario for certain non-insurance financial instruments (in billions)
100 basis point increase in interest rates
10% strengthening in U.S. dollar to foreign currencies
Loss in fair value
2017
2016
$
1.2
$ 0.5
$
$
1.0
0.4
The effect of a hypothetical increase in interest rates was determined by estimating the present value of future cash flows using various models,
primarily duration modeling. The impact of a hypothetical increase to interest rates at December 31, 2017 was greater than that at December 31,
2016 reflecting increased purchases of fixed maturities partially offset by additional issuances of long-term debt.
The effect of a hypothetical strengthening of the U.S. dollar relative to the foreign currencies of certain financial instruments held by us was
estimated to be 10% of the U.S. dollar equivalent fair value. Our foreign operations hold investment assets, such as fixed maturities, cash, and
cash equivalents, that are generally invested in the currency of the related liabilities. The effect of a hypothetical 10% strengthening in the U.S.
dollar to foreign currencies at December 31, 2017 was greater than that effect at December 31, 2016 due to increased amounts of investments
that are primarily denominated in the South Korean won.
CIGNA CORPORATION - 2017 Form 10-K 55
PART II
ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk
ITEM 7A.
Quantitative and Qualitative Disclosures About
Market Risk
The information contained under the caption ‘‘Market Risk’’ in the MD&A section of this Form 10-K is incorporated by reference.
56 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
ITEM 8.
Financial Statements and Supplementary Data
Report of Independent Registered Public Accounting Firm
To the Board of Directors
and Shareholders of Cigna Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Cigna Corporation and its subsidiaries as of December 31, 2017 and 2016,
and the related consolidated statements of income, comprehensive income, changes in total equity and cash flows for each of the three years in
the period ended December 31, 2017, including the related notes (collectively referred to as the ‘‘consolidated financial statements’’). We also
have audited the Company’s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control –
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the
Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period
ended December 31, 2017 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the
Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017 based on criteria
established in Internal Control – Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial
reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s
Annual Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on the Company’s consolidated financial
statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with
the Public Company Accounting Oversight Board (United States) (‘‘PCAOB’’) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or
fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the
consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures
as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A
company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and
directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or
that the degree of compliance with the policies or procedures may deteriorate.
/s/ PricewaterhouseCoopers LLP
Hartford, Connecticut
February 28, 2018
We have served as the Company’s auditor since 1983.
CIGNA CORPORATION - 2017 Form 10-K 57
PART II
ITEM 8. Financial Statements and Supplementary Data
Cigna Corporation
Consolidated Statements of Income
(In millions, except per share amounts)
Revenues
Premiums
Fees and other revenues
Net investment income
Mail order pharmacy revenues
Realized investment gains (losses)
Other-than-temporary impairments on fixed maturities
Other realized investment gains, net
Net realized investment gains
TOTAL REVENUES
Benefits and expenses
Global Health Care medical costs
Other benefit expenses
Mail order pharmacy costs
Other operating expenses
Amortization of other acquired intangible assets, net
TOTAL BENEFITS AND EXPENSES
Income before income taxes
Income taxes
Current
Deferred
TOTAL INCOME TAXES
Net income
Less: Net (loss) attributable to noncontrolling interests
SHAREHOLDERS’ NET INCOME
Shareholders’ net income per share
Basic
Diluted
Dividends declared per share
The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.
For the Years Ended
December 31,
2017
2016
2015
$ 32,307
4,867
1,226
2,979
$ 30,626
4,760
1,147
2,966
$ 29,642
4,488
1,153
2,536
(27)
264
237
(35)
204
169
(112)
169
57
41,616
39,668
37,876
19,967
5,439
2,456
10,033
115
38,010
3,606
1,132
242
1,374
2,232
(5)
$ 2,237
8.92
$
$
8.77
$ 0.04
$
$
$
$
19,009
5,477
2,468
9,584
151
36,689
2,979
1,062
74
1,136
1,843
(24)
1,867
7.31
7.19
0.04
18,354
4,936
2,134
8,982
143
34,549
3,327
1,229
21
1,250
2,077
(17)
$ 2,094
$
$
$
8.17
8.04
0.04
58 CIGNA CORPORATION - 2017 Form 10-K
Cigna Corporation
Consolidated Statements of Comprehensive Income
PART II
ITEM 8. Financial Statements and Supplementary Data
(In millions)
Shareholders’ net income
Shareholders’ other comprehensive income (loss), net of tax
Net unrealized (depreciation) on securities
Net unrealized (depreciation) appreciation on derivatives
Net translation of foreign currencies
Postretirement benefits liability adjustment
Shareholders’ other comprehensive income (loss), net of tax
Shareholders’ comprehensive income
Comprehensive income attributable to noncontrolling interests
Net (loss) attributable to redeemable noncontrolling interests
Net (loss) attributable to other noncontrolling interests
Other comprehensive (loss) attributable to redeemable noncontrolling interests
Other comprehensive (loss) attributable to other noncontrolling interests
Total comprehensive (loss) attributable to noncontrolling interests
For the Years Ended
December 31,
2017
2016
2015
$ 2,237
$ 1,867
$ 2,094
(34)
(3)
304
33
300
2,537
–
(5)
(3)
–
(8)
(56)
(4)
(95)
23
(132)
1,735
(7)
(17)
(10)
–
(34)
(202)
15
(212)
85
(314)
1,780
(6)
(11)
(17)
(1)
(35)
TOTAL COMPREHENSIVE INCOME
$ 2,529
$ 1,701
$ 1,745
The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.
CIGNA CORPORATION - 2017 Form 10-K 59
PART II
ITEM 8. Financial Statements and Supplementary Data
Cigna Corporation
Consolidated Balance Sheets
(In millions, except per share amounts)
Assets
Investments
Fixed maturities, at fair value (amortized cost, $21,867; $19,942)
Equity securities, at fair value (cost, $589; $583)
Commercial mortgage loans
Policy loans
Other long-term investments
Short-term investments
Total investments
Cash and cash equivalents
Premiums, accounts and notes receivable, net
Reinsurance recoverables
Deferred policy acquisition costs
Property and equipment
Deferred tax assets, net
Goodwill
Other assets, including other intangibles
Separate account assets
TOTAL ASSETS
Liabilities
Contractholder deposit funds
Future policy benefits
Unpaid claims and claim expenses
Global Health Care medical costs payable
Unearned premiums
Total insurance and contractholder liabilities
Accounts payable, accrued expenses and other liabilities
Short-term debt
Long-term debt
Separate account liabilities
TOTAL LIABILITIES
Contingencies – Note 21
Redeemable noncontrolling interests
Shareholders’ equity
Common stock (par value per share, $0.25; shares issued, 296; authorized, 600)
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Less: treasury stock, at cost
TOTAL SHAREHOLDERS’ EQUITY
Noncontrolling interests
Total equity
Total liabilities and equity
SHAREHOLDERS’ EQUITY PER SHARE
The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.
60 CIGNA CORPORATION - 2017 Form 10-K
As of December 31,
2017
2016
$ 23,138
588
1,761
1,415
1,518
199
28,619
2,972
3,380
6,046
2,237
1,563
33
6,164
2,316
8,423
$ 20,961
583
1,666
1,452
1,462
691
26,815
3,185
3,077
6,478
1,818
1,536
304
5,980
2,227
7,940
$ 61,753
$ 59,360
$ 8,196
10,040
5,168
2,719
724
26,847
7,260
240
5,199
8,423
47,969
$ 8,458
9,648
4,917
2,532
634
26,189
6,414
276
4,756
7,940
45,575
49
58
74
2,940
(1,082)
15,824
(4,021)
13,735
–
13,735
74
2,892
(1,382)
13,855
(1,716)
13,723
4
13,727
$ 61,753
$ 59,360
$ 56.30
$ 53.42
PART II
ITEM 8. Financial Statements and Supplementary Data
Cigna Corporation
Consolidated Statements of Changes in Total Equity
Additional
Accumulated
Other
Common
Stock
Paid-in Comprehensive Retained Treasury Shareholders’ Noncontrolling
Interests
Capital
Loss Earnings
Equity
Stock
Redeemable
Total Noncontrolling
Interests
Equity
$
74 $
2,769 $
(936) $ 10,289 $ (1,422) $
10,774 $
15 $ 10,789 $
90
(In millions, except per share amounts)
Balance at December 31, 2014
2015 Activity
Effect of issuing stock for employee benefit plans
Other comprehensive income (loss)
Net income (loss)
Common dividends declared (per share: $0.04)
Repurchase of common stock
Other transactions impacting noncontrolling interests
99
(9)
(252)
336
(314)
2,094
(10)
(683)
183
(314)
2,094
(10)
(683)
(9)
Balance at December 31, 2015
74
2,859
(1,250)
12,121
(1,769)
12,035
2016 Activity
Effect of issuing stock for employee benefit plans
Other comprehensive income (loss)
Net income (loss)
Common dividends declared (per share: $0.04)
Repurchase of common stock
Other transactions impacting noncontrolling interests
51
(18)
(132)
(123)
163
1,867
(10)
(110)
91
(132)
1,867
(10)
(110)
(18)
Balance at December 31, 2016
74
2,892
(1,382)
13,855
(1,716)
13,723
2017 Activity
Effect of issuing stock for employee benefit plans
Other comprehensive income (loss)
Net income (loss)
Common dividends declared (per share: $0.04)
Repurchase of common stock
Other transactions impacting noncontrolling interests
51
(3)
300
(258)
455
2,237
(10)
(2,760)
248
300
2,237
(10)
(2,760)
(3)
Balance at December 31, 2017
$
74 $
2,940 $
(1,082) $ 15,824 $(4,021) $
13,735 $
– $ 13,735 $
The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.
183
(315)
2,083
(10)
(683)
(3)
12,044
91
(132)
1,850
(10)
(110)
(6)
13,727
248
300
2,232
(10)
(2,760)
(2)
(1)
(11)
6
9
(17)
12
4
(5)
1
(17)
(6)
2
69
(10)
(7)
6
58
(3)
–
(6)
49
CIGNA CORPORATION - 2017 Form 10-K 61
PART II
ITEM 8. Financial Statements and Supplementary Data
Cigna Corporation
Consolidated Statements of Cash Flows
(In millions)
Cash Flows from Operating Activities
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Realized investment (gains), net
Deferred income taxes
Net changes in assets and liabilities, net of non-operating effects:
Premiums, accounts and notes receivable
Reinsurance recoverables
Deferred policy acquisition costs
Other assets
Insurance liabilities
Accounts payable, accrued expenses and other liabilities
Current income taxes
Debt extinguishment costs
Distributions from partnership investments (2)
Other, net (1)
NET CASH PROVIDED BY OPERATING ACTIVITIES (1)(2)
Cash Flows from Investing Activities
Proceeds from investments sold:
Fixed maturities and equity securities
Investment maturities and repayments:
Fixed maturities and equity securities
Commercial mortgage loans
Other sales, maturities and repayments (primarily short-term and other long-term
investments) (2)
Investments purchased or originated:
Fixed maturities and equity securities
Commercial mortgage loans
Other (primarily short-term and other long-term investments)
Property and equipment purchases, net
Acquisitions, net of cash acquired
Other, net
NET CASH (USED IN) INVESTING ACTIVITIES (2)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds
Withdrawals and benefit payments from contractholder deposit funds
Net change in short-term debt
Payments for debt extinguishment
Repayment of long-term debt
Net proceeds on issuance of long-term debt
Repurchase of common stock
Issuance of common stock
Other, net (1)
NET CASH (USED IN) FINANCING ACTIVITIES (1)
Effect of foreign currency rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, January 1,
Cash and cash equivalents, December 31,
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds
Interest paid
For the years ended December 31,
2017
2016
2015
$
2,232
$
1,843
$
2,077
566
(237)
242
(233)
214
(282)
(171)
506
639
92
321
161
36
4,086
2,012
2,051
335
1,702
(5,628)
(430)
(1,065)
(471)
(209)
–
(1,703)
1,230
(1,363)
80
(313)
(1,250)
1,581
(2,725)
131
(22)
(2,651)
55
(213)
3,185
2,972
1,036
240
$
$
$
610
(169)
74
663
142
(213)
134
683
124
1
–
144
(10)
4,026
1,544
1,755
316
1,431
(5,191)
(165)
(1,698)
(461)
(4)
(101)
(2,574)
1,460
(1,362)
(148)
–
–
–
(139)
36
(72)
(225)
(10)
1,217
1,968
3,185
1,064
244
$
$
$
585
(57)
21
(945)
55
(182)
16
657
423
(25)
100
137
71
2,933
1,555
1,435
640
1,160
(4,234)
(500)
(1,183)
(510)
(99)
–
(1,736)
1,429
(1,359)
(21)
(87)
(851)
894
(671)
154
(97)
(609)
(40)
548
1,420
1,968
1,194
245
$
$
$
(1) As required in adopting Accounting Standard Update (‘‘ASU’’) 2016-09 in 2016, the Company retrospectively reclassified $79 million of cash payments
from operating to financing activities in 2015. These payments were related to employee tax obligations associated with stock compensation. The
comparable amounts reported in financing activities were $61 million in 2017 and $72 million in 2016.
(2) As required in adopting ASU 2016-15 in 2016, the Company retrospectively reclassified $137 million of cash distributions of earnings from partnership
investments from investing to operating activities in 2015. The comparable amounts reported in operating activities were $161 million in 2017 and
$144 million in 2016.
The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.
62 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Notes to the Consolidated Financial Statements
Table of Contents
Note
Number
Footnote
BUSINESS AND CAPITAL STRUCTURE
1
2
3
4
5
6
INSURANCE INFORMATION
7
8
9
INVESTMENTS
10
11
12
13
14
WORKFORCE MANAGEMENT AND COMPENSATION
15
16
PROPERTY, LEASES AND OTHER ASSET BALANCES
17
18
COMPLIANCE, REGULATION AND CONTINGENCIES
19
20
21
RESULTS DETAILS
22
Description of Business .......................................................................................................................................................................................
Summary of Significant Accounting Policies................................................................................................................................................
Mergers, Acquisitions and Dispositions..........................................................................................................................................................
Earnings Per Share................................................................................................................................................................................................
Debt...........................................................................................................................................................................................................................
Common and Preferred Stock...........................................................................................................................................................................
Global Health Care Medical Costs Payable ...................................................................................................................................................
Liabilities for Unpaid Claims and Claim Expenses ......................................................................................................................................
Reinsurance .............................................................................................................................................................................................................
Fair Value Measurements....................................................................................................................................................................................
Investments, Investment Income and Gains and Losses...........................................................................................................................
Derivative Financial Instruments ......................................................................................................................................................................
Variable Interest Entities .....................................................................................................................................................................................
Accumulated Other Comprehensive Income (Loss)...................................................................................................................................
Pension and Other Postretirement Benefit Plans........................................................................................................................................
Employee Incentive Plans ...................................................................................................................................................................................
Goodwill, Other Intangibles and Property and Equipment......................................................................................................................
Leases and Rentals ...............................................................................................................................................................................................
Shareholders’ Equity and Dividend Restrictions .........................................................................................................................................
Income Taxes ..........................................................................................................................................................................................................
Contingencies and Other Matters ....................................................................................................................................................................
Segment Information ...........................................................................................................................................................................................
Quarterly Financial Data .....................................................................................................................................................................................
Page
64
64
71
71
72
73
73
75
78
80
85
89
91
92
92
95
98
100
100
100
102
105
108
CIGNA CORPORATION - 2017 Form 10-K 63
PART II
ITEM 8. Financial Statements and Supplementary Data
Description of Business
NOTE 1
Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as ‘‘Cigna,’’ the ‘‘Company,’’ ‘‘we,’’ ‘‘our’’ or ‘‘us’’)
is a global health services organization dedicated to a mission of helping individuals improve their health, well-being and sense of security. To
execute on our mission, Cigna’s evolved strategy is to ‘‘Go Deeper’’, ‘‘Go Local’’ and ‘‘Go Beyond’’ with a differentiated set of medical, dental,
disability, life and accident insurance and related products and services offered by our subsidiaries. The majority of these products are offered
through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna also offers
commercial health and dental insurance, Medicare and Medicaid products and health, life and accident insurance coverages to individuals in
the United States and selected international markets. In addition to these ongoing operations, Cigna also has certain run-off operations.
The financial results of the Company’s businesses are reported in the following segments:
Global Health Care aggregates the Commercial and Government operating segments due to their similar economic characteristics, products
and services and regulatory environment:
•
The Commercial operating segment (‘‘Commercial segment’’) encompasses both the U.S. commercial and certain international health care
businesses serving employers and their employees, other groups, and individuals. Products and services include medical, dental, behavioral
health, vision, and prescription drug benefit plans, health advocacy programs and other products and services to insured and self-insured
customers.
•
The Government operating segment (‘‘Government segment’’) offers Medicare Advantage and Medicare Part D plans to seniors. This
segment also offers Medicaid plans in selected markets.
Global Supplemental Benefits includes supplemental health, life and accident insurance products offered in selected international markets
and in the United States.
Group Disability and Life provides group long-term and short-term disability, group life, accident and specialty insurance products and related
services.
Other Operations consist of:
•
corporate-owned life insurance (‘‘COLI’’);
•
run-off reinsurance business that is predominantly comprised of guaranteed minimum death benefit (‘‘GMDB’’) and guaranteed minimum
income benefit (‘‘GMIB’’) business effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska
(‘‘Berkshire’’) in 2013;
•
deferred gains recognized from the 1998 sale of the individual life insurance and annuity business and the 2004 sale of the retirement benefits
business; and
•
run-off settlement annuity business.
Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less
net investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters,
intersegment eliminations, compensation cost for stock options and related excess tax benefits, expense associated with our frozen pension
plans and certain overhead and project costs.
Summary of Significant Accounting Policies
NOTE 2
Basis of Presentation
The Consolidated Financial Statements include the accounts of Cigna Corporation and its subsidiaries. Intercompany transactions and
accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting
principles generally accepted in the United States of America (‘‘GAAP’’). Amounts recorded in the Consolidated Financial Statements
necessarily reflect management’s estimates and assumptions about medical costs, investment valuation, interest rates and other factors.
Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change
in estimate is generally included in earnings in the period of adjustment. Certain reclassifications have been made to prior year amounts to
conform to the current presentation.
Variable interest entities. See Note 13 for a discussion of consolidated variable interest entities.
64 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Recent Accounting Guidance
The following tables provide information about recently adopted accounting guidance and accounting guidance not yet adopted that is
applicable to Cigna.
Recently Adopted Accounting Guidance
Accounting Standard and Adoption Date
Effects of Adopting New Guidance
GUIDANCE ADOPTED IN 2017
Securities and Exchange Commission (‘‘SEC’’) Staff Accounting Bulletin
No. 118 (‘‘SAB 118’’), adopted December 31, 2017
•
Guidance:
•
Allows a company to recognize the effects of U.S. tax reform as
provisional in its 2017 financial statements when it does not have
the necessary information in reasonable detail to complete its
accounting for the change in tax law.
Establishes a maximum one-year measurement period that ends
when a company has obtained the information necessary to finalize
its accounting. During the measurement period, adjustments for the
effects of the law will be recorded to the extent a reasonable
estimate for all or a portion of the effects of the law can be made.
Effects of adoption:
•
•
The Company has reported reasonable estimates of the income tax
effects of U.S. tax reform as provisional in its financial statements.
See Note 20 for disclosures about the impact of U.S. tax reform on
the Company’s financial statements.
Accounting Guidance Not Yet Adopted
Accounting Standard and Effective Date Applicable for Cigna
Requirements and Expected Effects of New Guidance Not Yet Adopted
GUIDANCE TO BE ADOPTED JANUARY 1, 2018
Requires:
•
•
•
Companies to estimate and allocate the expected customer
contract revenues among distinct goods or services based on
relative standalone selling prices
Revenues to be recognized as goods or services are delivered
New disclosures including presenting relevant categories of
revenues and information about related contract assets and
liabilities
Adoption through retrospective restatement with or without using
certain practical expedients or adoption with a cumulative effect
adjustment
Expected effects:
•
Revenue from Contracts with Customers (Accounting Standards Update
(‘‘ASU’’) 2014-09 and related amendments)
Required as of January 1, 2018
•
•
•
•
•
Guidance applies to the Company’s administrative service, mail
order pharmacy and other non-insurance contracts, but does not
apply to certain contracts within the scope of other GAAP, such as
the Company’s insurance and investment contracts accounted for
under the Financial Accounting Standards Board’s Accounting
Standards Codification (‘‘ASC’’) 944.
The Company has completed its evaluation of the new requirements
and the adoption of the new guidance will not have a material
impact to its pattern of revenue recognition or net income.
The Company will adopt the new guidance through retrospective
restatement and is currently working to develop required
disclosures and restate historical periods in line with its chosen
method of adoption. The Company does not anticipate significant
changes to its systems, processes or controls.
The Company’s cumulative effect of implementing this guidance will
result in an immaterial decrease to the opening balance of retained
earnings from establishing a contract liability for service fee revenue
that must be recognized when services are provided after the
termination of certain administrative service contracts.
The Company also will reclassify certain fees as a result of
clarifications in the new guidance and its related interpretations.
CIGNA CORPORATION - 2017 Form 10-K 65
PART II
ITEM 8. Financial Statements and Supplementary Data
Accounting Standard and Effective Date Applicable for Cigna
Requirements and Expected Effects of New Guidance Not Yet Adopted
GUIDANCE TO BE ADOPTED JANUARY 1, 2018
Requires:
•
Entities to measure equity investments at fair value in net income if
they are neither consolidated nor accounted for under the equity
method
Cumulative effect adjustment to the beginning balance of retained
earnings at adoption
•
Recognition and Measurement of Financial Assets and Financial
Liabilities (ASU 2016-01)
Required as of January 1, 2018
Expected effects:
•
•
•
Certain limited partnership interests carried at cost of
approximately $200 million as of December 31, 2017 will be
reported at fair value at adoption with future changes in fair value
reported in net investment income.
Changes in fair value for equity securities previously reported in
accumulated other comprehensive income will now be reported in
net realized investment gains.
Retained earnings will increase by approximately $60 million
after-tax on January 1, 2018.
Intra-Entity Asset Transfers of Assets Other than Inventory
(ASU 2016-16)
Required as of January 1, 2018
•
Requires:
•
Entities to recognize the tax impacts of all intra-entity sales of
assets other than inventory even though the pre-tax effects of
those transactions are eliminated in consolidation
Modified retrospective approach for adoption with a cumulative-
effect adjustment recorded in retained earnings
Expected effects: the adoption of this standard will not have a material
effect on the Company’s financial statements.
Clarifying the Definition of a Business (ASU 2017-01)
Required as of January 1, 2018
•
Guidance:
•
Revises the definition of a business and provides a more robust
framework for entities to use in determining when a set of assets
and activities is a business.
Requires entities to apply this new definition to business
transactions beginning in the first quarter of 2018.
Expected effects: the Company does not expect this change in definition
will have a material impact on its financial statements.
Improving the Presentation of Net Periodic Pension Cost and Net
Periodic Postretirement Benefit Cost (ASU 2017-07)
Required as of January 1, 2018
•
•
Requires:
•
Employers to separate the service cost component from the other
components of net benefit cost
Only service cost is eligible for capitalization (as either deferred
policy acquisition costs or capitalized software), to be applied
prospectively upon adoption
Income statement captions used for each component of net benefit
cost to be disclosed
Expected effects: the Company does not expect the effect of this new
guidance to be material to results of operations because its most
significant plans are frozen. See Note 15 for additional information.
GUIDANCE TO BE EARLY ADOPTED JANUARY 1, 2018
Targeted Improvements to Accounting for Hedging Activities
(ASU 2017-12)
•
Required as of January 1, 2019, with early adoption permitted in 2017
Guidance:
•
Relaxes requirements for financial and nonfinancial hedging
strategies to be eligible for hedge accounting and changes how
companies assess effectiveness.
Amends presentation and disclosure requirements to improve
transparency about the uses and results of hedging programs.
Expected effects: the Company is planning to adopt this guidance on
January 1, 2018 with an immaterial impact to its financial statements for
existing hedges.
GUIDANCE TO BE ADOPTED AFTER 2018 OR ADOPTION DATE HAS NOT BEEN DETERMINED
Guidance:
•
Allows companies to reclassify tax effects stranded in accumulated
other comprehensive income as a result of U.S. tax reform to
retained earnings.
Requires additional disclosures of the company’s accounting policy
for releasing income tax effects from accumulated other
comprehensive income.
Allows companies to apply the guidance retrospectively or in the
period of adoption.
•
•
Effects of adoption:
•
•
The Company is evaluating this new standard and its expected
timing of adoption.
If adopted as of December 31, 2017, approximately $230 million of
accumulated other comprehensive income would have been
reclassified to retained earnings.
Reclassification of Certain Tax Effects from Accumulated Other
Comprehensive Income (ASU 2018-02)
Effective as of January 1, 2019 with early adoption permitted for
reporting periods for which financials have not been issued.
66 CIGNA CORPORATION - 2017 Form 10-K
Accounting Standard and Effective Date Applicable for Cigna
Requirements and Expected Effects of New Guidance Not Yet Adopted
GUIDANCE TO BE ADOPTED AFTER 2018 OR ADOPTION DATE HAS NOT BEEN DETERMINED
PART II
ITEM 8. Financial Statements and Supplementary Data
Leases (ASU 2016-02)
Required as of January 1, 2019
Measurement of Credit Losses on Financial Instruments (ASU 2016-13)
Required as of January 1, 2020, with early adoption permitted as of
January 1, 2019
Requires:
•
•
•
Balance sheet recognition of assets and liabilities arising from
leases, including leases embedded in other contracts
Additional disclosures of the amount, timing and uncertainty of
cash flows from leases will be required
Modified retrospective approach for leases in effect as of and after
the date of adoption with a cumulative-effect adjustment recorded
in retained earnings
Expected effects:
•
•
•
The Company is continuing to evaluate the impact this standard will
have on its financial statements.
While not yet quantified, the Company expects a material impact to
the Consolidated Balance Sheets from recognizing additional assets
and liabilities of operating leases upon adoption. The actual
increase in assets and liabilities will depend on the volume and
terms of leases in place at the time of adoption.
The Company is implementing a new lease system in connection
with the adoption.
Requires:
•
A new approach using expected credit losses to estimate and
recognize credit losses for certain financial instruments such as
mortgage loans, reinsurance recoverables and other receivables
Changes in the criteria for impairment of available-for-sale debt
securities
Adoption using a modified retrospective approach with a
cumulative-effect adjustment recorded in retained earnings
•
•
Expected effects:
•
•
The Company is evaluating this new standard, its expected timing
of adoption and effects on its financial statements and disclosures.
An additional allowance for future expected credit losses for certain
financial instruments may be required at adoption.
Simplifying the Test for Goodwill Impairment (ASU 2017-04)
Required as of January 1, 2020, with early adoption permitted as of
January 1, 2017
•
•
Guidance:
•
Simplifies the accounting for goodwill impairment by eliminating
the need to determine the fair value of individual assets and
liabilities of a reporting unit to measure a goodwill impairment.
Redefines the amount of goodwill impairment to be equal to the
amount by which a reporting unit’s carrying value exceeds its fair
value, limited to the total amount of goodwill of the reporting unit.
Requires prospective adoption.
Expected effects: the Company is evaluating this new standard and its
expected timing of adoption.
CIGNA CORPORATION - 2017 Form 10-K 67
PART II
ITEM 8. Financial Statements and Supplementary Data
Significant Accounting Policies
The Company’s accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as
indicated in the table below.
Note
Number
Footnote and policy
4
7
8
9
10
11
12
13
15
16
17
20
21
Earnings per share ................................................................................................................................................................................................
Global Health Care medical costs payable....................................................................................................................................................
Liabilities for unpaid claims and claim expenses ........................................................................................................................................
Reinsurance .............................................................................................................................................................................................................
•
GMDB....................................................................................................................................................................................................................
•
GMIB......................................................................................................................................................................................................................
Fair value measurements ....................................................................................................................................................................................
•
Fixed maturities, equity securities, short-term investments and derivatives .................................................................................
•
Separate accounts ............................................................................................................................................................................................
•
Commercial mortgage loans .........................................................................................................................................................................
•
Contractholder deposit funds .......................................................................................................................................................................
•
Long-term debt .................................................................................................................................................................................................
Investments, investment income and gains and losses.............................................................................................................................
•
Fixed maturities and equity securities .......................................................................................................................................................
•
Commercial mortgage loans .........................................................................................................................................................................
•
Other long-term investments ........................................................................................................................................................................
•
Short-term investments and cash equivalents.........................................................................................................................................
•
Net investment income ...................................................................................................................................................................................
•
Realized investment gains and losses ........................................................................................................................................................
Derivative financial instruments........................................................................................................................................................................
Variable interest entities......................................................................................................................................................................................
Pension and other postretirement benefit plans.........................................................................................................................................
Employee incentive plans ...................................................................................................................................................................................
Goodwill, other intangibles and property and equipment .......................................................................................................................
Income taxes...........................................................................................................................................................................................................
Contingencies and other matters.....................................................................................................................................................................
Page
71
73
75
78
79
79
80
81
83
85
85
85
85
85
87
88
88
89
89
89
91
92
95
98
100
102
Investments – Policy Loans
A.
Policy loans are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are
collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on
a rolling average of benchmark interest rates.
Cash and Cash Equivalents
B.
Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities
of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to accounts payable, accrued expenses
and other liabilities when the legal right of offset does not exist.
C.
Premiums, Accounts and Notes Receivable and Reinsurance Recoverables
Premiums, accounts and notes receivable and reinsurance recoverables are reported net of allowances for doubtful accounts and
unrecoverable reinsurance of $210 million as of December 31, 2017 and $ 203 million as of December 31, 2016. The Company estimates these
allowances for doubtful accounts and unrecoverable reinsurance using management’s best estimates of collectability, taking into consideration
the age of the outstanding amounts, historical collection patterns and other economic factors. See Note 22 for additional discussion of the
allowance established in 2016 for the risk corridor receivable.
Deferred Policy Acquisition Costs
D.
Costs eligible for deferral include incremental, direct costs of acquiring new or renewal insurance and investment contracts and other costs
directly related to successful contract acquisition. Examples of deferrable costs include commissions, sales compensation and benefits, policy
68 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
issuance and underwriting costs and premium taxes. The Company records acquisition costs differently depending on the product line.
Acquisition costs for:
•
Supplemental health, life and accident insurance products (primarily individual products) that comprise the majority of the Company’s
deferred policy acquisition costs and group health and accident insurance products are deferred and amortized, generally in proportion to
the ratio of periodic revenue to the estimated total revenues over the contract periods.
•
Universal life products are deferred and amortized in proportion to the present value of total estimated gross profits over the expected lives
of the contracts.
•
Other products are expensed as incurred.
Deferred policy acquisition costs also include the value of business acquired for certain acquisitions with material long-duration insurance
contracts. The Company recorded amortization of deferred policy acquisition costs of $322 million in 2017, $292 million in 2016 and
$286 million in 2015 primarily in other operating expenses.
Each year, deferred policy acquisition costs are tested for recoverability. For universal life and other individual products, management
estimates the present value of future revenues less expected payments. For group health and accident insurance products, management
estimates the sum of unearned premiums and anticipated net investment income less future expected claims and related costs. If
management’s estimates of these sums are less than the deferred costs, the Company reduces deferred policy acquisition costs and records an
additional expense.
Other Assets, including Other Intangibles
E.
Other assets, including other intangibles consist primarily of GMIB assets, accrued net investment income, other intangible assets and various
other insurance-related assets. See Note 9 for the Company’s accounting policy for GMIB assets and see Note 17 for the Company’s accounting
policy for other intangibles. Additionally, these other assets include the carrying value of our equity-method investments in joint ventures in
China, India (as of 2017) and other foreign jurisdictions.
Contractholder Deposit Funds
F.
Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life
products and investment earnings on their fund balances. These liabilities are adjusted to reflect administrative charges and, for universal life
fund balances, mortality charges. In addition, this caption includes: 1) premium stabilization reserves under group insurance contracts
representing experience refunds left with the Company to pay future premiums; 2) deposit administration funds used to fund non-pension
retiree insurance programs; 3) retained asset accounts; and 4) annuities or supplementary contracts without significant life contingencies.
Interest credited on these funds is accrued ratably over the contract period.
Future Policy Benefits
G.
Future policy benefits represent the present value of estimated future obligations under long-term life and supplemental health insurance
policies and annuity products currently in force. These obligations are estimated using actuarial methods and consist primarily of reserves for
annuity contracts, life insurance benefits, GMDB contracts (see Note 9 for additional information) and certain health, life and accident
insurance products of our Global Supplemental Benefits segment.
Obligations for annuities represent specified periodic benefits to be paid to an individual or groups of individuals over their remaining lives.
Obligations for life insurance policies and GMDB contracts represent benefits expected to be paid to policyholders, net of future premiums
expected to be received. Management estimates these obligations based on assumptions as to premiums, interest rates, mortality or morbidity,
future claim adjudication expenses and surrenders, allowing for adverse deviation as appropriate. Mortality, morbidity and surrender
assumptions are based on the Company’s own experience and published actuarial tables. Interest rate assumptions are based on
management’s judgment considering the Company’s experience and future expectations, and range from 0.1% to 9%. Obligations for the
run-off settlement annuity business include adjustments for realized and unrealized investment returns consistent with GAAP when a premium
deficiency exists.
Redeemable Noncontrolling Interests
H.
Products and services are offered in Turkey and India through joint venture entities. The Company is the principal equity holder and primary
beneficiary of the Turkey joint venture and accordingly, this entity is consolidated. In 2017, Cigna modified the agreement governing its joint
venture in India due to changes in the local regulatory environment that require control by a local partner. As a result of the changes in the joint
venture agreement, the Company determined that it is no longer the primary beneficiary of the joint venture and, effective with the third
quarter of 2017, no longer consolidates its results.
As of December 31, 2017 the redeemable noncontrolling interests on our Consolidated Balance Sheets represent the Turkey joint venture
partner’s preferred and common stock interests in the entity. Our joint venture partner may, at their election, require the Company to purchase
their redeemable noncontrolling interests. We also have the right to require our joint venture partner to sell their redeemable noncontrolling
interests to us. The redeemable noncontrolling interests were recorded at fair value as of the dates of purchase. When the estimated
redemption value for a redeemable noncontrolling interest exceeds its carrying value, an adjustment to increase the redeemable
noncontrolling interest is recorded with an offsetting reduction to additional paid-in capital. When an adjustment is made to the carrying value
of the redeemable noncontrolling interest, the calculation of shareholders’ net income per share will be adjusted if the redemption value
exceeds the greater of the carrying value or fair value.
CIGNA CORPORATION - 2017 Form 10-K 69
PART II
ITEM 8. Financial Statements and Supplementary Data
Accounts Payable, Accrued Expenses and Other Liabilities
I.
Accounts payable, accrued expenses and other liabilities include liabilities for pension, other postretirement and postemployment benefits
(see Note 15), GMIB contract liabilities (see Note 9), self-insured exposures, management compensation, cash overdraft positions and various
insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio
rebate accruals under The Patient Protection and Affordable Care Act (the ‘‘ACA’’). Legal costs to defend the Company’s litigation and
arbitration matters are expensed when incurred in cases where the Company cannot reasonably estimate the ultimate cost to defend. In cases
where the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported.
Translation of Foreign Currencies
J.
The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local
currencies that are generally their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and
liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in accumulated other
comprehensive income (loss). The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S.
dollars.
Premiums and Related Expenses
K.
Premiums for group life, accident and health insurance and managed care coverages are recognized as revenue on a pro rata basis over the
contract period. Benefits and expenses are recognized when incurred and, for our Global Health Care insured business, medical costs are
presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for
experience-rated refunds based on contract terms and calculated using the customer’s experience (including estimates of incurred but not
reported claims).
Premium revenue also includes an adjustment to reflect the estimated effect of rebates due to customers under the commercial minimum
medical loss ratio provisions of the ACA. These rebates are settled in the year following the policy year.
Premiums received for the Company’s Medicare Advantage Plans and Medicare Part D products from the Centers for Medicare and Medicaid
Services (‘‘CMS’’) and customers are recognized as revenue ratably over the contract period. CMS provides risk-adjusted premium payments
for Medicare Advantage Plans and Medicare Part D products based on the demographics and wellness of enrollees. The Company recognizes
periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Additionally,
Medicare Part D premiums include payments from CMS for risk sharing adjustments. The risk sharing adjustments are estimated quarterly
based on claim experience by comparing actual incurred drug benefit costs to estimated costs submitted in original contracts. These
adjustments may result in more or less revenue from CMS. Final revenue adjustments are determined and settled with CMS in the year following
the contract year. Premium revenue also includes an adjustment to reflect the estimated effect of rebates due to CMS under the Medicare
Advantage and Medicare Part D minimum medical loss ratio provisions of the ACA.
The ACA prescribed three programs to mitigate the risk for participating health insurance companies selling coverage on the public exchanges:
risk adjustment, reinsurance and risk corridor. The reinsurance and risk corridor programs expired at the end of 2016, while the permanent risk
adjustment program continues. A summary of these programs and the Company’s accounting policy is provided below.
•
•
•
The risk adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the
relative risk scores of participants in non-grandfathered plans in the individual and small group markets, both on and off the exchanges. We
estimate our receivable or payable based on the risk of our members compared to the risk of other members in the same state and market,
considering data obtained from industry studies and the United States Department of Health and Human Services (‘‘HHS’’). Receivables or
payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably
estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.
The reinsurance program (discontinued as of December 31, 2016) was designed to provide reimbursement to insurers for high cost individual
business sold on or off the public exchanges. Reinsurance contributions associated with non-grandfathered individual plans were reported as
reductions in premium revenues, and estimated reinsurance recoveries were established with offsetting reductions in Global Health Care
medical costs. Reinsurance fee contributions for other insured business were reported in other operating expenses.
The risk corridor program (also discontinued as of December 31, 2016) was designed to limit insurer gains and losses by comparing allowable
medical costs to a target amount as defined by HHS. The Company recorded receivables or payables as adjustments to premium revenue
based on year-to-date experience when the amounts were reasonably estimable and collection was reasonably assured. In 2016, the
Company also recorded an allowance against these risk corridor receivables that is discussed further in Note 22.
Premiums for individual life, accident and supplemental health insurance and annuity products, excluding universal life and investment-related
products, are recognized as revenue when due. Benefits and expenses are matched with premiums.
Revenue for universal life products is recognized as follows:
•
Investment income on assets supporting universal life products is recognized in net investment income as earned.
•
Charges for mortality, administration and policy surrender are recognized in premiums as earned. Administrative fees are considered earned
when services are provided.
Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by
policyholders. Expenses are recognized when claims are incurred, and income is credited to policyholders in accordance with contract
provisions.
The unrecognized portion of premiums received is recorded as unearned premiums.
70 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Fees, Related Expenses and Mail Order Pharmacy Revenues and Costs
L.
Contract fees for administrative services only (‘‘ASO’’) programs and pharmacy programs and services are recognized in fees and other
revenues as services are provided, net of estimated pharmaceutical manufacturer rebates payable to ASO clients using our network of retail
pharmacies and estimated refunds under performance guarantees. Expenses associated with these programs and services are recognized in
other operating expenses as incurred, net of estimated pharmaceutical rebates from manufacturers for prescriptions filled through our
network of retail pharmacies.
In some cases, the Company provides performance guarantees associated with meeting certain service standards, clinical outcomes or
financial metrics. If these service standards, clinical outcomes or financial metrics are not met, the Company may be financially at risk up to a
stated percentage of the contracted fees or a stated dollar amount. The Company defers revenues for estimated payouts associated with these
performance guarantees. Approximately 11% of ASO fees reported for the year ended December 31, 2017 were at risk under performance
guarantees, with reimbursements estimated to be less than 1% of revenues.
Revenues for investment-related products are recognized as follows:
•
Investment income on assets supporting investment-related products is recognized in net investment income as earned.
•
Contract fees based upon related administrative expenses are recognized in fees and other revenues as they are earned ratably over the
contract period.
Benefits and expenses for investment-related products consist primarily of income credited to policyholders in accordance with contract
provisions.
Mail order pharmacy revenues and the cost of prescriptions are recognized as each prescription is shipped. Mail order pharmacy revenues are
presented net of estimated pharmaceutical manufacturer rebates payable to ASO clients using our mail order business. Mail order pharmacy
costs include the cost of prescriptions sold and other costs to operate this business including supplies, shipping and handling, net of estimated
pharmaceutical rebates from manufacturers for prescriptions filled through our mail order business.
Mergers, Acquisitions and Dispositions
NOTE 3
The following table presents transaction-related costs incurred by the Company for the years ended December 31, 2017, 2016 and 2015.
Transaction-related costs primarily consist of fees for legal, advisory and other professional services as well as employee costs. In addition,
because the merger with Anthem, Inc. (‘‘Anthem’’) was not consummated, certain transaction-related costs that were previously not
deductible for federal income tax purposes became deductible. The Company recognized an incremental tax benefit for these newly
deductible costs in 2017 as presented below.
(In millions)
Transaction-related costs
Tax (benefit) – previously non-deductible costs
Transaction-related costs, net
2017
2016
2015
Before-tax
After-tax
Before-tax
After-tax
Before-tax
After-tax
$ 126
–
$ 126
$ 92
(59)
$ 33
$ 166
–
$ 166
$ 147
–
$ 147
$ 66
–
$ 66
$ 57
–
$ 57
Earnings Per Share (‘‘EPS’’)
NOTE 4
Accounting policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and
deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted
stock using the treasury stock method and the effect of strategic performance shares.
Basic and diluted earnings per share were computed as follows:
(Shares in thousands,
dollars in millions, except per share amounts)
2017
Effect of
Dilution
Basic
Diluted
Basic
2016
Effect of
Dilution
Diluted
Basic
2015
Effect of
Dilution
Diluted
Shareholders’ net income
$
2,237
$
–
$
2,237
$
1,867
$
–
$
1,867
$
2,094
$
–
$
2,094
Shares
Weighted average
Common stock equivalents
Total shares
EPS
250,892
250,892
–
4,180
4,180
250,892
4,180
255,360
255,072
255,360
–
4,287
4,287
255,360
4,287
259,647
256,149
256,149
–
4,443
4,443
256,149
4,443
260,592
$
8.92
$ (0.15)
$
8.77
$
7.31
$ (0.12)
$
7.19
$
8.17
$ (0.13)
$
8.04
The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was
anti-dilutive.
(In millions)
Anti-dilutive options
2017
0.9
2016
2.3
2015
0.4
CIGNA CORPORATION - 2017 Form 10-K 71
PART II
ITEM 8. Financial Statements and Supplementary Data
NOTE 5
The outstanding amounts of debt and capital leases for the years ended December 31 were as follows:
Debt
(In millions)
Short-term debt
Commercial paper
Current maturities of long-term debt
Other, including capital leases
Total short-term debt
Long-term uncollateralized debt
$131 million, 6.35% Notes due 2018
$250 million, 4.375% Notes due 2020 (1)
$300 million, 5.125% Notes due 2020 (1)
$78 million, 6.37% Notes due 2021
$300 million, 4.5% Notes due 2021 (1)
$750 million, 4% Notes due 2022
$100 million, 7.65% Notes due 2023
$17 million, 8.3% Notes due 2023
$900 million, 3.25% Notes due 2025
$600 million, 3.05% Notes due 2027
$259 million, 7.875% Debentures due 2027 (2)
$45 million, 8.3% Step Down Notes due 2033 (2)
$191 million, 6.15% Notes due 2036 (2)
$121 million, 5.875% Notes due 2041 (2)
$317 million, 5.375% Notes due 2042 (2)
$1,000 million, 3.875% Notes due 2047
Other, including capital leases
Total long-term debt
2017
2016
$
$
$
100
131
9
240
–
249
299
78
299
745
100
17
894
594
258
45
190
119
315
988
9
$
$
$
–
250
26
276
131
252
301
78
302
744
100
17
893
–
299
82
498
296
743
–
20
$
5,199
$
4,756
(1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 for further information about the Company’s interest rate
risk management and these derivative instruments.
(2) The Company redeemed a portion of these debt issues through a cash tender offer in September 2017, the aggregate amount of which was $1.0 billion.
In the third quarter of 2017, the Company entered into two significant debt transactions: the issuance of new debt and a cash tender offer to
retire a portion of outstanding debt. These transactions are described in more detail below.
On September 14, 2017, the Company issued new long-term debt as follows:
(In millions)
Debt Instrument
10-Year Notes
30-Year Notes
Principal
Term
Maturity
Stated
Interest
Rate
Effective Amount net of
discount and
fees
Interest
Rate
Interest
payment
dates
$ 600
$ 1,000
10-Year October 15, 2027
30-Year October 15, 2047
3.05%
3.875%
3.183%
3.951%
$ 594
$ 987
April 15 and October 15
April 15 and October 15
The proceeds of this debt were mainly used to pay the consideration for the cash tender offer as described below. The Company intends to use
the remaining proceeds for general corporate purposes, including the maturity of its Notes due in 2018.
At any time prior to July 15, 2027 (three months prior to the maturity date of the 10-Year Notes) or April 15, 2047 (six months prior to the
maturity date of the 30-Year Notes), the Company may redeem the 10-Year Notes or the 30-Year Notes, in whole or in part, with accrued and
unpaid interest, at a redemption price equal to the greater of:
•
100% of the principal amount of the applicable Notes; or
•
the sum of the present values of the remaining scheduled payments of principal and interest (excluding interest accrued at the redemption
date) from the redemption date to the maturity date discounted at the applicable Treasury Rate plus 15 basis points for the 10-Year Notes and
20 basis points for the 30-Year Notes.
In the third quarter of 2017, the Company completed a cash tender offer to purchase $1.0 billion of aggregate principal amount of certain of its
outstanding debt securities. The Company recorded a pre-tax loss of $321 million ($209 million after-tax), consisting primarily of premium
payments on the tender.
During the first quarter of 2017, the Company repaid $250 million of long-term notes that had matured.
In April 2015, the Company redeemed two of its outstanding notes early. The Company paid $955 million, including accrued interest and
expenses that resulted in a pre-tax loss on early debt extinguishment of $100 million ($65 million after-tax).
In December 2017, the Company entered into an updated revolving credit and letter of credit agreement. This agreement extends through
December 2022 and is diversified among 15 banks. Under this agreement, the Company can borrow up to $1.5 billion for general corporate
purposes, of which up to $500 million can be used for letters of credit. The credit agreement includes options to increase the commitment
amount to $2 billion and to extend the term past December 2022, subject to consent by the lenders. The agreement contains customary
covenants and restrictions, including a financial covenant that the Company may not permit its leverage ratio – total consolidated debt to total
consolidated capitalization (each as defined in the credit agreement) – to be greater than 50%. The Company was in compliance with its debt
covenants as of December 31, 2017.
72 CIGNA CORPORATION - 2017 Form 10-K
As of December 31, 2017, the Company had $9.3 billion of borrowing capacity within the maximum debt leverage covenant in the credit
agreement, in addition to $5.4 billion of debt outstanding. The Company had $11 million of letters of credit outstanding as of December 31, 2017.
Maturities of long-term debt and capital leases are as follows:
PART II
ITEM 8. Financial Statements and Supplementary Data
(In millions)
2018
2019
2020
2021
2022
Maturities after 2022
Scheduled Maturities
Long-term
Debt (1)
Capital
Leases
$
$
$
$
$
$
131
–
550
378
750
3,550
$
$
$
$
$
$
9
8
1
–
–
–
(1) Long-term debt maturity amounts exclude capital leases.
Interest expense on long-term and short-term debt was $243 million in 2017, $251 million in 2016, and $252 million in 2015. These amounts
exclude losses on the early extinguishment of debt.
NOTE 6
As of December 31, the Company had issued the following shares:
Common and Preferred Stock
(Shares in thousands)
Common: Par value $0.25; 600,000 shares authorized
Outstanding – January 1,
Issued for stock option exercises and other benefit plans
Repurchased common stock
Outstanding – December 31,
Treasury stock
Issued – December 31,
2017
2016
2015
256,869
2,761
(15,663)
243,967
52,178
296,145
256,544
1,110
(785)
256,869
39,276
296,145
259,276
2,751
(5,483)
256,544
39,601
296,145
The Company maintains a share repurchase program authorized by its Board of Directors. Under this program, the Company may repurchase
shares from time to time. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general
business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases
or privately negotiated transactions in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through
Rule 10b5-1 trading plans. The program may be suspended or discontinued at any time.
The Company has authorized a total of 25 million shares of $1 par value preferred stock. No shares of preferred stock were outstanding at
December 31, 2017, 2016 or 2015.
Global Health Care Medical Costs Payable
NOTE 7
Medical costs payable for the Global Health Care segment reflects estimates of the ultimate cost of claims that have been incurred but not
reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process),
and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to
health care professionals and facilities.
Accounting policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and
recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with
actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.
This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on
reported claims. The liability is primarily calculated using ‘‘completion factors’’ developed by comparing the claim incurral date to the date
claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual
claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products. The Company uses historical completion
factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company
estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data.
This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.
For more recent months, the Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and
other relevant operational considerations. Medical cost trend is primarily impacted by medical service utilization and unit costs that are
affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and
deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.
For each reporting period, the Company compares key assumptions used to establish the medical costs payable to actual experience. When
actual experience differs from these assumptions, medical costs payable are adjusted through current period shareholders’ net income.
Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used
to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the
CIGNA CORPORATION - 2017 Form 10-K 73
PART II
ITEM 8. Financial Statements and Supplementary Data
variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company’s key assumptions,
specifically completion factors and medical cost trends.
Activity in medical costs payable for the years ended December 31 was as follows:
(In millions)
Balance at January 1,
Less: Reinsurance and other amounts recoverable
Balance at January 1, net
Incurred costs related to:
Current year
Prior years
Total incurred
Paid costs related to:
Current year
Prior years
Total paid
Balance at December 31, net
Add: Reinsurance and other amounts recoverable
Balance at December 31,
$
$
2017
2,532
275
2,257
20,233
(266)
19,967
17,979
1,791
19,770
2,454
265
$
2,719
$
2016
2,355
243
2,112
19,087
(78)
19,009
17,052
1,812
18,864
2,257
275
2,532
2015
2,180
252
1,928
18,564
(210)
18,354
16,588
1,582
18,170
2,112
243
2,355
$
$
Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and
pending claims for certain business where the Company administers the plan benefits but the right of offset does not exist. See Note 9 for
additional information on reinsurance.
The total of incurred but not reported liabilities plus expected development on reported claims, including reported claims in process, was
$2.6 billion at December 31, 2017 and $2.4 billion at December 31, 2016. The remaining balance in both periods reflects amounts due for
physician incentives and other medical care expenses and services payable.
For the years ended December 31, variances in incurred costs related to prior years’ medical costs payable that resulted from the differences
between actual experience and the Company’s key assumptions were as follows:
($ in millions)
Actual completion factors
Medical cost trend
Other (3)
Total favorable variance
2017
$
$ 124
133
9
$ 266
2016
% (1)
0.7%
0.7
–
1.4%
$
59
27
(8)
78
$
$
% (2)
0.3%
0.1
–
0.4%
(1) Percentage of current year incurred costs as reported for 2016.
(2) Percentage of current year incurred costs as reported for 2015.
(3) Other amounts in 2017 primarily related to an increase in the 2016 reinsurance reimbursement rate from CMS under the ACA. Other amounts in 2016 primarily related to increased medical
costs in the Government segment resulting from sharing additional risk adjustment revenue with providers.
Incurred costs related to prior years in the table above, although adjusted through shareholders’ net income, do not directly correspond to an
increase or decrease to shareholders’ net income. The primary reason for this difference is that decreases to prior year incurred costs
pertaining to the portion of the liability established for moderately adverse conditions are not considered as impacting shareholders’ net
income if they are offset by increases in the current year provision for moderately adverse conditions.
The net impact of prior year development on shareholders’ net income was a $112 million increase for the year ended December 31, 2017. The
net impact of prior year development on shareholders’ net income was insignificant in 2016. Favorable prior year development implies
primarily lower than expected utilization of medical services and vice versa while amounts close to zero imply utilization of medical services
that are consistent with expectations.
The following table depicts the incurred and paid claims development as of December 31, 2017 (net of reinsurance), claims frequency metrics
and incurred but not reported liabilities for Cigna’s Global Health Care medical costs payable. The information about incurred and paid claims
development for the year ended December 31, 2016 is presented as supplementary information and is unaudited.
74 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Medical Costs
Payable
$
$
159
2,254
Claims Frequency
2.7 million
3.3 million
($ in millions, except for claims frequency)
Incurral Year
2016
2017
Cumulative incurred costs for the periods presented
Incurral Year
2016
2017
Cumulative paid costs for the periods presented
Outstanding liabilities for the periods presented, net of reinsurance
Outstanding liabilities prior to 2016, net of reinsurance
Net outstanding liabilities for Global Health Care medical costs
payable
Reinsurance and other amounts recoverable
Total liability for Global Health Care medical costs payable
2016
(Unaudited)
$
19,087
Incurred Costs
2017
18,822
20,233
39,055
$
$
Cumulative Paid Costs
2016
(Unaudited)
$
17,052
2017
18,663
17,979
36,642
2,413
41
2,454
265
2,719
$
$
$
$
More than 95% of health claims for an accident year are paid within one year of their incurred date.
There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for the Global
Health Care segment is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim
was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.
NOTE 8
The following information relates to the Company’s unpaid claims and claim expense liabilities.
Liabilities for Unpaid Claims and Claim Expenses
Accounting policy. Liabilities for unpaid claims and claim expenses are established by book of business within the Company’s Group
Disability and Life, Global Supplemental Benefits and Other Operations segments. The Group Disability and Life segment’s liability for unpaid
claims and claim expenses consists of the following primary products: long-term and short-term disability, life insurance, and accident
coverages. Unpaid claims and claim expenses consist of (1) case or claims reserves for reported claims that are unpaid as of the balance sheet
date; (2) incurred but not reported reserves for claims when the insured event has occurred but has not been reported to the Company; and
(3) loss adjustment expense reserves for the expected costs of settling these claims. The Company consistently estimates incurred but not yet
reported losses using actuarial principles and assumptions based on historical and projected claim incidence patterns, claim size and the
expected payment period. The Company recognizes the actuarial best estimate of the ultimate liability within a level of confidence, consistent
with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. When estimates of these liabilities
change, the Company immediately records the adjustment in benefits and expenses.
The majority of the Company’s liability for disability claims consists of the present value of estimated future benefit payments, including
expected development, for each reported claim that is currently receiving benefit payments, or pending a decision on eligibility for benefits,
over the expected disability period. The Company projects the expected disability period by using historical resolution rates combined with an
analysis of current trends and operational factors to develop current estimates of resolution rates. Using the Company’s experience, expected
claim resolution rates may vary based upon the anticipated disability period, the covered benefit period, the cause of disability, the benefit
design and the claimant’s age, gender and income level. The gross monthly benefit is reduced (offset) by disability income received under
other benefit programs, most commonly Social Security Disability Income, workers’ compensation, statutory disability or other group benefit
plans. For certain offsets not yet finalized, the Company estimates the probability and amount of future offset awards and lapses based on the
Company’s experience.
The Company also establishes a liability for the expected present value of future benefit payments for known claims that have recently been
resolved but may reopen in the future, based on Company experience. Prior to a claim becoming known, the Company establishes a liability for
incurred but not reported claims, using standard actuarial techniques and calculations based on completion factors and loss ratio assumptions
using the Company’s experience combined with an analysis current trends and operational factors. Completion factors are impacted by several
key items including changes in claim inventory levels, claim payment patterns, changes in business volume and other factors. Loss ratio
assumptions are developed using historical Company experience, adjusted prospectively for expected changes in the underlying business
including rate actions, persistency and inforce growth.
Liability balance details. The liability for unpaid claims and claim expenses by segment as of December 31 is as follows:
(In millions)
Group Disability and Life
Global Supplemental Benefits
Other Operations
Unpaid claims and claim expenses
2017
4,491
484
193
5,168
$
$
2016
4,342
384
191
4,917
$
$
CIGNA CORPORATION - 2017 Form 10-K 75
PART II
ITEM 8. Financial Statements and Supplementary Data
The Company discounts certain liabilities, predominantly long-term disability, because benefits payments are made over extended periods.
Discount rate assumptions for these liabilities are based on projected investment returns for the supporting asset portfolios. Details of the
Company’s unpaid claim discounted liability balances as of December 31 were as follows:
(In billions)
Discounted liabilities
Aggregate amount of discount
Range of discount rates
2017
2016
$
$
4.0
1.0
4.5% - 5.2%
$
$
3.9
1.1
3.3% - 5.8%
Interest is accreted and recognized in other benefit expenses in the Consolidated Statement of Income.
Activity in the Company’s Group Disability and Life and the Global Supplemental Benefits segments’ liabilities for unpaid claims and claim
expenses are presented in the following table. Liabilities associated with the Company’s Other Operations segment are excluded because they
pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been fully reinsured.
(In millions)
Balance at January 1,
Less: Reinsurance
Balance at January 1, net
Incurred claims related to:
Current year
Prior years
Interest accretion
All other incurred
Total incurred
Paid claims related to:
Current year
Prior years
Total paid
Acquisitions
Foreign currency
Balance at December 31, net
Add: Reinsurance
Balance at December 31,
$
2017
4,726
121
4,605
4,341
163
(4)
4,500
2,724
1,572
4,296
–
29
4,838
137
$
2016
4,359
115
4,244
4,258
161
93
4,512
2,575
1,560
4,135
–
(16)
4,605
121
$
2015
4,178
104
4,074
3,813
163
(91)
3,885
2,325
1,382
3,707
11
(19)
4,244
115
$
4,975
$
4,726
$
4,359
Reinsurance in the previous table reflects amounts due from reinsurers related to unpaid claims liabilities. The Company’s insurance
subsidiaries enter into agreements with other companies primarily to limit losses from large exposures and to permit recovery of a portion of
incurred losses. See Note 9 for additional information on reinsurance.
The majority of the liability for unpaid claims and claim expenses is related to disability claims with long-tailed payouts. Interest earned on
assets backing these liabilities is an integral part of pricing and reserving. Therefore, interest accreted on prior year balances is shown as a
separate component of prior year incurred claims. This interest is calculated by applying the average discount rate used in determining the
liability balance to the average liability balance over the period. The remaining prior year incurred claims amount primarily reflects updates to
the Company’s liability estimates and variances between actual experience during the period relative to the assumptions and expectations
reflected in determining the liability. Assumptions reflect the Company’s expectations over the life of the book of business and will vary from
actual experience in any period, both favorably and unfavorably, with variation in resolution rates being the most significant driver for the
long-term disability business. Prior year incurred claims reported in 2016 included the impact of changes made to our disability claims
management process and a period of elevated life claims.
Long-term disability development tables. The table below presents information about incurred and paid claims development as of
December 31, 2017 (net of reinsurance) cumulative claim frequency and total incurred but not reported liabilities for the Company’s long-term
disability book of business. The information about incurred and paid claims development for the years ended 2012 through 2016 is presented
as supplementary information and is unaudited. As permitted under GAAP, the Company presented development table information beginning
in 2012 because obtaining information beyond this period was impracticable as historical data was not maintained in such detail.
76 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
(In millions, except for claims frequency)
Accident Year
2012
2013
2014
2015
2016
2017
Cumulative incurred claims for the periods presented
Incurred Claims (undiscounted)
2012
(Unaudited)
2013
(Unaudited)
2014
(Unaudited)
2015
(Unaudited)
2016
(Unaudited)
Incurred
But Not
Reported
Claims
2017 Liabilities Frequency
$
995
$
951
1,063
$
$
889
1,037
1,158
$
876
1,062
1,129
1,184
$
883
1,072
1,167
1,154
1,246
880
1,057
1,146
1,185
1,184
1,226
$ 6,678
$
–
–
–
5
20
540
21,180
23,516
25,281
25,609
24,722
10,569
Accident Year
2012
2013
2014
2015
2016
2017
2012
(Unaudited)
2013
(Unaudited)
2014
(Unaudited)
2015
(Unaudited)
2016
(Unaudited)
2017
Cumulative Paid Claims
$
81
$
288
92
$
429
342
111
$
$
504
503
379
114
571
600
575
417
122
Cumulative paid claims for the periods presented
All outstanding liabilities for the periods presented, net of reinsurance
All outstanding liabilities prior to 2012, net of reinsurance
Impact of discounting
Liability for long-term disability unpaid claims and claim expenses, net of reinsurance
$
621
670
667
603
411
110
$ 3,082
$ 3,596
1,142
(948)
$ 3,790
The claims frequency metric used for the Company’s long-term disability line of business represents the number of unique claim events for
which benefits have been approved and payments made. Claim events are identified using a unique claimant identifier and incurral date. Thus,
if an individual has multiple claims for different disabling events (and therefore different incurral dates), each will be determined to be a unique
claim event. However, if an individual receives multiple benefits under more than one policy (for example for supplemental disability benefits
such as pension contribution benefits or survivor benefits), the Company treats this as a single claim occurrence because they related to the
same claim event. Claims frequency metrics for the most recent year are expected to be low reflecting the long-term disability product features
including waiting and elimination periods that result in delayed eligibility for contract benefits. Claims that did not result in a liability are not
included in the frequency metric.
The following is supplementary and unaudited information about average historical claims payout patterns for the long-term disability
business for the years presented in the development table as of December 31, 2017. The average annual percentage payout of incurred claims,
net of reinsurance, is approximately 9% in year one, 24% in year two, 16% in year three, 9% in year four, 7% in year five, and 6% in year six.
The following table reconciles the long-term disability net incurred and paid claims development table to the liability for unpaid claims and
claim expenses in the Company’s Consolidated Balance Sheets as of December 31, 2017.
(In millions)
Net outstanding liabilities – Group Disability and Life segment
Long-term disability liabilities, net of reinsurance
Other short-duration insurance books of business, net of reinsurance
Liabilities for unpaid claims and claim expenses, net of reinsurance
Reinsurance recoverable on unpaid claims – Group Disability and Life segment
Long-term disability
Other short-duration insurance books of business
Total reinsurance recoverable on unpaid claims
Total liability for unpaid claims and claim expenses – Group Disability and Life segment
Global Supplemental Benefits segment
Other Operations segment
Total liability for unpaid claims and claim expenses
$
3,790
599
4,389
94
8
102
4,491
484
193
$
5,168
The other short-duration insurance books of business, net of reinsurance, primarily include liabilities for life, accident and short-term disability
insurance products. Liabilities for these products are typically complete within one year. Claim development on these liabilities is largely driven
by completion factors and loss ratio assumptions. In 2016, development on these liabilities was driven by a period of elevated life claims.
CIGNA CORPORATION - 2017 Form 10-K 77
PART II
ITEM 8. Financial Statements and Supplementary Data
Reinsurance
NOTE 9
The Company’s insurance subsidiaries enter into agreements with other insurance companies to assume and cede reinsurance. Reinsurance is
ceded primarily to limit losses from large exposures and to permit recovery of a portion of direct or assumed losses. Reinsurance is also used in
acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating
insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company
regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.
Reinsurance Recoverables
The majority of the Company’s reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting
company was not acquired. Components of the Company’s reinsurance recoverables are presented in the following table:
(Dollars in millions)
Line of Business
Ongoing Operations
Global Health Care, Global
Supplemental Benefits, Group
Disability and Life, COLI
Reinsurer(s)
Various
Total recoverables related to
ongoing operations
Acquisition, disposition or runoff activities
Individual Life and Annuity (sold in
1998)
Lincoln National Life and Lincoln
Life & Annuity of New York
GMDB (effectively exited in 2013)
Berkshire
Other
Prudential Retirement Insurance
and Annuity
Great American Life
Various
Retirement Benefits Business (sold
in 2004)
Supplemental Benefits Business
(2012 acquisition)
Other run-off reinsurance
Total recoverables related to
acquisition, disposition or runoff
activities
Total reinsurance recoverables
December 31, December 31,
2016
2017
Collateral and Other Terms at December 31, 2017
$
454
$
478 Recoverables from approximately 90 reinsurers,
used in the ordinary course of business. Current
balances range from less than $1 million up to
$80 million. Over 70% of the balance is from
companies rated as investment grade by
Standard & Poor’s, and 11% is secured by assets in
trusts or letters of credit.
454
478
3,436
928
34
850
283
61
3,586 Both companies’ ratings were sufficient to avoid
triggering a contractual obligation to fully secure
the outstanding balance.
1,085 100% secured by assets in a trust.
44 100% secured by assets in a trust or letters of
credit.
100% secured by assets in a trust.
921
297 100% secured by assets in a trust.
67 100% secured by assets in a trust or other deposits.
5,592
6,000
$ 6,046
$ 6,478
The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the
Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables if recovery is not considered
probable.
Effects of Reinsurance
The following table presents direct, assumed and ceded premiums for both short-duration and long-duration insurance contracts. It also
presents reinsurance recoveries that have been netted against benefits and expenses in the Company’s Consolidated Statements of Income.
(In millions)
Premiums
Short-duration contracts
Direct
Assumed
Ceded
Total short-duration contract premiums
Long-duration contracts
Direct
Assumed
Ceded
Individual life insurance and annuity business sold
Other
Total long-duration contract premiums
Total premiums
Reinsurance recoveries
Individual life insurance and annuity business sold
Other
Total reinsurance recoveries
2017
2016
2015
$
$
$
$
28,654
199
(150)
28,703
3,748
130
(143)
(131)
3,604
32,307
259
66
325
$
$
$
$
27,496
247
(229)
27,514
3,259
137
(153)
(131)
3,112
30,626
279
261
540
$
$
$
$
26,751
289
(254)
26,786
3,061
111
(158)
(158)
2,856
29,642
301
436
737
The effects of reinsurance on written premiums for short-duration contracts were not materially different from the recognized premium
amounts shown in the table above.
78 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Effective Exit of GMDB and GMIB Business
In 2013, the Company entered into an agreement with Berkshire to effectively exit the GMDB and GMIB business via a reinsurance transaction.
Berkshire reinsured 100% of the Company’s future claim payments in this business, net of other reinsurance arrangements existing at that time.
The reinsurance agreement is subject to an overall limit with approximately $3.4 billion remaining at December 31, 2017.
GMDB is accounted for as reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets
are reported in other assets, including intangibles, and GMIB liabilities are reported in accounts payable, accrued expenses and other liabilities.
GMDB
The majority of the GMDB exposure arises under annuities written by ceding companies that guarantee the benefit received at death will be no
less than the highest historical account value of the related mutual fund investments on a contractholder’s anniversary date. Under this type of
death benefit, the Company’s exposure arises when the highest anniversary account value exceeds the fair value of the related mutual fund
investments at the time of a contractholder’s death.
Accounting policy. The Company estimates the gross liability and reinsurance recoverable with an internal model based on the Company’s
experience and future expectations over an extended period, consistent with the long-term nature of this product. As a result of the
reinsurance transaction, reserve increases have a corresponding increase in the recorded reinsurance recoverable, provided the increased
recoverable remains within the overall Berkshire limit (including the GMIB asset presented below). The ending net retained reserve covers
ongoing administrative expenses, as well as minor claim exposure retained by the Company.
Because the product is premium deficient, the Company records an increase to the net retained reserve if it is inadequate based on the model.
The following table presents the account value, net amount at risk and average attained age of underlying contractholders for guarantees
assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders
died as of the specified date. Unless the Berkshire reinsurance limit is exceeded, the Company should be reimbursed in full for these payments.
(Dollars in millions, excludes impact of reinsurance ceded)
Account value
Net amount at risk
Average attained age of contractholders (weighted by exposure)
Number of contractholders
$
$
2017
10,109
2,112
75
245,000
$
$
2016
10,650
2,458
75
285,000
GMIB
In this business, the Company reinsured contracts with issuers of GMIB products. The Company’s exposure represents the excess of a
contractually guaranteed amount over the level of variable annuity account values. Payment by the Company depends on the actual account
value in the underlying mutual funds and the level of interest rates when the contractholders elect to receive minimum income payments that
must occur within 30 days of a policy anniversary after the appropriate waiting period. The Company has purchased retrocessional coverage
(‘‘GMIB assets’’) for these contracts.
Accounting policy. The Company reports GMIB liabilities and assets as derivatives at fair value because cash flows of these liabilities and
assets are affected by equity markets and interest rates, but are without significant life insurance risk and are settled in lump sum payments.
Periodically, the Company receives and pays fees based on either contractholders’ account values or deposits increased at a contractual rate.
The Company will also pay and receive cash depending on changes in account values and interest rates when contractholders first elect to
receive minimum income payments. Cash flows on these contracts are reported in operating activities.
As of December 31, 2017 and 2016, there were three reinsurers for GMIB as follows:
(In millions)
Line of Business
Reinsurer
GMIB
Berkshire
Sun Life Assurance Company of Canada
Liberty Re (Bermuda) Ltd.
Total GMIB recoverables reported in other assets
December 31,
2017
December 31,
2016
$
$
359
221
197
777
$
$
370
227
202
799
Collateral and Other Terms at December 31, 2017
100% were secured by assets in a trust.
100% were secured by assets in a trust.
Assumptions used in fair value measurement. GMIB assets and liabilities are established using capital market assumptions (including market
returns, interest rates and market volatilities of the underlying equity and bond mutual fund investments) and assumptions related to future
annuitant behavior (including mortality, lapse, and annuity election rates). As assumptions related to future annuitant behavior are largely
unobservable, the Company classifies GMIB assets and liabilities in Level 3 in the fair value hierarchy presented in Note 10.
The only assumption expected to impact future shareholders’ net income is non-performance risk. The non-performance risk adjustment
reflects a market participant’s view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the
GMIB liabilities to be paid by the Company, and (b) the GMIB assets to be paid by the reinsurers, after considering collateral.
The Company regularly evaluates each of the assumptions used in establishing these assets and liabilities. Significant decreases in assumed
lapse rates or spreads used to calculate non-performance risk of the Company, or significant increases in assumed annuity election rates or
spreads used to calculate the non-performance risk of the reinsurers, would result in higher fair value measurements. A change in one of these
assumptions is not necessarily accompanied by a change in another assumption.
CIGNA CORPORATION - 2017 Form 10-K 79
PART II
ITEM 8. Financial Statements and Supplementary Data
GMIB guarantees. Future payments are not fixed and determinable under the terms of these contracts. Accordingly, the Company calculated
exposure, without considering any reinsurance coverage, using the following hypothetical assumptions:
•
no annuitants surrendered their accounts;
•
all annuitants lived to elect their benefit;
•
all annuitants elected to receive their benefit on the next available date (2018 through 2022); and
•
all underlying mutual fund investment values remained at the December 31, 2017 value of $822 million with no future returns.
The Company has reinsurance coverage in place that covers the exposures on these contracts. Using these hypothetical assumptions, GMIB
exposure is $573 million, which is lower than the recorded liability for GMIB calculated using fair value assumptions.
Fair Value Measurements
NOTE 10
The Company carries certain financial instruments at fair value in the financial statements including fixed maturities, equity securities,
short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when
impaired.
Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance
sheet date. A liability’s fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that
would be paid to settle the liability with the creditor.
The Company’s financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy
gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1)
and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset’s or a liability’s
classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair
value would be classified in Level 3 if unobservable inputs were significant to the instrument’s fair value, even though the measurement may be
derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).
The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party
pricing services are based on reported trade activity and quoted market prices when available, and other market information that a market
participant may use to estimate fair value. The internal pricing methods are performed by the Company’s investment professionals and
generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable
terms and credit quality, as well as other qualitative factors. In instances where there is little or no market activity for the same or similar
instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant
would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes
significant with increasingly complex instruments or pricing models.
The Company is responsible for determining fair value, as well as for assigning the appropriate level within the fair value hierarchy, based on the
significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and
compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing
analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate
estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale
valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal
exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations.
Annually, we conduct an on-site visit of the most significant pricing service to review their processes, methodologies and controls. This on-site
review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.
A. Financial Assets and Financial Liabilities Carried at Fair Value
The following table provides information as of December 31, 2017 and 2016 about the Company’s financial assets and liabilities carried at fair
value. Separate account assets that are also recorded at fair value on the Company’s Consolidated Balance Sheets are reported separately in
the Separate Accounts section as gains and losses related to these assets generally accrue directly to policyholders.
80 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
As of December 31,
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
(In millions)
2017
2016
2017
2016
2017
2016
2017
2016
Financial assets at fair value
Fixed maturities
Federal government and agency
State and local government
Foreign government
Corporate
Mortgage and other asset-backed
Total fixed maturities
Equity securities
Subtotal
Short-term investments
GMIB assets
Other derivative assets
Total financial assets at fair value, excluding
separate accounts
Financial liabilities at fair value
GMIB liabilities
Other derivative liabilities
Total financial liabilities at fair value, excluding
separate accounts
$
$
$
$
253
–
–
–
–
253
412
665
–
–
–
665
–
–
–
$
$
$
$
374
–
–
–
–
374
396
770
–
–
–
$
526
1,287
2,442
17,658
343
22,256
73
22,329
199
–
2
$
503
1,435
2,066
15,552
329
19,885
113
19,998
691
–
10
$
–
–
45
430
154
629
103
732
–
777
–
770
$ 22,530
$ 20,699
$ 1,509
–
–
–
$
$
–
25
25
$
$
–
5
5
$
$
762
–
762
$
$
$
$
–
–
47
498
157
702
74
776
–
799
–
$
779
1,287
2,487
18,088
497
23,138
588
23,726
199
777
2
$
877
1,435
2,113
16,050
486
20,961
583
21,544
691
799
10
1,575
$ 24,704
$ 23,044
$
780
–
762
25
780
$
787
$
$
780
5
785
Level 1 Financial Assets
Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the
measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.
Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. Given the narrow definition of Level 1
and the Company’s investment asset strategy to maximize investment returns, a relatively small portion of the Company’s investment assets
are classified in this category.
Level 2 Financial Assets and Financial Liabilities
Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those
willing to trade in markets that are not active, or other inputs that are market observable or can be corroborated by market data for the term of
the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if
the Company determines that unobservable inputs are insignificant.
Fixed maturities and equity securities. Approximately 94% of the Company’s investments in fixed maturities and equity securities are
classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds,
non-government mortgage-backed securities and preferred stocks. Because many fixed maturities do not trade daily, third-party pricing
services and internal methods often use recent trades of securities with similar features and characteristics. When recent trades are not
available, pricing models are used to determine these prices. These models calculate fair values by discounting future cash flows at estimated
market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities, based on
the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a
combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and
economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes,
prepayment speeds and credit rating.
Nearly all of these instruments are valued using recent trades or pricing models. Less than 1% of the fair value of investments classified in Level 2
represents foreign bonds that are valued using a single unadjusted market-observable input derived by averaging multiple broker-dealer
quotes, consistent with local market practice.
Short-term investments are carried at fair value which approximates cost. On a regular basis, the Company compares market prices for these
securities to recorded amounts to validate that current carrying amounts approximate exit prices. The short-term nature of the investments
and corroboration of the reported amounts over the holding period support their classification in Level 2.
Other derivatives classified in Level 2 represent over-the-counter instruments such as interest rate and foreign currency swap contracts. Fair
values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely
published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of
these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that no
adjustment for credit risk was required as of December 31, 2017 or 2016. Level 2 also includes exchange-traded interest rate swap contracts.
CIGNA CORPORATION - 2017 Form 10-K 81
PART II
ITEM 8. Financial Statements and Supplementary Data
Credit risk related to the clearinghouse counterparty and the Company is considered minimal when estimating the fair values of these
derivatives because of upfront margin deposits and daily settlement requirements. The nature and use of these other derivatives are described
in Note 12.
Level 3 Financial Assets and Financial Liabilities
Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting
fair value measurement. Unobservable inputs reflect the Company’s best estimate of what hypothetical market participants would use to
determine a transaction price for the asset or liability at the reporting date.
The Company classifies certain newly issued, privately-placed, complex or illiquid securities, as well as assets and liabilities relating to GMIB, in
Level 3. Approximately 3% of fixed maturities and equity securities are priced using significant unobservable inputs and classified in this
category.
Fair values of mortgage and other asset-backed securities, corporate and government fixed maturities are primarily determined using pricing
models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit
quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. For
mortgage and other asset-backed securities, inputs and assumptions for pricing may also include collateral attributes and prepayment speeds.
Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in
its evaluation, as well as the issuer’s financial statements.
Quantitative Information about Unobservable Inputs
The following table summarizes the fair value and significant unobservable inputs used in pricing the following securities that were developed
directly by the Company as of December 31, 2017 and 2016. The range and weighted average basis point amounts (‘‘bps’’) for fixed maturity
spreads (adjustment to discount rates) and price-to-earnings multiples for equity investments reflect the Company’s best estimates of the
unobservable adjustments a market participant would make to calculate these fair values.
Mortgage and other asset-backed securities. The significant unobservable inputs used to value the following mortgage and other asset-
backed securities are liquidity and weighting of credit spreads. When there is limited trading activity for the security, an adjustment for liquidity
is made as of the measurement date that considers current market conditions, issuer circumstances and complexity of the security structure.
An adjustment to weight credit spreads is needed to value a more complex bond structure with multiple underlying collateral and no standard
market valuation technique. The weighting of credit spreads is primarily based on the underlying collateral’s characteristics and their
proportional cash flows supporting the bond obligations.
Corporate and government fixed maturities. The significant unobservable input used to value the following corporate and government fixed
maturities is an adjustment for liquidity. When there is limited trading activity for the security, an adjustment is needed to reflect current market
conditions and issuer circumstances.
Private equity securities. The significant unobservable input used to value the following private equity securities is a multiple of earnings
before interest, taxes, depreciation and amortization (‘‘EBITDA’’). These securities are comprised of private equity investments with limited
trading activity and therefore a ratio of EBITDA is used to estimate value based on company circumstances and relative risk characteristics.
Hybrid equity securities. The significant unobservable input used to value the following hybrid equity securities is an adjustment for liquidity
due to limited trading activity. These cumulative preferred shares are deemed likely to exercise certain call options and the Company estimates
an adjustment used to discount cash flows based on current market conditions and issuer circumstances.
As of December 31,
(Fair value in millions)
Fixed maturities
Fair Value
Unobservable Adjustment
Range (Weighted Average)
2017
2016
Unobservable Input
2017
2016
Mortgage and other asset-backed securities
$
154
$
157
Corporate and government fixed maturities
Total fixed maturities
Equity securities
Private equity securities
Hybrid equity securities
Total equity securities
Subtotal
Securities not priced by the Company (1)
Total Level 3 securities
$
446
600
70
33
103
703
29
732
490
647
74
–
74
721
55
$
776
Liquidity
Weighting of credit spreads
Liquidity
60 – 370 (90) bps
180 – 290 (230) bps
70 – 1,650 (300) bps
60 – 330 (90) bps
160 – 470 (230) bps
80 – 1,300 (340) bps
Price-to-EBITDA multiples
Liquidity
5.0 – 12.0 (8.9)
270 – 270 (270) bps
4.2 – 11.6 (8.5)
(1) The fair values for these securities use single, unadjusted non-binding broker quotes not developed directly by the Company.
Significant increases in liquidity or credit spreads would result in lower fair value measurements while decreases in these inputs would result in
higher fair value measurements. Significant decreases in equity price-to-EBITDA multiples would result in lower fair value measurements while
increases in these inputs would result in higher fair value measurements. Generally, the unobservable inputs are not interrelated and a change in
the assumption used for one unobservable input is not accompanied by a change in the other unobservable input.
82 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
GMIB contracts. See discussion in Note 9.
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value
The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the years ended December 31,
2017 and 2016. Separate account asset changes are reported in the Separate Accounts section as the changes in fair values of these assets
generally accrue directly to the policyholders. Gains and losses reported in this table may include net changes in fair value that are attributable
to both observable and unobservable inputs.
(In millions)
Balance at January 1,
Gains (losses) included in shareholders’ net income
GMIB fair value gain/(loss)
Other
Total gains (losses) included in shareholders’ net income
Losses included in other comprehensive income
Gains required to adjust future policy benefits for settlement annuities (1)
Purchases, sales, settlements
Purchases
Sales
Settlements
Total purchases, sales and settlements
Transfers into/(out of) Level 3
Transfers into Level 3
Transfers out of Level 3
Total transfers into/(out of) Level 3
Balance at December 31,
Total gains (losses) included in shareholders’ net income attributable to instruments held at the
reporting date
(1) Amounts do not accrue to shareholders.
Fixed
Maturities &
Equity
Securities
GMIB Assets
GMIB Liabilities
2017
2016
2017
2016
2017
2016
$ 776
$ 726
$ 799
$ 907
$ (780)
$ (885)
–
25
25
(11)
7
133
(95)
(74)
(36)
275
(304)
(29)
–
(18)
(18)
(1)
29
96
(140)
(74)
(118)
338
(180)
158
31
1
32
–
–
–
–
(54)
(54)
–
–
–
(47)
–
(47)
–
–
–
–
(61)
(61)
–
–
–
(31)
(5)
(36)
–
–
–
–
54
54
–
–
–
47
(3)
44
–
–
–
–
61
61
–
–
–
$ 732
$ 776
$ 777
$ 799
$ (762)
$ (780)
$ (9)
$ (18)
$ 32
$(47)
$ (36)
$
44
As noted in the preceding tables, total gains and losses included in shareholders’ net income are reflected in the following captions in the
Consolidated Statements of Income:
•
Realized investment gains (losses) and net investment income for amounts related to fixed maturities and equity securities and realized
investment gains (losses) for the impact of changes in non-performance risk related to GMIB assets and liabilities, similar to hedge
ineffectiveness; and
•
Other operating expenses for amounts related to GMIB assets and liabilities (GMIB fair value gain/loss), except for the impact of changes in
non-performance risk.
In the tables above, gains and losses included in other comprehensive income are reflected in net unrealized appreciation (depreciation) on
securities in the Consolidated Statements of Comprehensive Income.
Reclassifications impacting Level 3 financial instruments are reported as transfers into or out of the Level 3 category as of the beginning of the
quarter in which the transfer occurs. Therefore gains and losses in income only reflect activity for the period the instrument was classified in
Level 3.
Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company’s best estimate of what a market
participant would use to determine a current transaction price, become more or less significant to the fair value measurement. During 2017 and
2016, transfers between Level 2 and Level 3 primarily reflected changes in liquidity and credit risk estimates for certain private placement
issuers across several sectors including metals, mining, energy, utilities, capital goods, consumer products and transportation services.
Separate Accounts
Accounting policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment
objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company’s other
businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The
investment income and fair value gains and losses of these accounts generally accrue directly to the contractholders and, together with their
deposits and withdrawals, are excluded from the Company’s Consolidated Statements of Income and Cash Flows. Fees and charges earned for
mortality risks, asset management or administrative services are reported in either premiums or fees and other revenues. Investments that are
measured using the practical expedient of Net Asset Value (‘‘NAV’’) are excluded from the fair value hierarchy.
CIGNA CORPORATION - 2017 Form 10-K 83
PART II
ITEM 8. Financial Statements and Supplementary Data
At December 31, fair values of separate account assets were as follows:
(In millions)
Guaranteed separate accounts (See Note 21)
Non-guaranteed separate accounts (1)
Subtotal
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
2017
2016
Significant
Other
Observable
Inputs
(Level 2)
2017
2016
Significant
Unobservable
Inputs
(Level 3)
Total
2017
2016
2017
2016
$
215 $ 238 $ 308 $ 262 $
1,536
1,368
5,298
4,885
–
292
$
– $
331
523 $ 500
6,584
7,126
$ 1,751 $ 1,606 $ 5,606 $ 5,147 $ 292
$ 331
7,649
7,084
Non-guaranteed separate accounts priced at NAV as a practical expedient (1)
Total separate account assets
774
856
$ 8,423 $ 7,940
(1) Non-guaranteed separate accounts included $3.9 billion as of December 31, 2017 and $3.7 billion as of December 31, 2016 in assets supporting the Company’s
pension plans, including $0.3 billion classified in Level 3 for both periods and $0.8 billion as of December 31, 2017 and $0.9 billion as of December 31, 2016 priced
at NAV as a practical expedient for each year.
Separate account assets in Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:
•
corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated
market interest rates as described above; and
•
actively-traded institutional and retail mutual fund investments.
Separate account assets classified in Level 3 primarily support Cigna’s pension plans, and include certain newly issued, privately-placed,
complex, or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans that are valued according
to the methodologies discussed below. The following tables summarize the changes in separate account assets reported in Level 3 for the
years ended December 31, 2017 and 2016.
(In millions)
Balance at January 1
Policyholder gains (losses)
Purchases, issuances, settlements
Purchases
Sales
Settlements
Total purchases, sales and settlements
Transfers into/(out of) Level 3
Transfers into Level 3
Transfers out of Level 3
Total transfers into/(out of) Level 3:
Balance at December 31
$
$
2017
331
34
33
(53)
(13)
(33)
7
(47)
(40)
$
292
$
2016
297
2
22
(11)
(18)
(7)
65
(26)
39
331
Separate account investments in securities partnerships, real estate, and hedge funds are generally valued based on the separate account’s
ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments.
Substantially all of these assets support the Cigna Pension Plans. The following table provides additional information on these investments.
(In millions)
Securities partnerships
Real estate funds
Hedge funds
Total
Fair Value as of
December 31,
2017
December 31,
2016
$
$
458
239
77
774
$
$
424
231
201
856
Unfunded
Commitments
as of
December 31,
2017
$
$
365
–
–
365
Data as of December 31, 2017 and 2016
Redemption Frequency
(if currently eligible)
Redemption
Notice Period
Not applicable
Quarterly
Up to annually, varying by fund
Not applicable
45–90 days
30–90 days
B. Assets and Liabilities Measured at Fair Value under Certain Conditions
Some financial assets and liabilities are not carried at fair value each reporting period, but may be measured using fair value only under certain
conditions, such as investments in real estate, partnership entities and commercial mortgage loans when they become impaired. Impaired
values for these asset types classified as Level 3 representing less than 1% of total investments, were written down to their fair values, resulting
in immaterial realized investment losses in 2017 and 2016.
84 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
C. Fair Value Disclosures for Financial Instruments Not Carried at Fair Value
The following table includes the Company’s financial instruments not recorded at fair value that are subject to fair value disclosure
requirements at December 31, 2017 and 2016. In addition to universal life products and capital leases, financial instruments that are carried in
the Company’s Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table.
(In millions)
Commercial mortgage loans
Contractholder deposit funds, excluding universal life products
Long-term debt, including current maturities, excluding capital leases
Classification in
Fair Value
Hierarchy
Level 3
Level 3
Level 2
December 31, 2017
December 31, 2016
Fair Value
$ 1,766
1,121
$
$ 5,730
Carrying
Value
$ 1,761
$ 1,119
$ 5,321
Fair Value
1,682
$
1,215
$
$ 5,460
Carrying
Value
$ 1,666
$ 1,212
$ 4,991
The fair values for all financial instruments presented in the table above have been estimated using market information when available. The
following valuation methodologies and inputs are used by the Company to determine fair value.
Commercial mortgage loans. The Company estimates the fair value of commercial mortgage loans generally by discounting the contractual
cash flows at estimated market interest rates that reflect the Company’s assessment of the credit quality of the loans. Market interest rates are
derived by calculating the appropriate spread over comparable U.S. Treasury rates based on the property type, quality rating and average life
of the loan. The quality ratings reflect the relative risk of the loan considering debt service coverage, the loan-to-value ratio and other factors.
Fair values of impaired mortgage loans are based on the estimated fair value of the underlying collateral generally determined using an internal
discounted cash flow model. The fair value measurements were classified in Level 3 because the cash flow models incorporate significant
unobservable inputs.
Contractholder deposit funds, excluding universal life products. Generally, these funds do not have stated maturities. Approximately 70% of
these balances can be withdrawn by the customer at any time without prior notice or penalty. The fair value for these contracts is the amount
estimated to be payable to the customer as of the reporting date, which is generally the carrying value. Most of the remaining contractholder
deposit funds are reinsured by the buyers of the individual life and annuity and retirement benefits businesses. The fair value for these
contracts is determined using the fair value of these buyers’ assets supporting these reinsured contracts. The Company had reinsurance
recoverables equal to the carrying value of these reinsured contracts. These instruments were classified in Level 3 because certain inputs are
unobservable (supported by little or no market activity) and significant to their resulting fair value measurement.
Long-term debt, including current maturities, excluding capital leases. The fair value of long-term debt is based on quoted market prices for
recent trades. When quoted market prices are not available, fair value is estimated using a discounted cash flow analysis and the Company’s
estimated current borrowing rate for debt of similar terms and remaining maturities. These measurements were classified in Level 2 because
the fair values are based on quoted market prices or other inputs that are market observable or can be corroborated by market data.
Fair values of off-balance sheet financial instruments were not material as of December 31, 2017 and 2016.
Investments, Investment Income and Gains and Losses
NOTE 11
Cigna’s investment portfolio consists of a broad range of investments including fixed maturities and equity securities, commercial mortgage
loans, other long-term investments and short-term investments. The sections below provide more detail regarding our accounting policies,
investment balances, net investment income and realized investment gains and losses. See Note 10 for information about the valuation of the
Company’s investment portfolio.
A.
Investment Portfolio
Fixed Maturities and Equity Securities
Accounting policy. Fixed maturities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the
investor) and most equity securities are classified as available for sale and are carried at fair value with changes in fair value recorded in
accumulated other comprehensive income (loss) within shareholders’ equity. Net unrealized appreciation on investments supporting the
Company’s run-off settlement annuity business is reported in future policy benefit liabilities rather than accumulated other comprehensive
income (loss).
Equity securities include hybrid investments consisting of preferred stock with call features that are carried at fair value with changes in fair
value reported in other realized investment gains (losses) and dividends reported in net investment income. As of December 31, 2017, fair
values of these securities were $49 million and amortized cost was $61 million. As of December 31, 2016, fair values of these securities were
$36 million and amortized cost was $49 million.
The Company records impairment losses in net income for fixed maturities with fair value below amortized cost that meet either of the
following conditions:
•
•
If the Company intends to sell or determines that it is more likely than not to be required to sell these fixed maturities before their fair values
recover, an impairment loss is recognized for the excess of the amortized cost over fair value.
If the net present value of projected future cash flows of a fixed maturity (based on qualitative and quantitative factors, including the
probability of default, and the estimated timing and amount of recovery) is below the amortized cost basis, that difference is recognized as an
impairment loss. For mortgage and asset-backed securities, estimated future cash flows are also based on assumptions about the collateral
attributes including prepayment speeds, default rates and changes in value.
CIGNA CORPORATION - 2017 Form 10-K 85
PART II
ITEM 8. Financial Statements and Supplementary Data
The amortized cost and fair value by contractual maturity periods for fixed maturities were as follows at December 31, 2017:
(In millions)
Due in one year or less
Due after one year through five years
Due after five years through ten years
Due after ten years
Mortgage and other asset-backed securities
Total
Amortized
Cost
Fair Value
$
1,511
6,655
9,377
3,855
469
$
1,522
6,848
9,599
4,672
497
$ 21,867
$ 23,138
Actual maturities of these securities could differ from their contractual maturities used in the table above. This could occur because issuers
may have the right to call or prepay obligations, with or without penalties.
Gross unrealized appreciation (depreciation) on fixed maturities by type of issuer is shown below.
(In millions)
December 31, 2017
Federal government and agency
State and local government
Foreign government
Corporate
Mortgage and other asset-backed
Total
Investments supporting liabilities of the Company’s run-off settlement annuity business
(included in above total) (1)
December 31, 2016
Federal government and agency
State and local government
Foreign government
Corporate
Mortgage and other asset-backed
Total
Investments supporting liabilities of the Company’s run-off settlement annuity business
(included in above total) (1)
Amortized
Cost
Unrealized
Appreciation
Unrealized
Depreciation
Fair Value
$
$
$
$
$
$
541
1,196
2,360
17,301
469
21,867
2,200
658
1,342
1,998
15,483
461
19,942
2,196
$
$
$
$
$
$
239
93
142
868
29
$
(1)
(2)
(15)
(81)
(1)
1,371
$ (100)
681
223
99
129
716
29
1,196
539
$
$
$
$
(2)
(4)
(6)
(14)
(149)
(4)
(177)
(15)
$
$
$
$
$
$
779
1,287
2,487
18,088
497
23,138
2,879
877
1,435
2,113
16,050
486
20,961
2,720
(1) Net unrealized appreciation for these investments is excluded from accumulated other comprehensive income.
As of December 31, 2017, the Company had commitments to purchase $118 million of fixed maturities, all of which bear interest at a fixed market
rate.
Review of declines in fair value. Management reviews fixed maturities with a decline in fair value from cost for impairment based on criteria
that include:
•
length of time and severity of decline;
•
financial health and specific near term prospects of the issuer;
•
changes in the regulatory, economic or general market environment of the issuer’s industry or geographic region; and
•
the Company’s intent to sell or the likelihood of a required sale prior to recovery.
Based on this review, management believes the unrealized depreciation below to be temporary, and therefore has not impaired these amounts.
The table below summarizes fixed maturities with a decline in fair value from amortized cost by the length of time these securities have been in
an unrealized loss position.
(Dollars in millions)
One year or less
Investment grade
Below investment grade
More than one year
Investment grade
Below investment grade
December 31, 2017
December 31, 2016
Fair
Value
Amortized
Cost
Unrealized
Depreciation
Number of
Issues
Fair
Value
Amortized
Cost
Unrealized
Depreciation
Number of
Issues
$
$
$
$
3,272
543
1,503
155
$
$
$
$
3,309
553
1,549
162
$
$
$
$
(37)
(10)
(46)
(7)
797
643
373
42
$
$
$
$
4,346
724
308
186
$
$
$
$
4,475
736
327
203
$
$
$
$
(129)
(12)
(19)
(17)
992
591
53
28
There were no available for sale equity securities with a significant unrealized loss reflected in accumulated other comprehensive income at
December 31, 2017.
86 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Commercial Mortgage Loans
Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and
borrower. Loans are generally issued at a fixed rate of interest and are secured by high quality, primarily completed and substantially leased
operating properties.
Accounting policy. Commercial mortgage loans are carried at unpaid principal balances or, if impaired, the lower of unpaid principal or fair
value of the underlying real estate. See the ‘‘Impaired commercial mortgage loans’’ section below for the Company’s accounting policy for
impaired commercial mortgage loans.
At December 31, commercial mortgage loans were distributed among the following property types and geographic regions:
(In millions)
Property type
Office buildings
Apartment buildings
Industrial
Hotels
Retail facilities
Other
Total
U.S. geographic region
Pacific
South Atlantic
New England
Central
Middle Atlantic
Mountain
Total
2017
2016
$
$
$
652
608
197
141
135
28
1,761
841
210
238
237
203
32
$
$
$
592
428
302
205
139
–
1,666
714
268
227
239
186
32
$
1,761
$
1,666
As of December 31, 2017, approximately 86% of the Company’s commercial mortgage loan portfolio is scheduled to mature in 2022 or
thereafter.
Actual maturities could differ from contractual maturities for several reasons: borrowers may have the right to prepay obligations with or
without prepayment penalties; the maturity date may be extended; and loans may be refinanced.
As of December 31, 2017, the Company had commitments to extend credit under commercial mortgage loan agreements of $21 million.
Credit quality. The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and
continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system
designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review.
The Company evaluates and monitors credit quality on a consistent and ongoing basis, classifying each loan as a loan in good standing,
potential problem loan or problem loan.
Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as
rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most
significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio
measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating
that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage,
compares the amount of the loan to the fair value of the underlying property collateralizing the loan.
The following table summarizes the credit risk profile of the Company’s commercial mortgage loan portfolio based on loan-to-value and debt
service coverage ratios, as of December 31, 2017 and 2016:
(Dollars in millions)
Loan-to-Value Ratio
Below 60%
60% to 79%
80% to 100%
Total
2017
Average
Debt Service
Coverage
Ratio
Average
Loan-to-
Value
Ratio
2.03
2.24
–
2.11
57%
2016
Average
Debt Service
Coverage
Ratio
Average
Loan-to-
Value
Ratio
2.06
1.89
–
1.95
57%
Carrying
Value
$ 943
702
21
$ 1,666
Carrying
Value
$ 1,109
652
–
$
1,761
The Company’s annual in-depth review of its commercial mortgage loan investments is the primary mechanism for identifying emerging risks
in the portfolio. The most recent review was completed by the Company’s investment professionals in the second quarter of 2017 and included
an analysis of each underlying property’s most recent annual financial statements, rent rolls, operating plans, budgets, a physical inspection of
the property and other pertinent factors. Based on historical results, current leases, lease expirations and rental conditions in each market, the
Company estimates the current year and future stabilized property income and fair value for each loan.
CIGNA CORPORATION - 2017 Form 10-K 87
PART II
ITEM 8. Financial Statements and Supplementary Data
The Company will reevaluate a loan’s credit quality between annual reviews if new property information is received or an event such as
delinquency or a borrower’s request for restructure causes management to believe that the Company’s estimate of financial performance, fair
value or the risk profile of the underlying property has been impacted.
Impaired commercial mortgage loans. A commercial mortgage loan is considered impaired when it is probable that the Company will not
collect all amounts due according to the terms of the original loan agreement. These loans are included in either problem or potential problem
loans. The Company monitors credit risk and assesses the impairment of loans individually and on a consistent basis for all loans in the
portfolio. Impaired loans are carried at the lower of unpaid principal balance or the fair value of the underlying real estate. The Company
estimates the fair value of the underlying real estate using internal valuations generally based on discounted cash flow analyses. Certain
commercial mortgage loans without valuation reserves are considered impaired because the Company will not collect all interest due
according to the terms of the original agreements; however, the Company expects to recover the unpaid principal because it is less than the fair
value of the underlying real estate. Because of the risk profile of the underlying investment, the Company recognizes interest income on
impaired mortgage loans only when payment is actually received.
As of December 31, 2017 and 2016, impaired commercial mortgage loans and valuation reserves associated with impaired loans were not
material. For the years ended December 31, 2017 and 2016, the average recorded investment in impaired loans and interest income on impaired
loans were not material.
Other Long-Term Investments
Accounting policy. Other long-term investments include investments in unconsolidated entities. These entities include certain limited
partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company’s
ownership percentage of reported income or loss in cases where the Company has significant influence; otherwise the investment is carried at
cost. Income from certain entities is reported on a one quarter lag depending on when their financial information is received. Other long-term
investments are considered impaired, and written down to their fair value, when cash flows indicate that the carrying value may not be
recoverable. Fair value is generally determined based on a discounted cash flow analysis.
Other long-term investments also include investment real estate carried at depreciated cost less any impairment write downs to fair value
when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method
based on the estimated useful life of each asset. Investment real estate as of December 31, 2017 and 2016 is expected to be held longer than one
year and includes real estate acquired through the foreclosure of commercial mortgage loans.
Additionally, other long-term investments include interest rate and foreign currency swaps carried at fair value. See Note 12 for information on
the Company’s accounting policies for these derivative financial instruments.
Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. The following table
provides unfunded commitment and fair value information on these investments. The Company expects to disburse approximately 31% of the
committed amounts in 2018.
(In millions)
Real estate investments
Securities partnerships
Other
Total
Fair value as of
December 31,
2017
2016
591
863
64
1,518
$
$
738
650
74
1,462
$
$
Unfunded
Commitments
as of
December 31, 2017
$
$
270
876
32
1,178
Short-Term Investments and Cash Equivalents
Accounting policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as
short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with
maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.
Short-term investments and cash equivalents included the following types of issuers:
(In millions)
Corporate securities
Federal government securities
Foreign government securities
Money market funds
December 31,
2017
December 31,
2016
$
$
$
$
1,143
604
159
12
$
$
$
$
2,234
378
94
11
Concentration of Risk
As of December 31, 2017 and 2016, the Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of
shareholders’ equity.
88 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Net Investment Income
B.
Accounting policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is
earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when
certain terms (interest rate or maturity date) of the investment have been restructured.
The components of pre-tax net investment income for the years ended December 31 were as follows:
(In millions)
Fixed maturities
Equity securities
Commercial mortgage loans
Policy loans
Other long-term investments
Short-term investments and cash
Total investment income
Less investment expenses
Net investment income
Net investment income for separate accounts(1)
(1) Net investment income for these investments is excluded from the Company’s revenues.
2017
946
14
81
69
124
42
1,276
50
1,226
225
$
$
$
2016
899
4
91
72
98
26
1,190
43
1,147
236
$
$
$
2015
879
3
112
72
116
14
1,196
43
1,153
262
$
$
$
Real estate investments and securities partnerships with a carrying value of $191 million at December 31, 2017 and $220 million at December 31,
2016 were non-income producing during the preceding twelve months.
Realized Investment Gains And Losses
C.
Accounting policy. Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset
write-downs, changes in the fair values of certain derivatives and changes in valuation reserves on commercial mortgage loans.
The following realized gains and losses on investments for the years ended December 31 exclude amounts required to adjust future policy
benefits for the run-off settlement annuity business.
(In millions)
Fixed maturities
Equity securities
Commercial mortgage loans
Other investments, including derivatives
Net realized investment gains, before income taxes
Less income taxes
Net realized investment gains
2017
2016
2015
$
$
25
52
(1)
161
237
81
156
$
$
23
(1)
4
143
169
60
109
$
$
(82)
36
(2)
105
57
17
40
Included in the realized investment gains and losses in the above table were pre-tax asset write-downs on debt securities and other asset write-
downs of $31 million for the year ended December 31, 2017, $58 million for the year ended December 31, 2016 and $140 million for the year
ended December 31, 2015. Realized investment gains in other investments, including derivatives, represent primarily gains on sale of real estate
properties held in joint ventures.
Realized investment gains that are excluded from the Company’s revenues for the years ended December 31 were as follows:
(In millions)
Separate accounts
Investment gains required to adjust future policy benefits for the run-off settlement annuity business
2017
157
20
$
$
2016
16
63
$
$
2015
117
114
$
$
The following table presents sales information for available-for-sale fixed maturities and equity securities for the years ended December 31.
Gross gains on sales and gross losses on sales exclude amounts required to adjust future policy benefits for the run-off settlement annuity
business.
(In millions)
Proceeds from sales
Gross gains on sales
Gross losses on sales
2017
$ 2,012
103
$
(18)
$
2016
1,544
83
(7)
$
$
$
2015
1,555
85
(13)
$
$
$
NOTE 12
Derivative Financial Instruments
The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and
liquidity) to meet the varying demands of the related insurance and contractholder liabilities (such as paying claims, investment returns and
withdrawals) and to hedge interest rate risk of its long-term debt. The Company has written and purchased GMIB reinsurance contracts in its
run-off reinsurance business that are accounted for as freestanding derivatives and further discussed in Note 9. Derivatives in the Company’s
CIGNA CORPORATION - 2017 Form 10-K 89
PART II
ITEM 8. Financial Statements and Supplementary Data
separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate
account policyholders.
Accounting policy. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges.
Effectiveness is formally assessed and documented at inception and each period throughout the life of a hedge using various quantitative
methods appropriate for each hedge, including regression analysis and dollar offset. Under hedge accounting, the changes in fair value of the
derivative and the hedged risk are generally recognized together and offset each other when reported in shareholders’ net income. Changes in
the fair value of a derivative instrument may not always equal changes in the fair value of the hedged item. This is referred to as ‘‘hedge
ineffectiveness’’ and is generally recorded in realized investment gains and losses. In the event of an early hedge termination, the changes in fair
value of derivatives that qualified for hedge accounting are reported in shareholders’ net income, generally as a part of realized investment
gains and losses. Derivative cash flows are generally reported in operating activities.
The following tables provide information on the Company’s specific applications of derivative financial instruments during the years ended
December 31.
Fair Value Hedge of Long-Term Corporate Debt
Type of instrument.
Interest rate swap contracts
Notional Value (in millions)
2017
$ 750
2016
$ 750
Purpose. To convert a portion of the interest rate exposure on the Company’s long-term debt from fixed to variable rates. This more
closely aligns the Company’s interest expense with the interest income received on its cash equivalent and short-term investment balances.
The variable rates are benchmarked to LIBOR.
Terms of derivative instruments. The Company provides upfront margin and settles fair value changes and net interest between variable
and fixed rates daily with a central clearinghouse.
Accounting. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets, including other
intangibles, or accounts payable, accrued expenses, and other liabilities. The critical terms of these swaps match those of the long-term
debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by LIBOR. The
effects of those adjustments on other operating expenses are offset by the effects of corresponding changes in the swaps’ fair value. The
net impact from the hedge reported in other operating expenses reflects interest expense on the hedged debt at the variable interest rate.
Fair Value Hedges of Fixed Maturity Bonds
Type of instrument. Foreign currency swap contracts
Notional Value (in millions)
2017
$ 318
2016
$ 78
Purpose. To hedge the foreign exchange related changes in fair values of the Company’s fixed maturity bonds.
Terms of derivative instruments. The Company periodically exchanges cash flows between two currencies for both principal and interest.
Foreign currency swaps are Euros and British pounds and have terms for up to twelve years.
Accounting. Using fair value hedge accounting, fair values are reported in other long-term investments or accounts payable, accrued
expenses, and other liabilities. Changes in fair values of the swap contracts, as well as changes in the fair values of the hedged bonds
attributable to the hedged risk, are reported in other realized investment gains and losses.
Economic Hedges of a Fixed Maturity Bond Portfolio
Type of instrument. Foreign currency forward contracts
Notional Value (in millions)
2017
$ 255
2016
$ 149
Purpose. To hedge the foreign exchange related changes in fair values of a U.S. dollar-denominated fixed maturity bond portfolio to
reflect the local currency for one of the Company’s foreign subsidiaries.
Terms of derivative instruments. The Company agrees to purchase South Korean won in exchange for U.S. dollars at a future date,
generally within three months from the contracts’ trade dates.
Accounting. As these arrangements were not designated as accounting hedges, fair values are reported in short-term investments or
accounts payable, accrued expenses, and other liabilities, and changes in fair values are reported in other realized investment gains and
losses.
As of and for the years ended December 31, 2017 and 2016, the effects of these derivative instruments on the Consolidated Financial
Statements were not material, including the amounts of gains or losses reclassified from accumulated other comprehensive income into
shareholders’ net income. No material amounts were excluded from the assessment of hedge effectiveness and no significant gains or losses
were recognized due to hedge ineffectiveness.
Collateral and termination features. The Company routinely monitors exposure to credit risk associated with derivatives and diversifies the
portfolio among approved dealers of high credit quality to minimize this risk. As of December 31, 2017, the Company had $9 million in cash on
90 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
deposit representing the upfront margin required for the Company’s centrally-cleared derivative instruments. Certain of the Company’s
over-the-counter derivative instruments contain provisions requiring either the Company or the counterparty to post collateral or demand
immediate payment depending on the amount of the net liability position and predefined financial strength or credit rating thresholds.
Collateral posting requirements vary by counterparty. The net asset or liability positions of these derivatives were not material as of
December 31, 2017 or 2016.
NOTE 13
Variable Interest Entities
When the Company becomes involved with a variable interest entity, as well as when there is a change in the Company’s involvement with an
entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company would be considered the
primary beneficiary if it has the power to direct the entity’s most significant economic activities or has the right to receive benefits or obligation
to absorb losses that could be significant to the entity. The Company evaluates the following criteria:
•
•
•
the structure and purpose of the entity;
the risks and rewards created by and shared through the entity; and
the Company’s ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity
including its sponsors, equity holders, guarantors, creditors and servicers.
As of December 31, 2017 and 2016, the Company determined it was not a primary beneficiary in any material variable interest entities. The
Company’s involvement in variable interest entities where it is not the primary beneficiary is described below.
Securities limited partnerships and real estate limited partnerships. The Company owns interests in securities limited partnerships and real
estate limited partnerships that are defined as variable interest entities. These partnerships invest in the equity or mezzanine debt of privately
held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the
partnership’s operations and the limited partners do not have substantive kick-out or participating rights. The Company’s maximum exposure
to these entities of $2.4 billion across approximately 116 limited partnerships as of December 31, 2017 includes $1.2 billion reported in other
long-term investments and commitments to contribute an additional $1.2 billion. The Company’s non-controlling interest in each of these
limited partnerships is generally less than 10% of the partnership ownership interests.
In the normal course of its investing activities, the Company also makes passive investments in
Other asset-backed and corporate securities.
certain asset-backed and corporate securities that are issued by variable interest entities whose sponsors or issuers are unaffiliated with the
Company. The Company receives fixed-rate cash flows from these investments and the maximum potential exposure to loss is limited to the
carrying amount of $0.6 billion as of December 31, 2017 that is reported in fixed maturities. The Company’s combined ownership interests are
insignificant relative to the total principal amounts issued by these entities.
The Company is also involved in real estate joint ventures, independent physician associations (‘‘IPAs’’) and a joint venture in India that are
variable interest entities. The carrying values and maximum exposures associated with these arrangements are immaterial.
The Company has not provided, and does not intend to provide, financial support to any of the above entities that it is not contractually
required to provide. The Company performs ongoing qualitative analyses of its involvement with these variable interest entities to determine if
consolidation is required.
CIGNA CORPORATION - 2017 Form 10-K 91
PART II
ITEM 8. Financial Statements and Supplementary Data
Accumulated Other Comprehensive Income (Loss) (‘‘AOCI’’)
NOTE 14
AOCI includes the Company’s share from entities accounted for using the equity method. AOCI excludes amounts required to adjust future
policy benefits for the run-off settlement annuity business and a portion of deferred acquisition costs associated with the corporate-owned life
insurance business. Changes in the components of accumulated other comprehensive income (loss) were as follows:
(in millions)
Securities
Beginning balance
Appreciation (depreciation) on securities
Tax (expense) benefit
Net appreciation (depreciation) on securities
Reclassification adjustment for (gains) losses included in shareholders’ net income (net realized investment gains)
Tax benefit (expense)
Net (gains) losses reclassified from AOCI to net income
Other comprehensive (loss), net of tax
Ending balance
Derivatives
Beginning balance
(Depreciation) appreciation on derivatives
Tax (expense)
Net (depreciation) appreciation on derivatives
Reclassification adjustment for losses included in shareholders’ net income (other operating expenses)
Reclassification adjustment for (gains) included in shareholders’ net income (net realized investment gains)
Tax benefit (expense)
Net (gains) losses reclassified from AOCI to net income
Other comprehensive (loss) income , net of tax
Ending balance
Translation of foreign currencies
Beginning balance
Translation of foreign currencies
Tax (expense) benefit
Net translation of foreign currencies
Ending balance
Postretirement benefits liability
Beginning balance
Reclassification adjustment for amortization of net losses from past experience and prior service costs (other
operating expenses)
Reclassification adjustment for settlement (other operating expenses)
Tax (expense) benefit
Net adjustments reclassified from AOCI to net income
Valuation update
Tax benefit (expense)
Net change due to valuation update
Other comprehensive income (loss), net of tax
Ending balance
2017
2016
2015
$
$
$
$
$
$
362
35
(19)
16
(77)
27
(50)
(34)
328
3
(1)
–
(1)
1
(4)
1
(2)
(3)
$
–
$
418
(48)
6
(42)
(22)
8
(14)
(56)
362
7
–
–
–
1
(7)
2
(4)
(4)
3
$ (369)
309
(5)
$ (274)
(95)
–
304
(95)
$
$
$
$
$
620
(389)
157
(232)
46
(16)
30
(202)
418
(8)
10
(3)
7
12
–
(4)
8
15
7
(62)
(224)
12
(212)
$
(65)
$ (369)
$ (274)
$ (1,378)
$ (1,401)
$ (1,486)
64
7
(24)
47
(22)
8
(14)
33
64
–
(22)
42
(29)
10
(19)
23
68
–
(23)
45
63
(23)
40
85
$ (1,345)
$ (1,378)
$ (1,401)
NOTE 15
Pension and Other Postretirement Benefit Plans
About our Plans
A.
Pension plans. The Company’s principal qualified defined benefit pension plans, the Cigna Pension Plan and the Cigna Pension Plan for
Certain Former Employees, cover approximately 22,200 retirees, 14,500 vested former employees and 14,000 active employees. Current
retirees, certain vested former employees and longer-service active employees are entitled to an annuity benefit based on pay and length of
service. Most pension-eligible active employees and certain vested former employees are entitled to a cash balance defined benefit. The Cigna
Supplemental Pension Plan, a non-qualified and unfunded plan, covers only certain employees. We froze future benefit accruals for all of these
domestic pension plans in 2009. Additionally the Company has foreign pension and other postretirement benefit plans that are immaterial to
our results of operations, liquidity and financial position.
As further discussed in Note 21, Cigna Corporation and the Cigna Pension Plan are defendants in a class action lawsuit related to the Plan’s
conversion of certain employees from an annuity to a cash balance benefit in 1997. When the required plan amendment related to this litigation
is adopted, the pension benefit obligation will be updated to reflect benefits resulting from this litigation.
92 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Other postretirement benefit plans. The Company’s postretirement benefit medical plan covers approximately 18,400 retirees and 18,600
active employees. Post-1988 retirees contribute to the cost of this coverage, whereas pre-1989 retirees do not. For post-1988 retirees, the
Company’s cost is capped at 200% of the per capita cost in 2000. Pharmacy coverage for Medicare-eligible retirees is delivered using an
Employer Group Waiver Plan. Under that plan, the Company receives subsidies from CMS. The postretirement medical plan is unfunded and
future benefit accruals were frozen in 2013. The Company also offers certain postretirement life insurance benefits through various plans.
Retirees do not contribute to the cost of life insurance benefits.
Accounting policy. The Company measures the assets and liabilities of its domestic pension and other postretirement benefit plans as of
December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The
Company uses the ‘‘corridor’’ method to account for changes in the benefit obligation when actual results differ from those assumed, or when
assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized
actuarial gains (losses) are initially recorded in accumulated other comprehensive income. When the unrecognized gain (loss) exceeds 10% of
the benefit obligation, that excess is amortized to other operating expense over the expected remaining lives of plan participants.
For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are
reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a ‘‘market-related’’
asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The ‘‘market-
related’’ value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces
the short-term impact of market fluctuations on pension costs. At December 31, 2017, the market-related asset value was approximately
$4.1 billion compared with a fair value of approximately $4.3 billion.
B.
Funded Status and Amounts Included in Accumulated Other Comprehensive
Income
The following table summarizes the projected benefit obligations and assets related to our domestic and international pension and other
postretirement benefit plans as of, and for the years ended, December 31:
(In millions)
Change in benefit obligation
Benefit obligation, January 1
Service cost
Interest cost
Loss from past experience
Benefits paid from plan assets
Benefits paid – other
Benefit obligation, December 31
Change in plan assets
Fair value of plan assets, January 1
Actual return on plan assets
Benefits paid
Contributions
Fair value of plan assets, December 31
Funded status
Pension Benefits
2017
2016
Other
Postretirement
Benefits
2017
2016
$ 4,888
3
186
181 (1)
(277)
(12)
4,969
3,977
418
(277)
163
4,281
$
$ 4,934
2
199
57 (1)
(284)
(20)
4,888
3,981
279
(284)
1
3,977
277
–
9
1
(3)
(26)
258
5
–
(3)
–
2
$
295
–
11
2
(3)
(28)
277
8
–
(3)
–
5
$
(688)
$
(911)
$ (256)
$ (272)
(1) Loss in each year reflects a decrease in the discount rate, partially offset by a favorable change in the mortality assumption.
We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the
Pension Protection Act of 2006. For 2018, we do not expect to make any contributions to the qualified pension plans because none are
required. Future years’ contributions will ultimately be based on a wide range of factors including but not limited to asset returns, discount
rates and funding targets. Non-qualified pension and other postretirement benefit plans are generally funded on a pay-as-you-go basis as
there are no plan assets for these plans.
Benefit payments. The following benefit payments are expected to be paid in:
(In millions)
2018
2019
2020
2021
2022
2023-2027
Pension
Benefits
340
$
334
$
325
$
325
$
324
$
$ 1,573
Other
Postretirement
Benefits
$ 27
$ 26
$ 25
$ 23
$ 22
$ 87
CIGNA CORPORATION - 2017 Form 10-K 93
PART II
ITEM 8. Financial Statements and Supplementary Data
Amounts reflected in the pension and other postretirement benefit liabilities shown above that have not yet been reported in net income and
therefore are included in accumulated other comprehensive loss consisted of the following as of December 31:
(In millions)
Unrecognized net (losses)
Unrecognized prior service cost
Postretirement benefits liability adjustment
Pension Benefits
2017
2016
$ (2,113)
(6)
$ (2,163)
(6)
$ (2,119)
$ (2,169)
Other
Postretirement
Benefits
2017
$ –
46
$ 46
2016
$
–
49
$ 49
We expect to recognize pre-tax losses of $69 million in 2018 from amortization of the net actuarial loss in our pension plans and pre-tax gains
of $3 million in 2018 from amortization of prior service cost in the other postretirement benefit plans. These estimates are based on a weighted
average amortization period for the frozen and inactive plans that is based on the average expected remaining life of plan participants of
approximately 26 years.
Cost of Our Plans
C.
Components of net pension and other postretirement benefits cost for the years ended December 31 were as follows:
(In millions)
Service cost
Interest cost
Expected long-term return on plan assets
Amortization of:
Net loss from past experience
Prior service cost
Settlement loss
Net plan cost
Pension Benefits
2017
3
186
(260)
66
–
7
2
$
$
2016
2
199
(249)
65
1
–
18
$
$
2015
2
194
(267)
70
–
–
(1)
$
$
Other
Postretirement
Benefits
2016
2017
$
–
9
–
1
(3)
–
$
–
11
–
1
(3)
–
2015
$
–
11
–
–
(3)
–
$
7
$
9
$
8
Assumptions Used for Pension and Other Postretirement Benefit Plans
D.
Management determined the present value of the projected benefit obligation and the accumulated other postretirement benefit obligation
and related benefit costs based on the following weighted average assumptions as of and for the years ended December 31:
Discount rate:
Pension benefit obligation
Other postretirement benefit obligation
Pension benefit cost
Other postretirement benefit cost
Expected long-term return on plan assets:
Pension benefit cost
Other postretirement benefit cost
Mortality table for pension and postretirement benefit obligations
2017
3.51%
3.37%
3.95%
3.70%
2016
3.95%
3.70%
4.17%
3.89%
7.25%
5.00%
RP 2014 with MP 2017
projection scale
7.25%
5.00%
RP 2014 with MP 2016
projection scale
The Company used the Society of Actuaries mortality table RP2014 and the updated improvement scales published in 2016 and 2017 to value
its benefit obligations because the Company’s mortality experience closely matched these tables based on internal studies. The updated
improvement scales published in 2016 and 2017 both indicated that mortality improvement is expected to be lower than was originally
projected when the study was first published in 2014, resulting in decreases to the benefit obligations in both years.
The Company sets discount rates by applying actual annualized yields for high quality bonds at various durations to the expected cash flows of
the pension and other postretirement benefits liabilities. A discount rate curve is constructed using an array of bonds in various industries
throughout the domestic market, but only selects those for the curve that have an above average return at each duration. Management
believes that this curve is representative of the yields that the Company is able to achieve through its plan asset investment strategy.
Expected long-term rates of return on plan assets were developed considering actual long-term historical returns, expected long-term market
conditions, plan asset mix and management’s investment strategy that continues a significant allocation to domestic and foreign equity
securities as well as securities partnerships, real estate and hedge funds. Expected long-term market conditions take into consideration certain
key macroeconomic trends including expected domestic and foreign GDP growth, employment levels and inflation.
The estimated rate of future increases in the per capita cost of postretirement health care benefits is 6.50% in 2018, decreasing by 0.25% per
year to 4.75% in 2024 and beyond. The impact of a 1% increase or decrease in the estimated rate would be immaterial to postretirement cost
and benefit obligation.
94 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Pension Plan Assets
E.
As of December 31, 2017, pension assets included $3.9 billion invested in the separate accounts of Connecticut General Life Insurance Company
and Life Insurance Company of North America, subsidiaries of the Company, as well as an additional $342 million invested directly in funds
offered by the buyer of the retirement benefits business.
The fair values of pension assets by category are as follows as of December 31, 2017 and 2016.
(In millions)
Fixed maturities:
Federal government and agency
Corporate
Asset-backed
Fund investments
Total fixed maturities
Equity securities:
Domestic
International, including funds and pooled separate accounts(1)
Total equity securities
Securities partnerships
Real estate funds, including pooled separate accounts(1)
Commercial mortgage loans
Hedge funds
Guaranteed deposit account contract
Cash equivalents and other current assets, net
Total pension assets at fair value
$
2017
1
1,124
22
884
2,031
689
476
1,165
457
300
140
73
63
52
$
2016
1
1,125
22
630
1,778
681
350
1,031
424
289
129
196
67
63
$ 4,281
$ 3,977
(1) A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.
The Company’s current target investment allocation percentages (50% fixed income, 30% public equity securities and 20% in other
investments, including private equity (securities partnerships), real estate and hedge funds) are developed by management as guidelines,
although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company would expect to
further reduce the allocation to equity securities and other investments and increase the allocation to fixed income investments as funding
levels improve.
See Note 10 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we
use to validate fair value measurements. Within pension plan assets, the Company classifies substantially all fixed maturities in Level 2. These
assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price.
Within pension assets, a substantial portion of domestic equity securities are classified as Level 1, while international equity funds are
predominantly classified in Level 2 using daily net asset value.
Securities partnerships, real estate and hedge funds are valued using NAV as a practical expedient and are excluded from the fair value
hierarchy. See Note 10 for additional disclosures related to these assets invested in the separate accounts of the Company’s subsidiaries.
Certain securities as described in Note 10, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in
Level 3 because unobservable inputs used in their valuation are significant.
401(k) Plans
F.
The Company sponsors a 401(k) plan in which the Company matches a portion of employees’ pre-tax contributions. Participants in the plan
may invest in various funds that invest in the Company’s common stock, several diversified stock funds, a bond fund or a fixed-income fund.
The Company may elect to increase its matching contributions if the Company’s annual performance meets certain targets. The Company’s
annual expense for these plans was as follows:
(In millions)
Expense
2017
$ 122
2016
$
113
2015
$ 106
NOTE 16
Employee Incentive Plans
A. About Our Plans
The People Resources Committee (‘‘the Committee’’) of the Board of Directors awards stock options, restricted stock, deferred stock and
strategic performance shares (‘‘SPS’’) to certain employees. The Committee has issued common stock instead of cash compensation. The
Company issues shares from Treasury stock for these awards.
The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair
value at the grant date. Fair value is determined differently for each type of award as discussed below.
Shares of common stock available for award at December 31 were as follows:
(In millions)
Common shares available for award
2017
14.0
2016
6.8
2015
8.6
CIGNA CORPORATION - 2017 Form 10-K 95
PART II
ITEM 8. Financial Statements and Supplementary Data
B. Stock Options
Accounting policy. The Company awards options to purchase Cigna common stock at the market price of the stock on the grant date.
Options vest over periods ranging from one to three years and expire no later than 10 years from grant date. Fair value is estimated using the
Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be
forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to
reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in operating expenses on a straight
line basis over the vesting period.
Compensation cost for stock options recorded in operating expenses was as follows for the years ended December 31:
(In millions)
Stock options compensation cost
2017
$ 52
2016
$ 53
2015
$ 42
Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table.
Dividend yield
Expected volatility
Risk-free interest rate
Expected option life
Weighted average fair value of options
2017
0.0%
35.0%
1.8%
4.3 years
$ 46.38
2016
0.0%
35.0%
1.2%
4.3 years
42.01
$
2015
0.0%
35.0%
1.3%
4.3 years
$ 36.40
The expected volatility reflects the past daily stock price volatility of Cigna stock. The Company does not consider volatility implied in the
market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The
risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected
option life reflects the Company’s historical experience.
The following table shows the status of, and changes in, common stock options during the last three years.
(Options in thousands)
Outstanding – January 1
Granted
Exercised
Expired or canceled
Outstanding – December 31
Options exercisable at year-end
2017
Weighted
Average
Exercise Price
$
$
$
$
$
$
82.01
149.17
63.41
138.41
100.79
77.36
2016
Weighted
Average
Exercise Price
$
$
$
$
$
$
68.86
139.20
62.09
117.18
82.01
58.36
Options
6,433
1,336
(577)
(95)
7,097
4,409
2015
Weighted
Average
Exercise Price
$
$
$
$
$
$
51.84
120.94
43.63
86.04
68.86
46.55
Options
7,331
1,410
(2,146)
(162)
6,433
3,414
Options
7,097
1,230
(2,072)
(99)
6,156
3,894
Compensation expense of $39 million related to unvested stock options at December 31, 2017 will be recognized over the next two years
(weighted average period).
The table below summarizes information for stock options exercised during the last three years:
(In millions)
Intrinsic value of options exercised
Cash received for options exercised
Tax benefit from options exercised
The following table summarizes information for outstanding common stock options at December 31, 2017:
Number (in thousands)
Total intrinsic value (in millions)
Weighted average exercise price
Weighted average remaining contractual life
2017
$ 218
$ 131
$ 41
2016
41
36
11
$
$
$
2015
$ 179
$ 94
$ 42
Options
Outstanding
Options
Exercisable
6,156
$
630
$ 100.79
6.6
$
$
3,894
490
77.36
5.5
C. Restricted Stock
The Company awards restricted stock to the Company’s employees with vesting periods ranging from three to five years. Recipients of
restricted stock awards accumulate dividends during the vesting period, but forfeit their awards and accumulated dividends if their
employment terminates before the vesting date.
Accounting policy. Fair value of restricted stock awards is equal to the market price of Cigna’s common stock on the date of grant. This fair
value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts
96 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in other operating expenses
over the vesting period on a straight line basis.
Compensation cost for restricted stock awards was as follows for the years ended December 31:
(In millions)
Restricted stock compensation cost
2017
$ 53
2016
$ 40
2015
$ 33
The following table shows the status of, and changes in, restricted stock awards during the last three years.
(Awards in thousands)
Outstanding – January 1
Awarded
Vested
Forfeited
Outstanding – December 31
2017
2016
2015
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
97.78
155.21
67.09
121.74
126.44
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
72.58
138.61
50.01
92.51
97.78
Grants/Units
1,642
315
(591)
(57)
1,309
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
53.59
121.93
41.99
68.31
72.58
Grants/Units
2,121
352
(736)
(95)
1,642
Grants/Units
1,309
451
(409)
(56)
1,295
The fair value of vested restricted stock at the vesting date for the years ended December 31 was as follows:
(In millions)
Fair value of vested restricted stock
2017
$ 62
2016
$ 82
2015
$ 92
At the end of 2017, approximately 4,800 employees held 1.3 million restricted stock awards with $68 million of related compensation expense
to be recognized over the next two years (weighted average period).
D. Strategic Performance Shares (‘‘SPS’’)
The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these
shares are subject to a market condition (total shareholder return relative to industry peer companies) and half are subject to a performance
condition (cumulative adjusted net income). These targets are set by the Committee. At the end of the performance period, holders of SPSs are
awarded shares of Cigna common stock ranging anywhere from 0 to 200% of the original grant of SPSs.
Accounting policy. Compensation expense for SPSs is recorded over the performance period. For ‘‘market condition’’ SPSs, fair value is
determined at the grant date using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. For
‘‘performance condition’’ SPSs, expense is initially accrued based on the most likely outcome, but evaluated for adjustment each period for
updates in the expected outcome. At the end of the performance period, expense is adjusted to the actual outcome (number of shares
awarded times the share price at the grant date). At the grant date, the Company estimates forfeitures based on experience and adjusts the
expense to reflect actual forfeitures over the vesting period.
Compensation expense for SPSs was as follows for the years ended December 31:
(In millions)
Strategic performance shares compensation cost
2017
$ 40
2016
$ 35
2015
$ 36
The following table shows the status of, and changes in, SPSs during the last three years:
(Awards in thousands)
Outstanding – January 1
Awarded
Vested
Forfeited
Outstanding – December 31
2017
2016
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
109.14
150.06
78.91
138.19
136.57
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
81.68
139.05
60.15
112.70
109.14
Shares
1,547
311
(608)
(62)
1,188
Shares
1,188
286
(494)
(38)
942
2015
Weighted
Average Fair
Value at
Award Date
$
$
$
$
$
59.20
121.78
45.51
76.33
81.68
Shares
942
275
(386)
(53)
778
The fair value of vested SPSs at the vesting date for the years ended December 31 was as follows:
(Shares in thousands; $ in millions)
2017
2016
2015
Shares
Fair Value
Shares
Fair Value
Shares
Fair Value
Shares of Cigna common stock distributed upon SPS vesting
476
$
70
768
$
109
972
$
119
CIGNA CORPORATION - 2017 Form 10-K 97
PART II
ITEM 8. Financial Statements and Supplementary Data
At the end of 2017, approximately 1,500 employees held 778,000 SPSs and $38 million of related compensation expense is expected to be
recognized over the next two years. For ‘‘performance condition’’ SPSs, the amount of expense may vary based on actual performance in 2018
and 2019.
E. One-Time Employee Stock Award
In 2017, the Company granted most employees a one-time stock award of five shares that immediately vested. In connection with this program,
approximately 205,000 shares were issued at a price of $162.96, resulting in a pre-tax cost of $33 million.
F. Compensation Cost and Tax Effects of Share-based Compensation
During the vesting period, the Company records tax benefits in shareholders’ net income based on the amount of expense being recognized.
When stock options are exercised, or when restricted stock and SPSs vest, the difference between tax benefits based on the expense and the
actual tax benefit realized are also recorded in net income beginning in 2016 in accordance with ASU 2016-09. Prior to 2016, such excess tax
benefits were recorded as an adjustment to additional paid-in capital. The table below provides information about the cost and tax benefits
related to all of our share-based compensation arrangements discussed above.
(In millions)
Total compensation cost for shared-based awards
Tax benefits recognized
2017
178
79
$
$
2016
128
57
$
$
2015
111
24
$
$
NOTE 17
Goodwill, Other Intangibles and Property and Equipment
A. Goodwill
Accounting policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting
goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, allocated to reporting units based on relative
fair values, primarily reported in the Global Health Care segment ($5.9 billion) and, to a lesser extent, the Global Supplemental Benefits
segment ($0.3 billion).
The Company evaluates goodwill for impairment at least annually during the third quarter at the reporting unit level and writes it down through
shareholders’ net income if impaired. Fair value of a reporting unit is generally estimated based on either market data or a discounted cash flow
analysis using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price.
The significant assumptions and estimates used in determining fair value include the discount rate and future cash flows. A range of discount
rates is used that corresponds with the reporting unit’s weighted average cost of capital, consistent with that used for investment decisions
considering the specific and detailed operating plans and strategies within the reporting unit. Projections of future cash flows for the reporting
unit are consistent with our annual planning process for revenues, claims, operating expenses, taxes, capital levels and long-term growth rates.
Goodwill activity. Goodwill activity during 2017 and 2016 was as follows:
(In millions)
Balance at January 1,
Goodwill acquired, net
Impact of foreign currency translation
Balance at December 31,
2017
2016
$ 5,980
154
30
$ 6,019
1
(40)
$ 6,164
$ 5,980
B. Other Intangibles
Accounting policy. The Company’s other intangible assets include purchased customer and producer relationships, provider networks and
trademarks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase
using an income approach that relies on projected future net cash flows including key assumptions for the customer attrition rate and discount
rate. The Company amortizes other intangibles on an accelerated or straight-line basis over periods from five to 30 years. Management revises
amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs
incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.
98 CIGNA CORPORATION - 2017 Form 10-K
Components of other assets, including other intangibles. Other intangible assets were comprised of the following at December 31:
PART II
ITEM 8. Financial Statements and Supplementary Data
(In millions)
2017
Customer relationships
Other
Total reported in other assets, including other intangibles
Value of business acquired (reported in deferred policy acquisition costs)
Total other intangible assets
2016
Customer relationships
Other
Total reported in other assets, including other intangibles
Value of business acquired (reported in deferred policy acquisition costs)
Cost
Accumulated
Amortization
Net Carrying
Value
$ 1,280
291
1,571
232
$ 1,803
$
1,256
284
1,540
232
$ 1,056
170
$
$
1,226
86
1,312
965
151
1,116
68
$
$
$
$
224
121
345
146
491
291
133
424
164
588
Total other intangible assets
$
1,772
$
1,184
C. Property and Equipment
Accounting policy. Property and equipment is carried at cost less accumulated depreciation. When applicable, cost includes interest, real
estate taxes and other costs incurred during construction. Also included in this category is internal-use software that is acquired, developed or
modified solely to meet the Company’s internal needs, with no plan to market externally. Costs directly related to acquiring, developing or
modifying internal-use software are capitalized.
The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life
of each asset as follows: buildings and improvements, 10 to 40 years; purchased software, three to five years; internally developed software,
three to seven years; and furniture and equipment (including computer equipment), three to 10 years. Improvements to leased facilities are
depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and
circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. If the Company
determines the carrying value of any of these assets is not recoverable, an impairment charge is recorded.
Components of property and equipment. Property and equipment was comprised of the following as of December 31:
(In millions)
2017
Internal-use software
Other property and equipment
Assets recorded under capital leases(1)
Other property and equipment not recorded under capital leases
Total other property and equipment
Total property and equipment
2016
Internal-use software
Other property and equipment
Assets recorded under capital leases(1)
Other property and equipment not recorded under capital leases
Total other property and equipment
Total property and equipment
Cost
Accumulated
Amortization
Net Carrying
Value
$ 2,991
$ 2,184
$
807
49
1,573
1,622
31
835
866
18
738
756
$ 4,613
$ 3,050
$ 1,563
$ 2,766
$
1,997
$
769
87
1,511
1,598
49
782
831
38
729
767
$ 4,364
$ 2,828
$
1,536
(1) Current capital lease agreements are for equipment and generally have a term of 48 months with the equipment expected to be returned to the lessor at termination.
Components of depreciation and amortization. Depreciation and amortization was comprised of the following for the years ended
December 31:
(In millions)
Internal-use software
Other property and equipment(1)
Value of business acquired (reported in deferred policy acquisition costs)
Other intangibles(2)
Total depreciation and amortization
2017
$ 298
153
18
97
2016
$ 303
158
20
129
2015
$ 288
160
18
119
$ 566
$
610
$ 585
(1) Other property and equipment includes amortization on assets recorded under capital leases of $14 million in 2017, $20 million in 2016 and $22 million in 2015.
(2) Includes the one-time $23 million bargain purchase gain on an acquisition in 2015.
The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to
be as follows:
(In millions)
2018
2019
2020
2021
2022
Pre-tax Amortization
$
387
$ 299
177
$
114
$
88
$
CIGNA CORPORATION - 2017 Form 10-K 99
PART II
ITEM 8. Financial Statements and Supplementary Data
NOTE 18
Leases and Rentals
Description of operating leases. The Company’s operating leases are primarily for office space and certain computer and other equipment.
Some of these leases include renewal options and other incentives that are amortized over the life of the lease. Leases active in 2017 had terms
ranging from one month to 18 years.
Rental expense and payments. For the years ended December 31, net rental expenses for operating leases were approximately:
(In millions)
Net rental expense for operating leases
2017
2016
2015
$
162
$
151
$
165
As of December 31, 2017, future net minimum rental payments under non-cancelable operating leases were approximately $580 million,
payable as follows:
(In millions)
2018
2019
2020
2021
2022
2023 and thereafter
Operating Lease Payments
$ 130
$ 113
94
$
73
$
$
58
$ 114
The Company also has capital lease arrangements. See Note 17 and Note 5 for further information on assets recorded under capital leases and
the related obligations.
NOTE 19
Shareholders’ Equity and Dividend Restrictions
State insurance departments and foreign jurisdictions that regulate certain of the Company’s subsidiaries prescribe accounting practices
(differing in some respects from GAAP) to determine statutory net income and surplus. The Company’s life, accident and health insurance and
Health Maintenance Organization (‘‘HMO’’) subsidiaries are regulated by such statutory requirements. Due to regulatory changes in the
jurisdiction of one of our foreign insurance affiliates, surplus increased significantly in 2017, primarily due to including deferred policy
acquisition costs as an admitted asset. The statutory net income of the Company’s life, accident and health insurance and HMO subsidiaries for
the years ended, and their statutory surplus as of December 31, were as follows:
(In billions)
Net income
Surplus
2017
2.5
10.4
$
$
2016
2.0
8.5
$
$
2015
2.1
8.0
$
$
The Company’s HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may
be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries
may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that
insurance companies may extend to the parent company without prior approval. As of December 31, 2017, these amounts, including restricted
GAAP net assets of the Company’s subsidiaries, were as follows:
(In billions)
Minimum statutory surplus required by regulators
Investments on deposit with regulatory bodies
Maximum dividend distributions permitted in 2018 without regulatory approval
Maximum loans to the parent company permitted without regulatory approval
Restricted GAAP net assets of Cigna Corporation’s subsidiaries
2017
3.2
$
$ 0.6
1.6
$
$
1.3
$ 12.0
There were no permitted practices for the Company’s insurance subsidiaries that significantly differed from prescribed regulatory accounting
practices.
NOTE 20
Income Taxes
U.S. Tax Reform Legislation
Major U.S. tax reform legislation was signed into law on December 22, 2017. The legislation is highlighted by a reduction in the corporate
income tax rate from the current 35% to 21% effective January 1, 2018. The Company expects a significant decline in its effective tax rate
beginning in 2018 as a result of the rate reduction. The remaining provisions of the law, most of which take effect on January 1, 2018, are not
expected to have a material impact on the Company’s results of operations beginning in 2018.
The Company recorded additional tax expense of $232 million in 2017 resulting from this legislation, comprised of $144 million due to the
revaluation of net deferred tax assets to reflect the reduction in the corporate tax rate and $88 million due to the assessment of U.S. taxes
related to the Company’s accumulated unremitted foreign earnings. The legislation provides an election to pay these taxes over eight years,
and we expect to adopt this election. Both the revaluation of deferred tax assets and liabilities and the taxes on accumulated unremitted
100 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
foreign earnings are considered provisional as permitted under SAB 118 (see Note 2) because certain adjustments used to calculate the taxes at
year-end were based on estimates.
Also as a result of tax reform, the Company recorded a reduction in operating expenses of $56 million ($36 million after-tax) reflecting a
decrease in a liability to reimburse a reinsurer for taxes related to a block of business sold through reinsurance. An offsetting tax effect is
included in the $144 million charge discussed above, resulting in no after-tax effect for this item.
Accounting policy. Deferred income tax assets and liabilities are recognized for differences between the financial and income tax reporting
bases of the underlying assets and liabilities and established based upon enacted tax rates and laws, including the U.S. tax reform legislation
enacted in December 2017. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than
not. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the year,
excluding amounts reported as adjustments to accumulated other comprehensive income or amounts initially recorded due to business
combinations. The current income tax provision generally represents estimated amounts due on various income tax returns for the year
reported plus the effect of any uncertain tax positions. Uncertain tax positions are evaluated in accordance with GAAP.
Income taxes for the Company’s foreign operations are provided using the respective foreign jurisdictions’ tax rate.
The Company’s foreign operations continue to retain a significant portion of their earnings overseas. These undistributed earnings are
deployed outside of the United States in support of the liquidity and capital needs of our foreign operations as well as to support growth
initiatives overseas. The Company does not intend to repatriate these earnings.
A.
Income Tax Expense
The components of income taxes for the years ended December 31 were as follows:
(In millions)
Current taxes
U.S. income taxes
Foreign income taxes
State income taxes
Total current taxes
Deferred taxes (benefits)
U.S. income taxes
Foreign income taxes (benefits)
State income taxes (benefits)
Total deferred taxes
Total income taxes
2017
2016
2015
$
974
122
36
1,132
204
39
(1)
242
$
935
95
32
$ 1,076
93
60
1,062
1,229
69
9
(4)
74
22
(6)
5
21
$ 1,374
$
1,136
$
1,250
Total income taxes for the years ended December 31 were different from the amount computed using the nominal federal income tax rate of
35% for the following reasons:
(In millions)
Tax expense at nominal rate
Effect of U.S. tax reform legislation
Effect of undistributed foreign earnings
Health insurance industry tax
State income tax (net of federal income tax benefit)
Other
Total income taxes
2017
2016
$ 1,262
232
(70)
–
23
(73)
$ 1,043
–
(57)
108
18
24
$
2015
1,164
–
(67)
109
42
2
$ 1,374
$
1,136
$
1,250
Consolidated pre-tax income from the Company’s foreign operations was approximately 14% of the Company’s pre-tax income in 2017. The
comparable amount in prior years was 11% in 2016 and 2015. South Korean operations produced approximately 13% of the Company’s pre-tax
income in 2017, 11% in 2016 and 8% in 2015.
The consolidated effective tax rate was 38.1% in both 2017 and 2016. The additional tax expense associated with the recently enacted U.S. tax
reform legislation was offset by the favorable effects of the one-year moratorium on the non-deductible health insurance industry tax and
recognizing an incremental tax benefit associated with transaction-related costs that is included in ‘‘Other’’ in the above table.
The Company retains a significant portion of its foreign earnings overseas. If the Company intended to remit these earnings it would have
recorded additional deferred tax liabilities of approximately $120 million for foreign withholding taxes. A portion of these taxes may be eligible
for credit against the Company’s U.S. tax liability.
CIGNA CORPORATION - 2017 Form 10-K 101
PART II
ITEM 8. Financial Statements and Supplementary Data
B.
Deferred Income Taxes
Deferred income tax assets and liabilities as of December 31 were as follows:
(In millions)
Deferred tax assets
Employee and retiree benefit plans
Other insurance and contractholder liabilities
Net operating losses
Other accrued liabilities
Other
Deferred tax assets before valuation allowance
Valuation allowance for deferred tax assets
Deferred tax assets, net of valuation allowance
Deferred tax liabilities
Depreciation and amortization
Unrealized appreciation on investments and foreign currency translation
Other
Total deferred tax liabilities
Net deferred income tax assets
2017
2016
$
$
279
352
105
101
91
928
(72)
856
496
102
225
823
$
33
$
481
460
128
166
140
1,375
(87)
1,288
781
149
54
984
304
Deferred income tax balances as of December 31, 2017 have been adjusted to reflect the reduced statutory tax rate that took effect as of
January 1, 2018 pursuant to the recently enacted U.S. tax reform legislation. The Company has recorded incremental tax expense of $144 million
including the adjustment of deferred tax balances related to items reported in accumulated other comprehensive income.
Included in the consolidated net deferred tax asset of $33 million is approximately $175 million of deferred tax liabilities attributable to foreign
jurisdictions, most notably South Korea and Taiwan.
Management believes that future results will be sufficient to realize the Company’s deferred tax assets. With the exception of certain net
operating loss related tax benefits, the Company’s deferred tax benefits may be carried forward indefinitely. Net operating loss benefits are
primarily attributable to foreign jurisdictions. The Company establishes a valuation allowance when it determines that realization of a deferred
tax asset does not meet the more likely than not standard. Valuation allowances have been established against certain federal, foreign and
state deferred tax assets, generally when there is a requirement to assess them on a separate entity basis.
C.
Uncertain Tax Positions
A reconciliation of unrecognized tax benefits for the years ended December 31 was as follows:
(In millions)
Balance at January 1,
Increase due to current year positions
Reduction related to settlements with taxing authorities
Reduction related to lapse of applicable statute of limitations
Balance at December 31,
D.
Other Tax Matters
2017
$ 31
7
(1)
(2)
$ 35
2016
$ 31
10
(2)
(8)
$ 31
2015
$ 26
7
–
(2)
$ 31
The Internal Revenue Service has completed review of the Company’s consolidated income tax returns through 2012. The statute of limitations
for 2013 has expired, but the Company has filed an amended return for which the pending refund is subject to review. The Company conducts
business in a number of state and foreign jurisdictions, and may be engaged in multiple audit proceedings at any given time. Generally, no
further state or foreign audit activity is expected for tax years prior to 2011.
NOTE 21
The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.
Contingencies and Other Matters
A.
Financial Guarantees: Retiree and Life Insurance Benefits
The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. The sponsoring
employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed
a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits
business (Prudential Retirement Insurance and Annuity Company or ‘‘Prudential’’) has the right to redirect the management of the related
assets to provide for benefit payments. As of December 31, 2017, employers maintained assets that exceeded the benefit obligations under
these arrangements of approximately $470 million. Approximately 12% of these are reinsured by Prudential. The remaining guarantees are
provided by the Company with minimal reinsurance from third parties. The Company establishes an additional liability if management believes
102 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
that the Company will be required to make payment under the guarantees; there were no additional liabilities required for these guarantees as
of December 31, 2017. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy (see
Note 10).
The Company does not expect that these financial guarantees will have a material effect on the Company’s consolidated results of operations,
liquidity or financial condition.
B.
Guaranteed Minimum Income Benefit Contracts
See Note 9 for discussion.
C.
Certain Other Guarantees
The Company had indemnification obligations to a lender of approximately $90 million as of December 31, 2017, related to a borrowing by a
certain real estate joint venture that the Company records as an investment. This borrowing (a nonrecourse obligation of the Company) is
secured by the joint venture’s real estate property with a fair value in excess of the loan amount and matures in 2021. The Company’s
indemnification obligation would require payment to the lender for any actual damages resulting from certain acts such as unauthorized
ownership transfers, misappropriation of rental payments by others or environmental damages. Based on initial and ongoing reviews of
property management and operations, the Company does not expect that payments will be required under this indemnification obligation.
Any payment that might be required could be recovered through a refinancing or sale of the assets. The Company also has recourse to the
partner for their proportionate share of amounts paid. There were no liabilities required for this indemnification obligation as of December 31,
2017.
The Company had indemnification obligations as of December 31, 2017 in connection with acquisition and disposition transactions. These
indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for
the presentation of financial statements, the filing of tax returns, compliance with law or the identification of outstanding litigation. These
obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In
some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price,
while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum
potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.
There were no liabilities for these indemnification obligations as of December 31, 2017.
D.
Guaranty Fund Assessments
The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty
association laws. The Company’s exposure to assessments for certain obligations of insolvent insurance companies to policyholders and
claimants is based on its share of business written in the relevant jurisdictions.
On March 1, 2017, the Commonwealth Court of Pennsylvania entered an order of liquidation of Penn Treaty Network America Insurance
Company, together with its subsidiary American Network Insurance Company (collectively ‘‘Penn Treaty’’, a long-term care insurance carrier),
triggering guaranty fund coverage and accrual of a liability. For the year ended December 31, 2017, the Company recorded in operating
expenses approximately $130 million pre-tax (approximately $85 million after-tax), representing its estimate of the total assessments, net of
premium tax offsets for insurance contracts currently written. Some of the assessments were recorded on a discounted basis, using a weighted
average discount rate of 3.5%. As of December 31, 2017, the recorded liability was approximately $55 million and total future cash outflows as of
December 31, 2017 are expected to approximate $65 million. This assessment is expected to be updated in future periods for changes in the
estimate of the insolvency. In addition, a portion of this assessment is expected to be offset in the future by premium tax credits that will be
recognized in the period received.
E.
Legal and Regulatory Matters
The Company is routinely involved in numerous claims, lawsuits, regulatory audits, investigations and other legal matters arising, for the most
part, in the ordinary course of managing a global health services business. Except for the specific matters noted below, the Company believes
that the legal actions, regulatory matters, proceedings and investigations currently pending against it should not have a material adverse effect
on the Company’s results of operations, financial condition or liquidity based upon our current knowledge and taking into consideration
current accruals. Disputed tax matters arising from audits by the Internal Revenue Service (‘‘IRS’’) or other state and foreign jurisdictions,
including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Further information on income tax
matters can be found in Note 20.
Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss are described
below. When litigation and regulatory matters present loss contingencies that are both probable and estimable, the Company accrues the
estimated loss by a charge to shareholders’ net income. The estimated loss is the Company’s best estimate of the probable loss at the time or an
amount within a range of estimated losses reflecting the most likely outcome or the minimum amount of the range (if no amount is better than
any other estimated amount in the range.) The Company provides disclosure in the aggregate for material pending litigation and legal or
regulatory matters, including accruals, range of loss, or a statement that such information cannot be estimated. Due to numerous uncertain
factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the
uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by
the Company. An adverse outcome in one or more of these matters could be material to the Company’s results of operations, financial
CIGNA CORPORATION - 2017 Form 10-K 103
PART II
ITEM 8. Financial Statements and Supplementary Data
condition or liquidity for any particular period. The Company had pre-tax reserves as of December 31, 2017 of $195 million ($155 million
after-tax) for the matters discussed below under ‘‘Litigation Matters.’’ Litigation related to the Company’s claim processing practices for a
commercial client, for which the Company held a reserve of $40 million pre-tax ($25 million after-tax) at September 30, 2016, was settled for
that amount during the fourth quarter of 2016.
Litigation Matters
In December 2001, Janice Amara filed a class action lawsuit in the U.S. District Court for the
Amara cash balance pension plan litigation.
District of Connecticut against Cigna Corporation and the Cigna Pension Plan (the ‘‘Plan’’) on behalf of herself and other similarly situated Plan
participants affected by the 1998 conversion to a cash balance formula. The plaintiffs allege various violations of the Employee Retirement
Income Security Act of 1974 (‘‘ERISA’’), including that the Plan’s cash balance formula discriminates against older employees; that the
conversion resulted in a wear-away period (when the pre-conversion accrued benefit exceeded the post-conversion benefit); and that the Plan
communications contained inaccurate or inadequate disclosures about these conditions.
In 2008, the District Court (1) affirmed the Company’s right to convert to a cash balance plan prospectively beginning in 1998; (2) found for
plaintiffs on the disclosure claim only; and (3) required the Company to pay pre-1998 benefits under the pre-conversion traditional annuity
formula and post-1997 benefits under the post-conversion cash balance formula. From 2008 through 2015, this case has undergone a series of
court proceedings that resulted in the original District Court order being largely upheld. In 2015, the Company submitted to the District Court
its proposed method for calculating the additional pension benefits due to class members and plaintiffs responded in August 2015.
In January 2016, the District Court ordered the method of calculating the additional pension benefits due to class members. The court order left
several aspects of the calculation of additional plan benefits open to interpretation. From that time through the present, both parties have
disputed various aspects of the Court’s interpretation and the Court has attempted to clarify. On July 14, 2017, the Court issued a ruling
clarifying certain aspects of the January 2016 order. The Plaintiffs filed a motion for reconsideration of the July 14, 2017 ruling that was denied
by the Court on November 7, 2017. The Company’s reserve for this litigation is adequate at December 31, 2017, based on calculations consistent
with the Company’s interpretation of the latest guidance from the Court. Due to the continuing inability of the parties to agree on the details of
calculating the pension benefits, the final timing of the resolution of this matter remains uncertain. Once these issues are resolved, the Plan will
be amended to comply with the District Court’s orders and the benefits will begin to be paid.
In April 2004, the Company was sued in a number of putative nationwide class actions alleging that the Company improperly
Ingenix.
underpaid claims for out-of-network providers through the use of data provided by Ingenix, Inc., a subsidiary of one of the Company’s
competitors. These actions were consolidated into Franco v. Connecticut General Life Insurance Company, et al., pending in the U.S. District
Court for the District of New Jersey. The consolidated amended complaint, filed in 2009 on behalf of subscribers, health care providers and
various medical associations, asserted claims related to benefits and disclosure under ERISA, the Racketeer Influenced and Corrupt
Organizations (‘‘RICO’’) Act, the Sherman Antitrust Act and New Jersey state law and seeks recovery for alleged underpayments from 1998
through the present. Other major health insurers have been the subject of, or have settled, similar litigation.
In September 2011, the District Court (1) dismissed all claims by the health care provider and medical association plaintiffs for lack of standing;
and (2) dismissed the antitrust claims, the New Jersey state law claims and the ERISA disclosure claim. In January 2013 and again in April 2014,
the District Court denied separate motions by the plaintiffs to certify a nationwide class of subscriber plaintiffs. The Third Circuit denied
plaintiffs’ request for an immediate appeal of the January 2013 ruling. As a result, the case is proceeding on behalf of the named plaintiffs only.
In June 2014, the District Court granted the Company’s motion for summary judgment to terminate all claims, and denied the plaintiffs’ partial
motion for summary judgment. In July 2014, the plaintiffs appealed all of the District Court’s decisions in favor of the Company, including the
class certification decision, to the Third Circuit. On May 2, 2016, the Third Circuit affirmed the District Court’s decisions denying class
certification for the claims asserted by members, the granting of summary judgment on the individual plaintiffs’ claims, as well as the dismissal
of the antitrust claims. However, the Third Circuit also reversed the earlier dismissal of the providers’ ERISA claims. The Company will continue
to vigorously defend its position.
Regulatory Matters
Civil Investigative Demand. The U.S. Department of Justice (‘‘DOJ’’) is currently conducting an industry review of the risk adjustment data
submission practices and business processes, including review of medical charts, of Medicare Advantage organizations under Medicare Parts C
and D. In connection with this industry review, in December 2016, the Company received a Civil Investigative Demand from the Civil Division of
the DOJ. We are in the process of voluntarily cooperating with the DOJ’s request and responding to the information request.
Disability claims regulatory matter. During the second quarter of 2013, the Company finalized an agreement with the Departments of
Insurance for Maine, Massachusetts, Pennsylvania, Connecticut and California (together, the ‘‘monitoring states’’) related to the Company’s
long-term disability claims handling practices. The agreement requires primarily: (1) enhanced procedures related to documentation and
disposition and (2) a two-year monitoring period followed by a re-examination that began in the second quarter of 2016. Management believes
the Company has addressed the requirements of the agreement. If the monitoring states find material non-compliance with the agreement
upon re-examination, the Company may be subject to additional costs and penalties or requests to change its business practices that could
negatively impact future earnings for this business.
Other Legal Matters
In February 2017, the Company delivered a notice to Anthem terminating the merger agreement, and notifying
Litigation with Anthem.
Anthem that it must pay the Company the $1.85 billion reverse termination fee pursuant to the terms of the merger agreement. Also in
February 2017, the Company filed suit against Anthem in the Delaware Court of Chancery (the ‘‘Chancery Court’’) seeking declaratory
judgments that the Company’s termination of the merger agreement was valid and that Anthem was not permitted to extend the termination
date. The complaint also sought payment of the reverse termination fee and additional damages in an amount exceeding $13 billion, including
the lost premium value to the Company’s shareholders caused by Anthem’s willful breaches of the merger agreement.
104 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 8. Financial Statements and Supplementary Data
Also in February 2017, Anthem filed a lawsuit in the Chancery Court against the Company seeking (i) a temporary restraining order to enjoin
Cigna from terminating and taking any action contrary to the terms of the merger agreement, (ii) specific performance compelling Cigna to
comply with the merger agreement and (iii) damages.
On February 15, 2017, the Chancery Court granted Anthem’s motion for a temporary restraining order and temporarily enjoined the Company
from terminating the merger agreement. In May 2017, the Chancery Court denied Anthem’s motion for a preliminary injunction to enjoin Cigna
from terminating the merger agreement but stayed its ruling pending Anthem’s determination as to whether to seek an appeal. Anthem
subsequently notified Cigna and the Chancery Court that it did not intend to appeal the Chancery Court’s decision. As a result, the merger
agreement was terminated.
The litigation between the parties remains pending. Trial is scheduled for 2019. We believe in the merits of our claims and dispute Anthem’s
claims, and we intend to vigorously defend ourselves and pursue our claims. The outcomes of lawsuits are inherently unpredictable, and we
may be unsuccessful in the ongoing litigation or any future claims or litigation.
NOTE 22
See Note 1 for a description of our reporting segments.
Segment Information
In the Company’s segment disclosures, we present ‘‘operating revenues,’’ defined as total revenues excluding realized investment results. The
Company excludes realized investment results from this measure because its portfolio managers may sell investments based on factors largely
unrelated to the underlying business purposes of each segment. As a result, gains or losses created in this process may not be indicative of past
or future underlying performance of the business.
The Company uses ‘‘adjusted income from operations’’ as its principal financial measure of segment operating performance because
management believes it best reflects the underlying results of business operations and permits analysis of trends in underlying revenue,
expenses and profitability. Adjusted income from operations is defined as shareholders’ net income excluding after-tax realized investment
gains and losses, net amortization of other acquired intangible assets and special items. Income or expense amounts are excluded from
adjusted income from operations for the following reasons:
•
•
•
Realized investment results are excluded because, as noted above, our portfolio managers may sell investments based on factors largely
unrelated to the underlying business purposes of each segment.
Net amortization of other intangible assets is excluded because it relates to costs incurred for acquisitions and, as a result, it does not relate to
the core performance of the Company’s business operations. In 2015, the amortization amount was net of a bargain purchase gain on an
acquisition.
Special items, if any, are excluded because management believes they are not representative of the underlying results of operations. This is
generally because the nature and size of these matters are not indicative of our ongoing business operations. Additional details about these
items that provide further context as to why they are not considered indicative of ongoing business operations may be found in the footnotes
referenced in the table below.
The following table presents the special items recorded by the Company for the years ended December 31, 2017, 2016 and 2015.
(In millions)
Description of Special Item and Financial Statement Line Item(s)
Year ended December 31, 2017
Charges associated with U.S. tax reform
– Other operating expenses (see Note 20 for details)
– Tax expense (see Note 20 for details)
Total charges associated with U.S. tax reform
Debt extinguishment costs (Other operating expenses, see Note 5 for details)
Long-term care guaranty fund assessment (Other operating expenses, see Note 21(D) for details)
Transaction-related costs (Other operating expenses, see Note 3 for details)
Year ended December 31, 2016
Transaction-related costs (Other operating expenses, see Note 3 for details)
Risk corridor allowance (Other operating expenses, see page 107 in this Note for details)
Charges associated with litigation matters (Other operating expenses, see Note 21(E) for a discussion of litigation charges)
Year ended December 31, 2015
Debt extinguishment costs (Other operating expenses, see Note 5 for details)
Transaction-related costs (Other operating expenses, see Note 3 for details)
After-tax
Before-tax
$
$
$
$
$
$
$
$
$
$
(36)
232
196
209
83
33
147
80
25
65
57
$
$
$
$
$
$
$
$
$
$
(56)
–
(56)
321
129
126
166
124
40
100
66
CIGNA CORPORATION - 2017 Form 10-K 105
PART II
ITEM 8. Financial Statements and Supplementary Data
Summarized segment financial information for the years ended December 31, was as follows:
(In millions)
2017
Premiums
Fees and other revenues(1)
Net investment income
Mail order pharmacy revenues
Total operating revenues
Net realized investment gains (losses)
Total revenues
Depreciation and amortization
Total benefits and expenses
Income (loss) before income taxes
Income taxes (benefits) and net loss attributable to noncontrolling
interests
Shareholders’ net income (loss) by segment
After-tax adjustments to reconcile to adjusted income from
operations
Net realized investment (gains) losses
Amortization of other acquired intangible assets, net
Special items
U.S. tax reform
Debt extinguishment costs
Long-term care guaranty fund assessment
Transaction-related costs
Global Health
Care
Global
Supplemental
Benefits
Group
Disability
Other
and Life Operations Corporate
Total
$
$
24,538
4,722
378
2,979
32,617
136
32,753
477
29,440
3,313
1,031
2,282
(88)
48
(137)
–
68
–
$
3,684
66
122
–
3,872
32
3,904
54
3,407
497
195
302
(24)
18
73
–
–
–
$
3,985
106
350
–
4,441
74
4,515
30
4,044
471
113
358
(49)
–
(39)
–
15
–
$
112
10
346
–
468
(5)
463
1
316
147
222
(75)
4
–
138
–
–
–
(12)
(37)
30
–
(19)
–
(19)
4
$ 32,307
4,867
1,226
2,979
41,379
237
41,616
566
803
38,010
(822)
3,606
(192)
(630)
1,369
2,237
1
–
161
209
–
33
(156)
66
196
209
83
33
Adjusted income (loss) from operations
$
2,173
$
369
$
285
$
67
$
(226)
$ 2,668
(In millions)
2016
Premiums
Fees and other revenues(1)
Net investment income
Mail order pharmacy revenues
Total operating revenues
Net realized investment gains
Total revenues
Depreciation and amortization
Total benefits and expenses
Income (loss) before taxes
Income taxes (benefits) and net loss attributable to noncontrolling
interests
Shareholders’ net income (loss) by segment
After-tax adjustments to reconcile to adjusted income from
operations
Net realized investment (gains)
Amortization of other acquired intangible assets, net
Special items
Transaction-related costs
Risk corridor allowance
Charges associated with litigation matters
Global
Global Health Supplemental
Benefits
Care
Group
Disability
Other
and Life Operations Corporate
Total
$
23,295 $
4,623
315
2,966
3,226 $
49
110
–
4,002 $
98
343
–
103 $
11
358
–
– $ 30,626
4,760
1,147
2,966
(21)
21
–
31,199
119
31,318
526
28,467
2,851
1,100
1,751
(78)
74
–
80
25
3,385
(5)
3,380
54
3,052
328
60
268
6
20
–
–
–
4,443
59
4,502
28
4,273
229
65
164
(39)
–
–
–
–
472
(5)
467
1
369
98
30
68
2
–
–
–
–
–
1
1
1
39,499
169
39,668
610
528
36,689
(527)
2,979
(143)
(384)
–
–
147
–
–
1,112
1,867
(109)
94
147
80
25
Adjusted income (loss) from operations
$
1,852 $
294 $
125 $
70 $
(237) $ 2,104
(1)
Includes the Company’s share of the earnings of its joint ventures in China and India in the Global Supplemental Benefits segment.
106 CIGNA CORPORATION - 2017 Form 10-K
(In millions)
2015
Premiums
Fees and other revenues(1)
Net investment income
Mail order pharmacy revenues
Total operating revenues
Net realized investment gains
Total revenues
Depreciation and amortization
Total benefits and expenses
Income (loss) before taxes
Income taxes (benefits) and net income attributable to noncontrolling
interests
Shareholders’ net income (loss) by segment
After-tax adjustments to reconcile to adjusted income from
operations
Net realized investment (gains)
Amortization of other acquired intangible assets, net(2)
Special items
Debt extinguishment costs
Transaction-related costs
PART II
ITEM 8. Financial Statements and Supplementary Data
Global
Global Health Supplemental
Benefits
Care
Group
Disability
Other
and Life Operations Corporate
Total
$
22,696 $
4,357
340
2,536
29,929
43
29,972
526
27,028
2,944
1,150
1,794
(30)
84
–
–
3,000 $
46
103
–
3,843 $
91
337
–
103 $
13
369
–
– $ 29,642
4,488
1,153
2,536
(19)
4
–
3,149
–
3,149
31
2,849
300
33
267
(1)
(4)
–
–
4,271
5
4,276
26
3,796
480
152
328
(4)
–
–
–
485
9
494
1
374
120
40
80
(5)
–
–
–
(15)
–
(15)
1
37,819
57
37,876
585
502
34,549
(517)
3,327
(142)
(375)
1,233
2,094
–
–
65
57
(40)
80
65
57
Adjusted income (loss) from operations
$
1,848 $
262 $
324 $
75 $
(253) $ 2,256
(1)
Includes the Company’s share of the earnings of its joint ventures in China and India in the Global Supplemental Benefits segment.
(2) Includes a $23 million bargain purchase gain for a 2015 acquisition.
Revenue from external customers includes premiums, fees and other revenues and mail order pharmacy revenues. The following table presents
these revenues by product type for the years ended December 31:
(In millions)
Global Health Care premiums by product:
Guaranteed cost
Experience-rated
Stop loss
International health care
Dental
Medicare
Medicaid
Medicare Part D
Other
Total premiums
Fees
Total Global Health Care premiums and fees
Disability
Life, Accident and Supplemental Health
Mail order pharmacy
Other
Total
2017
2016
2015
$
6,245
2,741
3,483
1,934
1,791
5,534
1,061
764
985
24,538
4,503
29,041
2,091
5,704
2,979
338
$
4,610
2,383
3,082
1,859
1,586
6,621
1,146
1,122
886
23,295
4,368
27,663
2,045
5,300
2,966
378
$
4,761
2,329
2,701
1,834
1,392
6,142
1,102
1,589
846
22,696
4,107
26,803
1,899
5,054
2,536
374
$
40,153
$
38,352
$
36,666
Foreign and U.S. revenues from external customers for the three years ended December 31 are shown below. The Company’s foreign revenues
are generated by its foreign operating entities. In the periods shown, no foreign country contributed more than 5% of consolidated revenues
from external customers.
(In millions)
United States
South Korea
All other foreign countries
Total
2017
36,128
1,892
2,133
40,153
$
$
2016
34,672
1,666
2,014
$
2015
33,185
1,521
1,960
38,352
$
36,666
$
$
The Company had net receivables from CMS of $0.5 billion as of December 31, 2017 and $0.6 billion as of December 31, 2016. These amounts
were included in premiums, accounts and notes receivable and reinsurance recoverables. As a percentage of consolidated revenues, premiums
and fees from CMS were 17% in 2017, 20% in 2016 and 21% in 2015. These amounts were reported in the Global Health Care segment.
In 2016, the Company recorded an allowance for the balance of its risk corridor receivable from CMS of $124 million based on court decisions
and the large risk corridor program deficit. As of December 31, 2017, the Company continues to hold an allowance for the balance of its risk
corridor receivable of $109 million based on the current status of court decisions. However, the Company continues to believe that the
government has a binding obligation to satisfy the risk corridor receivable.
CIGNA CORPORATION - 2017 Form 10-K 107
PART II
ITEM 8. Financial Statements and Supplementary Data
Quarterly Financial Data (unaudited)
The following unaudited quarterly financial data is presented on a consolidated basis for each of the years ended December 31, 2017 and
December 31, 2016. Quarterly financial results necessarily rely heavily on estimates. This and certain other factors, such as the seasonal nature
of portions of the insurance business, suggest the need to exercise caution in drawing specific conclusions from quarterly consolidated results.
(In millions, except per share amounts)
Consolidated Results
2017
Total revenues
Income before income taxes
Shareholders’ net income
Shareholders’ net income per share
Basic
Diluted
2016
Total revenues
Income before income taxes
Shareholders’ net income
Shareholders’ net income per share
Basic
Diluted
Stock and dividend data
2017
Price range of common stock – high
– low
Dividends declared per common share
2016
Price range of common stock – high
– low
Dividends declared per common share
Three Months Ended
March 31,
June 30,
September 30,
December 31,
$
$
$
$
$
$
$
$
10,385
890
598(1)
2.34
2.30
9,884
819
519(1)
2.04
2.00
154.83
133.52
0.04
147.93
123.54
0.04
$
$
$
$
$
$
$
$
10,318
1,134
813(1)
3.20
3.15
9,960
813
510(1)
2.00
1.97
173.21
146.70
–
142.91
121.87
–
$
$
$
$
$
$
$
$
10,382
824
560(1)
2.25
2.21
9,880
742
456(1)
1.79
1.76
188.36
166.81
–
148.99
123.53
–
$
$
$
$
$
$
$
$
10,531
758
266(1)
1.09
1.07
9,944
605
382(1)
1.49
1.47
212.46
183.08
–
142.00
115.03
–
(1) Shareholders’ net income includes the following after-tax charges (benefits), described in Note 22 to the Consolidated Financial Statements:
2017 U.S. tax reform
2017 Debt extinguishment costs
2017 Long-term care guaranty fund assessment
2017 Transaction-related costs
Total 2017 charges (benefits)
2016 Risk corridor allowance
2016 Transaction-related costs
2016 Charges associated with litigation matters
Total 2016 charges
March 31,
June 30,
September 30,
December 31,
–
–
83
49
132
–
36
–
36
$
$
$
$
–
–
–
(47)
(47)
–
26
–
26
$
$
$
$
–
209
–
6
215
–
46
25
71
$
$
$
$
196
–
–
25
221
80
39
–
119
$
$
$
$
108 CIGNA CORPORATION - 2017 Form 10-K
PART II
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
ITEM 9.
None.
Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure
ITEM 9A.
Controls and Procedures
Disclosure Controls and Procedures
A.
Based on an evaluation of the effectiveness of Cigna’s disclosure controls and procedures conducted under the supervision and with the
participation of Cigna’s management, Cigna’s Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period
covered by this report, Cigna’s disclosure controls and procedures are effective to ensure that information required to be disclosed by Cigna in
the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the SEC’s rules and forms.
B.
Internal Control Over Financial Reporting
Management’s Annual Report on Internal Control over Financial Reporting
Management of Cigna Corporation is responsible for establishing and maintaining adequate internal controls over financial reporting. The
Company’s internal controls were designed to provide reasonable assurance to the Company’s management and Board of Directors that the
Company’s consolidated published financial statements for external purposes were prepared in accordance with accounting principles
generally accepted in the United States. The Company’s internal control over financial reporting includes those policies and procedures that:
(i)
(ii)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
and liabilities of the Company;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
accounting principles generally accepted in the United States, and that receipts and expenditures of the Company are being made only in
accordance with authorization of management and directors of the Company; and
(iii)
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the Company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Management assessed the effectiveness of the Company’s internal controls over financial reporting as of December 31, 2017. In making this
assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (‘‘COSO’’) in
Internal Control-Integrated Framework (2013). Based on management’s assessment and the criteria set forth by COSO, it was determined that
the Company’s internal controls over financial reporting are effective as of December 31, 2017.
The Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company’s
internal control over financial reporting, as stated in their report located on page 57 in this Form 10-K.
ITEM 9B.
Other Information
None.
CIGNA CORPORATION - 2017 Form 10-K 109
PART III
ITEM 10. Directors, Executive Officers and Corporate Governance
PART III
ITEM 10.
Directors, Executive Officers and Corporate
Governance
Directors of the Registrant
A.
The information under the captions ‘‘Corporate Governance Matters – Process for Director Elections,’’ ‘‘ – Board of Directors’ Nominees’’ and
‘‘ – Board Meetings and Committees’’ (as it relates to Audit Committee disclosure) in Cigna’s definitive proxy statement related to the 2018
annual meeting of shareholders is incorporated by reference.
Executive Officers of the Registrant
B.
See PART I – ‘‘Executive Officers of the Registrant’’ on page 31 in this Form 10-K.
Code of Ethics and Other Corporate Governance Disclosures
C.
The information under the caption ‘‘Corporate Governance Matters – Codes of Ethics’’ in Cigna’s definitive proxy statement related to the 2018
annual meeting of shareholders is incorporated by reference.
D. Section 16(a) Beneficial Ownership Reporting Compliance
The information under the caption ‘‘Ownership of Cigna Common Stock – Section 16(a) Beneficial Ownership Reporting Compliance’’ in
Cigna’s definitive proxy statement related to the 2018 annual meeting of shareholders is incorporated by reference.
ITEM 11.
Executive Compensation
The information under the captions ‘‘Corporate Governance Matters – Non-Employee Director Compensation,’’ ‘‘Compensation Matters –
Compensation Discussion and Analysis,’’ ‘‘ – Report of the People Resources Committee’’ and ‘‘ – Executive Compensation Tables’’ in Cigna’s
definitive proxy statement related to the 2018 annual meeting of shareholders is incorporated by reference.
110 CIGNA CORPORATION - 2017 Form 10-K
PART III
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
ITEM 12.
Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters
The following table presents information regarding Cigna’s equity compensation plans as of December 31, 2017:
Plan Category
Equity Compensation Plans Approved by Security Holders
Equity Compensation Plans Not Approved by Security Holders
Total
(a) (1)
Securities To Be Issued
Upon Exercise Of
Outstanding Options,
Warrants And Rights
(b) (2)
Weighted Average
Exercise Price Per
Share Of
Outstanding Options,
Warrants And Rights
7,959,003
–
7,959,003
$
$
100.79
–
100.79
(c) (3)
Securities Remaining
Available For Future
Issuance Under Equity
Compensation Plans
(Excluding Securities
Reflected In Column (a))
14,262,573
–
14,262,573
(1)
Includes, in addition to outstanding stock options, 139,124 restricted stock units, 108,113 deferred shares and 1,555,460 strategic performance shares that are reported at the maximum
200% payout rate. Also includes 140,744 shares of common stock underlying stock option awards granted under the HealthSpring, Inc. Amended and Restated 2006 Equity Incentive
Plan which was approved by HealthSpring, Inc.’s shareholders before Cigna’s acquisition of HealthSpring, Inc. in January 2012.
(2) The weighted-average exercise price is based only on outstanding stock options. The outstanding stock options assumed due to Cigna’s acquisition of HealthSpring, Inc. have a weighted-
average exercise price of $22.45. Excluding these assumed options results in a weighted-average exercise price of $102.62.
(3) Includes 248,185 shares of common stock available as of the close of business December 31, 2017 for future issuance under the Cigna Directors Equity Plan and 14,014,388 shares of
common stock available as of the close of business on December 31, 2017 for future issuance under the Cigna Long-Term Incentive Plan.
The information under the captions ‘‘Ownership of Cigna Common Stock — Stock Held by Directors, Nominees and Executive Officers’’ and
‘‘Ownership of Cigna Common Stock – Stock Held by Certain Beneficial Owners’’ in Cigna’s definitive proxy statement related to the 2018
annual meeting of shareholders is incorporated by reference.
ITEM 13.
Certain Relationships and Related Transactions, and
Director Independence
The information under the captions ‘‘Corporate Governance Matters – Director Independence’’ and ‘‘ – Certain Transactions’’ in Cigna’s
definitive proxy statement related to the 2018 annual meeting of shareholders is incorporated by reference.
ITEM 14.
Principal Accountant Fees and Services
The information under the captions ‘‘Audit Matters – Policy for the Pre-Approval of Audit and Non-Audit Services’’ and ‘‘ – Fees to Independent
Registered Public Accounting Firm’’ in Cigna’s definitive proxy statement related to the 2018 annual meeting of shareholders is incorporated by
reference.
CIGNA CORPORATION - 2017 Form 10-K 111
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
PART IV
ITEM 15.
Exhibits and Financial Statement Schedules
(a)
(1) The following Financial Statements appear on pages 57 through 107:
Report of Independent Registered Public Accounting Firm.
Consolidated Statements of Income for the years ended December 31, 2017, 2016 and 2015.
Consolidated Statements of Comprehensive Income for the years ended December 31, 2017, 2016 and 2015.
Consolidated Balance Sheets as of December 31, 2017 and 2016.
Consolidated Statements of Changes in Total Equity for the years ended December 31, 2017, 2016 and 2015.
Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016 and 2015.
Notes to the Consolidated Financial Statements.
(2) The financial statement schedules are listed in the Index to Financial Statement Schedules on page FS-1.
(b)
The exhibits listed in the accompanying ‘‘Index to Exhibits’’ in this Item 15 are filed or incorporated by reference as part of this Annual
Report on Form 10-K.
112 CIGNA CORPORATION - 2017 Form 10-K
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Index to Exhibits
Number
Description
Method of Filing
3.1
3.2
4.1
4.2
4.3
Restated Certificate of Incorporation of the registrant as last
amended October 28, 2011
By-Laws of the registrant as last amended and restated December 7,
2017
Indenture dated August 16, 2006 between Cigna Corporation and U.S.
Bank National Association
(a)
(b) Supplemental Indenture No. 1 dated November 10, 2006 between
Cigna Corporation and U.S. Bank National Association
(c) Supplemental Indenture No. 2 dated March 15, 2007 between Cigna
Corporation and U.S. Bank National Association
(d) Supplemental Indenture No. 3 dated March 7, 2008 between Cigna
Corporation and U.S. Bank National Association
(f) Supplemental Indenture No. 5 dated May 17, 2010 between Cigna
Corporation and U.S. Bank National Association
(g) Supplemental Indenture No. 6 dated December 8, 2010 between
Cigna Corporation and U.S. Bank National Association
(h) Supplemental Indenture No. 7 dated March 7, 2011 between Cigna
Corporation and U.S. Bank National Association
(i) Supplemental Indenture No. 8 dated November 10, 2011 between
Cigna Corporation and U.S. Bank National Associated
(j) Supplemental Indenture No. 9 dated as of March 20, 2015, between
Cigna Corporation and U.S. Bank National Association, as trustee.
(k) Supplemental Indenture No. 10 dated as of September 14, 2017
between Cigna Corporation and U.S. Bank National Association, as
trustee
Indenture dated January 1, 1994 between Cigna Corporation and
Marine Midland Bank
Indenture dated June 30, 1988 between Cigna Corporation and
Bankers Trust
Filed as Exhibit 3.1 to the registrant’s Form 10-Q for the quarterly
period ended September 30, 2011 and incorporated herein by
reference.
Filed as Exhibit 3.1 to the registrant’s Form 8-K filed on December 13,
2017 and incorporated herein by reference.
Filed as Exhibit 4.1(a) to the registrant’s Form 10-K for the year ended
December 31, 2012 and incorporated herein by reference.
Filed as Exhibit 4.1(b) to the registrant’s Form 10-K for the year ended
December 31, 2012 and incorporated herein by reference.
Filed as Exhibit 4.1(c) to the registrant’s Form 10-Q for the quarterly
period ended March 31, 2011 and incorporated herein by reference.
Filed as Exhibit 4.1 to the registrant’s Form 8-K on March 10, 2008
and incorporated herein by reference.
Filed as Exhibit 99.2 to the registrant’s Form 8-K on May 28, 2010 and
incorporated herein by reference.
Filed as Exhibit 99.2 to the registrant’s Form 8-K on December 9,
2010 and incorporated herein by reference.
Filed as Exhibit 99.2 to the registrant’s Form 8-K on March 8, 2011 and
incorporated herein by reference.
Filed as Exhibit 4.1 to the registrant’s Form 8-K on November 14, 2011
and incorporated herein by reference.
Filed as Exhibit 4.1 to the registrant’s Form 8-K on March 26, 2015 and
incorporated herein by reference.
Filed as Exhibit 4.1 to the registrant’s Form 8-K filed September 14,
2017 and incorporated herein by reference.
Filed as Exhibit 4.2 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 4.3 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
Exhibits 10.1 through 10.36 are identified as compensatory plans, management contracts or arrangements pursuant to Item 15 of
Form 10-K.
10.1
Deferred Compensation Plan for Directors of Cigna Corporation, as
amended and restated January 1, 1997
Deferred Compensation Plan of 2005 for Directors of Cigna
Corporation, Amended and Restated effective April 28, 2010
Cigna Corporation Non-Employee Director Compensation Program
amended and restated effective February 26, 2014
Cigna Restricted Share Equivalent Plan for Non-Employee Directors
as amended and restated effective January 1, 2008
Cigna Corporation Director Equity Plan
Cigna Corporation Stock Plan, as amended and restated through July
2000
Cigna Stock Unit Plan, as amended and restated effective
February 22, 2017
Cigna Executive Severance Benefits Plan as amended and restated
effective April 27, 2010
Description of Severance Benefits for Executives in Non-Change of
Control Circumstances
Filed as Exhibit 10.1 to the registrant’s Form 10-K for the year ended
December 31, 2011 and incorporated herein by reference.
Filed as Exhibit 10.2 to the registrant’s Form 10-K for the year ended
December 31, 2010 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 10-Q for the quarterly
period ended March 31, 2014 and incorporated herein by reference.
Filed as Exhibit 10.4 to the registrant’s Form 10-K for the year ended
December 31, 2012 and incorporated herein by reference.
Filed as Exhibit 10.3 to the registrant’s Form 10-Q for the quarterly
period ended March 31, 2010 and incorporated herein by reference.
Filed as Exhibit 10.7 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 10.5 to the registrant’s Form 10-Q for the quarterly
period ended March 31, 2017 and incorporated herein by reference.
Filed as Exhibit 10.2 to the registrant’s Form 10-Q for the quarterly
period ended June 30, 2010 and incorporated herein by reference.
Filed as Exhibit 10.10 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
CIGNA CORPORATION - 2017 Form 10-K 113
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Number
Description
Method of Filing
10.10
10.11
10.12
10.13
Cigna Executive Incentive Plan amended and restated as of January 1,
2012
Cigna Long-Term Incentive Plan as amended and restated effective as
of April 26, 2017
Cigna Deferred Compensation Plan, as amended and restated
October 24, 2001
Cigna Deferred Compensation Plan of 2005 effective as of January 1,
2005
10.14
(a) Cigna Supplemental Pension Plan as amended and restated effective
August 1, 1998
(b) Amendment No. 1 to the Cigna Supplemental Pension Plan, amended
and restated effective as of September 1, 1999
(c) Amendment No. 2 dated December 6, 2000 to the Cigna
Supplemental Pension
10.15
(a) Cigna Supplemental Pension Plan of 2005 effective as of January 1,
2005
(b) Amendment No. 1 to the Cigna Supplemental Pension Plan of 2005
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
10.26
10.27
10.28
10.29
10.30
Cigna Supplemental 401(k) Plan effective January 1, 2010
Description of Cigna Corporation Financial Services Program
Form of Cigna Long-Term Incentive Plan: Strategic Performance Share
Grant Agreement
Form of Cigna Long-Term Incentive Plan: Nonqualified Stock Option
Grant Agreement
Form of Cigna Long-Term Incentive Plan: Restricted Stock Grant
Agreement
Form of Cigna Long-Term Incentive Plan: Restricted Stock Unit Grant
Agreement
Offer Letter for Eric P. Palmer dated June 16, 2017
Schedule regarding Amended Deferred Stock Unit Agreements
effective December 31, 2008 with John M. Murabito and Form of
Amended Deferred Stock Unit Agreement
Nicole Jones’ Offer of Employment dated April 27, 2011
Matthew Manders’ Promotion Letter dated June 2, 2014
Agreement and Release between the Company and Matthew G.
Manders dated October 16, 2017
Thomas A. McCarthy’s Offer Letter dated May 9, 2013
Agreement and Release between the Company and Thomas A.
McCarthy dated June 16, 2017
Advisory Services Agreement between the Company and Thomas A.
McCarthy dated June 16, 2017
Employment Agreement for Jason D. Sadler dated May 7, 2010
Filed as Exhibit 10.1 to the registrant’s Form 10-Q for the quarterly
period ended March 31, 2012 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed May 1, 2017 and
incorporated herein by reference.
Filed as Exhibit 10.14 to the registrant’s Form 10-K for the year ended
December 31, 2011 and incorporated herein by reference.
Filed as Exhibit 10.15 to the registrant’s Form 10-K for the year ended
December 31, 2012 and incorporated herein by reference.
Filed as Exhibit 10.15(a) to the registrant’s Form 10-K for the year
ended December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 10.15(b) to the registrant’s Form 10-K for the year
ended December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 10.16(c) to the registrant’s Form 10-K for the year
ended December 31, 2011 and incorporated herein by reference.
Filed as Exhibit 10.15 to the registrant’s Form 10-K for the year ended
December 31, 2007 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 10-Q for the quarterly
period ended June 30, 2009 and incorporated herein by reference.
Filed as Exhibit 10.17 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 10.18 to the registrant’s Form 10-K for the year ended
December 31, 2009 and incorporated herein by reference.
Filed as Exhibit 10.2 to the registrant’s Form 10-Q for the period
ended March 31, 2017 and incorporated herein by reference.
Filed as Exhibit 10.3 to the registrant’s Form 10-Q for the period
ended March 31, 2017 and incorporated herein by reference.
Filed as Exhibit 10.4 to the registrant’s Form 10-Q for the period
ended March 31, 2017 and incorporated herein by reference.
Filed as Exhibit 10.6 to the registrant’s Form 10-Q for the period
ended March 31, 2017 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed June 19, 2017
and incorporated herein by reference.
Filed as Exhibit 10.20 to the registrant’s Form 10-K for the year ended
December 31, 2008 and incorporated herein by reference.
Filed as Exhibit 10.2 to the registrant’s Form 10-Q for the period
ended March 31, 2012 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed on June 4, 2014
and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed October 18, 2017
and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed on May 13, 2013
and incorporated herein by reference.
Filed as Exhibit 10.2 to the registrant’s Form 8-K filed June 19, 2017
and incorporated herein by reference.
Filed as Exhibit 10.3 to the registrant’s Form 8-K filed June 19, 2017
and incorporated herein by reference.
Filed as Exhibit 10.1(a) to the registrant’s Form 10-Q for the period
ended March 31, 2015 and incorporated herein by reference.
114 CIGNA CORPORATION - 2017 Form 10-K
Number
Description
Method of Filing
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
10.31
10.32
10.33
10.34
10.35
10.36
10.37
12
21
23
31.1
31.2
32.1
32.2
101
Promotion letter for Jason Sadler dated June 2, 2014
Agreement and Release between Cigna Corporation and Herbert A.
Fritch dated October 20, 2016
Advisory Services Agreement between Cigna Corporation and
Herbert A. Fritch dated October 20, 2016
HealthSpring, Inc. Amended and Restated 2006 Equity Incentive Plan
(the ‘‘HealthSpring Equity Incentive Plan’’)
HealthSpring Equity Incentive Plan: Form of Restricted Share Award
HealthSpring Equity Incentive Plan: Form of Non-Qualified Stock
Option Agreement
Master Transaction Agreement, dated February 4, 2013 among
Connecticut General Life Insurance Company, Berkshire Hathaway Life
Insurance Company of Nebraska and, solely for purposes of
Sections 3.10, 6.1, 6.3, 6.4, 6.6, 6.9 and Articles II, V, VII, and VIII,
thereof, National Indemnity Company (including the Forms of
Retrocession Agreement, the Collateral Trust Agreement, the Security
and Control Agreement, the Surety Policy and the ALC Model
Purchase Option Agreement as exhibits)
Computation of Ratios of Earnings to Fixed Charges
Subsidiaries of the Registrant
Consent of Independent Registered Public Accounting Firm
Certification of Chief Executive Officer of Cigna Corporation pursuant
to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of
1934
Certification of Chief Financial Officer of Cigna Corporation pursuant
to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of
1934
Certification of Chief Executive Officer of Cigna Corporation pursuant
to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350
Certification of Chief Financial Officer of Cigna Corporation pursuant
to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350
The following materials from Cigna Corporation’s Annual Report on
Form 10-K for the year ended December 31, 2017, formatted in XBRL
(Extensible Business Reporting Language): (i) the Consolidated
Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the
Consolidated Statements of Comprehensive Income; (iv) the
Consolidated Statements of Cash Flows; (v) the Consolidated
Statements of Changes in Total Equity; (vi) the Notes to Consolidated
Financial Statements and (vii) Financial Statement Schedules I, II, III,
IV and V.
Filed as Exhibit 10.1(b) to the registrant’s Form 10-Q for the period
ended March 31, 2015 and incorporated herein by reference.
Filed as Exhibit 10.1 to the registrant’s Form 8-K filed on October 21,
2016 and incorporated herein by reference
Filed as Exhibit 10.2 to the registrant’s Form 8-K filed on October 21,
2016 and incorporated herein by reference
Filed as Exhibit 10.3 to the registrant’s Form 10-Q for the period
ended March 31, 2013 and incorporated herein by reference.
Filed as Exhibit 10.4 to the registrant’s Form 10-Q for the period
ended March 31, 2013 and incorporated herein by reference.
Filed as Exhibit 10.5 to the registrant’s Form 10-Q for the period
ended March 31, 2013 and incorporated herein by reference.
Filed as Exhibit 10.29 to the registrant’s Form 10-K for the year ended
December 31, 2012 and incorporated herein by reference.
Filed herewith.
Filed herewith.
Filed herewith.
Filed herewith.
Filed herewith.
Furnished herewith.
Furnished herewith.
Filed herewith.
The registrant will furnish to the Commission upon request of any other instruments defining the rights of holders of long-term debt.
Shareholders may obtain copies of exhibits by writing to Cigna Corporation, Shareholder Services Department, 1601 Chestnut Street,
Philadelphia, PA 19192.
ITEM 16.
10-K Summary
None.
CIGNA CORPORATION - 2017 Form 10-K 115
PART IV
ITEM 15. Signatures
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
CIGNA CORPORATION
Date:
By:
February 28, 2018
/s/ ERIC P. PALMER
Eric P. Palmer
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities indicated as of February 28, 2018.
Signature
/s/ DAVID M. CORDANI
David M. Cordani
/s/ ERIC P. PALMER
Eric P. Palmer
/s/ MARY T. AGOGLIA HOELTZEL
Mary T. Agoglia Hoeltzel
/s/ ERIC J. FOSS
Eric J. Foss
/s/ ISAIAH HARRIS, JR.
Isaiah Harris, Jr.
/s/ JANE E. HENNEY, M.D.
Jane E. Henney, M.D.
/s/ ROMAN MARTINEZ IV
Roman Martinez IV
/s/ JOHN M. PARTRIDGE
John M. Partridge
/s/ JAMES E. ROGERS
James E. Rogers
/s/ ERIC C. WISEMAN
Eric C. Wiseman
/s/ DONNA F. ZARCONE
Donna F. Zarcone
/s/ WILLIAM D. ZOLLARS
William D. Zollars
Title
Chief Executive Officer and Director (Principal Executive Officer)
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
Vice President and Chief Accounting Officer (Principal Accounting Officer)
Director
Chairman of the Board
Director
Director
Director
Director
Director
Director
Director
116 CIGNA CORPORATION - 2017 Form 10-K
Cigna Corporation and Subsidiaries
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
INDEX TO FINANCIAL STATEMENT
SCHEDULES
Report of Independent Registered Public Accounting Firm on Financial Statement Schedules ......... FS-2
PAGE
Schedules
I – Summary of Investments – Other Than Investments in Related Parties as of December 31,
2017 ....................................................................................................................................................................................... FS-3
II – Condensed Financial Information of Cigna Corporation (Registrant).....................................................FS-4
Statements of Income for the Years Ended December 31, 2017, 2016, and 2015 ...........................FS-4
Balance Sheets as of December 31, 2017 and 2016.................................................................................... FS-5
Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015 ...................FS-6
Notes to Condensed Financial Statements.................................................................................................... FS-7
III – Supplementary Insurance Information ............................................................................................................... FS-8
IV – Reinsurance ................................................................................................................................................................FS-10
V – Valuation and Qualifying Accounts and Reserves.......................................................................................... FS-11
Schedules other than those listed above are omitted because they are not required or are not applicable, or the required information is shown
in the financial statements or notes thereto.
CIGNA CORPORATION - 2017 Form 10-K FS-1
PART IV
ITEM 15. Report of Independent Registered Public Accounting Firm on Financial Statement Schedules
Report of Independent Registered Public Accounting Firm on
Financial Statement Schedules
To the Board of Directors and Shareholders of Cigna Corporation
Our audits of the consolidated financial statements referred to in our report dated February 28, 2018 (which report and consolidated financial
statements are included under Item 8 in this Annual Report on Form 10-K) also included an audit of the financial statement schedules listed in
Item 15(a)(2) of this Form 10-K. In our opinion, these financial statement schedules present fairly, in all material respects, the information set
forth therein when read in conjunction with the related consolidated financial statements.
/s/ PricewaterhouseCoopers LLP
Hartford, Connecticut
February 28, 2018
FS-2 CIGNA CORPORATION - 2017 Form 10-K
Cigna Corporation and Subsidiaries
Schedule I – Summary of Investments – Other Than Investments in Related Parties
December 31, 2017
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
(in millions)
Type of Investment
Fixed maturities
Bonds
United States government and government agencies and authorities
States, municipalities and political subdivisions
Foreign governments
Public utilities
All other corporate bonds
Mortgage and other asset-backed
Redeemable preferred stocks
TOTAL FIXED MATURITIES
Equity securities
Common stocks
Industrial, miscellaneous and all other
Non-redeemable preferred stocks
TOTAL EQUITY SECURITIES
Commercial mortgage loans on real estate
Policy loans
Other long-term investments
Short-term investments
TOTAL INVESTMENTS
$
Fair
Value
779
1,287
2,487
2,342
15,739
497
7
23,138
496
92
588
Amount at
which shown in
the Consolidated
Balance Sheet
$
779
1,287
2,487
2,342
15,739
497
7
23,138
496
92
588
1,761
1,415
1,518
199
$
Cost
541
1,196
2,360
2,187
15,107
469
7
21,867
485
104
589
1,761
1,415
1,518
199
$ 27,349
$ 28,619
CIGNA CORPORATION - 2017 Form 10-K FS-3
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Cigna Corporation and Subsidiaries
Schedule II – Condensed Financial Information of Cigna Corporation (Registrant)
Statements of Income
(in millions)
Operating expenses
Interest
Intercompany interest
Debt extinguishment costs
Other
TOTAL OPERATING EXPENSES
Loss before income taxes
Income tax benefit
Loss of parent company
Equity in income of subsidiaries
SHAREHOLDERS’ NET INCOME
Shareholders’ other comprehensive income (loss)
Net unrealized (depreciation) on securities
Net unrealized (depreciation) appreciation on derivatives
Net translation of foreign currencies
Postretirement benefits liability adjustment
Shareholders’ other comprehensive income (loss):
SHAREHOLDERS’ COMPREHENSIVE INCOME
See Notes to Financial Statements on the following pages.
For the years ended December 31,
2017
2016
2015
$
$
237
18
321
204
780
(780)
(194)
(586)
2,823
2,237
(34)
(3)
304
33
300
$ 2,537
$
244
3
—
281
528
(528)
(146)
(382)
2,249
1,867
(56)
(4)
(95)
23
(132)
1,735
$
$
246
2
100
147
495
(495)
(135)
(360)
2,454
2,094
(202)
15
(212)
85
(314)
1,780
FS-4 CIGNA CORPORATION - 2017 Form 10-K
Cigna Corporation and Subsidiaries
Schedule II – Condensed Financial Information of Cigna Corporation (Registrant)
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Balance Sheets
(in millions)
Assets
Cash and cash equivalents
Short-term investments
Investments in subsidiaries
Intercompany receivable
Other assets
TOTAL ASSETS
Liabilities
Intercompany payable
Short-term debt
Long-term debt
Other liabilities
TOTAL LIABILITIES
Shareholders’ Equity
Common stock (shares issued, 296; authorized, 600)
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Less treasury stock, at cost
TOTAL SHAREHOLDERS’ EQUITY
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
See Notes to Financial Statements on the following pages.
As of December 31,
2017
2016
$
9
63
22,655
200
252
$
18
57
20,315
173
415
$ 23,179
$ 20,978
$
2,980
231
5,112
1,121
9,444
74
2,940
(1,082)
15,824
(4,021)
13,735
$
998
257
4,658
1,342
7,255
74
2,892
(1,382)
13,855
(1,716)
13,723
$ 23,179
$ 20,978
CIGNA CORPORATION - 2017 Form 10-K FS-5
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Cigna Corporation and Subsidiaries
Schedule II – Condensed Financial Information of Cigna Corporation (Registrant)
Statements of Cash Flows
(in millions)
Cash Flows from Operating Activities
Shareholders’ net income
Adjustments to reconcile shareholders’ net income to net cash provided by operating
activities
For the years ended December 31,
2017
2016
2015
$
2,237
$
1,867
$
2,094
Equity in income of subsidiaries
Dividends received from subsidiaries
Other liabilities
Debt extinguishment costs
Other, net (1)
NET CASH PROVIDED BY OPERATING ACTIVITIES (1)
Cash Flows from Investing Activities
Short-term investment purchased, net
Other, net
NET CASH (USED IN) INVESTING ACTIVITIES
Cash Flows from Financing Activities
Net change in amounts due to (from) affiliates
Net change in short-term debt
Payments for debt extinguishment
Repayment of long-term debt
Net proceeds on issuance of long-term debt
Issuance of common stock
Common dividends paid
Repurchase of common stock
Tax withholding on stock compensation (1)
Other
NET CASH (USED IN) FINANCING ACTIVITIES (1)
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
(2,823)
758
(224)
321
333
602
(6)
(11)
(17)
1,955
100
(313)
(1,250)
1,581
131
(10)
(2,725)
(61)
(2)
(594)
(9)
18
$
9
$
(2,249)
580
(9)
–
187
376
(3)
(8)
(11)
(78)
(100)
–
–
–
36
(10)
(139)
(72)
–
(363)
2
16
18
(2,454)
880
112
100
112
844
(54)
(14)
(68)
(161)
–
(87)
(851)
894
154
(10)
(671)
(79)
–
(811)
(35)
51
16
$
(1) As required in adopting Accounting Standard Update (‘‘ASU’’) 2016-09, the Company retrospectively reclassified $79 million cash payments from operating to financing activities in 2015.
These payments were related to employee tax obligations associated with stock compensation. The comparable amounts reported in financing activities were $61 million in 2017 and
$72 million in 2016.
See Notes to Financial Statements on the following pages.
FS-6 CIGNA CORPORATION - 2017 Form 10-K
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Cigna Corporation and Subsidiaries
Schedule II – Condensed Financial Information of Cigna Corporation (Registrant)
Notes to Condensed Financial Statements
The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the
accompanying notes thereto contained in this Annual Report on Form 10-K (‘‘Form 10-K’’).
Note 1 – For purposes of these condensed financial statements, Cigna Corporation’s (the ‘‘Company’’) wholly-owned and majority-owned
subsidiaries are recorded using the equity basis of accounting.
Note 2 – See Note 5 – Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of
Cigna Corporation and its subsidiaries. All debt is a direct obligation of Cigna Corporation, except for $78 million of 6.37% Notes due 2021 and
$18 million of capital leases.
Note 3 – Intercompany liabilities consist primarily of payables to Cigna Holdings, Inc. of $2.8 billion as of December 31, 2017 and $0.7 billion as
of December 31, 2016. Interest was accrued at an average monthly rate of 1.47% for 2017 and 0.93% for 2016.
Note 4 – The Company had guarantees of approximately $235 million as of December 31, 2017. These guarantees are primarily to secure
payment obligations or solvency requirements of certain wholly-owned subsidiaries. In 2017, no payments have been made on these
guarantees.
CIGNA CORPORATION - 2017 Form 10-K FS-7
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Cigna Corporation and Subsidiaries
Schedule III – Supplementary Insurance Information
(in millions)
Segment
Year Ended December 31, 2017
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total
Year Ended December 31, 2016
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total
Year Ended December 31, 2015
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total
Deferred
policy
acquisition
costs
Future policy
benefits and
contractholder
deposit funds
Medical costs
payable and
unpaid
claims(1)
Unearned
premiums
$
$
$
$
$
$
15
2,176
1
45
–
2,237
16
1,752
1
49
–
1,818
11
1,593
1
54
–
1,659
$
$
$
$
$
$
$
$
$
$
$
157
3,746
1,686
12,647
–
18,236
161
3,225
1,786
12,934
–
18,106
169
3,006
1,714
13,033
–
$
$
$
$
$
2,719
484
4,491
193
–
7,887
2,532
384
4,342
191
–
7,449
2,355
353
4,006
215
–
17,922
$
6,929
$
213
490
7
14
–
724
170
435
13
16
–
634
145
453
13
18
–
629
(1) Unpaid claims balances reported in Corporate in 2015 have been retrospectively reclassified to the Group Disability and Life segment to conform to the
presentation of unpaid claim balances in Note 8 to the Consolidated Financial Statements. These amounts represent elimination entries.
FS-8 CIGNA CORPORATION - 2017 Form 10-K
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Segment
Premiums(2)
Net
investment
income(3)
Benefit
expenses(2)(4)
Amortization
of deferred
policy
acquisition
expenses
Other
operating
expenses(5)
Year Ended December 31, 2017
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total
Year Ended December 31, 2016
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
Total
Year Ended December 31, 2015
Global Health Care
Global Supplemental Benefits
Group Disability and Life
Other Operations
Corporate
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
24,538
3,684
3,985
112
(12)
32,307
23,295
3,226
4,002
103
–
30,626
22,696
3,000
3,843
103
–
378
122
350
346
30
1,226
315
110
343
358
21
1,147
340
103
337
369
4
$
$
$
$
$
19,967
2,033
3,076
342
(12)
25,406
19,009
1,784
3,354
339
–
24,486
18,354
1,659
2,934
343
–
Total
$
29,642
$
1,153
$
23,290
$
56
259
1
6
–
322
47
238
1
6
–
292
53
227
1
5
–
286
$
$
$
$
$
9,417
1,115
967
(32)
815
12,282
9,411
1,030
918
24
528
11,911
8,621
963
861
26
502
$
10,973
(2) Amounts presented are shown net of the effects of reinsurance. See Note 9 to the Consolidated Financial Statements included in this Form 10-K. Premiums in
the Corporate segment represent the elimination of intercompany transactions.
(3) The allocation of net investment income is based upon the identification of certain portfolios with specific segments, the mean reserve method, or a
combination of both.
(4) Benefit expenses include Global Health Care medical costs and other benefit expenses.
(5) Other operating expenses includes mail order pharmacy costs, other operating expenses, and net amortization of other intangible assets. It excludes
amortization of deferred policy acquisition expenses. In 2017, other operating expenses in the Other Operations segment includes a reduction of $56 million
related to U.S. tax reform. See Note 20 to the Consolidated Financial Statements included in this Form 10-K.
CIGNA CORPORATION - 2017 Form 10-K FS-9
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Cigna Corporation and Subsidiaries
Schedule IV – Reinsurance
(in millions)
Year Ended December 31, 2017
Life insurance in force
Premiums
Life insurance and annuities
Accident and health insurance
Total
Year Ended December 31, 2016
Life insurance in force
Premiums
Life insurance and annuities
Accident and health insurance
Total
Year Ended December 31, 2015
Life insurance in force
Premiums
Life insurance and annuities
Accident and health insurance
Total
Gross amount
Ceded to other
companies
Assumed from
other companies
Net amount
Percentage
of amount
assumed to net
$
$
$
$
$
$
$
$
$
1,105,323
2,307
30,095
32,402
1,047,002
2,881
27,874
30,755
1,047,982
2,886
26,926
29,812
$
$
$
$
$
$
$
$
$
49,172
233
191
424
55,399
310
203
513
72,208
335
235
570
$
$
$
$
$
$
$
$
$
2,478
$ 1,058,629
22
307
329
$
$
2,096
30,211
32,307
2,827
$ 994,430
22
362
384
$
$
2,593
28,033
30,626
3,273
$ 979,047
106
294
400
$
$
2,657
26,985
29,642
0.2%
1.0%
1.0%
1.0%
0.3%
0.8%
1.3%
1.3%
0.3%
4.0%
1.1%
1.3%
FS-10 CIGNA CORPORATION - 2017 Form 10-K
Cigna Corporation and Subsidiaries
Schedule V – Valuation and Qualifying Accounts and Reserves
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
(in millions)
Description
2017
Investment asset valuation reserves
Commercial mortgage loans
Allowance for doubtful accounts
Premiums, accounts and notes receivable
Deferred tax asset valuation allowance
Reinsurance recoverables
2016
Investment asset valuation reserves
Commercial mortgage loans
Allowance for doubtful accounts
Premiums, accounts and notes receivable
Deferred tax asset valuation allowance
Reinsurance recoverables
2015
Investment asset valuation reserves
Commercial mortgage loans
Allowance for doubtful accounts
Premiums, accounts and notes receivable
Deferred tax asset valuation allowance
Reinsurance recoverables
Balance at
beginning of
year
Charged
(Credited)
to costs and
expenses (1)
Charged
(Credited)
to other
accounts
Other
deductions (2)
Balance at
end of year
$
$
$
$
$
$
$
$
$
$
$
$
5
200
87
3
15
75
71
3
12
101
49
4
$
$
$
$
$
$
$
$
$
$
$
$
1
19
11
–
–
134
21
–
7
(10)
8
–
$
$
$
$
$
$
$
$
$
$
$
$
–
(11)
(26)
–
–
(8)
(5)
–
–
(15)
14
(1)
$
$
$
$
$
$
$
$
$
$
$
$
(6)
(1)
–
–
(10)
(1)
–
–
(4)
(1)
–
–
$
$
$
$
$
$
$
$
$
$
$
$
–
207
72
3
5
200
87
3
15
75
71
3
(1) Amounts for 2017 and 2016 include risk corridor allowance. See Note 22 to the Consolidated Financial Statements for additional information.
(2) Amounts for commercial mortgage loans primarily reflect charge-offs upon sales and repayments, as well as transfers to foreclosed real estate.
CIGNA CORPORATION - 2017 Form 10-K FS-11
(This page has been left blank intentionally.)
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 12
Cigna Corporation – Computation of Ratio of Earnings to Fixed Charges
(Dollars in millions)
Year Ended December 31,
Income before income taxes
Adjustments
2017
2016
2015
2014
2013
$ 3,606
$ 2,979
$ 3,327
$ 3,304
$ 2,176
(Income) loss from equity investee, net (1)
(Income) loss attributable to noncontrolling interests
12
5
45
24
3
17
(18)
5
(17)
(3)
Income before income taxes, as adjusted
$ 3,623
$ 3,048
$ 3,347
$ 3,291
$ 2,156
Fixed charges included in income
Interest expense
Interest portion of rental expense
Interest credited to contractholders
Total fixed charges included in income
Income available for fixed charges
Ratio of Earnings to Fixed Charges:
(1) Beginning in 2015, net of distributions received from equity method investments
$
$ 243
54
2
251
50
1
$
252
54
1
$ 265
50
3
$ 270
38
5
$ 299
$ 302
$ 307
$
318
$
313
$ 3,922
$ 3,350
$ 3,654
$ 3,609
$ 2,469
13.1
11.1
11.9
11.3
7.9
CIGNA CORPORATION - 2017 Form 10-K E-1
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Subsidiaries of the Registrant
Exhibit 21
Listed below are subsidiaries of Cigna Corporation as of December 31, 2017 with their jurisdictions of organization. Those subsidiaries not listed
would not, in the aggregate, constitute a ‘‘significant subsidiary’’ of Cigna Corporation, as that term is defined in Rule 1-02(w) of Regulation S-X.
Entity Name
Allegiance Life & Health Insurance Company, Inc.
Allegiance Re, Inc.
American Retirement Life Insurance Company
Benefits Management Corp.
Bravo Health Mid-Atlantic, Inc.
Bravo Health Pennsylvania, Inc.
CareAllies, Inc.
Central Reserve Life Insurance Company
Ceres Sales of Ohio, LLC
Cigna & CMB Life Insurance Company Limited
Cigna Apac Holdings Limited
Cigna Arbor Life Insurance Company
Cigna Beechwood Holdings, SdC/MTS
Cigna Behavioral Health of California, Inc.
Cigna Behavioral Health of Texas, Inc.
Cigna Behavioral Health, Inc.
Cigna Bellevue Alpha, LLC
Cigna Benefits Financing, Inc.
Cigna Brokerage & Marketing (Thailand) Limited
Cigna Cedar Holdings, Ltd.
Cigna Chestnut Holdings, Ltd.
Cigna Corporate Services, LLC
Cigna Data Services (Shanghai) Company Limited
Cigna Dental Health of California, Inc.
Cigna Dental Health of Colorado, Inc.
Cigna Dental Health of Delaware, Inc.
Cigna Dental Health of Florida, Inc.
Cigna Dental Health of Illinois, Inc.
Cigna Dental Health of Kansas, Inc.
Cigna Dental Health of Kentucky, Inc.
Cigna Dental Health of Maryland, Inc.
Cigna Dental Health of Missouri, Inc.
Cigna Dental Health of New Jersey, Inc.
Cigna Dental Health of North Carolina, Inc.
Cigna Dental Health of Ohio, Inc.
Cigna Dental Health of Pennsylvania, Inc.
Cigna Dental Health of Texas, Inc.
Cigna Dental Health of Virginia, Inc.
Cigna Dental Health Plan of Arizona, Inc.
Cigna Dental Health, Inc.
Cigna Elmwood Holdings, SPRL
Cigna Europe Insurance Company S.A.-N.V.
Cigna European Services (UK) Limited
Cigna Finans Emeklilik ve Hayat A.S.
Cigna Global Holdings, Inc.
Cigna Global Insurance Company Limited
Cigna Global Reinsurance Company, Ltd.
Cigna Global Wellbeing Holdings Limited
Cigna Global Wellbeing Solutions Limited
Cigna Health and Life Insurance Company
Cigna Health Corporation
Cigna Health Management, Inc.
Cigna Health Solutions India Pvt. Ltd.
Cigna Healthcare Holdings, Inc.
Cigna Healthcare Mid-Atlantic, Inc.
Cigna Healthcare of Arizona, Inc.
Cigna Healthcare of California, Inc.
Cigna Healthcare of Colorado, Inc.
Cigna Healthcare of Connecticut, Inc.
Cigna Healthcare of Florida, Inc.
Cigna Healthcare of Georgia, Inc.
Cigna Healthcare of Illinois, Inc.
Cigna Healthcare of Indiana, Inc.
Cigna Healthcare of Maine, Inc.
Cigna Healthcare of Massachusetts, Inc.
Cigna Healthcare of New Hampshire, Inc.
Cigna Healthcare of New Jersey, Inc.
Cigna Healthcare of North Carolina, Inc.
Cigna Healthcare of Pennsylvania, Inc.
E-2 CIGNA CORPORATION - 2017 Form 10-K
Jurisdiction
Montana
Montana
Ohio
Montana
Maryland
Pennsylvania
Delaware
Ohio
Ohio
China
Bermuda
Connecticut
Belgium
California
Texas
Minnesota
Delaware
Delaware
Thailand
Malta
United Kingdom
Delaware
China
California
Colorado
Delaware
Florida
Illinois
Kansas
Kentucky
Maryland
Missouri
New Jersey
North Carolina
Ohio
Pennsylvania
Texas
Virginia
Arizona
Florida
Belgium
Belgium
United Kingdom
Turkey
Delaware
Guernsey, C.I
Bermuda
United Kingdom
United Kingdom
Connecticut
Delaware
Delaware
India
Colorado
Maryland
Arizona
California
Colorado
Connecticut
Florida
Georgia
Illinois
Indiana
Maine
Massachusetts
New Hampshire
New Jersey
North Carolina
Pennsylvania
Entity Name
Cigna Healthcare of South Carolina, Inc.
Cigna Healthcare of St. Louis, Inc.
Cigna Healthcare of Tennessee, Inc.
Cigna Healthcare of Texas, Inc.
Cigna Healthcare of Utah, Inc.
Cigna HLA Technology Services Company Limited
Cigna Holdings Overseas, Inc.
Cigna Holdings, Inc.
Cigna Hong Kong Holdings Company Limited
Cigna Insurance Public Company Limited
Cigna Insurance Middle East S.A.
Cigna Insurance Services (Europe) Limited
Cigna Intellectual Property, Inc.
Cigna International Corporation
Cigna International Health Services Kenya Limited
Cigna International Health Services SDN BHD
Cigna International Health Services BVBA
Cigna International Health Services, LLC
Cigna International Services Australia Pty. Ltd.
Cigna Investment Group, Inc.
Cigna Investments, Inc.
Cigna Korean Chusik Hoesa
Cigna Laurel Holdings, Ltd.
Cigna Legal Protection UK Ltd.
Cigna Life Insurance Company of Canada
Cigna Life Insurance Company of Europe S.A.- N.V.
Cigna Life Insurance Company of New York
Cigna Life Insurance New Zealand Limited
Cigna Linden Holdings, Inc.
Cigna Magnolia Holdings, Ltd.
Cigna Myrtle Holdings, Ltd.
Cigna Nederland Alpha Cooperatief U.A.
Cigna Nederland Beta B.V.
Cigna Nederland Gamma B.V.
Cigna Oak Holdings, Ltd.
Cigna Palmetto Holdings, Ltd.
Cigna Poplar Holdings, Inc.
Cigna Sequoia Holdings, SPRL
Cigna Taiwan Life Assurance Company Limited
CignaTTK Health Insurance Company Limited
Cigna Walnut Holdings, Ltd.
Cigna Willow Holdings, Ltd.
Cigna Worldwide General Insurance Company Limited
Cigna Worldwide Insurance Company
Cigna Worldwide Life Insurance Company Limited
Connecticut General Corporation
Connecticut General Life Insurance Company
FirstAssist Administration Limited
Great-West Healthcare of Illinois, Inc.
Grown Ups New Zealand Limited
Health-Lynx LLC
Healthsource, Inc.
HealthSpring, Inc.
HealthSpring of Alabama, Inc
HealthSpring of Florida, Inc.
HealthSpring Life & Health Insurance Company, Inc.
HealthSpring of Tennessee, Inc.
KDM Thailand Limited
Life Insurance Company of North America
LINA Financial Services
LINA Life Insurance Company of Korea
Loyal American Life Insurance Company
MCC Independent Practice Association of New York, Inc.
NewQuest, LLC
NewQuest Management Northeast, LLC
Olympic Health Management Services, Inc.
Provident American Life and Health Insurance Company
PT Asuransi Cigna
Qualcare Alliance Networks, Inc.
Qualcare Captive Insurance Company Inc. PCC
Qualcare Management Resources Limited Liability Company
Qualcare, Inc.
RHP (Thailand) Limited
Scibal Associates, Inc.
Sterling Life Insurance Company
Tel-Drug, Inc.
Tel-Drug of Pennsylvania, LLC
Temple Insurance Company Limited
United Benefit Life Insurance Company
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
Jurisdiction
South Carolina
Missouri
Tennessee
Texas
Utah
Hong Kong
Delaware
Delaware
Hong Kong
Thailand
Lebanon
United Kingdom
Delaware
Delaware
Kenya
Malaysia
Belgium
Florida
Australia
Delaware
Delaware
South Korea
Bermuda
United Kingdom
Canada
Belgium
New York
New Zealand
Delaware
Bermuda
Malta
Netherlands
Netherlands
Netherlands
United Kingdom
Bermuda
Delaware
Belgium
Taiwan
India
United Kingdom
United Kingdom
Hong Kong
Delaware
Hong Kong
Connecticut
Connecticut
United Kingdom
Illinois
New Zealand
New Jersey
New Hampshire
Delaware
Alabama
Florida
Texas
Tennessee
Thailand
Pennsylvania
South Korea
South Korea
Ohio
New York
Texas
Delaware
Washington
Ohio
Indonesia
New Jersey
New Jersey
New Jersey
New Jersey
Thailand
New Jersey
Illinois
South Dakota
Pennsylvania
Bermuda
Ohio
CIGNA CORPORATION - 2017 Form 10-K E-3
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-179307, No. 333-166583,
No. 333-163899, No. 333-147994, No. 333-64207, No. 333-129395, No. 333-107839, No. 333-90785, No. 333-218510, No. 333-31903,
No. 333-22391, No. 033-60053 and No. 033-51791) and Form S-3 (No. 333-219729) of Cigna Corporation of our reports dated February 28, 2018
relating to the financial statements, financial statement schedules and the effectiveness of internal control over financial reporting, which
appear in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Hartford, Connecticut
February 28, 2018
E-4 CIGNA CORPORATION - 2017 Form 10-K
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 31.1
I, DAVID M. CORDANI, certify that:
Certification
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Cigna Corporation;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
b)
c)
d)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ DAVID M. CORDANI
Chief Executive Officer
February 28, 2018
Date:
CIGNA CORPORATION - 2017 Form 10-K E-5
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 31.2
I, ERIC P. PALMER, certify that:
Certification
.1
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Cigna Corporation;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
b)
c)
d)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
a)
b)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ ERIC P. PALMER
Date:
Chief Financial Officer
February 28, 2018
E-6 CIGNA CORPORATION - 2017 Form 10-K
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 32.1
Certification of Chief Executive Officer of Cigna Corporation pursuant to
18 U.S.C. Section 1350
I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of Cigna Corporation for the fiscal period ending
December 31, 2017 (the ‘‘Report’’):
(1)
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Cigna
Corporation.
/s/ DAVID M. CORDANI
David M. Cordani
Chief Executive Officer
February 28, 2018
CIGNA CORPORATION - 2017 Form 10-K E-7
PART IV
ITEM 15. Exhibits and Financial Statement Schedules
EXHIBIT 32.2
Certification of Chief Financial Officer of Cigna Corporation pursuant to
18 U.S.C. Section 1350
I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of Cigna Corporation for the fiscal period ending
December 31, 2017 (the ‘‘Report’’):
(1)
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Cigna
Corporation.
/s/ ERIC P. PALMER
Eric P. Palmer
Chief Financial Officer
February 28, 2018
E-8 CIGNA CORPORATION - 2017 Form 10-K
TABLE OF CONTENTS
Letter to our shareholders
People
Purpose
Performance
Cigna in perspective
Corporate and Board of Directors
2
8
10
18
22
24
OUR MISSION
To help the people we serve improve their
health, well-being and sense of security.
All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut
General Life Insurance Company, Life Insurance Company of North America, Cigna Life Insurance Company of New York (New York, NY), Cigna Behavioral Health, Inc., Cigna Health
Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation and Cigna Dental Health, Inc. The Cigna name, logo, and other Cigna marks are owned by
Cigna Intellectual Property, Inc.
912978 03/2018 © 2018 Cigna. Some content provided under license.
20
1 7
ANNUAL
REPORT
People first. Performance follows.
900 Cottage Grove Road Bloomfield, CT 06002
Cigna.com